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Background: There is no good evidence to support the use of patient-reported outcome measures
(PROMs) in setting preoperative thresholds for referral for hip and knee replacement surgery. Despite this,
the practice is widespread in the NHS.
Objectives/research questions: Can clinical outcome tools be used to set thresholds for hip or knee
replacement? What is the relationship between the choice of threshold and the cost-effectiveness
of surgery?
Methods: A systematic review identified PROMs used to assess patients undergoing hip/knee replacement.
Their measurement properties were compared and supplemented by analysis of existing data sets. For
each candidate score, we calculated the absolute threshold (a preoperative level above which there is no
potential for improvement) and relative thresholds (preoperative levels above which individuals are less
likely to improve than others). Owing to their measurement properties and the availability of data from
their current widespread use in the NHS, the Oxford Knee Score (OKS) and Oxford Hip Score (OHS) were
selected as the most appropriate scores to use in developing the Arthroplasty Candidacy Help Engine
(ACHE) tool. The change in score and the probability of an improvement were then calculated and
modelled using preoperative and postoperative OKS/OHSs and PROM scores, thereby creating the ACHE
tool. Markov models were used to assess the cost-effectiveness of total hip/knee arthroplasty in the NHS
for different preoperative values of OKS/OHSs over a 10-year period. The threshold values were used to
model how the ACHE tool may change the number of referrals in a single UK musculoskeletal hub. A user
group was established that included patients, members of the public and health-care representatives,
to provide stakeholder feedback throughout the research process.
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Results: From a shortlist of four scores, the OHS and OKS were selected for the ACHE tool based on their
measurement properties, calculated preoperative thresholds and cost-effectiveness data. The absolute
threshold was 40 for the OHS and 41 for the OKS using the preferred improvement criterion. A range
of relative thresholds were calculated based on the relationship between a patient’s preoperative score
and their probability of improving after surgery. For example, a preoperative OHS of 35 or an OKS of
30 translates to a 75% probability of achieving a good outcome from surgical intervention. The economic
evaluation demonstrated that hip and knee arthroplasty cost of < £20,000 per quality-adjusted life-year for
patients with any preoperative score below the absolute thresholds (40 for the OHS and 41 for the OKS).
Arthroplasty was most cost-effective for patients with lower preoperative scores.
Limitations: The ACHE tool supports but does not replace the shared decision-making process required
before an individual decides whether or not to undergo surgery.
Conclusion: The OHS and OKS can be used in the ACHE tool to assess an individual patient’s suitability
for hip/knee replacement surgery. The system enables evidence-based and informed threshold setting
in accordance with local resources and policies. At a population level, both hip and knee arthroplasty are
highly cost-effective right up to the absolute threshold for intervention. Our stakeholder user group felt
that the ACHE tool was a useful evidence-based clinical tool to aid referrals and that it should be trialled in
NHS clinical practice to establish its feasibility.
Future work: Future work could include (1) a real-world study of the ACHE tool to determine its
acceptability to patients and general practitioners and (2) a study of the role of the ACHE tool in
supporting referral decisions.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Patients with severe hip and knee arthritis may require joint replacement. General practitioners makethe decision to refer patients to hospital based on an assessment of their symptoms. Pain and function
can be measured using patient questionnaires and the questionnaire scores can indicate whether or not
the severity of disease warrants referral (i.e. whether or not the patient is a candidate for joint replacement
based on their ‘capacity to benefit’). However, we do not know whether or not basing treatment decisions
on such scores is correct, nor do we know what exact pain score thresholds should be used for referral.
After a thorough search, we found that the Oxford Hip and Knee Scores were the best instruments.
A high score (i.e. a maximum score of 48) indicates less pain and better function. The threshold values for
referral for surgery were scores of 40 for hips and 41 for knees. The process of evaluating scoring systems,
the choice of scoring systems and the threshold values were discussed and agreed by a panel of patients
and by doctors throughout the study.
Most patients with severe joint pain benefit from joint replacement, and these operations are cost-effective.
However, above a certain level (a score of 40 for hips and 41 for knees), patients are not thought to typically
benefit from surgery. Below these values, lower presurgery scores indicate a steadily increasing likelihood of
benefit in terms of reduced pain and better function.
This information provides the basis for a tool to help doctors decide who to refer for joint replacement:
the Arthroplasty Candidacy Help Engine (ACHE). Use of the ACHE tool prevents patients who are unlikely to
benefit from joint replacement being referred unnecessarily and allows the NHS to concentrate resources on
those who will benefit most from arthroplasty treatment.
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Scientific summary
Background
Numerous health-care measures, including patient-reported outcome measures (PROMs), are used to
assess patients undergoing hip and knee replacement. It has been suggested that preoperative PROM
scores could be used to guide referrals by general practitioners (GPs) or musculoskeletal hubs to secondary
care. Local thresholds have been used in the NHS, although they have been arbitrary, not evidence based
and may have resulted in the overtreatment of some patients while inappropriately limiting access to care
for others. The aim was to develop a mechanism for identifying appropriate patients for hip and knee
replacement referral from primary to secondary care using safe and equitable thresholds. We did this by
creating an evidence-based tool, the Arthroplasty Candidacy Help Engine (ACHE), which used an existing
assessment score to evaluate and describe patients’ capacity to benefit from cost-effective surgery. To
achieve this aim, the following questions that were set out in the National Institute for Health Research
(NIHR) call for this research were addressed:
l Can clinical tools for assessment of a patient’s suitability for knee or hip replacement be used to set
thresholds for operation?
l How does the choice of threshold affect the cost-effectiveness of the procedure and subsequent
improvements in patient quality of life?
Objectives
l Create a shortlist of scoring systems that are potentially useful for selecting candidates for arthroplasty
surgery.
l Identify a single scoring system and threshold values that could to be used within the ACHE tool to
select candidates for surgery.
l Establish the cost-effectiveness of hip and knee surgery as the referral threshold changes.
l Explore the potential impact of using the ACHE tool within the NHS.
l Determine the acceptability of the tool and thresholds to stakeholders and patients.
Methods
Work package 1: a systematic review of established scores/instruments used to assess
hip and knee replacement
A sensitive filter for finding studies on measurement properties was used to search MEDLINE, EMBASE,
PsycINFO, and the Allied and Complementary Medicine Database (AMED). The Patient-Reported Outcome and
Quality Of Life Instruments Database (ProQolid), the Oxford PROMs Database, the Database of Abstracts of
Reviews of Effects (DARE) and EconLit were also searched using medical subject headings and free-text terms.
Titles and abstracts of all identified articles were assessed twice for inclusion/exclusion by two reviewers.
Selected full-text articles were then screened for all outcome measures using agreed inclusion and exclusion
criteria. From selected publications, data were extracted on the psychometric performance and operational
characteristics of each PROM. The following characteristics were included: reliability (test–retest reliability and
internal consistency), validity (content and construct validity), responsiveness, interpretability (precision of the
measure when used at an individual patient level), evidence of minimal clinically important differences/changes,
ceiling or floor effects and acceptability (respondents’ willingness to complete). Measurement properties
for each instrument were assessed for hip, knee, and mixed hip and knee populations (depending on the
availability of published studies). Our initial search yielded 3448 publications, leaving 135 after screening,
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from which 32 possible scoring systems were identified. Following data extraction, we identified the
Western Ontario and McMaster Universities Arthritis Index (WOMAC®), Oxford Hip Score (OHS), Oxford
Knee Score (OKS) and Short Form questionnaire-12 items (SF-12) to be the most promising scores, but all
scores required more data to enhance characterisation of measurement properties.
Work package 1: calculation of additional measurement properties
The calculation of additional measurement properties was undertaken using five established pre-existing
data sets of patients undergoing primary hip and knee replacement. The Knee Arthroplasty Trial (KAT)
and the Exeter Primary Outcome Study (EPOS) data sets were used for the analyses for OHS and OKS,
and the SF-12 physical component score (PCS) and mental component score (MCS). The European
Collaborative Database of Cost and Practice Patterns of Total Hip Replacement (EUROHIP) data set was
used for WOMAC scores. The Assessing Disability After Partial and Total Joint Replacement (ADAPT)
study and the Arthroplasty Pain EXperience (APEX) study were used for SF-12 PCS, MCS (ADAPT) and
WOMAC scores (both hip and knee) analyses.
The following measurement properties were evaluated:
l internal consistency (Cronbach’s alpha and corrected item–total correlation)
l construct validity (the magnitude and direction of correlations with other measures)
l responsiveness (magnitude and direction of Pearson and Spearman correlations of change scores)
l floor and ceiling effects (proportion of the top and the bottom scores at pre and post surgery)
l interpretability [using various definitions of improvement including minimally detectable change (MDC)
and group levels of minimally important change (MIC)/minimally important difference criteria].
High internal consistency of the instruments was observed with a Cronbach’s alpha of around 0.9 at pre
and post operation, and no improvement obtained by removal of any item [except for the preoperation
EuroQol-5 Dimensions, three-level version (EQ-5D-3L) index and pre- and post-operation SF-12 (version 1
with US weighting)] score. Construct validity was supported, with strong correlations between the
instruments pre and post operation (except the correlation between SF-12 MCS and other instruments:
WOMAC total, pain, physical function, stiffness and SF-12 PCS). There was evidence of responsiveness
(Spearman’s rank-order correlation of > 0.5) in terms of the correlation of the change scores between the
instruments, except the correlation between SF-12 MCS and other instruments. High ceiling effects were
found in the EQ-5D-3L index (39–46% for hip and 25–30% for knee), OHS (19%) and WOMAC total
(21%) for hip only post operation. MDCs [intracluster correlation coefficient (ICC) 0.9] were 0.23–0.24
for the EQ-5D-3L index and 12–16 for WOMAC total score across the data sets. After considering the
evidence, four scoring systems were shortlisted and taken forward for further analysis: the OHS [range of
scores from minimum = 0 (worst) to maximum = 48 (best)], the OKS [range of scores from minimum = 0
(worst) to maximum = 48 (best)], the SF-12 [range of scores from minimum = 0 (worst) to maximum = 100
(best)] and the WOMAC total [range of scores from maximum = 100 (worst) to minimum = 0 (best)].
Work package 2: calculation of threshold values for shortlisted scores
We estimated absolute and relative thresholds, using different definitions of improvement within the same
data sets mentioned above and data from the NHS PROMs collection (2012–15). Preoperative scores were
used to calculate absolute thresholds above which there is no potential for clinical benefit from surgery.
This is defined as the largest observed presurgery value for which any improvement was achieved. Four
improvement definitions included minimally clinically important difference (MCID) applying a ‘medium’
effect size (ES) (0.5) – criterion B. Linear and logistic regressions were used to estimate two relative
thresholds for patient probability of improvement at 50% and 75%. Specificity of using the absolute
threshold to rule out inability to benefit was also calculated in each data set.
In reporting the WOMAC score, we inverted the range [inverted range of scores from minimum = 0 (worst)
to maximum = 100 (best)] for consistency with the other measures (OKS/OHS/SF-12), giving in all measures
a high score, indicating better health status than a low score. The ranges of scores for the following
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measures are: OKS [minimum = 0 (worst) to maximum = 48 (best)], OHS [minimum = 0 (worst) to
maximum = 48 (best)], SF-12 (PCS and MCS) [minimum = 0 (worst) to maximum = 100 (best)] and the
inverted WOMAC [minimum = 0 (worst) to maximum = 100 (best)].
The absolute and relative thresholds for the OHS were 43 (specificity 2–9%) and 38–43 (specificity 2–6%),
respectively, based on criterion B. The absolute and relative thresholds for WOMAC in hip arthroplasty were
89–91 (specificity 0–22%) and 78–86 (specificity 20–56%), respectively. SF-12 PCS and MCS findings were
similar, with absolute threshold values of 65 for PCS and 66 for MCS (specificity 0% for both) and relative
thresholds of 35–47 for PCS (specificity 20–48%) and 37–42 for MCS (specificity 91–100%). Considering
knee replacement, the absolute threshold for OKS was 43 (specificity 1%) with relative thresholds of
29–40 (specificity 2–14%). The absolute and relative thresholds for WOMAC total in knee arthroplasty were
90–91 (specificity 0–7%) and 71–86 (specificity 5–19%), respectively. Relative thresholds using different
improvement definitions were calculated: thresholds calculated using a medium ES (0.5) MCID showed
similar outcomes with a MDC at 90% certainty using an ICC of 0.9. There was substantial variation in the
magnitude of absolute change between and within each preoperative score subset. The SF-12 PCS and
MCS findings were variable, with absolute threshold values of 66–71 (specificity 0%) and 65–74 (specificity
0–2%) and relative thresholds values of 22–43 (specificity 16–94%) and 26–49 (specificity 72–100%).
Work package 2: health economic evaluation of threshold scores
We conducted a cost–utility analysis comparing total hip arthroplasty (THA) and total knee arthroplasty
(TKA) with no arthroplasty from a UK NHS perspective. Six Markov models, each with probabilistic sensitivity
analysis (PSA), simulated progression of patient cohorts with different preoperative data to evaluate how
the cost-effectiveness of THA/TKA varies with OHS, OKS, WOMAC and SF-12 and with age and sex. Model
parameters were initially based on regressions of the parameter of interest on age, sex and preoperative
clinical tool score using patient-level data from the APEX study, the Clinical Outcomes in Arthroplasty Study
(COASt), EPOS, KAT and web-based PROMs data. Mortality and revision rates were taken from published
studies. The reference year for costs was 2014. We took a 10-year time horizon and used a 3.5% discount
rate. We considered arthroplasty to be cost-effective if it cost < £20,000 per quality-adjusted life-year
(QALY) gained. The results demonstrated that THA/TKA is cost-effective in almost all patients currently
undergoing surgery and that economic thresholds could be estimated for OKS and OHS. WOMAC failed
to identify any 60- or 70-year-old patients for whom knee replacement was not cost-effective; thresholds
for 50- and 80-year-old patients were higher than any scores observed in the available data sets. Hip
replacement was cost-effective for all WOMAC scores except for 90-year-old patients scoring 100.
Work package 2: further threshold analysis using the Oxford Hip and Knee Scores
After considering the evidence provided in the initial part of work package 2, our recommendation,
guided by the user group (see Work package 3: user group opinion), was that the OHS and OKS should be
selected to use in the ACHE tool. The decision was based on their measurement properties and the fact that
evidence-based thresholds could be calculated. In addition, the scores are already widely used in the NHS
patient pathway and this was felt to support future adoption of the ACHE tool. We then undertook more
extensive analysis using the NHS PROMs data set linked to Hospital Episode Statistics (HES) (2009–16). The
raw improving proportion was calculated and plotted by presurgery score. Improvement was defined as
receiver operating characteristic (ROC) curve best cut-off point-based MIC. Furthermore, two modelling
approaches were used for analyses of the Oxford Hip and Knee Scores. First, polynomial-based quantile
regression models were used to estimate the change score (postoperative minus preoperative) using the
presurgery Oxford Hip or Knee Score. Accuracy was assessed against observed percentiles and internal
comparison of subsets by key prognostic factors (e.g. gender). The second approach used was the fractional
polynomial logistic regressions to predict probability of improving. Using this second modelling approach,
the benefit of the baseline covariates on the capacity of benefit was investigated. Internal model validation
of the logistic regression models was performed in terms of discrimination and calibration. Sensitivity and
specificity values for the estimated relative threshold were calculated with corresponding 95% confidence
intervals. The raw probability of improvement was calculated with a pattern similar for both hip and knee
patients, although hip patients had a greater chance of improvement given preoperative score. The peak
DOI: 10.3310/hta23320 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 32
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Price et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix
probability for improvement for both hip and knee replacement occured when the preoperative score was
< 20 (approximately 90% of hip patients and 85% of knee patients significantly improving). These values
reduced as the preoperative score increased, with 75% of patients obtaining meaningful benefit at scores
of 35 for hips and 30 for knees. For a 50% chance of gaining meaningful benefit, the figures are 36 for
knee patients and 38 for hip patients. The absolute ROC–MIC-based threshold was 40 for hip replacement
and 41 for knee replacement. Quantile regression showed good fit against observed values except at very
high and very low preoperative values. Additional covariates did not substantively improve prognostic
accuracy with a substantial amount of unexplained variation in patient outcome. A smoothed curve of
the raw proportion of meaningful improvement was used in the ACHE tool.
Work package 2: further health economic analysis using the Oxford Hip and
Knee Scores
Nine parameters for the OKS and OHS Markov models were re-estimated using PROMs/HES-linked data.
The final models using PROMs/HES data found that hip and knee arthroplasty is cost-effective (i.e. costs
< £20,000 per QALY) for > 99.9% of patients who currently undergo surgery. Averaging across men and
women of all ages, it is cost-effective to conduct THA on patients with an OHS of ≤ 45 [95% credible
interval (CrI) 44 to 45] and to conduct TKA on patients with an OKS of ≤ 43 (95% CrI 43 to 44). The
economic threshold varied slightly with age but not with gender. PSAs suggested that there was relatively
little parameter uncertainty around the conclusions, and sensitivity analyses suggested that the results were
robust to large changes in the assumptions.
Work package 3: determining the outcome of using the Arthroplasty Candidacy Help
Engine tool in the NHS
We conducted an audit of anonymised data extracted from the medical records of patients who were referred
by Oxfordshire GPs with hip (n = 607) or knee (n = 315) osteoarthritis symptoms to the musculoskeletal hub at
the Nuffield Orthopaedic Centre in Oxford between July 2015 and July 2016. These data were combined with
PROMs/HES data and the results of the economic evaluation to model the potential impact that the ACHE
tool may have on cost and health benefits using different thresholds. This preliminary analysis suggested that
using the ACHE tool in a musculoskeletal hub would not reduce but may increase the number of referrals to
secondary care. In turn, this may increase costs to the NHS while still supporting cost-effective care.
Work package 3: patient, public and general practitioner survey
We used the probability of good outcome models to develop a prototype ACHE tool, which was web
based. We then undertook two web-based surveys in which we demonstrated the use of the ACHE tool
to patients/the public and GPs to gain their opinion regarding its use. We had a very low response to the
surveys from patients/the public (n = 22/271) and GPs (n = 10/348). The study data should be considered a
pilot analysis, but, encouragingly, those who did respond were broadly supportive of the ACHE tool being
used to assist in the decision to refer patients for possible joint replacement surgery.
Work package 3: user group opinion
The user group brought together stakeholders from across the hip and knee pathway in the NHS: patients,
members of the public, GPs, surgeons, extended-scope physiotherapists, commissioners, musculoskeletal
hub representatives and representatives of the British Orthopaedic Association, the British Hip Society and
the British Association for Surgery of the Knee. The user group was consulted four times in the process of
producing the ACHE tool, each time for opinions and guidance from users as the work progressed. The
process culminated in the final user group meeting in which opinion was gathered as to the ACHE tool’s
potential real-world use in the NHS. The group’s opinion was that the ACHE tool was potentially a very
useful tool for assisting and standardising the process of referral from primary to secondary care. There
was agreement that the ACHE tool should now be piloted and tested in the NHS to determine its uptake
and effect on referral patterns.
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Conclusions
The study has shown that the OHS and OKS can be used for assessment of a patient’s suitability for knee
or hip replacement using thresholds for candidacy based on the individual’s capacity for or probability of
improving. Our work has shown that hip and knee replacement, when undertaken in any patients with
preoperative scores below the absolute OKS and OHS thresholds, is extremely cost-effective. The ACHE
tool has been created and should now be carefully tested in the NHS.
Recommendations for future research
Future research could include (1) a real-world study of the ACHE tool to determine its acceptability with
patients and GPs and (2) a study of the role of the ACHE tool in supporting referral decisions.
Funding
Funding for this study was provided by the Health Technology Assessment programme of NIHR.
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Chapter 1 Introduction
Research questions specified in the National Institute for Health
Research Health Technology Assessment research call
l Can clinical tools for assessment of a patient’s suitability for knee or hip replacement be used to set
thresholds for an operation?
l How does the choice of threshold affect the cost-effectiveness of the procedure and subsequent
improvements in patient quality of life?
Background
Hip and knee osteoarthritis is a common musculoskeletal condition causing significant pain and loss of
function for patients. Using patient-reported outcome measures (PROMs), joint replacement treatment
for end-stage disease has been shown to be an effective treatment.1 Each year, 150,000 hip and knee
replacements are carried out in the UK, with the majority of patients having successful outcomes.2 However,
the nationally collected patient-reported outcome data for hip and knee replacements have identified two
striking issues with regard to the provision of joint replacement in the UK. First, there is marked variation in
current clinical practice in referring and undertaking surgery in patients with arthritis of the hip and knee.3
Previous studies from the UK support this observation, with recent evidence showing that access to joint
replacement is currently inequitable, with deprived areas associated with greater symptom severity and
lower surgery rates.4–6 A previous large national survey of UK NHS patients undergoing joint surgery7
also concluded that there was no evidence that patients were being prioritised on the basis of the severity
of their symptoms and function. Second, the national outcomes data have revealed that 10–15% of
patients undergoing hip or knee joint replacement are not satisfied with their treatment, and these findings,
particularly for the knee patients, are supported by other recent studies.8,9 It has been suggested that
selecting patients too early in their disease process may play a role in producing dissatisfaction with surgery.9
Overall, these findings suggest that there is no standardisation to the process by which patients are assessed
and selected for hip and knee replacement surgery. This is a particular concern given both the projected
increased need for joint replacement over the next decade to accommodate an ageing population and the
pressure of potential reductions in NHS funding.10
Assessing patients for joint replacement surgery within the NHS is generally a two-stage process that
begins with the patient presenting to a general practitioner (GP) with hip or knee pain (Figure 1).
The assessment process usually takes place over a number of consultations, often including an radiography
to confirm osteoarthritis. The GP continues to monitor symptoms and responses to non-operative
treatments, eventually deciding when the patient is a candidate for joint replacement surgery, and at this
point the patient is referred to secondary care. Currently, there are no widely accepted guidelines within
the NHS specifically to help health professionals estimate the level of patient symptoms that warrants
referral.11 In the secondary care setting, the specialist assesses the patient, confirms the diagnosis and
radiographic severity, reviews a patient’s symptoms and shares information with them about available
treatment options. For each patient, the decision to offer surgery requires a personalised assessment of
individual preferences, expectations, functional limitations and requirements, degree of radiographic
pathology, comorbidities and predicted outcome.11 Ideally, the patient and their specialist then make a
shared decision, with the patient ultimately deciding whether or not to undergo surgery. We estimate
that there are around 1 million GP patient assessments for hip and knee pain each year, with around
one-quarter of patients who present being referred to a specialist. Although only a small proportion of
these patients receive joint replacement, this amounts to 150,000 procedures a year.12,13 At the Nuffield
Orthopaedic Centre (NOC), our data suggest that approximately 15% of patients who are referred from
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primary care for possible joint replacement do not have symptoms at a level that requires joint replacement
and could have been safely managed without an appointment in secondary care.
Given the issues of unwarranted variation and poor outcome in some patients, outlined above, there has
been significant interest in trying to standardise the process of referral and selection for joint replacement.
The use of certain ‘priority criteria’ (such as the Western Canada Waiting List score,14 the Ontario criteria15
or the New Zealand score16) has been investigated as a more consistent method of selecting patients
for referral and treatment. These tools identify candidates for surgery in primary care and are based on
estimating a patient’s capacity to benefit from surgery. They are generic and attempt to standardise the
patient pathway for joint replacement at the entry point. The New Zealand priority criteria16 have been
used in some regions within the NHS but have not reached widespread acceptance, and the current
evidence of their reliability and validity is minimal.17,18 Other tools have been developed but not fully tested
in clinical practice within the UK.19–21 The Osteoarthritis Research Society International (OARSI) Standing
Committee for Clinical Trials Response Criteria Initiative and the Outcome Measures in Rheumatology
(OMERACT) international initiative has attempted to deliver a standardised approach and has highlighted
pain and disability as among the key domains for identifying the capacity to benefit.22–25 It has therefore
been a logical progression to investigate if existing assessment tools used in the joint replacement
pathway, that measure pain and disability, could be used as a single score to identify candidates for
surgery by referring their preoperative assessment score to a threshold for intervention.
In 2009, the Department of Health and Social Care introduced the routine collection of PROMs for hip and
knee surgery to measure the outcome of surgery undertaken in NHS hospitals.8,26 There has been government
support for extending the use of scoring systems preoperatively to create thresholds for referral and candidacy
for surgery.27,28 In fact, many primary care trusts and NHS trusts have already introduced PROM-based severity
score thresholds for surgery, although the thresholds used vary widely between regions.29–36 However,
evidence underpinning and endorsing the use of PROMs or any assessment score for thresholds is scant
and without validation. This poses a significant risk to patients as an incorrectly set threshold may unfairly
restrict access to care or, conversely, inappropriately select patients for joint replacement.2 The development
of a preoperative threshold score to identify candidates for hip and knee replacement offers a significant
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FIGURE 1 Patient pathway framework for the NHS to identify candidates for hip and knee replacement. The
selected assessment score may also be used later in the pathway to measure the outcome of surgery and to offer
surveillance for joint replacement post surgery. THA, total hip arthroplasty; TKA, total knee arthroplasty.
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opportunity to standardise the patient pathway. However, this Health Technology Assessment (HTA)
call reflects the pressing need within the NHS to produce evidence to support or refute their use.
A number of scoring systems are used to assess the patients in their care pathway. Many are PROM based,
such as the Intermittent and Constant Osteoarthritis Pain Measure (ICOAP),37 the EuroQol-5 Dimensions
(EQ-5D) and the Oxford Hip and Knee Scores,38–40 whereas others require a clinician’s involvement (e.g. the
New Zealand score16). Some systems were designed to measure the burden of osteoarthritis symptoms
[e.g. the Western Ontario and McMaster Universities Arthritis Index (WOMAC®) or ICOAP],41 whereas
others were designed to measure the effect of an intervention (e.g. Oxford Hip and Knee Scores). Some
scores were produced to measure more general aspects of health status [Short Form questionnaire-36
items (SF-36) or EQ-5D]42 and others aim to prioritise patients for surgery (e.g. the New Zealand priority
criteria16). None of these scores has been developed for the specific role of applying thresholds for access
to care for joint replacement within the setting of the NHS. It may be that one or more of these scores
may be appropriate for such use but evidence is required to validate and justify this role.
To be fit for purpose as a screening device, any candidate score must satisfy a number of requirements.
First, the score must have adequate measurement properties to enable assessment of patients for joint
replacement, namely adequate validity. This includes evidence of adequate reliability at an individual level
(test–retest and intraclass correlation coefficient), precision [standard error (SE) of the measurement] and
responsiveness to change [smallest detectable change and minimally clinically important difference (MCID)].
The effect of comorbidity on the score must also be established.
Second, valid evidence-based thresholds must be produced. The calculation of thresholds is not
straightforward, with several different methods available. To generate upper thresholds (i.e. least severity)
in preintervention scores, above which patients should not be considered candidates for arthroplasty,
methods must account for the likelihood of a patient’s capacity to benefit (i.e. likelihood of achieving a
positive change score) and perceive satisfactory improvement following surgery.43 The measurement
properties of the instrument (as described previously), such as the MCID (i.e. the smallest amount of
change in a score that patients detect and consider important) and standard error of the mean (SEM)
(which relates to the reliability of the instrument and denotes the amount of change that is ‘real’ and
beyond measurement error), are also important operational considerations when calculating thresholds.
Furthermore, any chosen threshold must distinguish between cases (patients in need of surgery) and
non-cases with a consistent level of diagnostic accuracy (discriminative ability).
The process of calculating absolute thresholds will also produce additional and valuable information for
patients who are found to be candidates for surgery. By highlighting an individual’s ‘chance’ of benefit
following surgery (based on their preoperative score), patients are provided with key information to help
with their decision-making, particularly in secondary care. It would provide evidence to support the use
of a score embedded within the NHS direct knee/hip osteoarthritis decision aid. Hence, clearly highlighting
the risks and benefits may make the decision to have surgery clearer for many patients. This type of
information allows patients to more comprehensively participate in the decisions made about their care.
Third, we must understand how the introduction of thresholds for surgery affects the cost-effectiveness of
the treatment. Lower-limb joint replacement has previously been shown to be highly cost-effective, costing
between €1276 and €18,300 per quality-adjusted life-year (QALY) gained for the average patient,44–48
which is substantially lower than the £20,000–30,000 per QALY range that the National Institute for
Health and Care Excellence (NICE) considers to be cost-effective for use within the NHS.49 However, it is
important for commissioners of hip and knee replacement surgery to understand how cost-effectiveness
varies between patient and procedure subgroups, and how thresholds for hip and knee surgery affect the
cost utility of the interventions. We have recently demonstrated the feasibility of this approach in a pilot
study exploring the relationship between costs and improvements in EQ-5D utility and preoperative PROM
scores in total knee arthroplasty (TKA).50
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Finally, having identified and validated a clinical tool and calculated valid and evidence-based thresholds
for surgery, within the NHS, it must be established whether or not the tools are acceptable to the
‘end-users’. Despite some thresholds for hip and knee replacement having already been introduced to
clinical practice in parts of the country, there has been little or no engagement with the wider stakeholders
about the appropriateness of this approach or how thresholds should be used in practice. The introduction
of thresholds requires the support of patients, health-care professionals and commissioners.
Although the requirements of threshold scores in primary and secondary care may differ, in order to provide
consistency for patients and health-care professionals any scoring system would ideally be applicable to
both sectors. One aim is to ensure this compatibility by consciously considering the requirements within
each setting. In primary care, the requirement is for a simple-to-use patient-based score linked to the
patient’s potential to benefit from arthroplasty. This would provide a distinct upper threshold for referral
and candidacy for joint replacement. The thresholds calculated for the identified scoring system will be
incorporated into a user-friendly knee and hip replacement candidacy assessment tool – the Arthroplasty
Candidacy Help Engine (ACHE) tool. Secondary care involves more complex assessments, involving
expectation, comorbidity and age-related factors. The ACHE tool would be a starting point for secondary
care assessment, linking to other patient decision-support tools.51,52
In summary, greater standardisation is required in the patient pathway leading to hip or knee joint
replacement surgery. The aim of this study is to develop an evidence-based method for identifying patients
in primary care who are possible candidates for surgery, using valid thresholds applied to scoring systems
that are already available (see Figure 1).
Research objectives
The following research objectives will be met:
l Create a shortlist of scoring systems that are potentially useful for selecting candidates for
arthroplasty surgery.
¢ From the literature, establish the scores/instruments available. Published evidence concerning their
measurement properties, and their past or projected use in setting thresholds for hip and knee
replacement, will be reviewed. This will generate a shortlist of potential scoring systems.
¢ Using existing data sets and guidance from users, refine the shortlist by establishing the necessary
measurement properties of potential scores/instruments when not available in the literature.
l Identify a scoring system, and a set of threshold values, to be used to select candidates for hip and
knee surgery.
¢ For each shortlisted instrument, determine score thresholds for candidacy for joint replacement surgery.
¢ Determine the relationship between threshold levels and cost-effectiveness of hip and knee
arthroplasty surgery.
¢ Select the most applicable single score and set of thresholds for incorporation into the ACHE tool.
l Explore the clinical effectiveness and cost-effectiveness of the ACHE tool and determine the potential
acceptability of the tool and thresholds to stakeholders and patients.
¢ Determine the effect of using the ACHE tool on patterns of referral of hip and knee patients to
secondary care.
¢ Evaluate user opinion – GPs and patients.
¢ Engage with a wider stakeholder group to assess the acceptability of the ACHE tool.
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The overall aim was to develop a standardised NHS framework for identifying patients for hip and knee
replacement surgery using safe and equitable thresholds. This was achieved by creating the ACHE tool,
based on a currently available assessment score, with thresholds that take account of patients’ capacity to
benefit from surgery and the cost-effectiveness of the treatment. The new system is applicable in both
primary and secondary care.
The user group
From the outset of the original design for this project, all service users’ perspectives were considered
integral to its success. The ACHE tool was to be designed to help patients, GPs, secondary care personnel,
arthroplasty specialists and health-care commissioning staff. It was therefore decided very early on to
utilise a ‘user group’ concept, in which representatives of these identified bodies inputted, critiqued and
reviewed the progress of the study at appropriate intervals. Importantly, the user group was established as
a proactive entity rather than as a passive and disengaged review and agreement exercise. The decisions
of the group were critical to the direction of the project and were instrumental in sanctioning various
aspects/decisions and vetoing others. The user group was given full autonomy under the direction of the
chairperson. Investigators of the study were allowed to be present but did not participate in the meeting
unless invited by the chairperson for clarification purposes only. As a result, the final ACHE tool did not
reflect the wishes of the researchers, but the group for whom the instrument was designed.
The user group was assembled and provided input at regular and preset intervals during the course of the
study. The sequence was predetermined and the role dovetailed with each stage of the project (Figure 2).
One option for this report was to describe user group input in separate sections (chapters) in sequence
and inserted within the main report at the appropriate temporal intervals. However, some meetings were
introductory or had limited remit and do not contain sufficient content to justify separate chapters. A
decision was made to report all user group activity in a single separate chapter (see Chapter 10). Readers
of the report are required to cross-reference this section and appreciate that user group input took place
for each academic section.
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Chapter 2 Systematic review of existing measures
(work package 1)
Background
The aim of this study was to develop an evidence-based system for identifying patients who might be
candidates for hip or knee replacement surgery, introducing valid thresholds based on scores that are
already available. The first objective in achieving this aim was to create a shortlist of scoring systems that
could be used in this way. After discussion within the user group (see Chapter 10), it was established that
candidate scores placed on the shortlist would need to meet certain essential criteria:
l A score must be a patient-reported measure to ensure that patients were engaged in the assessment
process and that the score used reflected their perspective on the outcome.
l A score must demonstrate adequate measurement properties and have been validated within the hip
and knee replacement populations.53–58
Many different scoring systems and outcome measures have been used for assessing the outcomes of hip
or knee arthroplasty, but not all measures have evidence of, or reach, even the minimum psychometric
standards for their proposed uses.1,59–61 Therefore, the aims of this work were to use systemic review
methodology to identify and evaluate English-language versions of PROMs that have been evaluated with
patients undergoing hip or knee replacement surgery and to provide a comprehensive profile of their
measurement properties so that a shortlist of candidate scores could be established.
Methods
Identification of studies
The search was conducted in May 2014; it was limited to English-language articles and no time restrictions
were set. MEDLINE, EMBASE, PsycINFO and the Allied and Complementary Medicine Database (AMED)
were searched using an adjusted methodological filter through Ovid ProQolid, the Oxford PROMs
Database, the Database of Abstracts of Reviews of Effects (DARE) and EconLit were also searched using a
combination of medical subject heading and free-text terms.62 Hand-searching of titles of the following key
journals in the 6 months preceding the search was also conducted: Health and Quality of Life Outcomes,
The Journal of Bone and Joint Surgery (American and British volumes) and The Journal of Arthroplasty.
Screening of articles and instruments
Titles and abstracts of all identified articles were assessed for inclusion/exclusion by two reviewers (KH and EG),
with agreement assessed on a screening sample of 313 abstracts. The first round of testing yielded a 77%
agreement rate and the second round yielded a 99% agreement rate between reviewers. Full texts of the
articles that were to be included in the review were retrieved. Inclusion criteria were:
l The instrument uses a standard scoring system (representing indices or scales).
l The instrument is already available and has been used in clinical settings or research to assess adult
(aged > 18 years) patients prior to hip or knee replacement.
l The instrument has been validated for the English-language population.
l The study design is principle development, concurrent revalidation or a prospective study of a score
with information on its measurement properties (e.g. reliability, validity and responsiveness).
Retrospective studies (except historical cohort studies) were excluded.
l The sample size in the study was > 50 subjects/patients.
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Titles and abstracts were obtained relating to any tools identified at this stage, and these were scrutinised
using the aforementioned inclusion criteria. The same methodology was applied to full-text documents
for their inclusion in the review. Selected full-text articles were then screened for all measures that were
used in analyses. The aforementioned inclusion criteria were applied to the list of identified measures.
Furthermore, the following exclusion criteria were applied to the initial list of measures:
l The assessment is not patient reported and requires the patient to be assessed on each/every occasion
by a clinician.
l The assessment requires some kind of technical information or equipment [such as a magnetic resonance
imaging (MRI) scan or radiographic report], which might not always be available or standardised, or which
might not make sense as part of an assessment conducted at both preoperative and postoperative stages.
l The measure is not capable of demonstrating patients’ ‘capacity to benefit’ because it was not
designed to be a health status/outcome measure, and therefore cannot measure change (e.g. purely
retrospective measures were excluded).
Instrument-specific search
A specific search was undertaken for each of the identified instruments, with a developmental study and then
a population and validation filter applied to the list of citations stemming from the developmental study.
Data extraction
Data were extracted on the psychometric performance and operational characteristics of each PROM.
Assessment and evaluation of the methodological quality of PROMs were undertaken independently by
three reviewers adapting the London School of Hygiene & Tropical Medicine appraisal criteria outlined in a
previous review.1
Measurement properties assessed
Reliability was assessed by test–retest reliability and internal consistency. Test–retest reliability refers to the
stability of a measuring instrument over time, assessed by administering the instrument to respondents on
two different occasions and examining the correlation between test and retest scores. Internal consistency
refers to the extent to which items constituting a scale measure the same construct (e.g. homogeneity of
items in a scale) and is assessed by Cronbach’s alpha and item–total correlations.
Content and construct validity were assessed. Content validity relates to the extent to which the content
of a scale is representative of the conceptual domain it is intended to cover and is usually assessed
qualitatively during the questionnaire development phase through pretesting with patients, with patients
involved in item generation. Construct validity looks at the evidence that the scale is correlated with other
measures of the same or similar constructs in the hypothesised direction and is assessed on the basis of
correlations between the measure and other similar measures, preferably based on an a priori hypothesis
with predicted strength of correlation.
Responsiveness refers to the ability of a scale to detect significant change over time and is assessed by
comparing scores before and after an intervention of known efficacy or when other evidence indicates
important change on the basis of various methods including paired t-tests, effect sizes (ESs), standardised
response mean values or responsiveness statistics. Ideally, evidence of responsiveness will include high
correlations between the change scores of the scale and relevant constructs, preferably based on an a
priori hypothesis with predicted strength of correlation.
Interpretability relates to the degree to which one can assign qualitative meaning – that is, clinical or
commonly understood connotations – to an instrument’s quantitative change in score. It can be assessed
by estimating the precision of the measure when used at an individual patient level, by multiplying the
SE of measurement with the standard score (z-value). In addition, MCIDs changes can be calculated by
relating change to an external anchor, using either mean change or the receiver operating characteristic
(ROC) curve method.
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Floor and ceiling effects relate to the ability of an instrument to accurately measure across the full
spectrum of a construct. If a measure has > 15% of participants achieving a top or bottom score, this is
indicative of a ceiling/floor effect.
Acceptability is a practical property of an instrument and reflects respondents’ willingness to complete it
without feeling unduly burdened, indicated by, for example, response rates and completion rates.
Measurement properties for each instrument were assessed separately for hip, knee and mixed hip and knee
populations (depending on the availability of published studies). The information was then summarised into
the appraisal summary tables, which rated the overall quality of evidence for each of the measurement
properties. Three authors (KH, EG and JD) reviewed their own respective sections, following which the results
were cross-checked to ensure consistency of assessment and scoring across the reviewers.
Results
Identification of studies
The initial search in Ovid yielded 3774 abstracts. After the removal of duplicates, the number of abstracts
for assessment was 2887. In addition, keyword searches (combination of knee, hip and orthopaedics) in
EconLit yielded 162 results, the PROMs database identified 454 results and DARE had no results (Figure 3).
Hand-searching of titles of the following key journals in the 6 months preceding the search was conducted:
l Health and Quality of Life Outcomes (number of articles, one)
l The Journal of Bone and Joint Surgery (American and British volumes; number of articles, one)
l The Journal of Arthroplasty (number of articles, three).
Screening of articles and instruments
Out of the 167 selected abstracts, 146 eligible full-text articles were then screened for all PROMs that were
analysed, identifying 135 instruments. If the instrument was not validated (developed for or subsequently
validated) for use in a population of patients undergoing hip or knee replacement surgery, it was excluded,
leaving 67 instruments. A reliability exercise was undertaken for 16 full-text articles between two reviewers,
and the agreement was 95% (38/40 questionnaires identified). An instrument-specific search was then
undertaken for each of the 67 identified instruments. By this method, 21 new validation papers (in addition
to 42 developmental papers) in the targeted population were identified. Furthermore, on closer examination
of shortlisted instruments, 21 initially identified instruments were additionally excluded.
Data extraction
Relevant data on the psychometric performance and operational characteristics were extracted for each
PROM. The summary texts were sent to corresponding authors from the developmental study of each
respective PROM, and further information was added as a result of this exercise. The appraisal summaries
are presented in Tables 1–4.
Table 1 summarises the evidence of measurement and operational performance applying the adapted
appraisal criteria for the hip PROMs identified in this review. On the basis of the volume and quality of
evidence, the Oxford Hip Score (OHS) clearly has the best evidence of measurement properties within the
hip-specific PROM category. Within the ‘knee scores’ subgroup (see Table 1), the Oxford Knee Score (OKS)
[with the OKS – Activity and Participation Questionnaire (OKS-APQ)] demonstrated best evidence of its
measurement properties within the knee-specific PROM category. The Knee injury and Osteoarthritis
Outcome Score (KOOS) and the KOOS – Physical Score (KOOS-PS) have some favourable evidence of their
measurement properties, although compared with the OKS, the evidence is lacking and further evaluations
are needed.
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FIGURE 3 Instrument flow diagram. AMED, Allied and Complementary Medicine Database; EconLit, American
Economic Association’s electronic bibliography; OU, University of Oxford. Reproduced with permission from
Harris et al.63 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 3.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/.
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Table 2 summarises the evidence of measurement and operational performance by applying the adapted
appraisal criteria to the lower-limb and pain PROMs identified in these reviews. The best-performing
lower-limb measure for hip/knee patients is the WOMAC, followed by the Lower Extremity Functional
Scale. The WOMAC also performed best when applied to separate hip or knee groups. Satisfactory
evidence of measurement properties was generally lacking for all of the three identified pain measures
(ICOAP, P4 and the McGill Pain-Short Form). ICOAP and McGill Pain-Short Form had no evidence in favour
of their responsiveness and P4 did not have any reported evidence of its responsiveness. Three utility and
generic measures identified in the review are listed in Table 3. As with the pain scores, the evidence for
utility PROMs was generally lacking, with the EQ-5D scoring worse on construct validity and responsiveness
than the Short Form questionnaire-6 Dimensions (SF-6D) and the Health Utilities Index Mark 2 (HUI2) and
Mark 3 (HUI3). On the basis of the volume and quality of evidence, among all identified generic measures,
the Short Form questionnaire-12 items (SF-12) is clearly the most promising one.
Nine measures identified in the review were categorised as ‘other’ scales. Table 4 summarises evidence of
their measurement properties. The World Health Organization Quality of Life (WHOQOL)-BREF instrument,
Aberdeen Impairment, activity limitation and participation restriction [Aberdeen Impairment, Activity
Limitation, and Participation Restriction (Aberdeen IAP)] and assessment of quality of life had the best
overall evidence in this subcategory (on a mixed hip/knee population). However, the overall evidence of
their validity was generally lacking.
TABLE 1 Hip and knee scores
Instrument
(groups tested)
Score
Hip Knee
HOOS HRQ PSI OHS
Knee disorders
subjective
history (VAS) KOOS KOOS-PS OKS OKS-APQ
Number of studies 5 1 4 20 1 3 2 23 1
Reproducibility ++ + + ++ 0 + 0 +++ +++
Internal consistency + 0 0 ++ 0 0 +++ +++ +++
Validity: content 0 0 ++ ++ + + + +++ +++
Construct ++ + ++ +++ + + ++ +++ +++
Responsiveness + + ++ +++ 0 0 ++ +++ +++
Interpretability 0 0 0 +++ 0 0 0 ++ 0
Floor and ceiling/
precision
+ 0 0 –/+ 0 + 0 ++ ++
Acceptability 0 0 0 +++ – 0 0 +++ +++
HOOS, Hip Disability and Osteoarthritis Outcome Score; HRQ, Hip Rating Questionnaire; PSI, patient-specific index;
VAS, visual analogue scale.
Notes
Psychometric and operational criteria: 0= not reported; –= no evidence in favour; + = some limited evidence in favour;
++= some good evidence in favour; +++= good evidence in favour; +/– =mixed evidence.
Reproduced with permission from Harris et al.63 This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 3.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/.
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TABLE 2 Lower limb and pain scores
Instrument (group tested)
Score
Lower limb Pain
LEFS
(h/k)
WOMAC
(h/k)
WOMAC
(h)
WOMAC
(k)
WOMAC
SF (h/k)
Lower limb
core score (h/k)
MODEMS-HK (AAOS)
hip and knee core
score (h/k)
ICOAP
(h/k) P4 (h/k)
McGill pain-short
form (h/k)
Number of studies 5 25 N/A N/A N/A 1 1 2 1 2
Reproducibility + ++ ++ + 0 0 0 + 0 ++
Internal consistency + + 0 0 + 0 0 + ++ 0
Validity: content + + + + + + + ++ + 0
Construct ++ +++ + ++ ++ 0 + + + +
Responsiveness ++ +++ ++ ++ + 0 ++ – 0 –
Interpretability + ++ ++ ++ 0 0 0 0 0 0
Floor and ceiling/precision 0 –/+ – 0 0 0 ++ 0 0 0
Acceptability 0 ++ + + 0 0 + 0 0 0
AAOS, American Academy of Orthopaedic Surgeons; h, hip; k, knee; LEFS, Lower Extremity Functional Scale; MODEMS-HQ, Musculoskeletal Outcome Data Evaluation and Management
System Hip and Knee Core Scale; N/A, not applicable; WOMAC-SF, WOMAC Short Form.
Notes
Psychometric and operational criteria: 0= not reported; –= no evidence in favour; + = some limited evidence in favour; ++ = some good evidence in favour; +++= good evidence in favour;
+/– =mixed evidence.
Reproduced with permission from Harris et al.63 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/.
SYSTEM
A
TIC
REVIEW
O
F
EXISTIN
G
M
EA
SU
RES
(W
O
RK
PA
CKA
G
E
1)
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
12
TABLE 3 Utility and generic scores
Instrument
(group tested)
Instrument group
Utility Generic
SF-6D (h)
HUI2 and
HUI3 (h) EQ-5D (h/k) EQ-5D (h) EQ-5D (k) SF-36 (h/k) SF-36 (h) SF-36 (k) SF-12 (h/k) SF-12 (h) SF-12 (k) SIP (h)
Number of studies 1 4 9 N/A N/A 14 N/A N/A 3 N/A N/A 2
Reproducibility 0 0 0 0 0 0 0 0 ++ 0 0 0
Internal consistency 0 0 N/A N/A N/A 0 0 – 0 0 0 0
Validity: content 0 0 0 0 0 0 0 0 0 0 0 +
Construct 0 ++ + 0 + + 0 + 0 0 + +
Responsiveness ++ + 0 0 + 0 ++ + 0 + + –
Interpretability 0 0 0 ++ ++ 0 + + 0 + + 0
Floor and ceiling/
precision
– 0 0 0 ++ 0 – 0 +++ 0 0 –
Acceptability 0 0 0 0 ++ 0 0 0 0 0 0 0
h, hip; HUI2, Health Utilities Index Mark 2; HUI3, Health Utilities Index Mark 3; k, knee; N/A, not applicable; SF-6D, Short Form questionnaire-6 Dimensions; SF-12, Short Form questionnaire-12
items; SIP, sickness impact profile.
Notes
Psychometric and operational criteria: 0= not reported; –= no evidence in favour; + = some limited evidence in favour; ++ = some good evidence in favour; +++= good evidence in favour;
+/– =mixed evidence.
Reproduced with permission from Harris et al.63 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/.
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TABLE 4 Other scores
Instrument
(group tested)
Instrument
WHOQOL-BREF
(h/k)
Aberdeen
IAP (h/k)
Aberdeen IAP
(modified) (h/k) NEADL (h) AQOL (h/k)
MSK functional
limitations index (k) HAQ (k) MHAQ (h/k) MHAQ (h) K10 (h/k)
Number of studies 1 1 1 1 2 1 2 2 N/A 1
Reproducibility 0 0 0 ++ 0 0 0 0 0 0
Internal consistency ++ + ++ ++ 0 0 – 0 0 0
Validity: content + + 0 – 0 0 0 0 + –
Construct 0 + + + + + ++ + + +
Responsiveness + 0 0 – ++ 0 – – + –
Interpretability 0 0 0 0 0 0 0 0 0 0
Floor and ceiling/
precision
++ + 0 + 0 0 + ++ 0 ++
Acceptability 0 0 0 0 0 + 0 0 0 0
Aberdeen IAP, Aberdeen Impairment, Activity Limitation, and Participation Restriction; AQOL, Assessment of Quality of Life; h, hip; HAQ, Health Assessment Questionnaire; k, knee;
K10, The Kessler Psychological Distress Scale; MHAQ, Modified Health Assessment Questionnaire; MSK, musculoskeletal; N/A, not applicable; NEADL, Nottingham Extended Activities of
Daily Living.
Notes
Psychometric and operational criteria: 0= not reported; –= no evidence in favour; + = some limited evidence in favour; ++ = some good evidence in favour; +++= good evidence in favour;
+/– =mixed evidence.
Reproduced with permission from Harris et al.63 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license, which
permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/3.0/.
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Discussion
Our review has identified the WOMAC, OHS and OKS to be the most promising disease-/site-specific
scores that perhaps provide best coverage of the construct of interest and better responsiveness.
The best-performing generic measure was the SF-12. However, further research on some of the missing
measurement properties in these measures is required. For the WOMAC, further evidence on ceiling/floor
effect, content validity and acceptability is required in both the hip and the knee groups of patients. The
OHS is currently lacking evidence on its ceiling/floor effects. Many other PROMs do not have sufficient
measurement property validation to recommend their use. Given its widespread use in this clinical area
(e.g. national PROMs data), it was disappointing that the EQ-5D score did not perform better.
Our findings are supported by existing literature. Alviar et al.60 published a systematic review of measurement
properties of 28 PROMs used in hip/knee arthroplasty based on published evidence up to December 2009
and found the WOMAC, OKS and SF-36 to be the most comprehensively tested measures at that time,
although the need for more rigorous evaluation of reliability, responsiveness and interpretability was noted.
Our review has updated this evidence, both in breadth (we have assessed 67 instruments) and time period
(our search was until May 2014). Browne et al.64 identified the OHS and OKS (used alongside the EQ-5D) as
primary outcome measures of choice to be used in the UK PROMs programme for hip and knee replacement.
It should be noted that the standards (and indeed scope/tolerance) for reporting details of qualitative
procedures and psychometric analysis have changed over the past 20 years (very much so in the
musculoskeletal literature), so that although measures that were devised earlier in that period have had a
longer time in which to accrue evidence of their measurement properties, they can frequently lack relevant
detail specifically in relation to the development of the instrument. Reporting has improved, probably
as a consequence of the evolving methods and the recognition that minimum standards are required
[e.g. Streiner et al.,65 COSMIN (COnsensus-based Standards for the selection of health Measurement
INstruments)54 and the US Food and Drug Administration55].
Further detail and supplementary material can be found in the publication based on this work by Harris et al.63
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Chapter 3 Calculation of measurement properties
(work package 1)
Background
The systematic review of the measurement properties reported the properties for the EuroQol-5 Dimensions,
three-level version (EQ-5D-3L), SF-12, OHS, OKS and WOMAC tools based on the existing literature. The
OHS (20 studies) and OKS (23 studies) are good in terms of reproducibility, internal consistency, validity
(content), construct, responsiveness, interpretability, floor and ceiling effects, precision (except OHS) and
acceptability. WOMAC (25 studies) was reported as good in terms of reproducibility, validity (content),
construct, responsiveness, interpretability and acceptability. Only fair outcomes for knee for EQ-5D-3L
(nine studies) were reported in terms of interpretability and acceptability when construct and responsiveness
were not applicable. SF-12 (three studies) was poor in terms of construct, responsiveness and interpretability.
There were a number of outcomes for which there was no or little available evidence on one of more of the
measurement properties. To be fit for purpose, any candidate score to be used as a screening instrument
must satisfy a number of requirements, one being that the score must have adequate measurement
properties to enable assessment of patients for joint replacement {i.e. adequate validity [ACHE protocol
version 4, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
(NDORMS), 2015]}.
Methods
General approach
Following the review of the evidence on the measurement properties of the possible instruments for
measuring outcome after knee and hip replacement operations, a number of gaps in the evidence base
were identified. Using available data sets, before we refined the shortlist of candidate tools (Table 5),
the missing measurement properties were calculated when possible using available data sets.
TABLE 5 Available data sets and instruments
Data set
Instrument
EQ-5D-3L index SF-12/SF-36 OKS OHS WOMAC
Knee
KAT ✓ ✓ ✓
ADAPT ✓ ✓
APEX ✓ ✓
Hip
EUROHIP ✓ ✓ ✓
EPOS ✓ ✓
ADAPT ✓ ✓
APEX ✓ ✓
ADAPT, Assessing Disability After Partial and Total Joint Replacement; APEX, Arthroplasty Pain EXperience study;
EPOS, Exeter Primary Outcome Study; EUROHIP, The European Collaborative Database of Cost and Practice Patterns
of Total Hip Replacement; KAT, Knee Arthroplasty Trial.
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Research aim and objectives
Patient-level data were available from a number of data sets, which included data on several relevant scoring
systems. As reported in Chapter 1 and summarised in Tables 1–4, most of the instruments identified in the
systematic review lacked evidence on one or more measurement properties. Using the available data sets,
missing measurement properties were calculated. The instruments covered varied across the data sets (see
Table 5). No data sets were available that included SF-6D, SF-36, ICOAP, KOOS or KOOS-PS, among others.
Data sets
A brief description of the data sets used is provided in the following sections.
The Knee Arthroplasty Trial
Summary
The Knee Arthroplasty Trial (KAT)66 is a National Institute for Health Research (NIHR) HTA programme-funded
study that has examined the outcome of 2352 total knee arthroplasties (TKAs) over a median of 10 years,
and includes data on costs and resource use. Continued development of TKA systems has seen improvement
in quality of life and increased duration of prosthetic survival. It was a pragmatic, multicentre (116 surgeons in
34 centres in the UK) randomised controlled trial (RCT). A total of 2352 participants were randomly allocated
to be treated with or without a metal backing of the tibial component (n = 409), a patellar resurfacing
(n = 1715) or a mobile bearing (n = 539); in total, 2318 patients took part.
The trial is registered as ISRCTN45837371.
Available outcome measures of interest
The available outcome measures of interest were the OKS, SF-12 [predominantly version 2 (n = 2091),
although a small number of version 1 questionnaires were initially used (n = 126)] and the EQ-5D-3L
descriptive system (referred to as the ‘EQ-5D-3L index’ in this report).
The European Collaborative Database of Cost and Practice Patterns of Total
Hip Replacement
Summary
This used a cohort of people having primary hip replacement for primary osteoarthritis from the UK and
other European countries. The European Collaborative Database of Cost and Practice Patterns of Total Hip
Replacement (EUROHIP) consortium includes 20 orthopaedic centres in 12 different European countries.67
The cohort was comprised of 1051 people having primary hip replacement for primary hip osteoarthritis.
Originally, 147 patients in the cohort came from the UK (143 remained for the analysis for the OHS) and
the remaining 1373 patients were from other European countries (1184 remained for the analysis). In
total, 1327 participants were used for analyses of WOMAC and the EQ-5D-3L index. A total of 908
participants (68.4%) completed the 12-month follow-up questionnaire. A minimum of 50 consecutive,
consenting patients receiving primary total hip arthroplasty (THA) for hip osteoarthritis in each of the
20 participating orthopaedic centres entered the study. Preoperative data included demographics,
employment and educational attainment, drug utilisation and involvement of other joints.67
Available outcome measures of interest
The available outcome measures of interest were the OHS, EQ-5D-3L index and WOMAC (a five-point
Likert version).
The Exeter Prosthesis Outcome Study
Summary
The Exeter Primary Outcome Study (EPOS) recruited 1590 patients who had undergone Exeter hip
replacement implants between March 1999 and February 2002.68 There were 1375 patients (1431 hips)
CALCULATION OF MEASUREMENT PROPERTIES (WORK PACKAGE 1)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
18
with a primary diagnosis of osteoarthritis. The unit of analysis was the implant rather than the patient, of
whom 56 had bilateral procedures. A total of 1431 THRs were undertaken by consultant and non-consultant
surgeons using anterolateral or posterior approaches.69
Available outcome measures of interest
The available outcome measures of interest were the OHS and SF-36.
After Partial and Total Joint Replacement
Between February 2010 and November 2011, 125 patients undergoing THA and 128 patients undergoing
TKA were recruited to the cohort. The protocol and full details of the research design and findings have
been published.70 The studies were approved by the Southampton and South West Hampshire Research
Ethics Committee (09/H0102/72) and all participants provided informed, written consent.71 The patients
recruited were due to undergo a range of hip and knee replacement procedures, meaning that functional
measures could be investigated across a range of people with diverse indications for surgery and degrees
of functional impairment.
Available outcome measures of interest
The available outcome measures of interest were the SF-12 version 1 and WOMAC.
Arthroplasty Pain Experience
Summary
Between 2009 and 2012, 322 patients undergoing THA and 316 patients undergoing TKA were recruited.
The inclusion criteria were waiting for a primary unilateral THA or TKA for osteoarthritis. The published
protocol and clinical results paper for the Arthroplasty Pain EXperience (APEX) study provide full details of
the research design and findings.70,72 The exclusion criteria were the inability to provide informed consent
or complete questionnaires and medical comorbidity precluding the use of spinal anaesthesia, regional
blocks or strong analgesics postoperatively.
Available outcome measures of interest
The available outcome measures of interest were the EQ-5D-3L index and WOMAC.
Approvals
We successfully sought direct approval from the data controller of each data set to obtain access to the
anonymised data.
Available data by data set
Tables 6 and 7 show the number of individuals who responded to each hip and knee measurement tool
for the respective data sets. The percentages of items missing in those with an incomplete measurement
tool were about 6–24% for the EQ-5D-3L index, 15–41% for the OHS and 12% for the OKS and 21–36%
for the WOMAC total score post operation (see Report Supplementary Material 1, Online Supplement 1,
for further details. Please note that all further citations to ‘online supplements’ refer to those within
Report Supplementary Material 1).
Statistical analysis
The statistical methods used to calculate the five measurement properties of interest are described in the
following sections.
Internal consistency
The corresponding Cronbach’s alpha was calculated using preoperation and postoperation data for the
SF-12 [physical component score (PCS) and mental component score (MCS)] and OKS (pain, function
and total scores). For the OKS total scores and subscales, the actual internal consistency can be assessed
(as these summary scores are simple summations of the individual items). For the EQ-5D-3L index and the
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TABLE 6 Hip measurement tools: observed and missing data
Measurement tool
Pre operation Post operation
Individuals who
responded to any
question in the
measurement tool (n)
Individuals who
fully completed
the measurement
tool (n)
Items missing for those
with an incomplete
measurement tool
response (%)
Individuals who
responded to any
question in the
measurement tool (n)
Individuals who
fully completed
the measurement
tool (n)
Items missing for those
with an incomplete
measurement tool
response (%)
APEX
EQ-5D-3L index 309 302 86.8 271 266 94.8
EUROHIP
EQ-5D-3L index 1266 1228 72.9 903 883 96.9
ADAPT
SF-12 MCS/PCS 125 119 53.8 112 104 76.0
EPOS
OHS 1534 1517 79.9 1262 1239 94.9
EUROHIP
OHS 140 127 33.9 123 114 74.7
OHS pain 140 133 51.7 123 120 92.0
OHS function 139 131 47.2 123 115 39.6
ADAPT
WOMAC total 125 112 34.5 111 102 70.4
WOMAC pain 125 122 77.5 111 109 93.3
WOMAC function 125 115 42.4 111 104 75.8
WOMAC stiffness 125 125 – 111 109 95.2
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Measurement tool
Pre operation Post operation
Individuals who
responded to any
question in the
measurement tool (n)
Individuals who
fully completed
the measurement
tool (n)
Items missing for those
with an incomplete
measurement tool
response (%)
Individuals who
responded to any
question in the
measurement tool (n)
Individuals who
fully completed
the measurement
tool (n)
Items missing for those
with an incomplete
measurement tool
response (%)
APEX
WOMAC total 324 261 42.7 283 234 65.7
WOMAC pain 324 323 96.0 283 279 95.0
WOMAC function 308 270 53.7 273 242 74.0
WOMAC stiffness 309 300 89.5 273 268 96.7
EUROHIP
WOMAC total 1272 1243 73.4 902 865 94.3
WOMAC pain 1268 1255 91.1 886 875 98.8
WOMAC function 1270 1253 86.7 901 888 98.4
WOMAC stiffness 1266 1266 – 888 888 –
ADAPT, Assessing Disability After Partial and Total Joint Replacement; MCS, mental component score; PCS, physical component score.
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TABLE 7 Knee PROMs: observed and missing data
Measurement tool
Pre operation Post operation
Individuals who
responded to any
question of the
measurement tool (n)
Patients who
fully completed
the measurement
tool (n)
Items missing in those
with incomplete
measurement tool (%)
Individuals who
responded to any
question of the
measurement tool (n)
Patients who
fully completed
the measurement
tool (n)
Items missing in those
with incomplete
measurement tool (%)
APEX
EQ-5D-3L index 302 298 92.2 263 261 97.9
KAT
EQ-5D-3L index 2156 2120 71.6 1995 1939 84.2
ADAPT
SF-12 MCS/PCS 128 116 43.2 110 96 68.5
KAT
SF-12 MCS/PCS 2156 2087 58.3 – 1904 –
KAT
OKS 2159 2112 59.9 1996 1691 47.9
OKS pain 2159 2136 76.4 1996 1906 76.2
OKS function 2159 2132 75.8 1996 1753 58.8
ADAPT
WOMAC total 128 118 41.4 110 102 74.6
WOMAC pain 127 123 64.4 110 109 96.5
WOMAC function 127 120 49.0 110 103 77.5
WOMAC stiffness 127 127 – 110 110 –
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Measurement tool
Pre operation Post operation
Individuals who
responded to any
question of the
measurement tool (n)
Patients who
fully completed
the measurement
tool (n)
Items missing in those
with incomplete
measurement tool (%)
Individuals who
responded to any
question of the
measurement tool (n)
Patients who
fully completed
the measurement
tool (n)
Items missing in those
with incomplete
measurement tool (%)
APEX
WOMAC total 318 246 41.6 277 214 59.0
WOMAC pain 318 318 0.0 277 269 90.9
WOMAC function 301 253 50.5 268 224 66.6
WOMAC stiffness 301 293 91.3 268 260 94.9
ADAPT, Assessing Disability After Partial and Total Joint Replacement; MCS, mental component score; PCS, physical component score.
Note
Individual-item-level response data were not available.
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SF-12 summary scores, the respective Cronbach’s alpha relates to a summary score of the five domains,
and, therefore, 12 items were carried out at the best indirectly assessed internal consistency. The SF-12
uses 12-item response values to generate two summary scores: physical and mental. This was carried out
for the baseline data only and by version. The analyses were carried out in Stata® (version 14; StataCorp
LP, College Station, TX, USA) using the alpha command. The Cronbach’s alpha including all standard
items, with each of the constituent items dropped in turn, was calculated along with the correlation
between each individual item and the sum of all the other items.
Construct validity
A priori hypotheses about the magnitude and direction of correlations between primary outcomes at pre
operation have been proposed (see Analysis plan document). Spearman’s and Pearson’s correlations were
calculated for each pair of measures. These were calculated in Stata® using the ci2 command with 95%
confidence intervals (CIs). The CI for Pearson’s correlation was calculated in two ways: using Fisher’s r-to-z
transformation and using bootstrapping with 1000 replications in Stata® using the bootstrap command.
Cohen’s convention is to interpret ES as follows: a correlation coefficient of 0.10 is thought to represent
a weak or small association, a correlation coefficient of 0.30 is considered a moderate correlation and a
correlation coefficient of 0.50 or larger is thought to represent a strong or large correlation.73
Responsiveness
Responsiveness was assessed by examining the magnitude and direction of correlations of the change
scores (pre to post operation) between the primary outcomes.
Floor and ceiling effects
The proportion of patients responding with the highest and lowest possible scores at pre and post
operation were calculated to assess the possibility of floor/ceiling effects. Jette et al.74 considered that for
the measurement of a stage to be useful, no more than 20% of patients’ measurements should show
floor and ceiling effects. More values close to the extremes of the instrument’s range suggest more limited
ability of a measurement to discriminate among patients’ function at the minimum or maximum possible
scale.74 The proportion specified to designate a floor/ceiling effect is arbitrary, with 20% used for the
current study.
Interpretability
The ACHE project methodology aims to calculate the minimal detectable change (MDC), minimally
important change (MIC) and minimally important difference (MID). Various approaches can be used to
assess these properties. Minor variations in these definitions exist. The definitions used for the estimation
of these attributes are given in the following sections.
The MDC was calculated as stated in the following section. The MIC was calculated in three ways: the
ROC MIC, MIC (group) and MIC (ES). The MID was calculated in two ways: using a patient-reported
global transition item MID (anchor) and using an ES approach MID. The specific methods used were in
accordance with the methodology proposed by Beard et al.75
Minimal detectable change (90% significance level)
This is often called a distribution method for calculating an important change. The SE of the measurement
can be defined as:
SE of the measurement = SD ×
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1−R)
p
, (1)
where SD is the standard deviation and R is a reliability parameter [e.g. test–retest reliability or intracluster
correlation coefficient (ICC)]. In this analysis, test–retest reliability was used.76,77 Applying a 90% significance
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level for z-distribution (z-statistics value of 1.645), a range for the possible difference between two
observations under the same conditions (test–retest scenario) was calculated to define the MDC:77
MDC =1:645 ×
ﬃﬃﬃ
2
p
× SE of the measurement. (2)
To calculate an estimate of the MDC, the ICC (test–retest reliability) should be imputed given repeatability
data because it is not possible to calculate an estimate of the ICC (i.e. the outcome measured at the same
time point multiple times) in the KAT data set. A previous study has estimated ICCs of 0.84 and 0.80 for
the SF-12 physical and mental scores, respectively, on a mixed sample of patients undergoing hip and knee
replacement surgery, comparing scores at 3 weeks and 1 week pre operation.78 Although these estimates
are not optimal (the ICC would preferably be estimated separately for hip and knee replacement surgery),
it is thought that they will be sufficiently close to be used to enable the respective MDCs to be calculated.
A previous study79 has reported ICCs of 0.73, 0.78 and 0.53 for WOMAC pain, physical function and
stiffness, respectively, at pre operation for patients undergoing THA. In this analysis, the MDCs were
calculated for the SF-12 physical and mental scores pre operation using the preoperative ICCs given
above.78
Minimally important change
Receiver operating characteristic minimally important change
The previous MIC approach can be modified by using ROC curve methodology (using the anchor definition
as the reference standard for an important change) in order to determine the optimal cut-point. The
optimal cut-point can be defined in various ways. In this analysis, Youden’s Index80 is used by maximising
(sensitivity + specificity – 1), and shortest distance by minimising:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1− sensitivity)2 + (1− specificity)2
q
. (3)
The area under the corresponding curve was calculated using a non-parametric ROC approach in Stata®
(roctab command) to generate an associated 95% CI.
Minimally important change (group)
The MIC can be calculated as the mean change score for patients who identify themselves as having a
‘minimal’ (e.g. ‘a little’) difference on a patient-reported global transition item (anchor). An anchor-based
MID was calculated using ‘somewhat satisfied’ versus ‘somewhat dissatisfied’ groups when there was no
neutral scale.
Minimally important change (effect size)
An ES for the MIC can be calculated as follows:
ES =
Mean ScoresBaseline somewhat satisfied−Mean ScoresPost somewhat satisfied
Pooled SD
, (4)
where pooled SD is:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(NBaseline somewhat satisfied−1) × SD2Baseline somewhat satisfied + (NPost somewhat satisfied−1) × SD
2
Post somewhat satisfied
NBaseline somewhat satisfied + NPost somewhat satisfied−2
s
, (5)
and SDs are group-specific SDs and Ns are study sample sizes. An ES of 0.5 has been proposed as an
estimate of a MIC; the MIC (ES).81 The MICs for health-related quality of life instruments have been noted
to be close to half a SD in other studies.77
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Minimally important difference
Minimally important difference (group)
The MID (group) can be calculated as the difference in the mean change score for patients who identify
themselves as having a ‘minimal’ difference (e.g. ‘a little better’) and those who identify themselves as
having no change (e.g. ‘about the same’) on a patient-reported global transition item (anchor). EPOS and
EUROHIP data sets both had a satisfaction Likert scale (Table 8). An anchor-based MID was calculated
using ‘somewhat satisfied’ versus ‘somewhat dissatisfied’ groups when there was no neutral scale.
Minimally important difference (effect size)
An ES estimate of the MID can be calculated using an anchor (e.g. satisfaction after the operation):
ES =
Mean Change ScoresPost somewhat satisfied −Mean Change ScoresPost somewhat dissatisfied
Pooled SD
, (6)
where pooled SD is:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(NPost somewhat satisfied−1) × SD2Post somewhat satisfied + (NPost somewhat dissatisfied−1) × SD
2
Post somewhat dissatisfied
NPost somewhat satisfied + NPost somewhat dissatisfied−2
,
s
(7)
and the SD is the group-specific SD and N is the study sample size.82 Half of a SD (ES approach) has been
proposed as an estimate of a MID.83 The MIDs for health-related quality of life instruments had previously
been suggested to be close to a half of a SD.84
Results
Internal consistency
Internal consistency results for hip and knee scores are shown in Table 9.
Hip
The internal consistency of all the instruments demonstrated that the total score can be adequately
considered as one scale for hip [except the preoperative EQ-5D-3L Index (Cronbach’s alpha = 0.66)], with
Cronbach’s alphas in the range of 0.88–0.89 and 0.93 at pre and post operation, respectively, for the OHS
and no improvement obtained by removal of any item. Likewise, no significant improvement was obtained
by removal of any item in the EQ-5D-3L index, SF-12 and WOMAC. Cronbach’s alpha values for each
individual item were similarly high and are provided in Appendix 1. The postoperation data set showed
slightly higher Cronbach’s alphas.
TABLE 8 Satisfaction at post operation: EUROHIP and EPOS data sets
Satisfaction
Data set
EUROHIP (12 months) EPOS (24 months)
n % n %
Very satisfied 165 68 829 79
Somewhat satisfied 59 24 167 16
Somewhat dissatisfied 13 5 39 4
Very dissatisfied 7 3 18 2
Total 244 100 1053 100
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Knee
The internal consistency of all of the instruments demonstrated that the total score can be adequately
considered as one scale for knee [except the preoperative EQ-5D-3L Index (Cronbach’s alpha = 0.55–0.66)
and the SF-12 (Cronbach’s alpha = 0.38 and 0.40 with KAT)], with Cronbach’s alphas in the range of 0.86
and 0.93 at pre and post operation, respectively, for the OKS and no improvement obtained by removal
of any item. No significant improvement was obtained by the removal of any item in the EQ-5D-3L index,
SF-12 and WOMAC. Alpha values for each individual item were similarly high and are provided in
Appendix 1. The postoperation data set showed slightly higher Cronbach’s alphas.
Construct validity
Construct validity results for hip and knee data sets are shown in Tables 10 and 11.
TABLE 9 Internal consistency at pre and post operation for hip and knee measurement tools
Measurement tool (total)
Time point
Pre operation Post operationa
n α n α
Hip
EQ-5D-3L index
APEX 302 0.66 266 0.82
EUROHIP 1228 0.66 883 0.81
SF-12
ADAPT 119 0.86 104 0.89
OHS
EPOS 1517 0.88 1239 0.93
EUROHIP 127 0.89 114 0.93
WOMAC
ADAPT 112 0.97 102 0.98
APEX 261 0.96 234 0.98
EUROHIP 1243 0.95 865 0.98
Knee
EQ-5D-3L index
APEX 298 0.66 261 0.80
KAT 2120 0.55 1939 0.79
SF-12a
ADAPT 116 0.81 96 0.89
KAT
Version 1 116 –0.40 –
Version 2 1791 0.38 –
OKS
KAT 2112 0.86 1691 0.93
WOMAC
ADAPT 118 0.96 102 0.98
ADAPT, Assessing Disability After Partial and Total Joint Replacement.
a In the KAT trial, version 2 was used for 2091 participants and version 1 was used for 126 participants.
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TABLE 10 Spearman’s correlations with 95% CIs at pre and post operation: hip
Comparator
Time point
Baseline 12 months
n Spearman’s correlation (95% CI) n Spearman’s correlation (95% CI)
EQ-5D index
APEX
WOMAC pain 301 0.59 (0.51 to 0.66) 262 0.67 (0.60 to 0.73)
WOMAC function 266 0.69 (0.62 to 0.75) 233 0.68 (0.60 to 0.74)
WOMAC stiffness 294 0.53 (0.44 to 0.61) 261 0.54 (0.44 to 0.62)
WOMAC total 259 0.70 (0.63 to 0.76) 228 0.70 (0.63 to 0.76)
EUROHIP
OHS 124 0.75 (0.66 to 0.82) 113 0.78 (0.70 to 0.84)
OHS function 128 0.71 (0.62 to 0.79) 114 0.78 (0.70 to 0.84)
OHS pain 130 0.70 (0.59 to 0.78) 119 0.62 (0.50 to 0.72)
SF-12 PCS
ADAPT
WOMAC total 118 0.57 (0.44 to 0.68) 75 0.70 (0.56 to 0.80)
WOMAC pain 118 0.45 (0.29 to 0.58) 75 0.71 (0.58 to 0.81)
WOMAC function 118 0.58 (0.45 to 0.69) 75 0.72 (0.59 to 0.82)
WOMAC stiffness 118 0.38 (0.21 to 0.52) 75 0.52 (0.33 to 0.67)
SF-12 MCS 118 –0.11 (–0.28 to 0.08) 75 –0.13 (–0.35 to 0.09)
SF-12 MCS
WOMAC total 118 0.28 (0.10 to 0.44) 75 0.18 (–0.05 to 0.39)
WOMAC pain 118 0.30 (0.12 to 0.45) 75 0.15 (–0.08 to 0.36)
WOMAC function 118 0.27 (0.09 to 0.43) 75 0.17 (–0.06 to 0.38)
WOMAC stiffness 118 0.24 (0.06 to 0.40) 75 0.24 (0.02 to 0.45)
SF-12 PCS 118 –0.11 (–0.28 to 0.08) 75 –0.13 (–0.35 to 0.09)
OHS
EPOS
SF-36 general health 1043 0.26 (0.21 to 0.32) 765 0.50 (0.44 to 0.55)
OHS function
SF-36 physical function 1042 0.71 (0.68 to 0.74) 773 0.79 (0.76 to 0.81)
SF-36 role physical 1038 0.37 (0.32 to 0.43) 785 0.63 (0.59 to 0.67)
SF-36 role emotional 1043 0.26 (0.20 to 0.31) 781 0.44 (0.38 to 0.49)
SF-36 pain 1048 0.65 (0.61 to 0.68) 800 0.65 (0.61 to 0.69)
SF-36 vitality 1033 0.42 (0.37 to 0.47) 780 0.60 (0.55 to 0.64)
SF-36 mental health 1034 0.30 (0.24 to 0.35) 780 0.41 (0.35 to 0.47)
SF-36 social function 1042 0.58 (0.54 to 0.62) 783 0.64 (0.58 to 0.67)
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TABLE 10 Spearman’s correlations with 95% CIs at pre and post operation: hip (continued )
Comparator
Time point
Baseline 12 months
n Spearman’s correlation (95% CI) n Spearman’s correlation (95% CI)
OHS pain
SF-36 physical function 1042 0.53 (0.49 to 0.58) 771 0.57 (0.52 to 0.62)
SF-36 role physical 1038 0.32 (0.26 to 0.37) 783 0.49 (0.43 to 0.54)
SF-36 pain 1048 0.69 (0.66 to 0.72) 800 0.61 (0.56 to 0.65)
WOMAC total
ADAPT
WOMAC pain 125 0.88 (0.83 to 0.91) 111 0.81 (0.74 to 0.87)
WOMAC function 125 0.99 (0.98 to 0.99) 111 0.97 (0.96 to 0.98)
WOMAC stiffness 125 0.85 (0.79 to 0.89) 111 0.74 (0.64 to 0.81)
SF-12 MCS 118 0.28 (0.10 to 0.44) 75 0.18 (–0.05 to 0.39)
SF-12 PCS 118 0.57 (0.44 to 0.68) 75 0.70 (0.56 to 0.80)
APEX
EQ-5D score 301 0.59 (0.51 to 0.66) 262 0.67 (0.60 to 0.73)
WOMAC function 269 0.77 (0.72 to 0.81) 241 0.70 (0.63 to 0.76)
WOMAC stiffness 299 0.63 (0.56 to 0.70) 264 0.58 (0.49 to 0.65)
WOMAC total 261 0.85 (0.81 to 0.88) 234 0.79 (0.74 to 0.84)
WOMAC function
EUROHIP
OHS function 115 0.84 (0.78 to 0.89) 114 0.85 (0.79 to 0.89)
WOMAC pain
EUROHIP
OHS pain 131 0.78 (0.70 to 0.84) 118 0.66 (0.54 to 0.75)
ADAPT, Assessing Disability After Partial and Total Joint Replacement.
TABLE 11 Spearman’s correlations with 95% CIs at pre and post operation: knee
Comparator
Time point
Baseline 12 months
n Spearman’s correlation (95% CI) n Spearman’s correlation (95% CI)
EQ-5D index
KAT
OKS 2073 0.70 (0.67 to 0.72) 1647 0.78 (0.76 to 0.80)
OKS function 2097 0.65 (0.63 to 0.68) 1702 0.74 (0.72 to 0.76)
OKS pain 2093 0.62 (0.59 to 0.65) 1857 0.74 (0.72 to 0.76)
SF-12 PCS 2055 0.43 (0.40 to 0.47) 1857 0.72 (0.70 to 0.74)
SF-12 MCS 2055 0.42 (0.38 to 0.45) 1857 0.46 (0.43 to 0.50)
continued
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TABLE 11 Spearman’s correlations with 95% CIs at pre and post operation: knee (continued )
Comparator
Time point
Baseline 12 months
n Spearman’s correlation (95% CI) n Spearman’s correlation (95% CI)
SF-12 PCS
ADAPT
WOMAC total 114 0.36 (0.19 to 0.51) 74 0.75 (0.64 to 0.84)
WOMAC pain 115 0.38 (0.21 to 0.52) 74 0.65 (0.49 to 0.76)
WOMAC function 115 0.35 (0.18 to 0.50) 74 0.74 (0.61 to 0.83)
WOMAC stiffness 115 0.20 (0.02 to 0.37) 74 0.57 (0.39 to 0.70)
SF-12 MCS 116 –0.36 (–0.51 to –0.19) 74 0.0 (–0.23 to 0.23)
KAT
OKS function 2062 0.50 (0.47 to 0.53) 1678 0.71 (0.68 to 0.73)
OKS pain 2066 0.50 (0.47 to 0.54) 1831 0.62 (0.59 to 0.65)
SF-12 MCS
ADAPT
WOMAC total 114 0.11 (–0.07 to 0.29) 74 0.25 (0.02 to 0.45)
WOMAC pain 115 0.02 (–0.16 to 0.21) 74 0.19 (–0.04 to 0.40)
WOMAC function 115 0.12 (–0.07 to 0.29) 74 0.26 (0.03 to 0.46)
WOMAC stiffness 115 0.19 (0.01 to 0.36) 74 0.23 (0.01 to 0.44)
SF-12 PCS 116 –0.36 (–0.51 to –0.19) 74 0 (–0.23 to 0.23)
KAT
OKS function 2062 0.41 (0.37 to 0.44) 1678 0.43 (0.39 to 0.47)
WOMAC total
ADAPT
WOMAC pain 126 0.86 (0.81 to 0.90) 110 0.92 (0.88 to 0.94)
WOMAC function 126 0.98 (0.97 to 0.98) 110 0.99 (0.98 to 0.99)
WOMAC stiffness 126 0.69 (0.59 to 0.77) 110 0.81 (0.73 to 0.87)
SF-12 MCS 114 0.11 (–0.07 to 0.29) 74 0.25 (0.02 to 0.45)
SF-12 PCS 114 0.36 (0.19 to 0.51) 74 0.75 (0.64 to 0.84)
APEX
EQ-5D index 244 0.72 (0.65 to 0.77) 209 0.80 (0.74 to 0.84)
WOMAC pain 246 0.85 (0.81 to 0.88) 214 0.89 (0.86 to 0.92)
WOMAC function 246 0.98 (0.98 to 0.99) 214 0.99 (0.98 to 0.99)
WOMAC stiffness 246 0.70 (0.63 to 0.76) 214 0.79 (0.73 to 0.84)
ADAPT, Assessing Disability After Partial and Total Joint Replacement.
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Hip
Construct validity (based on Spearman’s correlation) was generally supported with moderate to strong
correlations between the instruments, except for correlations involving the SF-12 PCS, SF-12 MCS and SF-36.
Correlations between the instruments at pre operation versus post operation were generally similar.
Knee
For the knee instruments, the pattern was broadly similar to the hip instruments. Construct validity (based
on Spearman’s correlation) was generally supported with moderate to strong correlations between the
instruments, except for correlations involving the SF-12 PCS and SF-12 MCS. Correlations between the
instruments at post operation tended to be higher than those at pre operation.
Responsiveness
Responsiveness results for hip and knee scores are shown in Tables 12 and 13, respectively.
Hip
Overall, correlations between the change scores of the instruments show a moderate (> 0.5) association,
except mainly for the correlations involving SF-12 MCS and PCS instruments. Some of the individual
EQ-5D-3L domains also had lower correlations. Pearson’s and Spearman’s correlations were similar.
TABLE 12 Spearman’s and Pearson’s correlations of change scores for hip measurement tools
Comparator n
Correlation (95% CI)
Spearman’s Pearson’s
EQ-5D-3L index
APEX
WOMAC pain 247 0.53 (0.44 to 0.62) 0.55 (0.46 to 0.63)
WOMAC function 198 0.58 (0.48 to 0.66) 0.59 (0.49 to 0.67)
WOMAC stiffness 243 0.46 (0.36 to 0.56) 0.48 (0.38 to 0.57)
WOMAC total 193 0.58 (0.48 to 0.67) 0.59 (0.49 to 0.67)
Change SF-12 PCS
ADAPT
SF-12 MCS 72 –0.27 (–0.47 to –0.04) –0.21 (–0.42 to 0.02)
WOMAC pain 72 0.47 (0.26 to 0.63) 0.44 (0.23 to 0.61)
WOMAC function 72 0.46 (0.25 to 0.62) 0.48 (0.28 to 0.64)
WOMAC stiffness 72 0.18 (–0.06 to 0.39) 0.22 (–0.01 to 0.43)
WOMAC total 72 0.45 (0.25 to 0.62) 0.47 (0.26 to 0.63)
Change SF-12 MCS
SF-12 PCS 72 –0.27 (–0.47 to –0.04) –0.21 (–0.42 to 0.02)
WOMAC pain 72 0.27 (0.04 to 0.47) 0.35 (0.13 to 0.54)
WOMAC function 72 0.24 (0.01 to 0.45) 0.31 (0.09 to 0.51)
WOMAC stiffness 72 0.34 (0.12 to 0.53) 0.33 (0.10 to 0.52)
WOMAC total 72 0.27 (0.04 to 0.47) 0.33 (0.11 to 0.52)
continued
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TABLE 12 Spearman’s and Pearson’s correlations of change scores for hip measurement tools (continued )
Comparator n
Correlation (95% CI)
Spearman’s Pearson’s
Change OHS
EPOS
SF-36 general health 739 –0.25 (–0.31 to –0.18) –0.27 (–0.34 to –0.20)
EUROHIP
EQ-5D-3L usual activities 113 0.44 (0.28 to 0.58) 0.44 (0.28 to 0.58)
EQ-5D-3L pain 113 0.58 (0.44 to 0.69) 0.57 (0.43 to 0.68)
EQ-5D-3L self-care 113 0.33 (0.15 to 0.48) 0.36 (0.18 to 0.51)
EQ-5D-3L index 110 0.57 (0.43 to 0.68) 0.56 (0.42 to 0.68)
WOMAC pain 110 0.63 (0.50 to 0.73) 0.60 (0.47 to 0.71)
EUROHIP
EQ-5D-3L index 107 0.54 (0.40 to 0.67) 0.53 (0.38 to 0.66)
WOMAC function 107 0.80 (0.71 to 0.86) 0.80 (0.72 to 0.86)
Change WOMAC total
ADAPT
SF-12 MCS 72 0.27 (0.04 to 0.47) 0.33 (0.11 to 0.52)
SF-12 PCS 72 0.45 (0.25 to 0.62) 0.47 (0.26 to 0.63)
WOMAC pain 110 0.89 (0.85 to 0.93) 0.89 (0.84 to 0.92)
WOMAC function 110 0.99 (0.99 to 0.99) 0.99 (0.99 to 0.99)
WOMAC stiffness 110 0.81 (0.74 to 0.87) 0.83 (0.77 to 0.88)
APEX
EQ-5D-3L index 193 0.58 (0.48 to 0.67) 0.59 (0.49 to 0.67)
WOMAC pain 200 0.79 (0.73 to 0.84) 0.84 (0.79 to 0.87)
WOMAC function 200 0.98 (0.97 to 0.99) 0.98 (0.98 to 0.99)
WOMAC stiffness 200 0.70 (0.62 to 0.76) 0.71 (0.63 to 0.77)
ADAPT, Assessing Disability After Partial and Total Joint Replacement.
TABLE 13 Spearman’s and Pearson’s correlations of change scores for knee measurement tools
Comparator n
Correlation (95% CI)
Spearman’s Pearson’s
Change EQ-5D-3L index
APEX
WOMAC pain 240 0.50 (0.40 to 0.59) 0.53 (0.43 to 0.62)
WOMAC function 180 0.53 (0.41 to 0.63) 0.56 (0.45 to 0.65)
WOMAC stiffness 233 0.50 (0.40 to 0.59) 0.53 (0.43 to 0.62)
WOMAC total 169 0.57 (0.46 to 0.67) 0.60 (0.49 to 0.69)
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TABLE 13 Spearman’s and Pearson’s correlations of change scores for knee measurement tools (continued )
Comparator n
Correlation (95% CI)
Spearman’s Pearson’s
KAT
OKS 1565 0.56 (0.52 to 0.59) 0.56 (0.53 to 0.60)
OKS function 1632 0.47 (0.43 to 0.51) 0.49 (0.45 to 0.53)
OKS pain 1784 0.55 (0.52 to 0.58) 0.55 (0.52 to 0.59)
SF-12 PCS 1749 0.41 (0.37 to 0.45) 0.42 (0.38 to 0.45)
SF-12 MCS 1749 0.24 (0.20 to 0.29) 0.27 (0.22 to 0.31)
Change SF-12 PCS
ADAPT
SF-12 MCS 65 0.04 (–0.20 to 0.28) 0.10 (–0.15 to 0.33)
WOMAC pain 65 0.56 (0.37 to 0.71) 0.56 (0.37 to 0.71)
WOMAC function 65 0.63 (0.45 to 0.76) 0.61 (0.43 to 0.75)
WOMAC stiffness 64 0.48 (0.26 to 0.65) 0.41 (0.18 to 0.59)
WOMAC total 64 0.64 (0.47 to 0.76) 0.62 (0.44 to 0.75)
KAT
OKS function 1581 0.54 (0.50 to 0.57) 0.55 (0.52 to 0.59)
OKS pain 1731 0.54 (0.50 to 0.57) 0.55 (0.52 to 0.58)
Change SF-12 MCS
ADAPT
SF-12 PCS 65 0.04 (–0.20 to 0.28) 0.10 (–0.15 to 0.33)
WOMAC pain 65 0.24 (–0.00 to 0.46) 0.28 (0.04 to 0.49)
WOMAC function 65 0.27 (0.03 to 0.49) 0.34 (0.10 to 0.54)
WOMAC stiffness 64 0.28 (0.03 to 0.49) 0.33 (0.09 to 0.53)
WOMAC total 64 0.28 (0.04 to 0.50) 0.34 (0.11 to 0.54)
KAT
OKS function 1581 0.27 (0.22 to 0.31) 0.30 (0.25 to 0.34)
Change WOMAC total
ADAPT
SF-12 MCS 64 0.28 (0.04 to 0.50) 0.34 (0.11 to 0.54)
SF-12 PCS 64 0.64 (0.47 to 0.76) 0.62 (0.44 to 0.75)
WOMAC pain 108 0.88 (0.83 to 0.92) 0.90 (0.86 to 0.93)
WOMAC function 108 0.98 (0.98 to 0.99) 0.99 (0.98 to 0.99)
WOMAC stiffness 108 0.74 (0.65 to 0.82) 0.73 (0.63 to 0.81)
APEX
EQ-5D-3L index 169 0.57 (0.46 to 0.67) 0.60 (0.49 to 0.69)
WOMAC pain 174 0.84 (0.79 to 0.88) 0.86 (0.82 to 0.90)
WOMAC function 174 0.98 (0.97 to 0.98) 0.98 (0.98 to 0.99)
WOMAC stiffness 174 0.74 (0.66 to 0.80) 0.77 (0.70 to 0.82)
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Knee
Overall, correlations between the change scores of the instruments show a moderate (> 0.5) association,
except for the correlations involving the SF-12, MCS and PCS instruments. Pearson’s and Spearman’s
correlations were similar.
Floor and ceiling effects
Floor and ceiling effect results for the hip and knee scores are shown in Tables 14 and 15, respectively.
TABLE 14 Floor and ceiling effects for hip measurement tools
Measurement tool
Time point
Pre operation Post operation
n Floor (%) Ceiling (%) n Floor (%) Ceiling (%)
EUROHIP
EQ-5D-3L index 1228 0.1 0.7 883 – 39.0
APEX
EQ-5D-3L index 302 0.0 1.3 266 0.0 46.2
ADAPT
SF-12 MCS 118 0.0 0.0 75 0.0 0.0
SF-12 PCS 118 0.0 0.0 75 0.0 0.0
EPOS
OHS total 1517 0.1 – 1239 – 19.1
OHS pain 1527 2.6 0.1 1247 – 33.8
OHS function 1520 0.3 0.1 1248 0.2 26.4
EUROHIP
OHS total 127 – – 114 – 14.0
OHS pain 133 3.8 – 120 – 35.8
OHS function 131 – – 115 – 19.1
ADAPT
WOMAC total 125 0 0 111 0 20.7
WOMAC pain 125 1.6 1.6 111 0 55.0
WOMAC function 125 0.8 1.6 111 0 24.3
WOMAC stiffness 125 4.8 4.8 111 0 53.2
APEX
WOMAC total 261 0.4 0 234 0 19.7
WOMAC pain 323 2.5 0.6 279 0 46.6
WOMAC function 270 0.7 0 242 0 27.7
WOMAC stiffness 300 4.3 3.3 268 0 44.8
EUROHIP
WOMAC total 1243 0.2 – 865 0.1 7.2
WOMAC pain 1255 1.0 0.2 875 0.1 33.3
WOMAC function 1266 5.9 1.6 888 0.5 26.6
WOMAC stiffness 1253 0.6 – 888 – 9.2
ADAPT, Assessing Disability After Partial and Total Joint Replacement.
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Hip
No floor effects were detected at pre operation for any of the instruments. Substantial ceiling effects were
noted at post operation only. This was particularly the case for the EQ-5D-3L index (39–46%), although all
instruments assessed mostly had a substantial proportion with the highest possible value. The minimum
ceiling effect was 7%, which was observed for the WOMAC total in the EUROHIP data set.
Knee
No floor effects were detected at pre operation for any of the instruments. Substantial ceiling effects were
noted, but to a lower extent than for hip data sets at post operation only for the EQ-5D-3L index and
WOMAC pain scores. Again, this was most strongly the case for the EQ-5D-3L index (25–30%).
Interpretability
Minimal detectable change (90% significance level)
Literature-based minimal detectable change
Minimal detectable change (90% significance) was calculated using the literature review ICC values
presented in Table 16. The SF-12 PCS, assuming an ICC of 0.84, had ± 7–8 MDC points. The MDC values
were 10–12 points for the SF-12 MCS with an ICC of 0.80 for hip and knee.78 MDC values for the WOMAC
pain, physical function and stiffness for hip and knee using ICCs of 0.73, 0.78 and 0.53, respectively, ranged
from 20–27, 20–27 and 23–39, respectively.79
TABLE 15 Floor and ceiling effects for knee measurement tools
Measurement tool
Time point
Pre operation Post operation
n Floor (%) Ceiling (%) n Floor (%) Ceiling (%)
APEX
EQ-5D-3L index 298 0 0.7 261 0.4 29.5
KAT
EQ-5D-3L index 2120 – 0.4 1939 – 25.4
SF-12 MCS 116 0 0 74 0 0
SF-12 PCS 116 0 0 74 0 0
KAT
OKS total 2112 0.1 – 1691 0.12 2.3
OKS pain 2132 0.1 0.1 1753 0.2 3.7
OKS function 2136 0.9 0.1 1906 0.1 17.0
ADAPT
WOMAC total 126 0.8 0.0 110 0.0 3.6
WOMAC pain 127 0.8 0.0 110 0.0 20.9
WOMAC function 127 0.8 0.0 110 0.0 9.1
WOMAC stiffness 127 3.9 2.4 110 0.9 17.3
APEX
WOMAC total 246 0.0 0.0 214 0.0 5.1
WOMAC pain 318 2.2 0.0 269 0.4 30.5
WOMAC function 253 0.0 0.0 224 0.0 9.4
WOMAC stiffness 293 2.7 1.0 260 0.8 17.3
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TABLE 16 Minimally detectable change (90%): literature-based ICCs for hip and knee measurement tools
Measurement tool
Pre operation
n ICC MDC 90%
Hip
ADAPT
SF-12 PCS 72 0.84 ±7.94
SF-12 MCS 72 0.80 ±9.55
ADAPT
WOMAC pain 110 0.73 ±26.60
WOMAC function 110 0.78 ±24.27
WOMAC stiffness 110 0.53 ±38.71
APEX
WOMAC pain 278 0.73 ±22.71
WOMAC function 209 0.78 ±20.64
WOMAC stiffness 255 0.53 ±36.60
EUROHIP
WOMAC pain 1255 0.73 ±21.55
WOMAC function 1253 0.53 ±26.67
WOMAC stiffness 1266 0.78 ±22.62
Knee
ADAPT
SF-12 PCS 65 0.84 ±6.67
SF-12 MCS 65 0.80 ±9.54
KAT
SF-12 PCS 2087 0.84 ±7.60
SF-12 MCS 2087 0.80 ±11.99
ADAPT
WOMAC pain 109 0.73 ±22.89
WOMAC function 109 0.78 ±19.87
WOMAC stiffness 108 0.53 ±32.34
APEX
WOMAC pain 269 0.73 ±20.20
WOMAC function 187 0.78 ±19.54
WOMAC stiffness 242 0.53 ±32.21
ADAPT, Assessing Disability After Partial and Total Joint Replacement.
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Minimal detectable change using assumed intracluster correlation coefficient values
Reported ICC values from previous studies reflect the limitations of those studies in terms of population
and precision. The arbitrary ICC figures of 0.5, 0.7 and 0.9 that were also used to calculate MDCs are
reported in Table 17 for hip and knee scores.
Hip
Using an ICC of 0.9 provided MDCs of 0.24 for the EQ-5D-3L index, 6 points for the OHS total score,
6 and 7 for the SF-12 PCS and MCS, respectively, and 12–16 points for the WOMAC total score across the
data sets. MDCs with ICCs of 0.5 and 0.7 were substantially larger, as would be anticipated.
TABLE 17 Minimally detectable change (90%): assumed ICC values for hip and knee measurement tools
Measurement tool
Pre operation
n
MDC (90%)
ICC 0.5 ICC 0.7 ICC 0.9
Hip
EUROHIP
EQ-5D-3L index 1228 ±0.54 ±0.42 ±0.24
APEX
EQ-5D-3L index 250 ±0.54 ±0.42 ±0.24
ADAPT
SF-12 PCS 72 ±14.04 ±10.87 ±6.28
SF-12 MCS 72 ±15.11 ±11.70 ±6.76
EPOS
OHS 1517 ±13.12 ±10.16 ±5.87
EUROHIP
OHS 127 ±13.10 ±10.15 ±5.86
ADAPT
WOMAC total 110 ±35.00 ±27.11 ±15.65
WOMAC pain 110 ±36.20 ±28.04 ±16.19
WOMAC function 110 ±36.59 ±28.34 ±16.36
WOMAC stiffness 110 ±39.92 ±30.92 ±17.85
APEX
WOMAC total 200 ±29.47 ±22.83 ±13.18
WOMAC pain 278 ±30.90 ±23.93 ±13.82
WOMAC function 209 ±31.11 ±24.10 ±13.91
WOMAC stiffness 255 ±37.75 ±29.24 ±16.88
EUROHIP
WOMAC total 1243 ±26.41 ±20.46 ±11.81
WOMAC pain 1255 ±29.33 ±22.72 ±13.12
WOMAC function 1253 ±27.51 ±21.31 ±12.30
WOMAC stiffness 1266 ±34.10 ±26.41 ±15.25
continued
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Knee
Using an ICC of 0.9 provided MDCs of 0.23 for the EQ-5D-3L index, 5 and 6 for the SF-12 PCS and MCS,
respectively, 6 points for the OKS total score and 13 for the WOMAC subscales across the data sets. MDCs
with assumed ICCs of 0.5 and 0.7 were substantially larger, as would be anticipated.
Minimally important change and minimally important difference
Hip
A suitable anchor was available in two data sets: EUROHIP (EQ-5D-3L, OHS and WOMAC) and EPOS (OHS)
and applied to the total score only. In EUROHIP, 244 patients answered for the satisfaction question after
operation for EUROHIP. Of these, 59 patients (24%) answered ‘somewhat satisfied’ and 13 patients
(5.3%) answered ‘somewhat dissatisfied’. These ‘somewhat satisfied’ versus ‘somewhat dissatisfied’
groups were used for the anchor-based analyses in this report when there was no neutral scale. In EPOS,
1053 patients answered the satisfaction question after operation. Of these, 167 patients (16%) answered
‘somewhat satisfied’ and 39 patients (4%) answered ‘somewhat dissatisfied’. These ‘somewhat satisfied’
versus ‘somewhat dissatisfied’ groups were used for the anchor-based analyses in this report.
TABLE 17 Minimally detectable change (90%): assumed ICC values for hip and knee measurement tools (continued )
Measurement tool
Pre operation
n
MDC (90%)
ICC 0.5 ICC 0.7 ICC 0.9
Knee
KAT
EQ-5D-3L index 2120 ±0.51 ±0.39 ±0.23
APEX
EQ-5D-3L index 248 ±0.51 ±0.39 ±0.23
KAT
SF-12 PCS 2087 ±13.43 ±10.40 ±6.01
SF-12 MCS 2087 ±18.96 ±14.68 ±8.48
ADAPT
SF-12 PCS 65 ±11.78 ±9.13 ±5.27
SF-12 MCS 65 ±15.08 ±11.68 ±6.74
KAT
OKS 2112 ±12.40 ±9.60 ±5.54
ADAPT
WOMAC total 108 ±28.68 ±22.22 ±12.83
WOMAC pain 109 ±31.15 ±24.13 ±13.93
WOMAC function 109 ±29.96 ±23.20 ±13.40
WOMAC stiffness 108 ±33.36 ±25.84 ±14.92
APEX
WOMAC total 174 ±27.06 ±20.96 ±12.10
WOMAC pain 269 ±27.49 ±21.29 ±12.29
WOMAC function 187 ±29.45 ±22.82 ±13.17
WOMAC stiffness 242 ±33.23 ±25.74 ±14.86
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CALCULATION OF MEASUREMENT PROPERTIES (WORK PACKAGE 1)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Figure 4 shows the EQ-5D-3L index ROC curve for the EUROHIP data. Table 18 gives the pre and post
operative values in accordance with the anchor, and Table 19 gives the area under the curve (AUC), MIC
(ROC), MIC (group), MIC (ES), MID (group) and MID (ES) estimates, along with the sensitivity and specificity
for the optimal cut-off point. The AUC was 0.69. The MIC ROC values were 0.07 for both the Youden
and the shortest distance methods. MIC (group) and MID (group) were much larger, at 0.36 and
0.28 points, respectively. The values for MIC (ES) and MID (ES) were both around 1.00.
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FIGURE 4 The EQ-5D-3L index: EUROHIP data set ROC curve.
TABLE 18 The EQ-5D-3L index by satisfaction for the EUROHIP data set
Score
Satisfaction
Somewhat satisfied Somewhat dissatisfied
n Mean score SD n Mean score SD
Preoperative 56 0.33 0.32 13 0.34 0.33
Postoperative 59 0.69 0.25 13 0.42 0.32
Change 56 0.36 0.29 13 0.08 0.33
Note
Change score was calculated as postoperative minus preoperative score.
TABLE 19 The EQ-5D-3L index MIC/MID by satisfaction for the EUROHIP data set
MIC
MID
Individual-level MIC (ROC analysis)
Scale MICAUC (95% CI) Optimal cut-off point Sensitivity 1 – specificity
0.69 (0.52 to 0.85)
Youden’s index 0.07 0.79 0.46 Group 0.36 0.28
Shortest distance 0.07 0.79 0.46 ES 1.26 0.97
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Owing to the low number of OHS observations in the EUROHIP data set (Table 20), in which the
satisfaction was ‘somewhat satisfied’ and ‘somewhat dissatisfied’, the MIC ROC was not calculated in this
report when there was no neutral scale.
Figure 5 shows the OHS ROC curve for the EPOS data set. Table 21 gives the pre and post operative values
in accordance with the anchor, and Table 22 gives the corresponding AUC, MIC (ROC), MIC (group), MIC
(ES), MID (group) and MID (ES) estimates, along with the sensitivity and specificity for the optimal cut-off
point. The AUC was 0.69. The MIC ROC values were 7 and 14 points for the Youden and shortest
distance methods, respectively. The MIC (group) was larger, at 16 points, but the MID (group) was similar,
at 6 points. The MIC (ES) and MID (ES) were 2 and 1, respectively.
TABLE 20 The total OHS, by satisfaction for the EUROHIP data set
Score
Satisfaction
Somewhat satisfied Somewhat dissatisfied
n Mean SD n Mean SD
Preoperative 11 14.36 3.61 3 13.33 10.50
Postoperative 11 30.50 7.99 4 26.50 3.32
Change 10 16.14 6.09 3 13.17 7.12
Note
Change score was calculated as postoperative minus preoperative score.
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FIGURE 5 The total OHS: EPOS data set ROC curve.
TABLE 21 The total OHS, by satisfaction for the EPOS data set
Score
Satisfaction
Somewhat satisfied Somewhat dissatisfied
n Mean SD n Mean SD
Preoperative 163 14.52 7.10 39 14.80 8.00
Postoperative 164 30.85 9.09 38 25.05 8.13
Change 163 16.33 8.16 39 10.25 8.06
Note
Change score was calculated as postoperative minus preoperative score.
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Figure 6 shows the WOMAC total ROC curve for the EUROHIP data. Table 23 gives the preoperative and
postoperative values in accordance with the anchor, and Table 24 gives the AUC, MIC (ROC), MIC (group),
MIC (ES), MID (group) and MID (ES) estimates, along with the sensitivity and specificity for the optimal
cut-off point. The AUC was 0.76. The MIC ROC optimal cut-off point was the same for the Youden and
shortest distance methods: 26 points. The MIC (group) and MID (group) were larger, at 31 and 19 points,
respectively. The MIC (ES) and MID (ES) were 2 and 1 points, respectively.
Knee
None of the available knee data sets had a suitable anchor for which interpretability properties could
be assessed.
TABLE 22 The total OHS MIC/MID, by satisfaction for the EPOS data set
MIC
MID
Individual-level MIC (ROC analysis)
Scale MIDAUC (95% CI) Optimal cut-off point Sensitivity 1 – specificity
0.69 (0.59 to 0.78)
Youden’s index 7 0.01 1 Group 16.33 6.08
Shortest distance 14 0.44 0.68 ES 2 0.75
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FIGURE 6 The total WOMAC score: EUROHIP data set ROC curve.
TABLE 23 The total WOMAC score, by satisfaction for the EUROHIP data set
Score
Satisfaction
Somewhat satisfied Somewhat dissatisfied
n Mean SD n Mean SD
Preoperative 58 63.37 14.41 13 61.23 13.33
Postoperative 58 32.10 18.63 13 48.64 20.55
Change 55 –31.27 16.60 13 –12.59 17.32
Note
Change score was calculated as postoperative minus preoperative score.
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Discussion
We calculated the measurement properties of the candidate scores using various statistical methods, using
multiple hip and knee replacement data sets for the candidate instruments. This enabled us to obtain
estimates for some of the properties for which population-specific estimates had not been previously
reported. Estimates for most of the missing measurement properties could be calculated given the
available data sets for the measurement tools of interest.
The OHS (EUROHIP and EPOS) and OKS (KAT) showed generally positive additional evidence regarding the
measurement properties (internal consistency, construct validity, responsiveness and interpretability). Similarly,
the WOMAC [ADAPT (Assessing Disability After Partial and Total Joint Replacement), the APEX study and
EUROHIP] showed generally positive additional evidence regarding the measurement properties. For the
SF-12 PCS and MCS, the evidence was more mixed and the lack of agreement between MCS and PCS was
noteworthy and, although perhaps unsurprising, is problematic in terms of use in the proposed context.
There was no sign of a flooring effect in any instruments. The OHS showed high ceiling effects at post
operation, whereas the OKS had a ceiling effect of only 2% at post operation. The high ceiling effects of
the OHS after the arthroplasty surgery could be examined in relation to patient-reported satisfaction and/or
assessments measuring success. The EQ-5D-3L index showed high ceiling effects for both hip and knee data
sets, in keeping with previous evidence.85 In respect of the systematic review, there is a substantial ceiling
effect for patient ratings in the EQ-5D-3L measurement tool. Different versions of SF-12 questionnaires
were used in different studies, illustrating how it can be difficult to obtain unified data sets for one
measurement tool. Further research is still required for responsiveness, between the generic questionnaires
[e.g. the EQ-5D-3L/EuroQol-5 Dimensions, five-level version (EQ-5D-5L) and SF-12] and disease-specific
questionnaires. Taken overall, there was generally a reasonable amount of positive evidence of the
measurement properties of the OHS, OKS and WOMAC.
Although the WOMAC physical function, pain and stiffness scales were reported as reliable in the
systematic review of measurement properties presented in Chapter 2, the pain scale was highly related
to physical function including item scales.86 In this study, we focused on the relationship between the
WOMAC total score and WOMAC subscales; further research may be required regarding the WOMAC
subscales and their use as instruments for developing thresholds. Measurement properties of the SF-12
PCS were more positive than the MCS, which is similar to some previous studies.87,88 Further research may
be required to clarify what values of the SF-12 MCS are plausible as thresholds for referral and candidacy
for the joint replacement surgery and the role, if any, it can play in this context.
The study had a number of limitations. Most important were the variations between available data sets in
terms of size and also the collection of relevant instruments and variables (e.g. anchor questions). Evidence
on a number of properties for a number of instruments is still lacking or limited. None of the data sets
was ideal and they only contained a subset of relevant instruments, which made comparison between
instruments difficult. For the WOMAC score, only relatively small data sets were available. Imbalance
TABLE 24 The total WOMAC score MIC/MID, by satisfaction for the EUROHIP data set
MIC
MID
Individual-level MIC (ROC analysis)
Scale MIDAUC (95% CI) Optimal cut-off point Sensitivity 1 – specificity
0.76 (0.62 to 0.90)
Youden’s Index 26 0.63 0.15 Group 31.27 18.68
Shortest distance 26 0.63 0.15 ES 1.88 1.13
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between data sets and outcomes collected makes direct comparison between the instruments very
problematic, and, therefore, we have restricted reporting to the individual properties as opposed to the
contrasting instruments. Similarly, the version of the instrument used varied and in some cases (e.g. the
EQ-5D-3L) a more recent version of the tool has been proposed (the EQ-5D-5L) for which no data sets
were available. The methods used to assess the measurement properties were relatively simplistic, although
commonly used in the literature and in general do not provide definitive answers, only suggestive findings.
Conclusion
From the data sets available, additional data on measurement properties were calculated for the EQ-5D-3L,
OHS, OKS, WOMAC, SF-12 (PCS and MCS) and SF-36. These results were added to the information
identified from the systematic review to produce a summary table of the measurement properties of each
of the 36 instruments originally identified. This additional information was used to update the summary
of instrument measurement property evidence produced as part of the systematic review in Chapter 2.
This updated summary, shown in Tables 25–28, was presented to the user group to inform the choice of
candidate instrument to take forward.
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TABLE 25 Psychometric and operational criteria tables: hip and knee instruments
Criteria
Instrument
HOOS HRQ PSI OHS
Knee disorders
subjective
history (VAS) KOOS KOOS-PS OKS OKS-APQ
LEFS
(h/k)
LEFS
(h)
LEFS
(K)
WOMAC
(h/k)
WOMAC
(h)
WOMAC
(K)
WOMAC
SF (h/k)
WOMAC
SF (h)
WOMAC
SF (k)
Number of studies 5 1 4 20 1 3 2 23 1 5 0 0 25 0 0
Reproducibility ++ + + ++ 0 + 0 +++ +++ + 0 0 ++ ++ + 0 0 0
Internal consistency + 0 0 +++ 0 0 +++ +++ +++ + 0 0 + +++ +++ + 0 0
Validity: content 0 0 ++ ++ + + + +++ +++ + 0 0 + + + + 0 0
Construct ++ + ++ +++ + + ++ +++ +++ ++ 0 0 +++ + ++ ++ 0 0
Responsiveness + + ++ +++ 0 0 ++ +++ +++ ++ 0 0 +++ ++ ++ + 0 0
Interpretability 0 0 0 +++ 0 0 0 ++ 0 + 0 0 ++ ++ ++ 0 0 0
Floor and ceiling/precision + 0 0 –/+ 0 + 0 ++ ++ 0 0 0 –/+ –/+ –/+ 0 0 0
Acceptability 0 0 0 +++ – 0 0 +++ +++ 0 0 0 ++ + + 0 0 0
Data accessible N N N Y N N N Y N N N N N N N N N N
0, not reported; –, no evidence in favour; +, some limited evidence in favour; ++, some good evidence in favour; +++, good evidence in favour; +/–, mixed evidence; h, hip; HOOS, Hip Disability and Osteoarthritis Outcome Score;
HRQ, Hip Rating Questionnaire; LEFS, Lower Extremity Functional Scale; k, knee; N, no; PSI, patient-specific index; VAS, visual analogue scale; Y, yes.
TABLE 26 Psychometric and operational criteria tables: lower-limb and pain instruments
Criteria
Instrument
Lower
limb core
score (h/k)
Lower
limb core
score (h)
Lower
limb core
score (k)
MODEMS-HK/
(AAOS) hip
and knee core
score (h/k)
MODEMS-HK/
(AAOS) hip
and knee
core score (h)
MODEMS-HK/
(AAOS) hip
and knee core
score (k) ICOAP (h/k) ICOAP (h) ICOAP (k) P4 (h/k) P4 (h) P4 (k)
McGill
Pain-SF (h/k)
McGill
Pain-SF (h)
McGill
Pain-SF (k)
Number of studies 1 0 0 1 0 0 2 0 0 1 0 0 2 0 0
Reproducibility 0 0 0 0 0 0 + 0 0 0 0 0 ++ 0 0
Internal consistency 0 0 0 0 0 0 + +++ +++ ++ 0 0 0 0 0
Validity: content + 0 0 + 0 0 ++ 0 0 + 0 0 0 0 0
Construct 0 0 0 + 0 0 + 0 0 + 0 0 + 0 0
Responsiveness 0 0 0 ++ 0 0 – 0 0 0 0 0 – 0 0
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Criteria
Instrument
Lower
limb core
score (h/k)
Lower
limb core
score (h)
Lower
limb core
score (k)
MODEMS-HK/
(AAOS) hip
and knee core
score (h/k)
MODEMS-HK/
(AAOS) hip
and knee
core score (h)
MODEMS-HK/
(AAOS) hip
and knee core
score (k) ICOAP (h/k) ICOAP (h) ICOAP (k) P4 (h/k) P4 (h) P4 (k)
McGill
Pain-SF (h/k)
McGill
Pain-SF (h)
McGill
Pain-SF (k)
Interpretability 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Floor and ceiling/
precision
0 0 0 ++ 0 0 0 – – 0 0 0 0 0 0
Acceptability 0 0 0 + 0 0 0 0 0 0 0 0 0 0 0
Data accessible N N N N N N N Y Y N N N N N N
0, not reported; –, no evidence in favour; +, some limited evidence in favour; ++, some good evidence in favour; +++, good evidence in favour; +/–, mixed evidence; AAOS, American Academy of Orthopaedic Surgeons; h, hip;
k, knee; MODEMS-HQ, Musculoskeletal Outcome Data Evaluation and Management System Hip and Knee Core Scale; N, no; SF, short form; Y, yes.
TABLE 27 Psychometric and operational criteria tables: utility and generic scores
Criteria
Instrument
SF-6D (h) SF-6D (k)
SF-6D
(h/k)
HUI2 and
HUI3 (h)
HUI2 and
HUI3 (h)
HUI2 and
HUI3 (h) EQ-5D (h/k) EQ-5D (h) EQ-5D (k) SF-36 (h/k) SF-36 (h) SF-36 (k) SF-12 (h/k) SF-12 (h) SF-12 (k) SIP (h) SIP (k) SIP (h/k)
Number of studies 1 0 0 4 0 0 9 14 3 2 0 0
Reproducibility 0 0 0 0 0 0 0 0 0 0 0 0 ++ 0 0 0 0 0
Internal consistency 0 0 0 0 0 0 N/A N/A N/A 0 0 – 0 +++ +++ 0 0 0
Validity: content 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 + 0 0
Construct 0 0 0 ++ 0 0 + – – + + + 0 + –/+ + 0 0
Responsiveness ++ 0 0 + 0 0 0 – – 0 +/– + 0 + –/+ – 0 0
Interpretability + 0 0 0 0 0 0 ++ ++ 0 + + 0 + + 0 0 0
Floor and ceiling/
precision
0 0 0 0 0 0 0 – + 0 – 0 +++ +++ +++ 0 0 0
Acceptability 0 0 0 0 0 0 0 0 ++ 0 0 0 0 0 0 0 0 0
Data accessible N N N N N N Y Y Y N Y N Y Y Y N N N
0, not reported; –, no evidence in favour; +, some limited evidence in favour; ++, some good evidence in favour; +++, good evidence in favour; +/–, mixed evidence; h, hip; k, knee; N, no; N/A, not applicable; SIP, sickness impact profile; Y, yes.
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TABLE 28 Psychometric and operational criteria tables: other instruments
Criteria
Instrument
WHOQOL-
BREF (h/k)
WHOQOL-
BREF (h)
WHOQOL-
BREF (k)
Aberdeen
IAP (h/k)
Aberdeen
IAP (h)
Aberdeen
IAP (k)
Aberdeen IAP
(modified)
(h/k)
Aberdeen IAP
(modified) (h)
Aberdeen IAP
(modified) (k)
NEADL
(h/k)
Number of
studies
1 0 0 1 0 0 1 0 0 0
Reproducibility 0 0 0 0 0 0 0 0 0 0
Internal
consistency
++ 0 0 + 0 0 ++ 0 0 0
Validity:
content
+ 0 0 + 0 0 0 0 0 0
Construct 0 0 0 + 0 0 + 0 0 0
Responsiveness + 0 0 0 0 0 0 0 0 0
Interpretability 0 0 0 0 0 0 0 0 0 0
Floor and
ceiling/
precision
++ 0 0 + 0 0 0 0 0 0
Acceptability 0 0 0 0 0 0 0 0 0 0
Data accessible N N N N N N N N N N
0, not reported; –, no evidence in favour; +, some limited evidence in favour; ++, some good evidence in favour; +++, good evidence in favour; +/–, mixed
evidence; Aberdeen IAP Impairment, Activity Limitation, and Participation Restriction; AQoL, Assessment of Quality of Life; h, hip; HAQ, Health Assessment
Questionnaire; k, knee; K10, The Kessler Psychological Distress Scale; MHAQ, Modified Health Assessment Questionnaire; MSK, musculoskeletal; N, no;
NEADL, Nottingham Extended Activities of Daily Living Scale; Y, yes.
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NEADL
(h)
NEADL
(k)
AQOL
(h/k)
AQOL
(h)
AQOL
(k)
MSK
Functional
Limitations
Index (h/k)
MSK
Functional
Limitations
Index (h)
MSK
Functional
Limitations
Index (k)
HAQ
(h/k)
HAQ
(h)
HAQ
(k)
MHAQ
(h/K)
MHAQ
(h)
MHAQ
(k)
K10
(h/k)
K10
(h)
K10
(k)
1 0 2 0 0 0 0 1 0 0 2 2 0 1 0 0
++ 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
++ 0 0 0 0 0 0 0 0 0 – 0 0 0 0 0 0
– 0 0 0 0 0 0 0 0 0 0 0 + 0 – 0 0
+ 0 + 0 0 0 0 + 0 0 ++ + + 0 + 0 0
– 0 ++ 0 0 0 0 0 0 0 – – + 0 – 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
+ 0 0 0 0 0 0 0 0 0 + ++ 0 0 ++ 0 0
0 0 0 0 0 0 0 + 0 0 0 0 0 0 0 0 0
N N N N N N N N N N N N N N N N N
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Chapter 4 Calculation of threshold values
(work package 2)
Background
The selected candidate tools are shown in Table 29. The OKS and OHS consist of 12 questions with
0–48 integer score ranges, with higher scores indicating better health status. The SF-12 has two component
scores: PCS, with a theoretical range of 4.3 to 76.4 (US version 2), and MCS, with a theoretical range of
–1.1 to 79.6 (US version 2), with higher scores also indicating better health status (see Appendix 2). The
WOMAC total score consists of 24 questions: the pain subsection has five questions, the physical function
subsection has 17 questions and the stiffness subsection has two questions (all have a score range of
0–100). The WOMAC scores were converted to higher scores indicating better health status. The KOOS-PS
consists of seven questions (score range of 0–100); no data were available for the KOOS-PS for evaluating in
this study.
Methods
Data sets
Multiple data sets were used to calculate the thresholds of individual candidate scores when possible
(Table 30). We used the 2012–15 web-based NHS PROMs data together with the KAT and EPOS data sets
for the analyses of the OHS and OKS, SF-12 PCS and MCS scores. The EUROHIP data set was used for
WOMAC scores. The ADAPT and APEX studies were used for the SF-12 PCS and MCS (ADAPT) scores and
TABLE 29 List of PROM candidate tools
Tool Subscale
Hip
OHS
Knee
KOOS-PS (no data)
OKS
Hip and knee
SF-12 PCS
MCS
WOMAC Total
Pain
Physical function
Stiffness
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the WOMAC scores (for both hip and knee) analyses. Postoperative scores were assessed at 6 months
post surgery for NHS PROMs; at 12 months for the KAT, EUROHIP, ADAPT and APEX studies; and at 2 years
for EPOS. The inclusion criterion was that patients had to have received primary knee or hip replacement
surgery (no revision). Cross-validation has been completed when multiple data sets were used for both
development and validation.
TABLE 30 The PROM of interest for hip and knee
PROM tool
Data set
1 2 3
Hip
OHS NHS PROMs EPOS –
SF-12
PCS ADAPT – –
MCS ADAPT – –
Total ADAPT APEX EUROHIP
WOMAC
Pain ADAPT APEX EUROHIP
Physical function ADAPT APEX EUROHIP
Stiffness ADAPT APEX EUROHIP
KOOS-PS (no data) – – –
Knee
OKS NHS PROMs KAT –
SF-12 PCS KAT ADAPT
MCS KAT ADAPT
Total ADAPT APEX
WOMAC Pain ADAPT APEX
Physical function ADAPT APEX
Stiffness ADAPT APEX
KOOS-PS (no data) – – –
Notes
KAT: SF-12 version 2 is majority; version 2, n= 2091; version 1, n = 126 (US weighing was used for UK wording for SF-12
version 2).
ADAPT: SF-12 version 1 with US weighting.
The numbers of observation available in each data set for each instrument were:
l NHS PROMs – OHS (n = 102,404) and OKS (n= 108,832).
l KAT – OKS (n = 1634) and SF-12 (n= 1518).
l EPOS – OHS (n= 1179).
l EUROHIP – WOMAC total (n= 845), pain (n= 865), physical function (n= 874) and stiffness (n= 883).
l APEX – WOMAC total (n = 200 for hip and 174 for knee), pain (n= 278 for hip and 269 for knee), physical function
(n= 209 for hip and 187 for knee) and stiffness (n= 255 for hip and 242 for knee).
l ADAPT – WOMAC total (n= 110 for hip and 108 for knee), pain (n = 110 for hip and 109 for knee), physical function
(n= 110 for hip and 109 for knee) and stiffness (n= 110 for hip and 108 for knee) and SF-12 (n= 72 for hip and
65 for knee).
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Improvement criteria
Patient benefit can be defined in various ways. We restricted the definition in this study to improvement and
used approaches that were applicable to all candidate scores (limited by data; see Online Supplement 2).
Four definitions of improvement were applied:
(A) any increase after surgery from before surgery (change score of > 0)
(B) medium ES (0.5) × SD of change score (MCID)
(C) minimal detectable change (MDC90 and ICC of 0.7)
(D) minimal detectable change (MDC90 and ICC of 0.9).
In this study, the MCID is derived from the assumption that the mean change score needed to obtain a
medium or large ES to be clinically meaningful.89 Clinically meaningful refers to a change indicating the
efficacy of an intervention (i.e. hip and knee replacement surgery in this study) in domains of health-
related functional status tools.90 For clinical evaluation studies such as this one, the usefulness of the
measurement candidate tools will depend on their ability to detect a change that is clinically meaningful.90
Applying a 0.5 ES (medium/moderate practical importance), classified by Cohen,73 using the variability of
the change scores is ideal in this context. It was calculated using the SD of the change score of the
candidate tools multiplied by the medium ES (i.e. 0.5 × the SD of the change score (b). For the remainder
of this chapter, results based on criterion B are presented.
The MDC was defined as the minimal change that falls beyond the measurement error in the score of a
candidate tool measuring a symptom.91 In this study, the fixed (arbitrary) reliability parameter (e.g. test–retest
reliability or ICC) values of 0.7 and 0.9 were applied. We applied the 90% confidence level with z-distribution
(z-statistics value of 1.645), a range for the possible difference between the two observations under the same
conditions (test–retest scenario) to define the MDC as ± 1.645 ×√2 × SE of the measurement, where the SE
of the measurement is defined as the SD of the preoperative score ×√((1 – R)) and R is the reliability parameter
of 0.7 and 0.9 (improvement criteria C and D).92 Stata® version 14 was used for all statistical analyses.
Statistical analysis
Absolute threshold
We estimated an absolute threshold in the preoperative score, using each data set above, at a level in
which an individual could not improve. We examined the theoretical thresholds for the different definitions
of improvement (B, C and D) with the method of subtracting each improvement score from the maximum
possible score of the candidate tools. The specificity (i.e. true negative) of each threshold was calculated
for all data sets. Sensitivity was 100% by definition.
Relative threshold
We calculated the preoperative value (relative threshold) in which individuals are more likely to improve
than in others, using each improvement criterion (A–D). We used two modelling approaches and assessed
model properties for the four different definitions of improvement (A–D).
Linear regression
Linear regressions including the best-fit third-degree polynomials of the change score (postoperative to
preoperative score) were used to estimate at what preoperative score the predicted change is likely to fall
below each criterion.
The equation of the linear regression is:
y^1 = β0 + β1xi + β2x
2
i + β3x
3
i + ei, (8)
where y^1 = (y1−x1) and ei ∼ N(0, σ2), and y1 and x1 indicate the postoperative and preoperative scores for
the ith observation, respectively.
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Logistic regression
Logistic regressions with dichotomised change score (postoperative to preoperative score) by each
improvement criterion were used to estimate the preoperative score at which the probability of improving
fell below 50% and 75%.
ln
pi
1−pi
 
= β0 + β1xi + β2x
2
i + β3x
3
i , (9)
where p is the probability that p^ of improved/N of preoperative score, yi ∼ B(ni, p), and yi and xi indicate
the postoperative and preoperative scores for the ith observation, respectively.
Model performance for the relative threshold
The area under the ROC curve with 95% binomial exact CIs was calculated to examine discriminative
ability with each improvement criterion using the observed (rather than estimated) postoperative score.
In addition, goodness of fit incorporated inspection using plots of observed versus fitted values, plots of
residuals versus fitted values and mean/SD of residuals by decile (or quintile). The predictive models’
performance for the logistic regression was assessed using calibration graphs: an illustration of the
Hosmer–Lemeshow goodness-of-fit test, by decile (or quintile) of the predicted probabilities.93
Threshold reporting
Thresholds for the OHS, OKS, SF-12 and WOMAC were reported, always rounding up the estimated value
(e.g. 89.1 to 90.1) to avoid excluding any individuals who can benefit through rounding down. Sensitivity
and specificity values were calculated using these thresholds and rounded to the nearest integer except
when < 1%.
Percentages of population coverage
Percentages of study population coverage, which is the cumulative percentage up to the estimated
absolute and relative thresholds and indicates the percentage of those who achieved the improvements,
were calculated for each data set.
Results
Characteristics of the data sets
The mean ages of participants were 65–70 years (SD 8–14 years), the mean body mass index (BMI) values
were 27–32 kg/m2 (SD 4–6 kg/m2) and the percentage of females was between 52% and 62% (Table 31).
Minimally clinically important difference and minimally detectable change (90%) values
Hip
The MCID was 5 (range 5.0–5.1) units for the OHS; 5.4 and 4.5 for the SF-12 PCS and MCS, respectively;
and 9.5–11.1 for the WOMAC total score across the data sets. Using an ICC of 0.9 provided MDCs of 6
(range 5.9–6.0) units for the OHS; 6.3 and 6.8 for the SF-12 PCS and MCS, respectively; and 11.8–15.7 for
the WOMAC total score (Table 32).
Knee
The MCID was 5 (range 4.9–5.1) units for the OKS, 5.3–5.4 for the SF-12 PCS, 4.6–5.8 for the SF-12 MCS,
and 9.8–10.0 for the WOMAC total score. Using an ICC of 0.9 provided MDCs of 6 (range 5.5–5.7) units
for the OKS; 5.3–6.0 and 6.7–8.5 for the SF-12 PCS and MCS, respectively; and 12.1–12.8 for the
WOMAC total score (see Table 32).
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TABLE 31 Data set descriptive statistics
Characteristic
Data set
NHS PROMsa KAT EPOS EUROHIP ADAPT APEX
Hip Knee Knee Hip Hip Hip Knee Hip Knee
Age (years)
n 95,890 103,519 1634 1580 1298 125 128 343 339
Mean – – 69.8 68.3 65.7 64.5 66.6 67.0 69.8
SD (< 60%) 13.7 9.5 8.1 10.8 10.9 11.7 9.7 11.0 8.6
IQR: 25 (60–80%) 73.2 78.3 65.0 62.6 59.0 57 60.1 60.0 63.3
IQR: 75 (≥ 80%) 13.1 12.2 76.0 75.8 73.8 72.5 73.5 75.0 75.9
BMI (kg/m2)
n – – 1584 1487 1225 130 132 338 334
Mean – – 29.7 27.2 27.5 27.5 31.5 29.0 32.4
SD – – 5.5 4.9 4.4 4.4 5.9 5.5 6.4
IQR: 25 – – 26.1 24.1 24.5 24.5 27.5 26.0 27.9
IQR: 75 – – 32.5 30.0 29.8 29.8 35.3 32.0 36.1
Sex
n 95,816 103,412 1634 1581 1267 130 132 343 339
Female (%) 61.4 58.3 55.9 62.2 55.9 49.2 53.0 59.0 52.2
Male (%) 38.7 41.8 44.1 37.8 44.1 50.8 47.0 41.0 47.8
IQR, interquartile range.
a 10-year age category band information was obtained from NHS PROMs.
TABLE 32 The MCID and MDC 90% for hip and knee data sets
Data set
Candidate tools
OKS OHS
SF-12 WOMAC
PCS MCS Total Pain Function Stiffness
K H K H K H K H K H K H K H
PROMs
MCID 0.5 SD 4.9 5
MDC (±)
L
F
0.7 9.8 10.3
0.9 5.7 6
KAT
MCID 0.5 SD 5.1 5.4 5.8
MDC (±)
L 7.6 12
F
0.7 9.6 10 15
0.9 5.5 6 8.5
continued
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Percentage of population improving
Using the MCID 0.5 improvement criterion B, the OHS shows a 94% improvement and the OKS shows an
85–88% improvement. The WOMAC total scores show an 84–86% improvement for hip score and a
75–88% improvement for knee score (Tables 33 and 34). The SF-12 has some theoretically possible scores,
which are unrealistic to obtain from the postoperative quality-of-life or health status outcome.
TABLE 32 The MCID and MDC 90% for hip and knee data sets (continued )
Data set
Candidate tools
OKS OHS
SF-12 WOMAC
PCS MCS Total Pain Function Stiffness
K H K H K H K H K H K H K H
EPOS
MCID 0.5 SD 5.1
MDC (±)
L
F
0.7 10
0.9 5.9
EUROHIP
MCID 0.5 SD 10.7 11.6 10.9 14.3
MDC (±)
L 21.6 18.3 33.1
F
0.7 20.5 22.7 21.3 26.4
0.9 11.8 13.1 12.3 15.3
ADAPT
MCID 0.5 SD 5.3 5.4 4.6 4.5 10 11.1 11.2 10.9 10.2 11.7 12.6 12.5
MDC (±)
L 6.7 7.9 9.5 9.6 22.9 26.6 19.9 24.3 32.3 38.7
F
0.7 9.1 10.9 11.7 11.7 22.2 27.1 24.1 28 23.2 28.3 25.8 11.7
0.9 5.3 6.3 6.7 6.8 12.8 15.7 13.9 16.9 13.4 16.4 14.9 6.8
APEX
MCID 0.5 SD 9.8 9.5 10.5 11 9.9 10.4 12.7 12.3
MDC (±)
L 20.2 22.7 19.5 20.6 32.2 36.6
F
0.7 21 22.8 21.3 23.9 22.8 24.1 25.7 29.2
0.9 12.1 13.2 12.3 13.8 13.2 13.9 14.9 16.9
F, fixed/arbitrary ICC-based calculation; H, hip; K, knee; L, literature ICC-based calculation.
Notes
Literature ICC: SF-12 PCS ± 0.841 and MCS± 0.81.78
Literature ICC: WOMAC pain ± 0.732, pain and function± 0.782, and stiffness ± 0.532.79
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TABLE 33 Percentage of the population improving, by the improvement criteria: hip
Candidate tools
Data sets
PROMs EPOS EUROHIP ADAPT APEX
n
Improvement
criteria
n
Improvement
criteria
n
Improvement
criteria
n
Improvement
criteria
n
Improvement
criteria
A B C D A B C D A B C D A B C D A B C D
OHS 102,404 97 94 86 93 1179 98 94 90 94
SF-12
PCS 118 86 65 49 61
MCS 118 47 26 15 21
WOMAC
Total 845 93 86 76 85 125 96 84 56 75 261 98 95 87 95
Pain 865 93 83 72 83 125 96 87 61 76 323 97 94 86 94
Physical function 874 93 85 73 84 125 95 81 55 69 270 97 94 82 94
Stiffness 883 71 53 71 83 125 96 89 56 73 300 98 89 60 77
A, any increase after surgery from before surgery (change score of > 0); B, medium ES (0.5) × SD of change score (MCID); C, minimal detectable change (MDC90 and ICC of 0.7);
D, minimal detectable change (MDC90 and ICC of 0.9).
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TABLE 34 Percentage of the population improving, by the improvement criteria: knee
Candidate tools
Data sets
PROMs KAT ADAPT APEX
n
Improvement criteria
n
Improvement criteria
n
Improvement criteria
n
Improvement criteria
A B C D A B C D A B C D A B C D
OHS 108,832 94 88 76 86 1634 91 85 74 85
SF-12
PCS 1518 60 46 62 80 127 77 51 40 51
MCS 1518 54 33 12 25 127 55 35 12 22
WOMAC
Total 126 90 75 52 69 246 93 88 73 86
Pain 127 93 82 59 82 318 97 89 78 89
Physical function 127 88 78 47 63 253 93 86 70 82
Stiffness 127 91 64 36 64 293 94 67 45 67
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Absolute threshold using criterion B
In this section, results based on improvement in criterion B are provided (see Online Supplement 3 for
results based on the other criteria). Tables 35 and 36 describe the absolute threshold with specificity
(95% CIs) and the study population coverage (%) by the thresholds for hips and knees, respectively.
Hip
The absolute threshold was 43 for the OHS. The preoperative scores of the SF-12 PCS and MCS were
66 and 65, respectively. We found the threshold range of scores to be 89–91 for the WOMAC total,
89–90 for the WOMAC pain, 89–90 for the WOMAC physical function and 86–88 for the WOMAC
stiffness. Study population coverages were 100% for the OHS and SF-12 and ≥ 94% for the WOMAC
(see Table 35).
Knee
The absolute threshold was 43 for the OKS. The ranges of the preoperative scores for the SF-12 PCS
and MCS were 66–71 and 65–74, respectively. The threshold range was 90–91 for the WOMAC total,
89–90 for the WOMAC pain, 90–91 for the WOMAC physical function and 88 for the WOMAC stiffness.
The study population coverages were 100% for the OHS and SF-12 and ≥ 98% for the WOMAC
(see Table 36).
TABLE 35 Hip: absolute threshold using criterion B
Candidate tools Preoperative threshold Specificity (%) (95% CI) Population coverage (%)
OHS
NHS PROMs 43 2 (1 to 2) 100
EPOS 43 2 (< 0.1 to 9) 100
SF-12 PCS
ADAPT 66 0 (0 to 14) 100
SF-12 MCS
ADAPT 65 0 (0 to 7) 100
WOMAC total
ADAPT 89 22 (6 to 48) 96
APEX 91 0 (0 to 31) 100
EUROHIP 90 0 (0 to 2) 100
WOMAC pain
ADAPT 90 21 (5 to 51) 96
APEX 89 18 (4 to 43) 99
EUROHIP 89 4.2 (1 to 9) 100
WOMAC physical function
ADAPT 89 33 (15 to 57) 94
APEX 90 17 (2 to 48) 99
EUROHIP 90 0.8 (0.0 to 5) 100
WOMAC stiffness
ADAPT 88 42 (15 to 72) 95
APEX 88 29 (13 to 49) 97
EUROHIP 86 8.1 (5 to 12) 99
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Relative threshold using criterion B
Tables 37 and 38 show the relative threshold with sensitivity and specificity (95% CIs) (see Online
Supplement 4 for full results) and the study population coverage (%) by each threshold. The AUC (95% CI)
for the OHS, OKS, SF-12 PCS and WOMAC total showed poor (< 0.7) discrimination abilities overall.
Hip
The range of relative thresholds was 38–43 with specificity of 2–6 for the OHS. A histogram of the
preoperative OHS distribution for the NHS PROMs data sets is given in Figure 7. Threshold ranges of the SF-12
PCS and MCS were 35–47 (specificity 20–48%) and 37–42 (specificity 91–100%), respectively. The threshold
ranges were 78–87 (specificity 1–56%) for the WOMAC total, 78–89 (specificity 4–36%) for the WOMAC
pain, 78–88 (specificity 3–52%) for the WOMAC physical function and 36–91 (specificity 20–50%, EUROHIP
81) for the WOMAC stiffness. Study population coverages for the thresholds of a 50% probability level
were 100% for the OHS, 19% for the SF-12 PCS, 92% for the SF-12 MCS and 91–100% for the WOMAC.
Figures 8 and 9 give the linear regression model, absolute threshold and logistic regression model estimates.
The CI bands (see Figure 8) show the lack of fit for the variation in the OHS outcome for the linear model,
although the point estimate seems reasonable. Linear regression models for the other outcomes (not shown)
showed a similar lack of fit.
TABLE 36 Knee: absolute threshold using criterion B
Candidate tools Preoperative threshold Specificity (%) (95% CI) Population coverage (%)
OKS
NHS PROMs 43 0.5 (0.4 to 0.7) 100
KAT 43 0.9 (0.1 to 3) 100
SF-12 PCS
ADAPT 66 0 (0 to 11) 100
KAT 71 0 (0 to 1) 100
SF-12 MCS
ADAPT 65 2 (0 to 13) 100
KAT 74 0.3 (0.1 to 0.9) 100
WOMAC total
ADAPT 90 7 (1 to 24) 100
APEX 91 0 (0 to 16) 100
WOMAC pain
ADAPT 89 5 (0 to 25) 100
APEX 90 0 (0 to 12) 100
WOMAC physical function
ADAPT 90 8 (1 to 27) 99
APEX 91 7 (1 to 24) 100
WOMAC stiffness
ADAPT 88 8 (2 to 21) 98
APEX 88 3 (0 to 9) 99
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TABLE 37 Hip: relative threshold using criterion B
Candidate tools Probability level
Preoperative
threshold
Specificity (%)
(95% CIs) AUC (95% CI)
Population
coverage (%)
OHS
NHS PROMs
Model 1 40 4 (4 to 5) 100
Model 2 0.5 43 2 (1 to 2) 0.65 (0.65 to 0.66) 100
0.75 38 6 (6 to 7) 99
EPOS
Model 1 40 3 (0 to 12) 100
Model 2 0.5 42 2 (0 to 9) 0.62 (0.59 to 0.64) 100
0.75 39 3 (0 to 12) 99
SF-12 PCS
ADAPT
Model 1 46 24 (9 to 45) 91
Model 2 0.5 47 20 (7 to 41) 0.58 (0.46 to 0.7) 92
0.75 35 48 (28 to 69) 70
SF-12 MCS
ADAPT
Model 1 42 91 (79 to 97) 26
Model 2 0.5 39 96 (87 to 100) 0.93 (0.85 to 0.98) 19
0.75 37 100 (93 to 100) 16
WOMAC total
ADAPT
Model 1 81 50 (26 to 74) 90
Model 2 0.5 85 44 (22 to 69) 0.76 (0.67 to 0.84) 94
0.75 78 56 (31 to 78) 86
APEX
Model 1 86 20 (3 to 56) 99
Model 2 0.5 86 20 (3 to 56) 0.61 (0.53 to 0.67) 99
0.75 82 20 (3 to 56) 98
EUROHIP
Model 1 83 3 (1 to 8) 99
Model 2 0.5 87 1 (0 to 5) 0.56 (0.53 to 0.59) 100
0.75 80 4 (1 to 9) 99
WOMAC pain
ADAPT
Model 1 83 36 (13 to 65) 94
Model 2 0.5 89 36 (13 to 65) 0.66 (0.57 to 0.75) 96
0.75 82 36 (13 to 65) 94
continued
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TABLE 37 Hip: relative threshold using criterion B (continued )
Candidate tools Probability level
Preoperative
threshold
Specificity (%)
(95% CIs) AUC (95% CI)
Population
coverage (%)
APEX
Model 1 83 18 (4 to 43) 99
Model 2 0.5 88 18 (4 to 43) 0.65 (0.59 to 0.7) 99
0.75 83 18 (4 to 43) 99
EUROHIP
Model 1 84 6 (3 to 12) 99
Model 2 0.5 89 4 (2 to 9) 0.58 (0.55 to 0.62) 100
0.75 78 8 (4 to 14) 98
WOMAC physical function
ADAPT
Model 1 81 48 (26 to 70) 86
Model 2 0.5 86 43 (22 to 66) 0.82 (0.73 to 0.89) 91
0.75 78 52 (30 to 74) 82
APEX
Model 1 86 17 (2 to 48) 99
Model 2 0.5 88 17 (2 to 48) 0.65 (0.58 to 0.72) 99
0.75 83 17 (2 to 48) 99
EUROHIP
Model 1 82 5 (2 to 10) 99
Model 2 0.5 86 3 (1 to 8) 0.55 (0.52 to 0.58) 100
0.75 79 7 (3 to 13) 99
WOMAC stiffness
ADAPT
Model 1 82 50 (21 to 79) 95
Model 2 0.5 91 42 (15 to 72) 0.81 (0.72 to 0.88) 100
0.75 86 50 (21 to 79) 95
APEX
Model 1 82 32 (16 to 52) 97
Model 2 0.5 90 29 (13 to 49) 0.77 (0.71 to 0.82) 100
0.75 83 32 (16 to 52) 97
EUROHIP
Model 1 65 20 (15 to 25) 98
Model 2 0.5 67 20 (15 to 25) 0.71 (0.68 to 0.74) 98
0.75 36 81 (75 to 85) 61
Notes
Model 1= linear regression.
Model 2= logistic regression.
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TABLE 38 Knee: relative threshold using criterion B
Candidate tools Probability level
Preoperative
threshold
Specificity (%)
(95% CI) AUC (95% CI)
Population
coverage (%)
OKS
NHS PROMs
Model 1 37 4 (4 to 5) 99
Model 2 0.5 40 2 (2 to 2) 0.62 (0.61 to 0.62) 100
0.75 33 11 (10 to 11) 96
KAT
Model 1 35 5 (3 to 9) 98
Model 2 0.5 39 3 (1 to 6) 0.62 (0.60 to 0.65) 100
0.75 29 14 (10 to 20) 93
SF-12 PCS
ADAPT
Model 1 36 25 (11 to 43) 87
Model 2 0.5 34 31 (16 to 50) 0.64 (0.5 to 0.75) 78
0.75 – – –
KAT
Model 1 39 27 (23 to 31) 86
Model 2 0.5 43 16 (13 to 19) 0.65 (0.63 to 0.68) 92
0.75 22 94 (92 to 96) 13
SF-12 MCS
ADAPT
Model 1 40 93 (81 to 99) 22
Model 2 0.5 49 74 (58 to 86) 0.81 (0.7 to 0.9) 51
0.75 34 100 (92 to 100) 8
KAT
Model 1 43 85 (83 to 88) 28
Model 2 0.5 49 72 (69 to 75) 0.78 (0.75 to 0.80) 45
0.75 26 100 (99 to 100) 2
WOMAC total
ADAPT
Model 1 86 7 (1 to 24) 100
Model 2 0.5 81 15 (4 to 34) 0.55 (0.46 to 0.65) 97
0.75 71 19 (6 to 38) 92
APEX
Model 1 81 10 (1 to 30) 99
Model 2 0.5 85 5 (0 to 24) 0.60 (0.53 to 0.68) 100
0.75 75 10 (1 to 30) 97
continued
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TABLE 38 Knee: relative threshold using criterion B (continued )
Candidate tools Probability level
Preoperative
threshold
Specificity (%)
(95% CI) AUC (95% CI)
Population
coverage (%)
WOMAC pain
ADAPT
Model 1 78 5 (0 to 25) 98
Model 2 0.5 82 5 (0 to 25) 0.56 (0.46 to 0.65) 100
0.75 71 10 (1 to 32) 98
APEX
Model 1 81 0 (0 to 12) 100
Model 2 0.5 – – 0.59 (0.53 to 0.65) –
0.75 85 0 (0 to 12) 100
WOMAC physical function
ADAPT
Model 1 87 13 (3 to 32) 98
Model 2 0.5 89 8 (1 to 27) 0.47 (0.37 to 0.57) 99
0.75 82 13 (3 to 32) 96
APEX
Model 1 82 15 (4 to 34) 98
Model 2 0.5 86 11 (2 to 29) 0.62 (0.55 to 0.69) 99
0.75 75 19 (6 to 38) 94
WOMAC stiffness
ADAPT
Model 1 72 18 (8 to 34) 97
Model 2 0.5 65 18 (8 to 34) 0.69 (0.59 to 0.77) 97
0.75 24 97 (87 to 100) 24
APEX
Model 1 68 28 (18 to 39) 97
Model 2 0.5 65 28 (18 to 39) 0.71 (0.65 to 0.77) 97
0.75 34 86 (76 to 93) 58
–, could not get the estimation.
Notes
Model 1= linear regression.
Model 2= logistic regression.
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Knee
The range of the relative (observed) threshold was 29–40 with a specificity of 2–14 for the OKS. A histogram
of the preoperative OHS distribution for the NHS PROMs data sets is given in Figure 10. Threshold ranges of
the preoperative score of the SF-12 PCS and MCS were 22–43 (specificity 16–31%, KAT 94) and 26–49
(specificity 72–100%), respectively. The threshold ranges were 71–86 (specificity 5–19%) for the WOMAC
total, 71–85 (specificity 0–10%) for the WOMAC pain, 75–89 (specificity 8–19%) for the WOMAC physical
function and 24–72 (specificity 18–28%, ADAPT 97 and APEX 86) for the WOMAC stiffness. Study population
coverages for the thresholds of a 50% probability level were 100% for the OHS, 78–92% for the SF-12 PCS,
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FIGURE 7 The OHS: NHS PROMs preoperative histogram with the absolute and linear relative thresholds using
criterion B.
48
36
24
12
C
h
an
g
e 
sc
o
re
 (
p
o
st
 –
 p
re
)
5
0
0 5 10 15 20 25 30 35 40 45 48
Preoperative score
FIGURE 8 The OHS: NHS PROMs change scores.
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45–51% for the SF-12 MCS and 97–100% for the WOMAC. Figures 11 and 12 give the linear regression
model, absolute threshold and logistic regression model estimates. The CI bands (see Figure 11) show the
lack of fit for the variation in the OHS outcome for the linear model, although the point estimate seems
reasonable. Linear regression models for the other outcomes (not shown) showed a similar lack of fit.
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FIGURE 9 The OHS: NHS PROMs percentage improved using criterion B.
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FIGURE 10 The OKS: NHS PROMs preoperative histogram with the absolute and linear relative thresholds using
criterion B.
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Discussion
Main findings
We examined the percentage of the population who improved in accordance with each improvement
criterion. Based on the MCID 0.5 improvement criterion B, all the candidate tools show > 75%
improvement for the OHS, OKS and WOMAC scores (except the WOMAC stiffness: 53–64%)
(see Tables 33 and 34).
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FIGURE 11 The OKS: NHS PROMs change scores.
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FIGURE 12 The OKS: NHS PROMs percentage improved using criterion B.
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The ability to predict postoperative quality-of-life or health status outcome from the preoperative score has
limitations; it is apparent from the AUC values that although the preoperative score is informative, it does
not fully determine what the postoperative outcome will be. Other factors may improve the prediction
(this was explored for the OHS and OKS in Chapter 5); however, it is worth noting that the variability in
postoperative quality of life or health status is substantial. Related to this, the linear regression model fitted
poorly in terms of representing the variability, although, as it was being used as a best guess, this is not
problematic per se to the estimation of the relative threshold based on the average response. Regression
analysis techniques that can deal with this are available, such as the use of transformations, modelling the
variability separately and quantile regression.
The estimated absolute threshold for the OHS, OKS, SF-12 and WOMAC, when applied retrospectively,
only excluded a very small proportion of the patients within our data sets who received hip and knee
replacement surgery, which is reassuring. Use of this threshold is reliant on the definition of improvement
used, not on the predictive performance. Although a small proportion of patients did receive surgery that
may not have been suitable, it is possible that other benefits not detected with these outcome tools could
explain and justify the operations for these individuals.
There was a suggestion of ceiling effects in the postoperative OHS, although this may to some degree
reflect the real positive postoperative results. However, we need to be cautious about the ability of the
OHS to distinguish postoperative results at the very top of the range. The OKS seemed to show a ceiling
effect only for the function subscale in work package 1; it may be that function after the surgery may not
be as well differentiated as pain by the instrument. For the OHS and OKS, we used the web-based NHS
PROMs data set (2012–15), which was also used for work package 1. Interpreting with the specificity
(false-negative) scores suggests that the NHS PROMs data set could be a more reliable source to develop
the tools than other data sets.
The SF-12 PCS and, especially, the SF-12 MCS showed very high specificity (very poor false-negative) scores
for relative thresholds (hip ranges of 20–48 for PCS and 91–100 for MCS, and knee ranges of 16–94 for
PCS and 72–100 for MCS). The SF-12 PCS and MCS did not well cover the range of possible scores in the
population (see Appendix 1). This may suggest that the SF-12 may not be an ideal tool for developing the
standardised thresholds for hip or knee replacement surgeries. Use of the SF-12 PCS and MCS individually
was problematic given that they are negatively correlated. The SF-12 MCS, perhaps unsurprisingly, did not
perform well in terms of face validity of the threshold impact.
Strengths and limitations
The main strengths of our study were (1) the use of diverse methods to define the thresholds and assess
prognostic performance and impact, (2) the inclusion of multiple candidate instruments that were selected
after a comprehensive search and selection process and (3) the use of multiple data sets including a
number of large cohorts in musculoskeletal populations (e.g. NHS PROMs data).
The difficulties of defining a clinically important improvement, particularly for measuring quality of life
(whether it is generic or disease-specific), are well known.90,94 Furthermore, criteria had to be applicable to
all of the candidate tools. Given the variation in available information on this despite the work carried out
in work package 1, the choice was restricted to definitions that could be applied on data sets and were
not reliant on pre-existing work (e.g. the anchor estimate of the MIC in the relevant population), which
was not available for all the measures. We used four methods, of which most emphasis was given to the
medium ES (0.5)-based definition, in which a medium ES is of moderate clinical importance.95 It is worth
noting that these are relatively simple approaches, for instance, which do not take into account the
preoperative score level, which itself may have influence on the clinically important improvement. We also
applied the following approaches: any increase in the change score (> 0) and MDC defined as the minimal
change beyond the measurement error. None of these is without criticism as a definition of clinically
important improvement, although the need to compare evenly across measurement tools limited the
options. Nevertheless, we believe that the findings have value, particularly the medium ES definition.
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The study had a number of limitations. Potential sources of bias or limitations in the study methodology
were (1) the improvement criteria used reflected limitations in the literature and data sets available for the
candidate tools; (2) estimation did not control for the baseline characteristic information, such as patient
age, gender and comorbidities, which could be prognostically important; (3) complete-case analyses were
undertaken (without imputation of the missing data), which could influence the findings; (4) the thresholds
will be influenced by the measurement tool’s properties, such as responsiveness, which may mean that
there is a failure to reflect meaning impact in some patients; and (5) only point threshold estimations were
reported in this study.
Further research needed
Our definition of improvement could be more rigorous. Additional benefit could be extended beyond
‘improvement’ to incorporate other concepts (e.g. patient satisfaction) or impacts of treatment (i.e. other
relevant measures of benefit will be needed, especially for relative threshold). The MCID approaches
can be defined and calculated in various ways, for example the approaches could be defined subjectively
based on a patient’s satisfaction after the surgery (an anchor-based approach). The MIC using the mean
change score (pre and post operation) is another potential alternative.
The NHS PROMs data were from a very large data set but only had a 6-month follow-up period, whereas
most other data sets used 12 months of follow-up (except EPOS, which used 24 months). This may have
somewhat influenced the magnitude of findings.96 It would have been advantageous to have access to
larger data sets to assess the other tools (i.e. non-Oxford scores), particularly with regard to the WOMAC
score, for which more precise estimates of relative thresholds could have been achieved. The impact of the
baseline characteristics (i.e. main prognostic variables) on the estimation of the relative threshold will be
applied in work package 3.
Conclusion
In this study, various improvement definitions and analytical methods were used systemically to calculate
threshold levels for the candidate tools in various data sets. The results demonstrated that thresholds of
three candidate tools (the OHS, OKS and WOMAC), which suggested promising initial cross-sectional
psychometric properties (from work package 1), were consistent across data sets (except for the SF-12).
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Chapter 5 Health economic evaluation of
thresholds values (work package 2)
Background
This chapter aims to answer the following two inter-related questions:
1. What is the economic threshold for each clinical tool (i.e. what is the highest score at which
arthroplasty is cost-effective)?
2. How do the incremental costs, QALYs and cost-effectiveness of arthroplasty vary depending on the
threshold and clinical tool used?
We addressed these questions in a UK setting from a NHS perspective by conducting a series of cost–utility
analyses, comparing the incremental cost-effectiveness of TKA and THA with no arthroplasty in men and
women of different ages with different preoperative scores on each clinical tool.
The analyses presented in this chapter focused on total joint arthroplasty (TJA) because this type of
surgery constitutes 92% of knee and 99% of hip arthroplasty procedures conducted in the UK.97 We
compared immediate TJA with having no arthroplasty surgery during the 10-year time horizon used in
the analysis. This enabled us to calculate the economic threshold for each clinical tool by comparing the
cost-effectiveness in different groups with one another and with the £20,000-per-QALY ceiling ratio
typically used in NHS decision-making.98 The economic threshold simply comprised the highest clinical tool
score at which the incremental cost-effectiveness ratio (ICER) is < £20,000 per QALY gained. In practice,
patients who are not deemed to warrant immediate surgery may have treatment later, after their condition
has worsened. However, there are relatively limited data on how clinical tool scores change over time
without surgery,99–102 and modelling the referral pathway and outcomes for patients who undergo surgery
at different times would have greatly complicated the analysis. Instead, by directly comparing immediate
TJA with no arthroplasty over 10 years, we made the most of existing UK data sets and directly assessed
the cost-effectiveness of arthroplasty.
We focused on NHS and Personal Social Services costs in line with current UK guidelines,103 but have
narrowed the perspective further to focus on NHS costs because only one of the available data sets (APEX)
included non-NHS costs. Health benefits were measured in terms of QALYs, in line with guidelines and in
order to capture the effect of surgery on both quality of life and mortality.103 The cost-effectiveness of TJA
versus no arthroplasty was therefore calculated as the difference in cost (between patients undergoing TJA
and those having no arthroplasty) divided by the difference in QALYs.
The analysis primarily concerned patients aged between 50 and 90 years and with an ASA (American
Society of Anesthesiologists) grade of 1–3 who were undergoing unilateral TKA or THA for osteoarthritis.
However, patients not meeting these criteria were not explicitly excluded from the regression analyses
used to estimate input parameters to ensure consistency with the clinical analyses. Because the model
begins when patients undergo (or do not undergo) TJA, the analyses presented in this chapter would apply
regardless of whether the thresholds are applied in the setting of general practice, musculoskeletal hubs or
secondary care.
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Methods
Costs and QALYs for hypothetical patients with different clinical tool scores and demographic
characteristics were estimated using decision-analytic models built in Microsoft Excel® 2010 (Microsoft
Corporation, Redmond, WA, USA). Model-based economic evaluation enabled us to synthesise data from
different data sets and extrapolate beyond the end of the available data. Separate models were built for
TKA and THA for each of the three clinical tools. Model parameters (e.g. costs, utilities and the probability
of death or revision) were based on regression models estimated using patient-level data from existing
data sets; such models were used to estimate model parameters for patients with different preoperative
characteristics. Hypothetical patients of different ages and genders with a wide range of clinical tool scores
were run through the models separately and the costs and QALYs with and without TJA were calculated
for each hypothetical patient. The models were probabilistic and took account of uncertainty around
regression parameters.
Like the analyses described in Chapter 4, we considered hypothetical patients with different total OKSs
or total OHSs on a 0–48 scale. For the WOMAC, for simplicity we focused on total scores, rather than
considering pain, physical functioning and stiffness separately. As for the clinical analyses, the scale on the
total WOMAC score (the sum of the three subscores ranging from 0 to 96) was multiplied by a factor
of 10096 to rescale it, and then reversed by subtracting it from 100, such that 0 indicates severe problems
and 100 indicates no problems. However, because there is no single summary score for the SF-12, we
considered the physical and mental scores as two separate patient characteristics and evaluated the
cost-effectiveness of different combinations of physical and mental scores, estimating threshold SF-12
physical scores for patients with different mental scores.
Model
Literature reviews on modelling approach
A comprehensive literature review was conducted to identify previous decision-analytic models that assessed
the cost-effectiveness of arthroplasty, specific types of surgery or prostheses or changes to the timing of
surgery (see Online Supplement 7). This review identified 41 previous model-based economic evaluations.
Almost all of the published studies used Markov models to allow for repeating cycles. Models typically
allowed for a proportion of patients having one or more revision operations, which were sometimes
separated into one- and two-stage revisions, revisions for infection or other causes, or total and partial
revisions. Some models used separate health states to differentiate between patients with good and poor
outcomes or quality of life after surgery. Some of the models differentiated between patient groups based
on age, sex, comorbidities, ASA grade and/or obesity, and one analysis estimated results for patients with
different Kellgren and Lawrence grades with and without symptoms.104 However, no model-based evaluations
calculated how costs and QALYs varied with clinical tool scores. Five studies using patient-level data assessed
how costs and/or QALYs varied with the Oxford Hip and Knee Scores or the WOMAC.2,68,105–107 One study that
was published after our search date assessed how cost-effectiveness varied with the SF-12.108
Description of the Markov model
We used the results of this literature review to inform the design of our model. Like most studies in the
literature, we used a Markov model with annual cycles to allow for the fact that patients are at risk of
death or needing a revision each year. We estimated costs and QALYs using cohort simulation, because
modelling thousands of individual patient trajectories for up to 1410 hypothetical patients using patient-
level simulation would have been too computationally time-consuming. Revision rates and mortality varied
depending on the time since primary arthroplasty and the age and sex of the hypothetical individual.
Costs and EQ-5D utilities also varied depending on the time since primary arthroplasty, age, sex and clinical
tool score.
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The model started at the point at which patients in the arthroplasty arm underwent primary TKA or THA
(Figure 13). Revision was defined in the same way as in the National Joint Registry (NJR), namely an:
. . . operation performed to remove (and usually replace) one or more components of a total joint
prosthesis for whatever reason.
Reproduced with permission from the National Joint Registry
(www.njrcentre.org.uk) from the 12th Annual Report (2015)97
The base-case analysis used a 10-year time horizon because it was considered clinically unrealistic to
assume that patients in the no arthroplasty arm would never have surgery. This also approximated the
longest follow-up time available in the data sets used to estimate model parameters. However, different
time horizons were examined in the sensitivity analysis. Costs, QALYs and life-years accrued beyond year 1
were discounted at 3.5% per annum.103,109
The model did not apply a standard half-cycle correction to all health states, because the cost of primary
TJA was assumed to be at the start of the year regardless of what subsequently happened to the patient
and is not evenly distributed across the first 12-month period. We assumed that patients who die in the
same year as having a primary TJA or revision surgery will incur the entire cost of the hospital stay in which
the TJA or revision surgery was conducted. The cost of the admission for primary or revision surgery was
assumed to be the same regardless of whether patients died during or soon after surgery. Other costs
were assumed to be evenly distributed across the year, such that patients who die in any given year were
assumed to accrue half of the cost and half of the number of QALYs that they would have accrued if they
had lived for the whole year.
The model used a probabilistic sensitivity analysis (PSA) to propagate the uncertainty around all uncertain
parameters (see Presentation of results and analysis of uncertainty).
Dead
Patient with
knee/hip pain
Primary
arthroplasty
> 1 year after
primary
arthroplasty
> 1 year after
revision
Revision
arthroplasty
No
arthroplasty
FIGURE 13 State transition diagram for the Markov model.
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Data sets
Data inputs
Model input parameters were estimated using regression models predicting the model parameter as a
function of clinical tool score, age and sex. Each of the six Markov models required regression models
informing 19 sets of model parameters (Table 39). As described in Literature reviews on model inputs,
we began by conducting literature searches to identify any published regression models that could
be directly used in the model. If no suitable regression model was identified, the following data sets
(described in Chapter 3, Data sets) were considered as candidates for estimating the regression models
conducted before the second user group meeting:
l PROMs data freely available at www.hscic.gov.uk/proms (accessed 7 October 2015)
l the KAT66
l the ADAPT71,127
l the APEX study72,127,128
l the EPOS68,69,129,130
l the Clinical Outcomes in Arthroplasty Study (COASt)113,131
l the EUROHIP132
l Belfast.
The COASt is a prospective, dual-centre longitudinal cohort study recruiting patients across two hospitals:
the University Hospital Southampton NHS Foundation Trust and NOC as part of Oxford University Hospitals
NHS Foundation Trust. The COASt was established in 2010, and patients who were placed on the waiting
list for knee or hip replacement surgery were recruited to the study.131 The data sets extracted for the ACHE
tool contained observations for 810 hip surgery patients and 858 patients undergoing knee surgery. After
excluding patients who underwent procedures other than TKA/THA (e.g. hip resurfacing), the data sets
contained 806 observations on THA patients and 484 observations for TKA patients. Data were collected
prior to surgery as well as at 6 weeks and then annually for 5 years thereafter. COASt is funded by NIHR
under its Programme Grants for Applied Research programme (reference number RP-PG-0407–10064). The
study obtained ethics approval from Oxford Research Ethics Committee (reference number 10/H0604/91)
and written consent was obtained from each participant.
As detailed in Chapter 7 and Table 39, nine of the parameters within the OKS/OHS models were
re-estimated after the second user group meeting and after a new linked extract of Hospital Episode
Statistics (HES) and PROMs data became available. This provides a much larger sample of more recent
data, including patients’ exact age, and can be directly used to calculate the payment by results tariff
applicable to each patient.
Data sets were not pooled, because they differed substantially in age and data collected and there was
little advantage in pooling a small data set with a much larger one (e.g. PROMs). Instead, we selected the
most appropriate data set among those reporting the tool and outcome of interest based on size, age of
the data set and consistency with other analyses. When possible, we aimed to use the same data set for
several time points, tools or arms of the model and aimed to use data sets that measured quality of life at
the same time point.
Utility was measured using the EQ-5D-3L using the UK time trade-off tariff133 to ensure consistency across
models and with NICE guidelines.103
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TABLE 39 Data sets and published models used to estimate regression models
Parameter
Data sources: knees Data sources: hips
OKS SF-12 WOMAC OHS SF-12 WOMAC
Preoperative EQ-5D
utility (mapping)
l Dakin et al.50
l PROMs
l KAT and COASt
l KAT
l Le110
l APEX
l Barton et al.111
l Pinedo-Villanueva
et al.126
l PROMs
l COASt
l KAT
l Le110
l APEX
l Barton et al.111
Postoperative EQ-5D
utility 3–12 months after
arthroplasty
l Free PROMs
l PROMs/HES
l KAT and COASt
l KAT l APEX l Free PROMs
l PROMs/HES
l EUROHIP and COASt
l EPOS l APEX
l EUROHIP
Annual change in EQ-5D
at > 3–6 months after
arthroplasty, in patients
with and without
revision
l KAT l KAT l KAT (estimated
models of how
baseline EQ-5D
affects the slope)
l Ara and Brazier112
l EPOS
l Ara and Brazier112
l EPOS
l Ara and Brazier112
l EPOS (estimated
models of how
baseline EQ-5D
affects the slope)
EQ-5D utility before
revision
l Free PROMs
(assuming EQ-5D
before revision is
independent of
pre-primary
score)
l PROMs/HES
l Free PROMs
(assuming EQ-5D
before revision
is independent of
pre-primary score)
l Free PROMs
(assuming EQ-5D
before revision is
independent of
pre-primary score)
l PROMs/HES
l Free PROMs (assuming that EQ-5D before revision is independent
of pre-primary clinical tool score)
l PROMs/HES
EQ-5D utility after
revision
l KAT
l PROMs/HES
l KAT l KAT (assuming that
EQ-5D varies with
observed or predicted
pre-primary EQ-5D)
l Free PROMs (assuming that EQ-5D after revision is independent
of pre-primary clinical tool score)
l PROMs/HES
Cost of the initial
arthroplasty procedure
and hospital stay
l COASt
l PROMs/HES
l KAT and Belfast
l KAT l APEX l COASt
l PROMs/HES
l EPOS and Belfast
l EPOS l APEX
Community, outpatient
and re-admission costs
beyond the initial
hospital stay: year 1
l KAT
l Re-admissions
based on PROMs/
HES; ambulatory
costs based
on KAT
l COASt
l KAT l APEX l COASt
l Re-admissions based
on PROMs/HES;
ambulatory costs
based on COASt
l Pinedo Villanueva113
l COASt (estimated a
model predicting
costs conditional on
EQ-5D)
l Pinedo Villanueva113
l APEX
l Pinedo Villanueva113
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TABLE 39 Data sets and published models used to estimate regression models (continued )
Parameter
Data sources: knees Data sources: hips
OKS SF-12 WOMAC OHS SF-12 WOMAC
Community, outpatient
and re-admission costs
beyond the initial
hospital stay: > 1 year
after TJA
l KAT
l Re-admissions
based on PROMs/
HES; ambulatory
costs based
on KAT
l KAT l KAT (estimated a
model predicting
costs conditional on
EQ-5D)
l Pinedo Villanueva113
l Re-admissions based
on PROMs/HES;
ambulatory costs
based on
Pinedo Villanueva113
l Pinedo Villanueva113 l Pinedo Villanueva113
Cost of revision
arthroplasty procedure
and hospital stay
l KAT
l PROMs/HES
l KAT l KAT (estimated a
model predicting
costs conditional on
EQ-5D)
l Pinedo Villanueva113
l PROMs/HES
l Pinedo Villanueva113 l Pinedo Villanueva113
Community, outpatient
and re-admission costs
beyond the initial
hospital stay for revision
(estimated separately for
the year of revision and
> 1 year after revision)
l KAT
l Re-admissions based on PROMs/HES;
ambulatory costs based on KAT
l Use KAT to estimate
a model predicting
costs conditional on
EQ-5D
l Pinedo Villanueva113
l Re-admissions based
on PROMs/HES;
ambulatory costs
based on
Pinedo Villanueva113
l Pinedo Villanueva113 l Pinedo Villanueva113
Community, outpatient
and inpatient costs
without arthroplasty
l COASt
(preoperative
costs)
l COASt (estimated
a model predicting
preoperative costs
conditional on
EQ-5D)
l COASt (estimated a
model predicting
preoperative costs
conditional on
EQ-5D)
l COASt
(preoperative costs)
l Pinedo Villanueva113
and Vale et al.114
l COASt (estimated a
model predicting
preoperative costs
conditional on
EQ-5D)
l Pinedo Villanueva113
and Vale et al.114
l COASt (estimated a
model predicting
preoperative costs
conditional on
EQ-5D)
l Pinedo Villanueva113
and Vale et al.114
Annual change in
clinical tools without
arthroplasty
l Assumed no change in clinical tools and only age-related decline in EQ-5D utility
l Belfast, OAI, MOST, Vale et al.,114 Batsis et al.,115 Bruyere et al.,116 Kapstad et al.,117 Ostendorf et al.100 and Passey et al.99
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Parameter
Data sources: knees Data sources: hips
OKS SF-12 WOMAC OHS SF-12 WOMAC
Annual change in EQ-5D
utility without
arthroplasty
l Ara and Brazier112
l Pennington et al.118 and Dakin et al.2
Probability of revision
surgery
l Pennington et al.119 (assumed that the probability of revision
surgery is unrelated to clinical score)
l KAT, APEX, ADAPT and Sibanda et al.120
l Pennington et al.121 (assumed that the probability of revision surgery
is unrelated to clinical score)
l EPOS, APEX, ADAPT, Pulikottil-Jacob et al.,122 Pennington et al.118,123
Clarke et al.124 and Sibanda et al.120
Probability of re-revision l Pennington et al.119 (assumed that the probability of revision
surgery is unrelated to clinical score)
l Pennington et al.121 (assumed that the probability of revision surgery
is unrelated to clinical score)
Operative mortality:
primary arthroplasty
l Pennington et al.119 (assumed that mortality is unrelated to
clinical score)
l Pennington et al.121 (assumed that mortality is unrelated to
clinical score)
Operative mortality:
revision arthroplasty
l Pennington et al.119 (assumed that mortality is unrelated to
clinical score)
l Pennington et al.121 (assumed that mortality is unrelated to
clinical score)
Healthy patient effect l Pennington et al.119 (assumed that mortality is unrelated to
clinical score)
l Pennington et al.121 (assumed that mortality is unrelated to
clinical score)
All-cause mortality l Office for National Statistics125
MOST, Multicenter Osteoarthritis Study; OAI, Osteoarthritis Initiative.
Note
The data sets or published models used to estimate model inputs for the analyses presented in this chapter are shown in bold typeface; those used in analyses presented in Chapter 7 are
shown in standard typeface, whereas other data sets or published studies that also provide suitable data but were not selected for use in the model are shown in italics.
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Literature reviews on model inputs
We began by conducting literature searches to identify any previous studies that reported regression
models that could be used directly in our analysis. Five specific searches were conducted:
1. A review of previous economic evaluations and costing studies using patient-level data (see Online
Supplement 7) aimed to inform the model structure and identify data for all model parameters.
2. A review of studies reporting changes in clinical tool scores over time for osteoarthritis patients without
arthroplasty surgery (see Online Supplement 9) aimed to inform assumptions about how clinical tool
scores change over time.
3. A review of studies reporting long-term changes in clinical scores, mortality and risk of revision after
arthroplasty surgery (see Online Supplement 9) aimed to identify any data for long-term costs, utilities
and transition probabilities.
4. A review of studies mapping from any of the clinical tools onto the EQ-5D, or between any of the
clinical tools (see Online Supplement 11) aimed to identify models predicting baseline EQ-5D utility,
because several such studies were identified in a previous systematic review.134
5. A review of studies reporting mortality after primary or revision knee/hip arthroplasty (see Online
Supplement 10) aimed to identify studies on mortality, because none of the available data sets provided
data on mortality for a large sample.
The second literature review aimed to inform a key assumption in the model by identifying studies that
reported changes in clinical tool scores over time for patients without arthroplasty; this is the comparator
for the analysis and therefore has a strong influence on the results. A total of 22 such studies were
identified.99–101,115–117,135–150 However, the reported results were ambiguous. Most studies focused only on
changes in WOMAC subscores and only reported data over a 2- to 5-year follow-up period. Only two
studies reported results for the OHS or SF-12.100,115 Overall, the results indicated that patients’ clinical tool
scores might either improve or worsen, with several studies reporting approximately equal probabilities
for both.101,142,145 We therefore assumed that, in the absence of arthroplasty, clinical tool scores remain
constant over the 10-year time horizon (see Other model assumptions and inputs). However, we did allow
for reductions in EQ-5D utility with age. The review of economic evaluations identified three previous
estimates of the rate of change in utility with age;2,112,118 we used the Ara and Brazier112 model 1 in our
analysis because it is based on patient-level UK data and is not specific to patients with certain comorbid
conditions; the variance–covariance matrix for the model was obtained from the authors.
The reviews identified nine studies estimating how mortality varied with age, sex and/or other characteristics.
However, only one series of studies reported the full set of model coefficients, or considered mortality beyond
90 days after surgery;118,119,121,123 therefore, we used the most recent of these studies in our model.119,121
Four studies were identified that mapped from the OKS, OHS and WOMAC total scores or from the
SF-12 version 2 physical and domain scores onto the EQ-5D.50,110,111,126 It was necessary to focus on models
mapping from total scores or from physical/mental scores, to match the way in which clinical tool scores
are modelled in the rest of the model. However, the study mapping from the WOMAC used a small
sample [348 observations vs. 978 (knees)/1067 (hips) available in the APEX study] and presented no
measures of uncertainty around model coefficients.111 The study on the SF-12 version 2 was based on
general public samples, rather than patients with arthritis, and mapped onto the US EQ-5D tariff, rather
than the UK EQ-5D tariff.110 Furthermore, variance–covariance matrices were only available for the studies
mapping from the OKS and OHS. We therefore used the published studies mapping from the OKS and
OHS for the economic evaluations described in this chapter and estimated new mapping algorithms for
the WOMAC and SF-12 using the available data sets.50,126 For the further analyses, we subsequently
re-estimated mapping algorithms for the OKS and OHS using PROMs data providing patients’ exact ages.
An analysis conducted as part of the COASt work programme using data from HES and the Clinical
Practice Research Datalink (CPRD) was used to provide estimates of ambulatory costs accrued > 1 year
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after primary THA and the cost of revision surgery, because none of the available data sets provided data
on these parameters.113,131
However, the literature reviews identified no studies predicting any of our model parameters conditional
on any of the clinical tools under consideration. Therefore, we used the individual patient data available to
us to estimate new regression models.
Costing analyses
The reference year for costs was 2014. Within the data sets giving individual patient data on resource
use, the cost of primary TJA was estimated based on the national payment by results tariff for relevant
Healthcare Resource Groups (HRGs), whereas other health-care resources were valued using unit costs
(see Online Supplement 8). Costs taken from Pinedo Villanueva113 were inflated from 2010–11 to 2013–14
using the Hospital and Community Health Services Index.151
The analysis focused on resource use associated with the joint that was replaced, because resource use
unrelated to the joint in question was excluded from all of the available data sets. The analyses estimating
the community, outpatient and re-admission costs after hospital discharge also excluded medications,
personal care, nursing homes, convalescence care, equipment, home modifications, alternative practitioners,
etc. These costs were available for certain data sets (e.g. the APEX study), but not others (e.g. KAT).
Excluding such costs greatly reduced the analysis time and made it easier to make fair comparisons between
clinical tools. We assumed that all physiotherapy was paid for by the NHS.
None of the data sets available before the second user group meeting provided sufficient data to put
through the NHS Payment Grouper,152 a computer program that allocates individual hospital episodes to
HRGs based on procedures, diagnoses and patient characteristics. In the analyses presented in this chapter,
we, therefore, manually synthesised an estimate of the cost of the initial hospital stay for primary TJA using
information from the national tariff 2014–15153 and the NHS Payment Grouper152 and excess bed-days
using the NHS tariff. Under the payment by results scheme, hospitals are paid a fixed amount for each
HRG unless the patient remains in hospital for longer than the ‘trim point’. For hospital stays lasting
beyond the trim point, hospitals are paid an excess bed-day tariff for each additional day beyond the
trim point. For primary arthroplasty, there are separate HRGs for patients with no complications, minor
complications and major complications; these HRGs differ in their tariff price and trim point, whereas the
excess bed-day price is the same across the relevant HRGs. Because it is difficult to establish defensible
and consistent methods for identifying which patients would have had minor or major complications
based on the comorbidity and/or complication fields in other data sets, we used national data to estimate
weighted average costs for every possible length of stay, taking into account the trim point, tariff price and
excess bed-day price, and applied this to all patients with that length of stay (see Online Supplement 12).
This approach implicitly assumes that the incidence of complications is unrelated to clinical tool score and
ignores the association between age and complications.
Changes in guidelines and waiting time targets have halved the average length of stay for arthroplasty in
the last 15 years.154,155 Consequently, length-of-stay data from trials that started in the early 2000s (e.g.
KAT and EPOS) do not accurately reflect current practice. However, because KAT and EPOS are the only
data sets containing the SF-12 instrument that also report resource use, we relied on these two data
sets to estimate how the cost of primary arthroplasty varies with preoperative SF-12 scores. Applying the
current national tariff to these older data sets would have systematically overestimated costs, because
the share of patients with excess bed-days would be considerably higher than the share for more recent
studies. We addressed this problem by adjusting the length-of-stay data for primary TJA using data from
the COASt study, which was conducted in 2011 (see Online Supplement 12).131
A simple approach was used to value re-admissions occurring after patients were discharged from hospital
following primary TJA. Such re-admissions were costed up by estimating a (weighted) mean cost per
orthopaedic bed-day for those HRGs with the word ‘hip’ or ‘knee’ in the Department of Health and Social
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Care reference costs HRG description, and multiplying this by the length of stay.156 A similar method
was used to value day cases, which was applied to all admissions in which the admission and discharge
dates were the same. No adjustment was made for the calendar year in which the re-admission or revision
took place, because any such adjustment would have been extremely complex as the re-admissions
observed in the KAT data set were spread over a 12-year period. The COASt questionnaires on costs before
arthroplasty provide no data on length of stay for re-admissions, only the number of such re-admissions.
In these cases, we therefore applied to each admission the (weighted) mean cost per orthopaedic
admission for HRGs with the word ‘hip’ or ‘knee’ in the description from NHS Reference Costs 2013 to
2014.156 In order to avoid underestimating costs by excluding patients with missing length of stay data for
re-admissions, we applied the same weighted average cost to all patients with missing data on length of
stay unless the providers of the data set also provided clear guidance on how to impute missing length of
stay data. For KAT, we used the same mean imputation that was already applied in the KAT data set,
whereby a length of stay of about 9 days for washout procedures with missing length of stay (mean
imputation) was applied, and a length of stay of 14.25 days for the second stage of a two-stage revision
with missing length of stay. However, these simple analyses were superseded by the HES data used to
calculate re-admissions in the analyses presented in Chapter 7.
Owing to lack of data, the cost of re-admissions other than revisions that took place > 1 year after THA
were excluded from the analyses presented in this chapter. No patient-level data giving costs > 1 year after
THA were available at that time and the only available cost estimates cover only ambulatory consultations,
not re-admissions.113 The analyses presented within this chapter may, therefore, slightly underestimate
costs for patients who have had THA. The cost of re-admissions was therefore added to the analyses
conducted after the second user group meeting once HES data became available.
Regression analyses
Regression models predicting each model parameter conditional on preoperative clinical tool score,
age and sex were estimated on the individual patient data using Stata® version 14.
A complete-case analysis was conducted to avoid overcomplicating the analysis with multiple imputed
data sets. Observations with missing data on the clinical tool or the model parameter in question would
have provided very little information to inform model estimation, and there is no reason to expect the
relationship between clinical tool and outcome to differ between people with and without missing data
on these variables. Each individual analysis excluded patients with missing data on age, sex or either the
clinical tool score or the outcome variable being estimated in that regression analysis. As a result, sample
sizes differed between regression analyses using the same data set.
The EPOS was the only data set providing information on THA patients beyond year 1. However, EPOS
participants who did not complete the EQ-5D and SF-6D utilities cannot be directly compared with those
measured using the EQ-5D because the SF-6D values health states using standard gamble rather than time
trade-off and tends to produce non-comparable utilities (e.g. higher utilities for patients with poor health
states).157 We therefore mapped participants’ SF-12 responses onto the EQ-5D before analysis. Based on
the literature review on mapping studies (see Online Supplement 11), we selected a response-mapping
algorithm mapping from the SF-12 version 1 item responses that was slightly modified from the one
estimated by Gray et al.158 and estimated predictions using the expected value method.159 This algorithm
was chosen as it had better prediction accuracy than other algorithms based on the same version of the
SF-12 that was used in the EPOS (see Online Supplement 11). Postoperative EQ-5D utilities calculated in
this way were used in subsequent regression models in the same way as observed EQ-5D utilities, ignoring
the uncertainty around the mapping model (which is in any case likely to be small owing to the large
sample size used in the mapping study).
For each model parameter, we began by conducting exploratory data analysis to identify the distribution of
the dependent variable and the shape of the relationship between the dependent variable and the clinical
tool score, age and (when appropriate) time since primary arthroplasty. Exploratory data analysis was used
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to identify the most appropriate model specifications for each dependent variable. We then estimated
regression models on each of the parameters listed in Table 39 and selected the model specification best
predicting each model parameter using mean squared error (MSE). MSE was chosen in preference to
information criteria in order to focus on model prediction and because information criteria cannot easily be
calculated for some model types (e.g. two-part models) or necessarily be compared between linear and
non-linear models.
We used K-fold cross-validation to reduce overfitting. For each of the below steps for each model
parameter, each data set was divided into 10 parts of approximately equal size using pseudo-randomly
generated numbers. Unless otherwise stated, for the analyses estimated on long format data sets (i.e. costs
and EQ-5D utility before/after revision and long-term trends in EQ-5D utility), patients were divided into 10
groups and all observations for the same patient were included in the same part. For the analyses based
on KAT and EPOS, we also stratified patients based on whether or not they had a revision ≥ 12 months
after primary TJA when dividing patients between the 10 parts; no such stratification was done for PROMs/
HES when conducting the analyses described in Chapter 7, because the sample size was markedly larger.
Candidate models being considered in any given step were estimated on 9 of the 10 parts and validated
on the 10th part; estimation and validation were repeated for each of the 10 validation samples, resulting
in an estimate of the squared error (i.e. the squared difference between predicted and observed values in
the validation sample) for each candidate model for each observation. MSE was calculated as the crude
mean across the squared errors and the model specification with the lowest MSE was chosen for use in
the next step.
Regression analyses on each of the parameters listed in Table 39 were conducted using the following steps.
Step 1. Functional form of the outcome variable:
l Choose a number of candidate regression functions [e.g. ordinary least squares (OLS), generalised
linear model (GLM), two-part model] based on the exploratory data analysis.
l Define a simple model with the following covariates, with no polynomials or interactions –
– Clinical tool score.
– Age (this comprised dummies for 10-year age bands for the freely available PROMs data set,
and continuous age for other data sets).
– Sex.
– For analyses including RCT data, we added a covariate for treatment effect if the treatment
allocation was very different from current practice and the trial found significant differences
between treatments. A dummy for treatment effect was therefore included in analyses on the
APEX study, but not in KAT. However, no dummy was included in the mapping models predicting
EQ-5D utility conditional on patients’ contemporaneous clinical tool scores.
– For certain model parameters, we also included time since primary arthroplasty and indicators of
previous revision surgery as covariates (see Online Supplement 12).
l Estimate the simple model using the candidate regression functions.
l Calculate MSE for each model.
l Choose functional form with lowest MSE to use in step 2
l Optional step 1b. Functional form for time:
¢ For the models of long-term EQ-5D utility, re-admission costs beyond year 1, and the cost utility of
revisions, step 1(b) then identified the functional form for time since primary operation based
on MSE.
Step 2. Functional form of the clinical tool:
l Based on the exploratory data analysis, we chose candidates for the parameterisation of the clinical tool
scores. Depending on the exploratory data analysis results, these included logarithms, polynomials, splines
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and/or interactions between different domain scores. For the SF-12, we chose the parameterisation for
the physical domain first, then the mental domain, then assessed whether or not an interaction between
physical and mental domains improved MSE. If non-logarithmic forms were chosen for the SF-12, we only
considered the interaction between the absolute physical and absolute mental domain scores (i.e. no
splines, quadratic or cubic terms for the interaction); if logarithmic forms were chosen for one (or both)
SF-12 domains, we also considered interactions between linear and log scores, or between log-physical
and log-mental scores. The model with the lowest MSE was used in step 3.
Step 3. Functional form of covariates:
(a) Based on the exploratory data analysis, we chose a limited range of candidates for the parameterisation
of age, estimated the candidate models and selected the model with the lowest MSE to use in step 3(b).
Interactions between the clinical tool and other covariates were not considered. We also considered
models that dropped age. For the models of re-admission costs beyond year 1 and the cost or utility of
revisions, we first compared MSE with age at the time of primary surgery with MSE with age at the time
of revision/year of data and selected the parameterisation for age based on the variable with the lowest
MSE. Analyses of costs > 1 year after revisions used age in the current year throughout (owing to the
Markovian assumption inherent within the model).
(b) We assessed whether or not dropping the sex variable reduces the MSE. The model with the lowest
MSE from step 3(b) was chosen for step 4.
Step 4. Final regression models and their variance–covariance matrices:
For two-part models, the selection of variables in steps 2 and 3 was done simultaneously for both parts of
the model, such that the same variables were included in both parts of the model unless one of the final
selected models was unstable (e.g. SEs of > 600 for a logit model); in such cases, we reran model selection
for the problematic part of the model, leaving the other part unchanged. Online Supplement 12 describes
how models for specific parameters were estimated, specific data cleaning and processing steps were
conducted on specific data sets and model parameters, and specific assumptions were used when applying
the parameters in the Markov models.
Other model assumptions and inputs
The model made the following assumptions:
l Patients in the no arthroplasty arm were assumed to undergo no knee or hip arthroplasty during
the 10-year time horizon. In practice, patients whose symptoms are not currently severe enough to
warrant arthroplasty may have surgery later, once their symptoms have deteriorated. However, modelling
arthroplasty procedures conducted at different time points as well as allowing for changes in revision rates,
mortality, utilities and costs over time would have greatly complicated the model structure and required
six patient-level simulation models, each following up to 1410 hypothetical individuals. Furthermore, there
were very limited data on the proportion of patients whose clinical tool scores would deteriorate in the
absence of arthroplasty, or on the rate at which scores are likely to deteriorate.
l As discussed in Literature reviews on model inputs, the studies identified in the literature review
suggested that some patients’ symptoms worsened over time in the absence of arthroplasty, whereas
symptoms for other patients improved or remained the same (see Online Supplement 9). Although the
literature review identified several US studies using WOMAC, we identified only one UK study using the
WOMAC physical functioning subscale144 and one study showing how OHS100 and SF-12,115 respectively,
change over time in the absence of arthroplasty. It is also unclear whether or not all of the patients in
such data sets would be considered candidates for TJA. We therefore assumed that clinical tool scores
remain unchanged for the time horizon of the model in patients who do not have arthroplasty, but
assumed that EQ-5D utility decreases with age following a published model.112 If patients’ osteoarthritis
symptoms did, on average, deteriorate in the absence of arthroplasty, this would mean that our analyses
overestimate the QALYs accrued in the no arthroplasty arm and, therefore, overestimate ICERs and
underestimate the economic threshold.
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l We placed no restrictions on the number of revisions that patients could have within the Markov
models, although patients could not have more than one revision operation per year.
l Patients in the no arthroplasty arm were assumed to accrue a fixed cost each year. This cost was based
on the costs accrued by patients in the COASt study in the year before arthroplasty, because no UK
data were available on patients who were potentially eligible for arthroplasty but did not have surgery.
l For certain parameters (e.g. community, outpatient and re-admission costs or utility > 1 year after TJA),
there were no data for WOMAC. Furthermore, the only UK data set providing information on costs
before or without arthroplasty (COASt) did not include the SF-12.131 In these cases, we estimated
regression models that used preoperative EQ-5D utility as an explanatory variable in place of the
WOMAC or SF-12. Mapping models were used to calculate preoperative EQ-5D utility from
preoperative clinical tool scores. For those parameters that were estimated as a function of EQ-5D,
we calculated predicted costs/utilities by multiplying mapped preoperative EQ-5D utility by the
regression coefficient for preoperative EQ-5D utility.
l In all analyses, we assumed that costs and quality-of-life questionnaires were completed at the
designated time. For example, if a patient had a revision 1.99 years after primary TJA, we assumed that
the year 2 EQ-5D questionnaires were completed after the revision (rather than before).
l Mortality rates incorporated a healthy patient effect estimated by Pennington et al.119,121 using NJR data
that allows for the fact that patients selected to undergo TJA have lower mortality for around 8 years
after surgery than people who are not considered candidates for TJA. This was operationalised as a
multiple of the annual all-cause mortality risk for individuals in the UK of the relevant age and sex,
in which the multiple varies with age, sex and time since TJA.125 Because the patients in the no
arthroplasty arm were assumed to be identical to those patients in the arthroplasty arm, the healthy
patient effect was also applied for the first 8 years of the no arthroplasty arm.
l Mortality associated with revision surgery was excluded from the analyses described in this chapter,
unless the models developed by Pennington et al.119,121 predicted that mortality would be > 10% higher
than would be expected in the absence of revision surgery (in which case mortality was assumed to be
10% higher than without revision surgery). Furthermore, no excess mortality was applied to revisions
taking place within 12 months of primary arthroplasty. However, the published models of mortality
associated with revision surgery were applied to all revision procedures in Chapter 7. This assumption is
unlikely to have any significant effect on the conclusions because only a small minority of patients have
revisions and revision rates are assumed to not vary with clinical tool score.
l The cost of re-admissions and ambulatory costs were excluded for those patients who were revised in
year 1 in the analyses described in this chapter. This assumption is unlikely to have any significant
effect on the conclusions because only a small minority of patients have revisions and revision rates are
assumed to not vary with clinical tool score.
l After a patient’s 100th birthday, we assumed that the all-cause mortality for patients’ 100th year
applies for all subsequent years. This assumption was only used in sensitivity analyses extending the
time horizon beyond 10 years.
l We assumed that revision rates do not vary with clinical tool score, because the PROMs/HES extract
was not linked to NJR and the available data sets included very few revisions that could be linked to
clinical scores measured before primary procedures. We therefore used published models estimated
using NJR data that predict revision rates conditional on age, sex, time since primary TJA and other
variables.119,121 In these models, revision rates have a non-linear relationship with several variables that
are not explicitly captured as patient characteristics in the model.
l Postoperative EQ-5D utility and the cost of re-admissions and community/outpatient consultations in
year 1 were estimated for all patients, regardless of whether or not they had been revised. This
simplification was made because it was not possible to reliably identify the patients who were revised
within 12 months of primary surgery in the freely available PROMs data set. This assumption should not
affect estimates of economic thresholds, because revision rates were assumed to not vary with clinical
tool score.
l When modelling the QALY profile in the first year after arthroplasty, we assumed that EQ-5D utility at
3 months is the same as EQ-5D utility at 6 months and we assumed a linear change in utilities in the
first 3 months after primary arthroplasty. Exploratory data analysis on the APEX study suggested that
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this approach gives a good approximation of the QALYs that we would calculate for the first year after
primary arthroplasty if we had more frequent measurements, and performs at least as well as more
complex methods. A recent study on SF-6D utilities after TKA confirmed this finding.160
l In all other cases, we assumed that utility changes linearly during the year; therefore, the QALYs
accrued during the year equal the crude average of utility at the start of the year and utility at the
end of the year. For simplicity, this assumption was also applied in the year of revision surgery, because
for some data sets (e.g. KAT) revision surgery may take place at any point in the year. Furthermore,
patients undergoing revision are likely to have had a quality of life similar to the pre-revision utility in
the months leading up to revision surgery and experience utility similar to that observed 6 months after
revision later in the year.
l Because the > 1 year after revision state includes people with revision operations that took place anywhere
between 1 and 9 years earlier and the Markov model cannot differentiate between people with respect to
time since revision, we assumed that the utility in this state was equal to the post-revision utility that would
have occurred if the revision had taken place in the present year relative to the annual EQ-5D questionnaire.
As a result, any effect of ageing on utility after revision is assumed to be captured in the post-revision
utility model.
l For THA, the cost of community and outpatient care > 1 year after hospital discharge was based on an
analysis of CPRD data done as part of the COASt study because no individual patient data were available
(see Online Supplement 12 for a description of the assumptions made when applying these costs).131
l In PSA, all utilities were constrained to be between –0.594 and 1. Utilities that would otherwise be
< –0.594 were set to –0.594 and those that would otherwise be > 1 were set to 1. With the exception
of the community costs taken from Pinedo Villanueva,113 all costs were constrained to be ≥ £0 and
values that would otherwise be < £0 were set to £0. The community costs taken from Pinedo
Villanueva113 represent differences between resource use in patients with osteoarthritis and resource
use in those without osteoarthritis and were, therefore, permitted to be negative, in line with how they
were used in the original study.
Presentation of results and analysis of uncertainty
Hypothetical individuals with different combinations of age, sex and clinical tool score were run through
the model sequentially, both using mean values for all parameters and using parameter values sampled
from their distributions (PSA). PSA was run separately on the six Markov models representing TKA and
THA with each of the three tools. However, within each model, the same set of sampled values was
used for all hypothetical individuals to ensure that differences between hypothetical individuals were not
masked by differences between sampled values.
All uncertain parameters, including all regression coefficients, were varied in PSA. We allowed for correlations
between coefficients estimated in the same regression model by assuming a multivariate normal distribution.161
Variance–covariance matrices for published models were obtained from the authors;50,112,119,121,126 those for
the models estimated on patient-level data were estimated in Stata® and are available on request. However,
for simplicity, we did not allow for correlations between the coefficients from different regression models,
or between the coefficients for the logit and OLS/GLM parts of two-part models. Differences in the cost of
ambulatory consultations after THA were assumed to follow independent normal distributions, whereas
the cost of hip revision surgery in different patient subgroups was assumed to follow independent
gamma distributions.113
We ran all six models using men and women aged exactly 50, 60, 70, 80 and 90 years. It should be noted
that several data sets include relatively few people at the upper and lower ends of this age range and that
the published models of mortality and revision rates excluded individuals aged < 55 or > 85 years.119,121
Results for patients aged 50 or 90 years should, therefore, be interpreted with caution, but may give an
indication of incremental cost-effectiveness for these patients. A wide range of integer values for the OKS,
OHS, WOMAC and SF-12 physical score were selected to cover the range of possible scores for the
instrument, with greater concentration of scores in the region where preliminary analyses had shown the
threshold to be. For the SF-12, results were also repeated for patients with SF-12 mental scores of 30,
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50 or 70; although 30 and 70 represent very extreme values that were observed for very few patients,
they were chosen to give an indication of the range of possible values. In total, between 490 and
1410 hypothetical individuals were analysed using point estimates for all model parameters and between
220 and 780 hypothetical individuals were analysed in PSA. For the WOMAC, OKS and OHS models,
2000 PSA runs were conducted; for the SF-12 models, 1000 PSA runs were conducted, because there
was insufficient computing time for 2000 runs for each of the three mental scores.
We also present the weighted average across men and women and across ages; unless otherwise stated,
all figures averaging across sexes and/or ages are weighted by the proportion of people in each group.
The proportion of men and women in different age groups was calculated using the number of
procedures per 100,000 people aged ≥ 10 years by age and sex published in the final PROMs report for
2013–14162 and the corresponding population numbers from the Office for National Statistics’ Mid-2013
Population Estimates in England163 (see Online Supplement 12). These proportions were multiplied by the
total number of primary arthroplasty procedures conducted solely for osteoarthritis in England in 2014–15
(76,617 knee replacements and 69,313 hip replacements) to give patient numbers. The total number of
primary arthroplasty procedures (79,726 knee replacements and 77,880 hip replacements) was calculated
from HES based on the number of finished consultant episodes for the OPCS (Office of Population
Censuses and Surveys Classification of Surgical Operations and Procedures) codes beginning with O or
W that the NJR used to identify primary hip/knee replacement and was multiplied by the proportion
of all primary arthroplasty procedures conducted solely for osteoarthritis (96% for knees and 89% for
hips).154,164,165 Data from PROMs/HES, the APEX study, KAT and EPOS were used to calculate the proportion
of people with different clinical tool scores (see Online Supplement 12). We allowed for the fact that the
age distribution varies between men and women and the fact that the distribution of SF-12 mental scores
varies with physical scores. However, for simplicity and to ensure consistency between models on different
clinical tools, we assumed that the distribution of clinical tool scores was independent of age and sex.
The base-case results represent the point estimates, keeping all parameters at their mean values.
This approach was used because it was not feasible to run PSA for all analyses in time for the second
user group meeting. Allowing for non-linearities by taking the expected value from PSA had very little
effect on ICERs or thresholds (results not shown).161
The costs and QALYs with and without TJA were calculated for each hypothetical individual and were
used to calculate the cost per QALY gained for TJA versus no TJA; these ICERs are displayed in the decision
grids shown in Results. The threshold clinical tool score was defined as the highest clinical tool score at
which the ICER for TJA versus no arthroplasty was < £20,000 per QALY gained for patients of any given
age, sex and, when applicable, SF-12 mental score.
We also used PSA results to calculate 95% credible intervals (CrIs) around the threshold clinical score.
These intervals were calculated by first examining the results of each individual PSA replicate to identify
the threshold clinical tool score for that PSA draw (within each age/sex group). The 95% CrI limits for the
threshold were assumed to equal the 2.5th percentile and the 97.5th percentile across the sets of PSA
results. However, because PSA was run for only a finite number of hypothetical individuals owing to the
long simulation time, only even-numbered SF-12 physical scores were evaluated and, for this reason, the
95% CrI around the SF-12 thresholds consider only even-numbered scores. Similarly, we only conducted
PSA on WOMAC scores that were multiples of five or > 95. We also averaged incremental net benefits
(INBs) (INB = Rc • ΔQALYs –ΔCost) across men and women at a £20,000-per-QALY ceiling ratio (Rc),
and also across ages and calculated 95% CrIs across thresholds based on these averaged results.
We also used data on the distribution of patients by age, sex and clinical tool score to calculate the
number of people who currently undergo arthroplasty but would no longer have access to surgery if
different threshold tool scores were introduced. We also calculated the net health benefit (or net harm) of
stratifying access to TJA using different thresholds using published methods.166,167 These estimates explicitly
exclude patients who do not currently have arthroplasty but might gain access to surgery if national
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guidelines were to introduce a threshold that was higher than that currently used by local commissioners
or primary health-care services; estimates of the impact of different thresholds that include this population
of people are described in Chapter 8.
The expected value of stratifying access to TJA based on different clinical tool thresholds, age and sex
(ValueofStratifying) was calculated by first multiplying the number of people in England of age (a), sex (s)
and clinical tool score (c) (Nasc) by the incremental net (health) benefit of TJA calculated in the model
for that patient group (INBasc = Rc • ΔQALYsasc –ΔCostasc). The expected value of introducing a specific
threshold was calculated by summing these figures across all clinical tool scores less than or equal to the
threshold (T) and subtracting that sum from 0:
ValueofStratifyingByAge, Sex and ClinicalToolScore = 0− ∑
a=50, 60, 70, 80, 90;
∑
s=M, F;
∑
T
c=0
Nasc • INBasc. (10)
For example, if the economic threshold was estimated to be 1 for tool (c) for people of age group (a) and
sex (s) and the INB was 2 for the 100 patients with a score of 0 and 1 for the 200 patients with a score of 1,
we would calculate the value of stratifying by clinical tool score in this demographic group as:
∑
T
c=0
Nasc • INBasc = 0− (2 × 100 + 1 × 200). (11)
We would then add these values across all demographic groups.
Because there may be practical and equity arguments against rationing access to surgery by age or sex,
we also calculated the weighted average incremental costs and incremental QALYs for TJA versus no
arthroplasty at different clinical tool scores, weighting by the proportion of people of different ages and
sexes (see Online Supplement 12). These values were used to calculate the ICER for different clinical tool
scores averaged across sexes or across all age/sex groups. We then calculated the value of stratifying only
by clinical tool score, and the value of stratifying only by clinical tool score and age:
ValueofStratifyingByAge and ClinicalToolScore = 0− ∑
a=50, 60, 70, 80, 90;
∑
T
c=0
Nac • INBac. (12)
ValueofStratifyingByClinicalToolScore = 0− ∑
T
c=0
Nc • INBc. (13)
The proportion of PSA draws that find TJA to be cost-effective compared with no TJA (i.e. the proportion
that have positive INB) was identified for each hypothetical patient group at different ceiling ratios. The
probability that TKA is cost-effective was plotted against clinical tool score. For brevity, we present figures
averaged over men and women by calculating the weighted average probability that TKA is cost-effective,
weighted by the proportion of patients who are female.
We also conducted four sensitivity analyses on each of the six Markov models:
1. Taking a 5-year time horizon (cf. 10 years in the base-case analysis).
2. Taking a 60-year (lifetime) time horizon.
3. Assuming that EQ-5D utility without TJA worsens by 0.025 per year (cf. a 0.0036–0.0069 decrease per
year, depending on age in the base-case analysis). The figure of 0.025 was based on the smallest
measurable difference in the original study used to estimate the EQ-5D time trade-off tariff (3 months
in 10 years).168
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4. Assuming that EQ-5D without TJA increases by 0.115 per year in the first year of the model and then
follows an age-related decline after that. The figure of 0.115 was based on the increase in EQ-5D in
the non-surgical treatment arm of a recent RCT that compared TKA against 12 weeks’ non-surgical
treatment comprising exercise, education, dietary advice, insoles and pain medication.169 This figure is
conservative because the non-surgical treatment used in the trial was relatively intensive and many NHS
patients may have already received similar conservative management before being listed for surgery.
For brevity, and to reduce computation time, we present point estimates only for sensitivity analyses, not
PSA. Furthermore, sensitivity analyses were run using the same reduced set of clinical tool score values
used for PSA; subsequently, the thresholds estimated for sensitivity analyses on the SF-12 and WOMAC are
approximate and may slightly overestimate the true threshold, because costs and QALYs for hypothetical
individuals that were not simulated were assumed to equal those for patients with a score one point
higher than the score that was not simulated.
Results
Effect of scores on costs and utilities
Regression analyses demonstrated that the preoperative OKS, OHS, WOMAC and SF-12 physical and
mental scores had a statistically significant effect on preoperative EQ-5D utility, EQ-5D utility 3–12 months
after primary arthroplasty, EQ-5D utility > 12 months after primary arthroplasty and EQ-5D utility after
knee revision surgery (p < 0.05; see Online Supplement 12). The OKS, OHS and SF-12, but not the
WOMAC, had a significant effect on the cost of primary arthroplasty surgery (p < 0.05). The OHS had a
significant effect on costs in the absence of hip arthroplasty (p = 0.003), but allowing for preoperative
EQ-5D worsened prediction accuracy. However, within the analyses conducted before the second user
group meeting, the clinical tool score was found to have no significant impact on EQ-5D utility before
revision surgery, the cost of revision surgery and costs in the absence of knee arthroplasty (p > 0.05;
see Online Supplement 12). The results of all regression models are shown in Online Supplement 12.
There was a strong relationship between preoperative clinical tool score and both preoperative and
postoperative utility that varied slightly with age (Figures 14–19). The magnitude of the difference between
preoperative and postoperative utility was, in turn, the main driver determining the QALYs gained from
TJA, the ICERs and the threshold clinical tool scores.
Figure 14 shows the relationship between the preoperative OKS and preoperative and postoperative
EQ-5D utility estimated using regression equations used in the Markov model. Preoperative EQ-5D utility
was estimated using a published linear mapping model,50 whereas 6-month utility was estimated on
freely available PROMs data using a Tobit model that included quadratic and cubic terms for OKS. Both
preoperative and postoperative utility increase sharply with preoperative OKS; however, the relationship
between the preoperative OKS and 6-month EQ-5D utility is non-linear and is markedly less steep for
patients with a baseline OKS of > 20. As a result, the change in utility following TKA is greatest at an
OKS of 9 or 10, and declines steadily at higher scores until the difference becomes negative (i.e. TKA is
expected to reduce quality of life) at an OKS of 41–44 or higher. Age had a relatively modest effect, with
the postoperative utility being between 0.02 and 0.08 lower for 50-year-old patients than for those aged
70–90 years. After adjusting for age and OKS, gender was found to have no significant impact on utility
after TKA and was dropped from the final model. Results for the OHS were similar (see Figure 15).
The relationship between preoperative WOMAC and preoperative and postoperative utility was similar
to that for the OKS and OHS (see Figures 16 and 17). However, the models for WOMAC predicted that
postoperative utility would always be higher than preoperative utility at all baseline WOMAC scores. The
linear models predicted postoperative EQ-5D utility to be > 1 for patients with high baseline WOMAC;
such predictions were set to 1 in the model.
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FIGURE 14 Effect of the preoperative OKS and age on preoperative and 6-month EQ-5D utility.
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FIGURE 16 Effect of the preoperative WOMAC score and age on preoperative and 6-month EQ-5D utility in TKA patients, based on the APEX study data. Preoperative utilities
were predicted based on a Tobit model that included quadratic and cubic terms, whereas postoperative utilities were modelled using linear regression.
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FIGURE 18 Effect of the preoperative SF-12 physical score on preoperative and 6-month EQ-5D utility in 70-year-old
TKA patients at SF-12 mental scores of (a) 30, (b) 50 or (c) 70, based on Tobit models on KAT data that included
polynomial terms for SF-12 scores.
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FIGURE 19 Effect of the preoperative SF-12 physical score on preoperative and 6-month EQ-5D utility in 70-year-old
THA patients at SF-12 mental scores of (a) 30, (b) 50 or (c) 70. Postoperative utility was based on a GLM with
log-link estimated on EPOS.
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The relationship between preoperative SF-12 physical score and preoperative and postoperative EQ-5D
utility varied with SF-12 mental score (see Figure 18). At a mental score of 30, the change in utility
following TKA was very small and was negative for patients with physical scores of ≥ 36, whereas the
change in utility was markedly larger for patients with high mental scores and declined more sharply with
SF-12 physical score. The way in which SF-12 is calculated means that patients cannot simultaneously get
very low scores on both the physical and mental scales, or get very high scores on both. In particular, the
highest possible physical score for patients with a mental score of 70 is 42.13, which is lower than the
physical score at which the models predict that the change in utility following TKA becomes negative; TKA
is therefore predicted to be beneficial for all patients with high mental scores.
For THA, the relationship between SF-12 physical score and change in utility following THA (see Figure 19)
was similar to that of TKA at high mental scores. However, for patients with a SF-12 mental score of 30,
the curve for utility after THA crossed the curve for utility before THA in two places. As a result, the
change in utility was negative for patients with low SF-12 physical scores as well as for those with high
scores. For 70-year-olds, the physical scores at which the change in utility is negative are below the
minimum possible score for patients with SF-12 mental scores of 30, although the models predict that
for 90-year-olds there are some attainable combinations of low physical and mental scores at which the
change in utility following THA is negative.
Because operative mortality is rare, relatively few patients have revision surgery and patients’ utility remains
relatively constant after 6 months (see Online Supplement 12), the change in utility in the first 6 months
after TKA is approximately proportional to the QALY gain from TKA.119 Figures 14–19 therefore indicate the
relationships that are driving the ICERs and clinical tool thresholds shown in the next six sections.
Effect of the Oxford Knee Score on the cost-effectiveness of knee replacement
The Markov models used the regression models predicting EQ-5D utilities, costs, mortality and revision
rates shown in Online Supplement 12 to calculate the costs and QALYs that different patient subgroups
would accrue over the 10-year period after TKA or after the decision was made not to operate. These
results were used to calculate the incremental cost-effectiveness of TKA versus no arthroplasty in people of
different ages with different preoperative OKSs (Table 40).
The results show that, as expected, TKA is highly cost-effective for most patients who currently undergo
surgery (see Table 40). The light blue area in Table 40 and subsequent decision grids indicates patient groups
for which TKA is cost-effective (i.e. costs < £20,000 per QALY gained compared with no arthroplasty). Table 40
shows only selected OKS values, focusing on values close to the threshold; for the OKS values not shown in
the decision grids, TKA costs < £20,000 per QALY gained. Based on the distribution of the preoperative OKS,
age and sex within the final PROMs/HES extract (see Online Supplement 12), TKA costs < £20,000 per QALY
gained compared with no arthroplasty in 99.7% of patients who currently undergo surgery and it costs
< £5000 per QALY gained in 97.4% of patients. TKA was most cost-effective (i.e. has the lowest cost/QALY)
for those patients with low preoperative OKSs.
The QALY gains from TKA are highest for patients with a preoperative OKS of around 10 and decrease
steadily as the OKS increases (mean incremental QALYs: 2.570 at OKS of 0, 3.301 at OKS of 9 and –0.355
at OKS of 48, averaged over all age and sex groups). This follows naturally from the difference in EQ-5D
utility before and after TKA shown in Figure 14. The difference in cost between patients undergoing TKA
and those having non-operative management was highest for patients with very low and very high OKS,
and lowest for patients with scores between 14 and 21 (mean incremental cost: £5539 at OKS of 0,
£6055 at OKS of 48 and £1710 at OKS of 16, averaged over all age and sex groups).
Cost-effectiveness results were primarily driven by the difference in QALYs, and the ICER (calculated as
the difference in cost divided by the difference in QALYs) increased sharply as the difference in QALYs
approached zero. For any given age group, the ICER for TKA versus no arthroplasty was very low for
patients with an OKS of below around 35, but increased sharply as the OKS increases and the difference
HEALTH ECONOMIC EVALUATION OF THRESHOLDS VALUES (WORK PACKAGE 2)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
90
TABLE 40 Cost-effectiveness of TKA in patients with different ages and baseline OKSs (results averaged over men
and women)
Preoperative OKS
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
0 £2059 £1643 £1978 £2781 £4762 £2155
10 £33 £221 £566 £1230 £2778 £655
20 Dominant £211 £616 £1377 £3154 £710
21 £53 £266 £680 £1460 £3291 £778
24 £378 £508 £956 £1812 £3858 £1071
28 £1167 £1061 £1597 £2627 £5151 £1748
29 £1457 £1254 £1828 £2924 £5624 £1990
30 £1799 £1475 £2099 £3276 £6187 £2274
31 £2207 £1730 £2418 £3696 £6863 £2608
32 £2697 £2025 £2800 £4204 £7689 £3006
33 £3296 £2370 £3263 £4830 £8717 £3485
34 £4044 £2778 £3834 £5619 £10,027 £4073
35 £5003 £3267 £4556 £6641 £11,752 £4811
36 £6277 £3865 £5499 £8020 £14,125 £5765
37 £8058 £4614 £6786 £9981 £17,593 £7049
38 £10,733 £5582 £8652 £12,998 £23,145 £8874
39 £15,226 £6888 £11,616 £18,258 £33,482 £11,687
40 £24,418 £8761 £17,084 £29,791 £59,554 £16,616
41 £54,138 £11,690 £30,672 £75,796 £253,711 £27,568
42 Dominated £16,983 £124,962 Dominated Dominated £73,754
43 Dominated £29,746 Dominated Dominated Dominated Dominated
44 Dominated £99,241 Dominated Dominated Dominated Dominated
45 Dominated Dominated Dominated Dominated Dominated Dominated
46 Dominated Dominated Dominated Dominated Dominated Dominated
47 Dominated Dominated Dominated Dominated Dominated Dominated
48 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold (95% CrI) 39 (37 to 43) 42 (41 to 45) 40 (39 to 42) 39 (38 to 40) 37 (24 to 41) 40 (39 to 42)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Dark green = dominant.
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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in quality of life between patients with and without TKA approached zero. For those patient subgroups
shown in dark or medium green in Table 40, TKA costs > £20,000 per QALY gained; although arthroplasty
improves quality of life, it is not cost-effective compared with the cost-effectiveness threshold that is
generally used in NHS decision-making. For patient subgroups with very high OKSs (the dominated area,
shown in white, in Table 40), TKA is dominated: it increases costs to the NHS and, on average, people in
these groups will have fewer QALYs than those having no arthroplasty because their EQ-5D utility is
expected to be lower with TKA than without and (to a lesser extent) because of surgical mortality.
For any given age group, we can identify the economic threshold as the score at the bottom of the light
blue area in Table 40. The economic threshold varies with age, being highest for 60-year-olds [42 (95%
CrI 41 to 45)] and lowest for 90-year-olds [37 (95% CrI 24 to 41)]. The economic threshold is slightly
lower for older patients because they have lower life expectancy and therefore enjoy the quality of life
improvements for a shorter period of time.125 Similarly, thresholds were somewhat lower for 50-year-olds
as they have higher revision rates and lower postoperative EQ-5D utility than patients aged 60–80 years.119
Cost-effectiveness also varied slightly between men and women, with all ICERs being slightly lower for
women than for men (see Online Supplement 12). However, the threshold OKS did not differ.
Averaging costs and QALYs across all age and sex groups suggests that if a single threshold were to be
applied for patients of all ages, the threshold OKS would be 40 (95% CrI 39 to 42).
However, there was uncertainty around the results, particularly for 90-year-olds (see Table 40) and
patients with an OKS close to the economic threshold. Figure 20 shows how the probability that TKA is
cost-effective compared with no arthroplasty (i.e. costs < £20,000 per QALY gained) changes with the
amount that the NHS is willing or able to pay to gain 1 QALY. For 70-year-olds with preoperative OKSs of
< 40, we can be > 99% confident that TKA is good value for money. However, this decreases to 73% at
an OKS of 40 and to 18% at an OKS of 41.
Effect of the Western Ontario and McMaster Universities Arthritis Index on the
cost-effectiveness of total knee arthroplasty
To facilitate the comparison of results across the different clinical tools, the results presented here are
based on a reversed and rescaled WOMAC total score, in which 0 represents the worst possible score
and 100 represents the best possible score. As in the previous section, incremental cost-effectiveness was
calculated using the Markov model, in which EQ-5D utility, costs, revision rates and mortality were
predicted based on a patient’s preoperative characteristics.
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FIGURE 20 Effect of the OKS on the probability that TKA is cost-effective at a £20,000-per-QALY ceiling ratio.
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For almost all WOMAC total scores, TKA is highly cost-effective (Table 41). The QALY gains were highest
for patients with low WOMAC scores (mean incremental QALYs at a score of 0 = 6.428) and decreased
steadily with WOMAC score (mean incremental QALYs at a score of 50 = 1.509; at a score of 100= 0.109).
Similarly, incremental costs for patients with TKA compared with patients without TKA were lowest for
patients with WOMAC scores of 5 (mean incremental cost = £2) and highest for patients with high scores
(mean incremental costs for a score of 100= £3361).
TABLE 41 Cost-effectiveness of TKA in patients with different ages and baseline WOMAC scores (results averaged
over men and women)
WOMAC score (rescaled
to 0–100; 0 indicates
poor function)
Cost
Age (years)
50 60 70 80 90 Average
0 Dominant Dominant £57 £354 £949 £83
10 Dominant Dominant £14 £460 £1350 £68
20 Dominant £28 £313 £940 £2276 £401
30 £262 £362 £713 £1588 £3574 £851
40 £647 £706 £1131 £2312 £5168 £1329
50 £989 £996 £1489 £2968 £6816 £1743
60 £1265 £1220 £1768 £3490 £8321 £2064
70 £1522 £1427 £2026 £3993 £9895 £2366
80 £1827 £1677 £2345 £4707 £12,190 £2755
85 £2289 £2055 £2873 £6029 £17,305 £3408
86 £2472 £2201 £3085 £6609 £19,984 £3674
87 £2689 £2371 £3331 £7295 £23,561 £3983
88 £2943 £2566 £3617 £8118 £28,555 £4343
89 £3236 £2788 £3944 £9117 £35,977 £4759
90 £3578 £3040 £4321 £10,350 £48,101 £5244
91 £3978 £3327 £4758 £11,901 £71,295 £5813
92 £4451 £3656 £5267 £13,899 £132,863 £6486
93 £5014 £4033 £5863 £16,549 £763,143 £7289
94 £5688 £4466 £6565 £20,207 Dominated £8256
95 £6504 £4965 £7396 £25,534 Dominated £9432
96 £7503 £5538 £8387 £33,931 Dominated £10,881
97 £8739 £6198 £9578 £48,964 Dominated £12,693
98 £10,294 £6957 £11,019 £83,197 Dominated £14,997
99 £12,286 £7829 £12,780 £235,097 Dominated £17,997
100 £14,902 £8830 £14,958 Dominated Dominated £22,018
Threshold (95% CrI) 100
(80 to 100)
100
(85 to 100)
100
(80 to 100)
93
(65 to 99)
86
(40 to 90)
99
(80 to 100)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Dark green = dominant.
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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The economic threshold averaged across age and gender was identified as 99 (95% CrI 80 to 100; see
Table 41), which is very close to the maximum value of 100. It should be noted that the highest observed
WOMAC score in the APEX study data was 87; the identified threshold value of 99 lies out with the sample.
However, there was considerable variation with age. For patients aged ≤ 70 years, TKA is cost-effective
at all WOMAC scores. TKA ceases to be cost-effective at a WOMAC score of 93 (95% CrI 65 to 99) for
patients aged 80 years, and the threshold is 86 (95% CrI 40 to 90) for those aged 90 years. Again, this
reflects the lower life expectancy at these ages, which means that the small benefits of TKA for patients
with a relatively good clinical score (see Figure 16) are not accrued for as long a period as younger patients.
There is considerable uncertainty around these threshold values, as shown by the wide 95% CrI. For example,
the 95% CI for the threshold averaged over all age and gender groups (99) ranges from 80 to 100. Similarly,
the 95% CrI for patients aged 90 years ranges from 40 to 90, covering half of all possible scores. This is likely
because of the relatively small sample sizes of the data sets used for the regression models (the regressions of
WOMAC on EQ-5D utility were based on 221 patients whereas those on costs of the primary operation were
based on 272 patients).
There was slight variation in cost-effectiveness between men and women. At higher ages (80 and 90 years),
the threshold for men was (in both cases) 3 points higher than for women (95 vs. 92 at age 80 years and
87 vs. 84 at age 90 years).
The PSA demonstrated that there is greater uncertainty around the results for the WOMAC than for the
OKS (Figure 21). For 70-year-olds, the probability that TKA was cost-effective was > 99% for patients with
WOMAC scores of ≤ 65 and fell to 96% for patients with a score of 90, 78% for a score of 98 and 62%
for a score of 100. For 90-year-olds, the probability that TKA was cost-effective was < 99% for scores of
≥ 40 and was < 0.1% for scores of ≥ 96.
Effect of the Short Form questionnaire-12 items on the cost-effectiveness of total
knee arthroplasty
For the SF-12, results were estimated for a range of physical scores at each of three mental scores (30, 50
and 70). The SF-12 scoring system decreases the physical scores for patients who have good mental health
or good social function and decreases the mental scores for patients with poor physical or general health.
As a result, it is not possible for the same person to have the lowest (or highest) scores on both the physical
domain and the mental domain. Results are only presented for those combinations of scores that are
possible on the SF-12 scoring system.
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For all three mental scores, the incremental cost of TKA versus no arthroplasty changed very little with
SF-12 physical score, whereas QALYs decreased very sharply. For example, for a mental score of 50, the
average incremental cost increased from £1954 per patient at a physical score of 15 to £3169 per patient
at a physical score of 60, whereas incremental QALYs decreased from 3.591 at a physical score of 12 to
–1.388 at a physical score of 60.
At a mental score of 30 (indicating very poor mental health), the threshold physical score was 58 (95% CrI
54 to 60), averaging across all ages (Table 42). For patients with a mental score of 50 (indicating average
mental health), thresholds were generally markedly lower than they were at a mental score of 30, and the
effect of age was more pronounced. Averaging across ages, the threshold physical score at a mental score
of 50 was 50 (95% CrI 48 to 52) (Table 43).
TABLE 42 Cost-effectiveness of TKA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 30
SF-12 physical
score
Cost
Age (years)
50 60 70 80 90 Average
18 £367 £440 £682 £1273 £3586 £789
19 £321 £400 £652 £1257 £3620 £760
20 £287 £370 £631 £1247 £3658 £739
25 £236 £314 £594 £1249 £3860 £708
30 £279 £334 £616 £1297 £4088 £738
35 £367 £391 £672 £1389 £4440 £807
40 £509 £490 £774 £1562 £5164 £931
45 £769 £669 £969 £1919 £7018 £1172
49 £1206 £953 £1282 £2544 £12,030 £1573
50 £1391 £1065 £1404 £2806 £15,284 £1734
51 £1633 £1204 £1557 £3145 £21,478 £1939
52 £1966 £1384 £1752 £3600 £37,694 £2206
53 £2450 £1624 £2007 £4236 £186,187 £2566
54 £3216 £1957 £2355 £5181 Dominated £3078
55 £4610 £2449 £2852 £6722 Dominated £3853
56 £7924 £3247 £3618 £9648 Dominated £5161
57 £25,718 £4757 £4937 £17,221 Dominated £7803
58 Dominated £8646 £7707 £80,227 Dominated £15,819
59 Dominated £40,402 £17,051 Dominated Dominated Dominated
60 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold
(95% CrI)
56 (52 to 60) 58 (54 to 60) 59 (56 to 60) 57 (53.95 to 60) 50 (44 to 54.05) 58 (54 to 60)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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For patients with a mental score of 70 (indicating very good mental health), the highest possible physical
score is 42. The threshold physical score is above the maximum that can be achieved at this mental score
for all groups other than 90-year-olds (Table 44) and 50- or 80-year-old men (see Online Supplement 13).
Averaging across all ages, the threshold physical score is 44 (95% CrI 42 to 46) (see Table 44); this is
2 points higher than the maximum achievable.
The ICERs and threshold SF-12 physical scores varied with age, with 70-year-olds having the highest threshold
SF-12 physical score and (generally) the lowest ICERs. Thresholds were markedly lower for 90-year-olds. There
was also substantially more uncertainty around thresholds for older patients, shown by the wider 95% CrI.
Thresholds were between 0 and 5 points higher for women than for men for subgroups aged 50–80 years,
with large differences between sexes for 90-year-olds (see Online Supplement 13).
TABLE 43 Cost-effectiveness of TKA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 50
SF-12 physical score
Cost
Age (years)
50 60 70 80 90 Average
12 Dominant £198 £506 £1101 £3255 £581
15 Dominant £175 £516 £1182 £3736 £601
20 Dominant £225 £598 £1377 £4736 £707
25 £108 £322 £718 £1614 £6028 £855
30 £263 £447 £866 £1909 £7970 £1039
35 £483 £619 £1075 £2351 £12,162 £1303
38 £692 £775 £1265 £2784 £19,302 £1551
39 £787 £843 £1347 £2981 £24,634 £1661
40 £902 £923 £1444 £3219 £34,769 £1791
42 £1229 £1133 £1696 £3877 £326,196 £2139
43 £1473 £1276 £1864 £4349 Dominated £2380
47 £4823 £2490 £3202 £9381 Dominated £4550
48 £9637 £3230 £3938 £13,673 Dominated £5978
49 £193,008 £4562 £5129 £25,787 Dominated £8763
50 Dominated £7654 £7374 £272,840 Dominated £16,538
51 Dominated £22,689 £13,137 Dominated Dominated £152,507
52 Dominated Dominated £59,560 Dominated Dominated Dominated
53 Dominated Dominated Dominated Dominated Dominated Dominated
60 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold (95% CrI) 48 (44 to 52) 50 (48 to 52) 51 (48 to 52) 48 (46 to 50) 38 (25 to 44) 50 (48 to 52)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Dark green = dominant.
l Light green= ICER of < £20,000.
l Light blue= ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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The PSA demonstrated that we can be > 99% confident that TKA is cost-effective for 70-year-olds with
SF-12 mental scores of 50 and SF-12 physical scores of ≤ 48 at a £20,000-per-QALY ceiling ratio (Figure 22).
However, as would be expected, there is substantially more uncertainty around cost-effectiveness for patients
around the threshold: at a mental score of 50, the probability that TKA is cost-effective for patients with a
SF-12 physical score of 50 is 75%, which decreases to 40% for patients with a physical score of 52 and to
0% for patients with a score of 56. The level of uncertainty was similar across the range of mental scores,
but was markedly greater for 90-year-olds.
Effect of the Oxford Hip Score on cost-effectiveness of total hip arthroplasty
The incremental cost of THA compared with no arthroplasty increased with the OHS, from £779 per patient
at an OHS of 0 up to £4258 at an OHS of 48 (averaged across men and women of all ages). THA was less
costly than conducting no arthroplasty for 50- and 60-year-old patients with an OHS of 0 or 1, because
the cost of non-surgical management was highest for patients with very low OHSs. The QALY gains from
surgery were highest for patients with an OHS of 6 or 7: THA produced an increase of 3.68 QALYs for the
average patient with an OHS of 0, 4.47 QALYs at an OHS of 6 and –0.61 QALYs at an OHS of 48.
TABLE 44 Cost-effectiveness of TKA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 70
SF-12 physical score
Cost
Age (years)
50 60 70 80 90 Average
12 Dominant Dominant £274 £845 £2630 £314
15 Dominant Dominant £353 £1000 £3189 £407
20 Dominant £81 £508 £1309 £4485 £589
25 Dominant £209 £695 £1706 £6689 £813
30 Dominant £373 £940 £2282 £11,907 £1118
31 £5 £414 £1002 £2437 £14,066 £1197
32 £44 £459 £1070 £2614 £17,205 £1285
33 £89 £511 £1147 £2818 £22,217 £1386
34 £141 £569 £1235 £3057 £31,542 £1501
35 £204 £637 £1336 £3342 £55,118 £1637
36 £282 £717 £1454 £3690 £233,756 £1798
37 £382 £814 £1594 £4126 Dominated £1994
38 £516 £932 £1763 £4687 Dominated £2238
39 £703 £1083 £1973 £5442 Dominated £2551
40 £986 £1279 £2241 £6509 Dominated £2967
41 £1461 £1546 £2594 £8136 Dominated £3548
42 £2421 £1930 £3080 £10,919 Dominated £4416
Threshold (95% CrI) 43 (38 to 46) 44 (42 to 48) 44 (44 to 48) 43 (40 to 46) 32 (25 to 38) 44 (42 to 46)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Dark green = dominant.
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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Therefore, conducting THA dominated no arthroplasty for 50- and 60-year-olds with an OHS of 0 or 1,
given that it was less costly and generated more QALYs.
The threshold OHS above which THA ceased to be cost-effective was 43 (95% CrI 42 to 43) for 70-year-olds,
but fell to 38 (95% CrI 34 to 41) for 90-year-olds (Table 45). The analysis averaging across all age groups
suggested that if it was not acceptable to have different thresholds for different age groups, a single threshold
of 42 (95% CrI 42 to 42) would be most appropriate. PSA demonstrated that there is very little uncertainty
around the economic threshold, with 95% of the 2000 PSA replicates indicating a threshold of 42 when
results were averaged across men and women of all age groups. The difference between men and women
was negligible: the threshold was 1 point higher for 80-year-old men and 1 point lower for 70-year-old
women, although thresholds for men and women were otherwise the same as those shown in Table 45
(see Online Supplement 13).
The PSA demonstrated that there was relatively little uncertainty around cost-effectiveness for patients
aged ≤ 80 years (Figure 23). For 70-year-olds, the probability that THA cost < £20,000 per QALY gained
was > 99% for patients with an OHS of ≤ 42 and fell to 47% for patients with an OHS of 43 and to
< 0.1% for patients with an OHS of ≥ 44. Uncertainty was markedly greater for 90-year-olds over a wide
range of OHSs.
Effect of the Western Ontario and McMaster Universities Arthritis Index on the
cost-effectiveness of total hip arthroplasty
The QALY gains from THA were highest for patients with low WOMAC scores (mean incremental QALYs
at a score of 0 = 8.228) and decreased for patients with higher scores (mean incremental QALYs at a score
of 50 = 3.054, and at a score of 100 = 0.289). In contrast, the model results suggest that WOMAC scores
do not predict costs of THA compared with no arthroplasty. The mean incremental costs were around
£3200, regardless of WOMAC score.
Total hip arthroplasty was cost-effective at almost all WOMAC scores (Table 46). The only exception was
for patients aged 90 years and those with a WOMAC score of 100 (the best possible score). In contrast to
the results for TKA, the 95% CrIs indicate little uncertainty about the threshold; for almost all age groups,
the CrIs range from 98 to 100. There are almost no differences in cost-effectiveness between men and
women, the only exception being patients aged 90 years with a clinical score of 99, among whom THA is
cost-effective for women but not for men. Again, it should be noted that there were no patients observed
at these scores in the available data sets.
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FIGURE 22 Effect of the SF-12 score on the probability that TKA is cost-effective at a £20,000-per-QALY ceiling ratio.
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The PSA suggested that there was relatively little parameter uncertainty within the model: the probability
that THA was cost-effective at a £20,000-per-QALY ceiling ratio was ≥ 99% for all patients with WOMAC
scores of ≤ 90 (Figure 24).
Effect of the Short Form questionnaire-12 items on the cost-effectiveness of total
hip arthroplasty
For patients with SF-12 mental scores of 30 or 50, incremental QALYs were highest at physical scores of
between 18 and 28 and were markedly lower for patients with higher or lower scores. By contrast, for
patients with a mental score of 70, incremental QALYs were highest at a physical score of 12 and declined
steadily with an increasing physical score. For all three mental scores, the incremental cost of TKA versus no
arthroplasty changed very little with SF-12 physical score. For example, for a mental score of 50, the average
incremental cost (across men and women of all ages) decreased from £4267 per patient at a physical score
of 19 to £3058 per patient at a physical score of 60, whereas incremental QALYs decreased from 3.42 to
–0.26. As was the case for TKA, THA was dominated by no arthroplasty (generating fewer QALYs at a
TABLE 45 Cost-effectiveness of THA in patients with different ages and baseline OHSs (results averaged over men
and women)
Preoperative OHS
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
0 Dominant Dominant £326 £571 £1208 £212
10 £630 £616 £737 £958 £1885 £779
20 £1055 £966 £1029 £1273 £2171 £1105
30 £1936 £1699 £1762 £2214 £4101 £1928
35 £3080 £2600 £2737 £3556 £7682 £3027
36 £3480 £2902 £3071 £4042 £9310 £3410
37 £3994 £3280 £3497 £4680 £11,816 £3901
38 £4682 £3769 £4058 £5556 £16,172 £4554
39 £5648 £4426 £4830 £6832 £25,631 £5467
40 £7105 £5355 £5960 £8865 £61,836 £6832
41 £9557 £6769 £7775 £12,616 Dominated £9097
42 £14,554 £9187 £11,169 £21,853 Dominated £13,592
43 £30,346 £14,265 £19,787 £81,441 Dominated £26,810
44 Dominated £31,771 £86,085 Dominated Dominated £910,589
45 Dominated Dominated Dominated Dominated Dominated Dominated
46 Dominated Dominated Dominated Dominated Dominated Dominated
47 Dominated Dominated Dominated Dominated Dominated Dominated
48 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold (95% CrI) 42 (41 to 43) 43 (43 to 43) 43 (42 to 43) 41 (41 to 42) 38 (34 to 41) 42 (42 to 42)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Dark green = dominant.
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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FIGURE 23 Effect of the OHS on the probability that THA is cost-effective at a £20,000-per-QALY ceiling ratio.
TABLE 46 Cost-effectiveness of THA in patients with different ages and baseline WOMAC total scores (results
averaged over men and women)
Preoperative WOMAC
score (rescaled to 0–100;
0= poor function;
selected values only)
Cost
Age (years)
50 60 70 80 90 Average
0 £372 £366 £399 £499 £743 £424
10 £427 £418 £454 £574 £878 £485
20 £510 £496 £537 £683 £1060 £577
30 £624 £604 £652 £829 £1294 £702
40 £762 £735 £790 £1005 £1570 £852
50 £922 £885 £949 £1205 £1885 £1024
60 £1115 £1065 £1137 £1441 £2257 £1229
70 £1395 £1323 £1406 £1777 £2791 £1522
80 £1915 £1796 £1899 £2392 £3774 £2060
85 £2391 £2222 £2342 £2944 £4663 £2545
90 £3227 £2952 £3094 £3879 £6188 £3373
95 £5069 £4484 £4650 £5804 £9402 £5104
96 £5742 £5019 £5186 £6465 £10,529 £5706
97 £6631 £5707 £5870 £7306 £11,980 £6478
98 £7861 £6623 £6771 £8411 £13,919 £7504
99 £9672 £7906 £8016 £9929 £16,644 £8933
100 £12,610 £9830 £9844 £12,148 £20,753 £11,064
Threshold (95% CrI) 100
(98 to 100)
100
(99 to 100)
100
(99 to 100)
100
(98 to 100)
99
(96 to 100)
100
(99 to 100)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Light green= ICER of < £20,000.
l Light blue= ICER of £20,000–30,000.
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higher cost) for patients with very high physical scores. However, THA was also dominated for 90-year-old
patients with extremely low physical scores and below-average mental scores. For patients with very poor
mental health (a mental score of 30), the threshold physical score was 59 (95% CrI 56 to 60), averaging
across all ages (Table 47). Thresholds were slightly lower for patients with a mental score of 50 (i.e. average
mental health), for whom the threshold physical score was 56 (95% CrI 54 to 58), averaging across ages
(Table 48).
The threshold physical score for patients with a mental score of 70 (i.e. very good mental health) was
substantially higher than the maximum that can be achieved at this mental score for all age groups (Table 49).
Averaging across all ages, the models predicted that the threshold physical score is 55 (95% CrI 52 to 56) for
a mental score of 70: 13 points higher than the maximum achievable score (42).
The PSA suggested that there was very little uncertainty around the results for 70-year-olds (Figure 25).
The probability that THA costs < £20,000 per QALY gained was > 99% for 70-year-olds with SF-12 physical
scores of ≥ 52 and fell sharply as physical scores increased. However, there was markedly greater uncertainty
for 90-year-olds across the range of physical scores.
Sensitivity analysis
Sensitivity analyses demonstrated that the results are reasonably robust to large changes in two key
assumptions (Table 50). Reducing the time horizon from 10 to 5 years reduced thresholds slightly, because
it reduces the duration for which patients are assumed to experience the postarthroplasty EQ-5D utility.
Conversely, increasing the time horizon to 60 years had minimal impact on thresholds.
In the base-case analysis, we assumed that patients’ osteoarthritis symptoms would remain at a constant
level in the absence of arthroplasty, with EQ-5D utility reducing by around 0.0036–0.0069 per year because
of ageing. Increasing the rate at which EQ-5D utility decreases to an arbitrary rate of 0.025 per year (the
smallest difference in valuations that was possible in the EQ-5D valuation study168) substantially increased all
thresholds, because it reduced the number of QALYs accrued in the no arthroplasty arm. We also conducted
an analysis that assumed that EQ-5D utility for patients in the no arthroplasty arm would increase by
0.115 in year 1 (the mean EQ-5D change in a trial comparing arthroplasty against an intensive non-surgical
management intervention)169 and then decline at the same age-dependent rate assumed in the base-case
analysis; this analysis substantially reduced thresholds.
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FIGURE 24 Effect of the WOMAC on the probability that THA is cost-effective at a £20,000-per-QALY ceiling ratio.
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TABLE 47 Cost-effectiveness of THA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 30
Preoperative SF-12
physical score
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
18 £1268 £1096 £1204 £2051 Dominated £1439
19 £1205 £1057 £1166 £1930 Dominated £1376
20 £1159 £1028 £1138 £1843 £103,982 £1329
21 £1124 £1007 £1117 £1778 £23,002 £1294
22 £1098 £991 £1102 £1730 £13,811 £1268
30 £1043 £977 £1106 £1650 £5200 £1236
40 £1094 £827 £936 £1659 £5086 £1151
50 £1293 £1245 £1467 £2448 £11,212 £1690
51 £1392 £1340 £1590 £2708 £13,914 £1837
52 £1516 £1456 £1745 £3049 £18,758 £2022
53 £1672 £1603 £1945 £3514 £29,816 £2262
54 £1877 £1794 £2209 £4180 £79,333 £2585
55 £2154 £2050 £2573 £5208 Dominated £3029
56 £2547 £2407 £3104 £6981 Dominated £3694
57 £3144 £2938 £3941 £10,715 Dominated £4781
58 £4148 £3801 £5435 £23,396 Dominated £6853
59 £6164 £5423 £8798 Dominated Dominated £12,230
60 £12,140 £9504 £22,862 Dominated Dominated £56,760
Threshold (95% CrI) 60 (58 to 60) 60 (58 to 60) 59 (58 to 60) 57 (54 to 60) 52 (11 to 56) 59 (56 to 60)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Light green= ICER of < £20,000.
l Light blue= ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
TABLE 48 Cost-effectiveness of THA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 50
Preoperative SF-12
physical score
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
12 £1226 £1091 £1214 £1987 £580,230 £1419
15 £1079 £996 £1120 £1711 £7280 £1268
20 £1045 £993 £1050 £1670 £4454 £1222
30 £864 £849 £976 £1488 £4257 £1103
40 £1110 £1105 £1310 £2051 £4913 £1455
50 £2060 £2056 £2625 £4737 £17,623 £2933
51 £2311 £2304 £2990 £5621 £26,282 £3351
52 £2643 £2630 £3485 £6936 £52,926 £3923
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TABLE 48 Cost-effectiveness of THA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 50 (continued )
Preoperative SF-12
physical score
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
53 £3103 £3075 £4189 £9078 Dominated £4748
54 £3772 £3715 £5257 £13,126 Dominated £6027
55 £4826 £4699 £7046 £23,438 Dominated £8244
56 £6702 £6382 £10,592 £99,530 Dominated £12,941
57 £10,892 £9850 £20,671 Dominated Dominated £29,016
58 £27,878 £20,768 £218,915 Dominated Dominated Dominated
59 Dominated Dominated Dominated Dominated Dominated Dominated
60 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold (95% CrI) 57 (54 to 58) 57 (56 to 58) 56 (54 to 58) 54 (52 to 56) 50 (40 to 54) 56 (54 to 58)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
TABLE 49 Cost-effectiveness of THA in patients with different ages and baseline SF-12 physical scores (results
averaged over men and women) and a SF-12 mental score of 70
Preoperative SF-12
physical score
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
12 £940 £855 £817 £1419 £3356 £1020
15 £691 £662 £730 £1061 £2976 £826
20 £749 £726 £809 £1168 £2572 £898
25 £836 £816 £921 £1333 £2709 £1014
30 £946 £929 £1063 £1552 £3094 £1165
35 £1096 £1081 £1256 £1861 £3700 £1373
40 £1328 £1317 £1562 £2375 £4822 £1703
41 £1393 £1383 £1649 £2524 £5169 £1797
42 £1467 £1458 £1748 £2698 £5586 £1904
Threshold (95% CrI) 57 (54 to 58) 57 (56 to 58) 56 (54 to 58) 54 (52 to 56) 50 (40 to 54) 56 (54 to 58)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Light green = ICER of < £20,000.
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FIGURE 25 Effect of the SF-12 physical score on the probability that THA is cost-effective at a £20,000-per-QALY
ceiling ratio.
TABLE 50 Results of sensitivity analysis
Sensitivity analysis
Economic threshold for TKA ignoring
age and sex
Economic threshold for THA ignoring
age and sex
OKS
WOMAC
score
SF-12 physical and
mental scores of:
OHS
WOMAC
score
SF-12 physical and
mental scores of:
30 50 70 30 50 70
Base-case analysis 40 98 58 49 44 42 100 59 56 56
5-year time horizon 38 94 57 48 43 41 99 59 55 53
60-year (lifetime) time horizon 40 98 57 49 44 42 100 60 57 55
EQ-5D utility without TJA
worsens by 0.025 per year
46 100 59 54 50 47 100 60 60 60
EQ-5D utility without TJA
increases by 0.115 in the first
year and follows age-related
decline thereafter
33 80 52 43 37 36 89 55 51 47
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Discussion
Summary of the results
We were able to calculate thresholds for TKA and THA for the OKS, OHS, WOMAC and SF-12 physical scores
that represent the highest score at which arthroplasty is cost-effective if the NHS is willing or able to pay
£20,000 per QALY gained (Table 51). These thresholds were generally somewhat higher than the relative
thresholds calculated in Chapter 4, but a little lower than the absolute thresholds. The economic thresholds
are more similar to the absolute thresholds than relative thresholds as they are based on the score at which
there is zero difference in net benefits, rather than a MID. However, unlike the clinical analyses, the economic
evaluation measures outcomes using the EQ-5D rather than the score in question and takes account of
mortality, revisions, complications and costs. The economic evaluation also explicitly compares costs and
outcomes with arthroplasty against the costs and outcomes that are expected to be accrued without
arthroplasty. Unlike the relative thresholds described in Chapter 4, the economic thresholds also evaluate
outcomes on a continuous scale (being more like the linear regression models described in Chapter 4 than
the logistic regression models) and are also based on the average (mean) benefit, rather than the probability of
benefit. No MID is imposed on the data, and the analysis directly takes account of operative mortality and the
cost of surgery and subsequent follow-up and revision surgery. Because arthroplasty is relatively cheap and
TABLE 51 Summary of the economic and clinical thresholds and the impact of different thresholds on the number
of operations conducted in England each year
Clinical tool Threshold (95% CrI)
QALYs gained
from stratifyinga
Number of
operations avoideda
Knees
OKS
Economic thresholdb 40 (39 to 42) 53 219
Clinical relative thresholdc 32 –2020 3342
WOMAC
Economic thresholdb 99 (80 to 100) 0 0
Clinical relative thresholdc 71 –4234 4813
SF-12d
Economic thresholdb 50 (48 to 52) 867 1584
Clinical relative thresholdc 37 –15,655 17,326
Hips
OHS
Economic thresholdb 42 (42 to 42) 25 100
Clinical relative thresholdc 37 –314 814
WOMAC
Economic thresholdb 100 (99 to 100) 0 0
Clinical relative thresholdc 80 –1775 1411
SF-12d
Economic thresholdb 56 (54 to 58) 54 224
Clinical relative thresholdc 35 –22,389 11,566
a The number of operations that would be avoided by introducing a threshold and the QALY gain from introducing the
threshold compared with treating all patients currently undergoing surgery were calculated across the patients who
currently have surgery, excluding potential patients who currently do not have arthroplasty.
b Economic threshold if age and sex are ignored (see Tables 40–49).
c Clinical threshold based on logistic regression, defining the threshold as the clinical tool score at which 75% of patients
are expected to show a ≥ 0.5 SD improvement.
d Threshold SF-12 physical scores are shown based on patients with a mental score of 50.
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produces such large QALY gains for those people who benefit, it is cost-effective for almost all patients who are
expected to have any improvement in quality of life.
We also calculated how the number of operations currently done in England would change using each of the
six economic thresholds and the corresponding clinical relative thresholds, based on the distribution of scores
in the best available data sets (see Online Supplement 12) and assuming that 76,617 knee replacements and
69,313 hip replacements are done each year (see Presentation of results and analysis of uncertainty).154,165
This calculation has two parts: (1) operations currently done that would be avoided (based on those patients
currently receiving operations who are above the threshold) and (2) operations not currently done that might
be considered (based on patients who are below the threshold but at present are not listed for arthroplasty).
The calculations presented in this chapter focused only on the first part (i.e. the number of current operations
conducted on patients above the threshold).
If the economic threshold of 40 (ignoring age and sex) was applied to all 76,617 knee replacements done in
England each year,154,165 then 219 operations could be avoided, because only 219 patients (0.29%) having
knee replacement operations have an OKS of > 40 (see Table 51). If the NHS stopped doing knee arthroplasty
on those 219 patients, the equivalent of 53 QALYs would be gained from avoiding undertaking surgery that
would reduce quality of life in some of these 219 patients, and by saving money that could be spent on other
patients who would gain additional health benefits. Similarly, applying the economic threshold of 42 would
avoid 100 of the 69,313 hip replacements currently done each year,154,165 gaining 25 QALYs.
For comparison, the clinical analysis suggested a relative threshold for an OKS of 32; using this threshold,
we would avoid 3342 operations, but this policy would be expected to reduce the amount of health
benefits gained from the NHS budget by 2020 QALYs, by avoiding treatment in patients for whom knee
replacement would improve quality of life. Similarly, the clinical relative threshold for hip replacement (37)
would avoid 731 operations but reduce health by 284 QALYs.
The economic thresholds estimated for the WOMAC were extremely close to the top of the scale and
WOMAC did not identify any patients aged < 90 years for whom THA is not cost-effective, nor any patients
aged 60 or 70 years for whom TKA is not cost-effective. No patients recruited to the studies used to estimate
EQ-5D utility and costs after TKA had WOMAC scores of > 87, whereas the highest score observed among
THA patients was 93. Taken at face value, this implies that no patients who currently undergo surgery would
be denied treatment based on the economic thresholds estimated in the analysis. However, owing to the
lack of data in patients with high WOMAC scores, the results for patients with high WOMAC scores and
the estimated WOMAC thresholds should be interpreted with caution as they are based on predictions
extrapolated outside the range of the observed data. In particular, it seems implausible that TJA would
be cost-effective in patients with a WOMAC score of 100, who would have no pain, stiffness or loss of
function. Conversely, the clinical thresholds estimated for WOMAC are low relative to those for the OKS and
OHS and would, therefore, be expected to avoid more operations, but with greater loss of patients’ health.
Therefore, more research on larger data sets including patients with scores of > 85 is needed to estimate
economic thresholds for the WOMAC.
The threshold SF-12 physical score varied markedly with SF-12 mental scores. As would be expected,
thresholds were lower for patients with mental scores of 30 (poor mental health) than for patients with
mental scores of 50 (average mental health). However, other than for TKA patients aged 90 years, the
threshold physical score for patients with SF-12 mental scores of 70 (indicating very good mental health)
was higher than the maximum score that can be achieved at that mental score. As a result, SF-12 cannot
distinguish between those people who would benefit from arthroplasty and those who would not among
those with very good mental health. Furthermore, the scoring of the SF-12 is such that people with very
poor physical scores are assigned better mental scores than people who have good physical scores
but the same level of mental health.
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The model also suggested that THA (but not TKA) is poor value for money in 90-year-old patients with
extremely low SF-12 physical scores and SF-12 mental scores of either 30 or 50. One possible explanation
for this unexpected finding is that the generic SF-12 instrument captures a wide range of health problems,
including comorbid conditions, whereas the OHS and WOMAC focus on hip or musculoskeletal symptoms.
It is possible that these comorbid conditions are worsened by arthroplasty or that, in patients who have other
conditions limiting their quality of life, THA produces relatively limited improvements in EQ-5D utility because
patients still experience severe pain and limited function because of their other health problems. However,
this result could also be an artefact of the way that SF-12 scores are calculated or the shortage of data in
this patient group; only nine patients in EPOS were aged ≥ 90 years and no patients (of any age) had SF-12
mental scores of < 35 and SF-12 physical scores of < 22.
The results for the OKS are similar to those estimated previously for KAT by Dakin et al.:2 we estimate the
economic threshold to be 40 (95% CrI 39 to 42), and Dakin et al.2 estimated a threshold of 39 for patients
with an ASA grade of 1 or 2 and a threshold of 34 for patients with an ASA grade of 3. However, the
difference between men and women appears to be smaller in the current analysis than was suggested by
Dakin et al.2 These differences appear to be largely attributable to the differences in time horizon (5 years
vs. 10 years in the current analysis), because the sensitivity analysis using a 5-year time horizon estimated
the OKS threshold to be 38. Furthermore, the additional data sets available in this analysis (particularly
COASt) enabled us to allow for the costs and quality-of-life changes likely to arise without arthroplasty.
Although we used KAT data for costs and long-term outcomes, we also used data from published
studies,50,112,119,125 COASt and national PROMs and used very different analytical methods, synthesising data
from different sources in a Markov model rather than estimating total costs and total QALYs for individual
trial participants in a within-trial analysis. In particular, PROMs provided a much larger sample of patients
with very high OKSs. The current study also allowed for a wide range of non-linear models, which
suggested that it may be appropriate to have lower thresholds for patients aged < 60 years. Given the
differences in analytical approach and data inputs, the similarity of the thresholds in the two studies
appears to suggest that the thresholds estimated are relatively robust.
Jenkins et al.105 also estimated the relationship between the Oxford Hip and Knee Scores and QALYs for both
TKA and THA, and Fordham et al.68 assessed how cost-effectiveness varied with the OHS. Lavernia et al.106
assessed how cost-effectiveness varied with preoperative WOMAC score and, unlike the current analysis,
found that patients in the top quartile for WOMAC scores (with worst function and pain) had the largest
QALY gains and lowest ICERs for THA. Whereas these previous studies had found arthroplasty to be highly
cost-effective for most patients, Ferket et al.108 found TKA to cost more than US$100,000 per QALY gained
unless treatment was restricted to patients with SF-12 physical scores of ≤ 20. The high ICERs in the Ferket
et al.108 study appear to largely arise from the small estimates of the improvements in utility achieved through
arthroplasty (0.008), which appear to contradict the findings of a RCT (which found the difference in EQ-5D
utility between patients with and without TKA to be 0.078)169 and English National PROMs data (which
observe a mean increase in EQ-5D utility of 0.310). The difference could reflect differences between EQ-5D
and SF-12 utilities, use of propensity weights in the Ferket et al.108 study or the small sample of US patients
with mild osteoarthritis who were analysed by Ferket et al.108 None of these studies estimated thresholds that
can be directly compared with the current analysis.
Limitations
The economic evaluation compared immediate TJA with conducting no arthroplasty for 10 years. In practice,
arthroplasty may simply be delayed in those patients who have high PROM scores. Although the choice of a
10-year time horizon is arbitrary, sensitivity analyses suggested that extending or shortening the time horizon
had minimal effect on the results.
Whereas the NHS PROMs data provided Oxford Hip and Knee Scores for > 80% of all arthroplasty
operations conducted in England,162 the data sets available for the WOMAC and SF-12 were < 2% of the
size and included very few patients with very high scores, which meant that the economic threshold for
the WOMAC could only be estimated by extrapolating beyond the observed data. Furthermore, the only
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data set providing preoperative costs (COASt) did not use the WOMAC or SF-12 and no data sets with
preoperative WOMAC scores provided more than 1 year’s follow-up; as a result, it was necessary to
estimate the relationship between the WOMAC and SF-12 and these outcomes indirectly via EQ-5D
utilities. KAT was the only study using both the SF-12 and the EQ-5D. All estimates of improvements in
EQ-5D utility and long-term changes in utility for the SF-12 in THA are therefore based on mapped utilities,
which introduces additional errors not propagated through the analysis, and this could introduce bias.
Unlike the Oxford Hip and Knee Scores, there are two available versions of the SF-12; in this analysis,
we assumed that versions 1 and 2 are equivalent.
Equity implications
At present, GPs, commissioning groups and hospitals use a wide variety of different tools and mechanisms
to determine eligibility for arthroplasty.170–176 As a result, patients’ access to surgery depends on where
they live, not just their clinical need. Furthermore, the thresholds used by commissioning groups, such as
19 or 24,170,171,176 are far below the score at which arthroplasty ceases to be cost-effective and, therefore,
thousands of patients who would get substantial benefit from surgery are denied treatment. In principle,
introducing an evidence-based threshold across the country could reduce postcode rationing and improve
equity of access.
The results suggest that a modest amount of population health could be gained by setting different
thresholds for patients of different ages. Focusing on those patients currently undergoing surgery and
ignoring the large numbers of patients who are currently not being referred for treatment suggests that
society could avoid 219 operations and gain 53 QALYs by stopping all operations on patients with OKSs
of > 40, but could avoid 247 operations and gain 62 QALYs by having different thresholds for patients
of different ages. Similarly, for the OHS, we could avoid 100 operations and gain 25 QALYs using a fixed
threshold of 42, and could avoid 114 operations and gain 29 QALYs by having different thresholds for
patients of different ages. However, restricting access to care by age as well as clinical need raises equity
and ethics concerns. NICE guidance may refer only to age if age is a good indicator of health status or
response to treatment and/or adverse effects, or if there is no practical way of identifying patients other
than by age.98 Our regression models and those identified in our literature review demonstrate that age
does influence mortality, revision rates, quality of life and the cost of surgery, suggesting that setting
different thresholds by age could be clinically justifiable. However, we found the effect of age on the
estimates of the economic thresholds to be generally quite small and most noticeable in the highest age
groups (e.g. ≥ 90 years) in which very few data were available. Moreover, the effect of age is likely to arise
largely through physical activity, general health and comorbidities, which have not been taken into account
in this analysis, and it may be possible to identify those patients likely to have minimal benefit or greatest
risk based on these characteristics, rather than relying on age.
In principle, thresholds could also vary by gender; thresholds for the OHS were 1 point lower for women
aged 70 years and 1 point higher for men aged 80 years, although OKS thresholds were the same for
men and women. However, a policy varying thresholds by sex would avoid no knee operations and only
three hip operations and gain 0.25 QALYs across England compared with thresholds that varied only by
age. These modest gains are unlikely to be sufficient to justify the additional complexity or the equity
implications of rationing access to care by gender.
Implementation issues
Our results suggest that population health could be improved by introducing thresholds that are markedly
higher than those used by most hospitals and commissioning groups. If such thresholds were introduced,
it is highly likely that more patients would come forward for surgery and be referred for surgical assessment.
This would require additional funding for arthroplasty procedures. Our results suggest that health would be
improved by increasing spending on arthroplasty in preference to less cost-effective interventions. However,
to achieve these health gains, less cost-effective interventions would have to be identified and deprioritised.
Furthermore, capacity constraints of trained surgeons and operating theatres would have to be addressed.
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The current analysis is based on UK data and may not necessarily be generalisable to other countries,
particularly those in which the cost of TJA or non-surgical management are very different. The analysis
also focuses on TJA for osteoarthritis; the costs and benefits of unicompartmental knee arthroplasty or hip
resurfacing may also differ from those of total arthroplasty, and the risks and benefits of arthroplasty may
be very different for patients with conditions other than osteoarthritis.
Additional findings
The models developed to map from the WOMAC and SF-12 to EQ-5D utilities could also be applied in other
settings in which WOMAC or SF-12 data are available, but EQ-5D utilities are not. Coefficients for these
models are shown in Online Supplement 12. However, owing to the nature of our analysis, we focused on
models based on the WOMAC total score and the SF-12 physical and mental scores; more accurate models
could have been obtained by exploring the effect of subdomain scores or dummy variables for individual
questions. Our analyses suggested that published models mapping from the SF-12 onto EQ-5D utility that
were estimated on general public samples performed poorly in knee arthroplasty candidates,110,158,177
probably because these patients have low utility compared with the general public. This highlights the
importance of selecting a mapping model that has been developed or validated in the sample of interest.
Conclusion
In conclusion, economic thresholds have been estimated for the OKS, OHS, WOMAC and SF-12 physical
score, which reflect the incremental costs and benefits of total hip/knee arthroplasty compared with
conducting no arthroplasty. However, there is a shortage of data on the WOMAC, particularly from
patients with very high scores, which means that we cannot identify patients for whom arthroplasty is
not cost-effective based on the available data. The threshold SF-12 physical score varies with mental score
and, among those patients with very good mental health, the SF-12 physical score cannot identify any
patients for whom arthroplasty is not cost-effective. The economic thresholds for the Oxford Hip and Knee
Scores are somewhat higher than the relative clinical thresholds estimated in Chapter 4 and are markedly
higher than those currently used in clinical practice. There is some evidence that modest additional health
gains could be achieved by using different thresholds for patients of different ages, but setting different
thresholds for men and women is unlikely to be justifiable.
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Chapter 6 Further analysis of threshold values
(work package 2)
Background
Based on the work presented in the previous chapters and after input from the user group (see Chapter 10),
the Oxford Hip and Knee Scores were selected as the candidate tools. In this chapter, relative thresholds for
the OHS and OKS were estimated through more advanced modelling approaches using the NHS PROMs
data set (2009–15) linked to HES. It was agreed in the third user group meeting to develop the ACHE tool
based on the principle of the capacity of a patient to benefit from surgery. To do this, more detailed
information was required on the effect of the patient’s preoperative score on the potential range of
outcomes. The data could then be incorporated into delivering the ACHE tool.
Research aims
The aims of this work were to:
l estimate the postoperative Oxford score using the respective hip and knee preoperative scores and the
respective relative thresholds using an improvement criterion based on an individual-level ROC estimate
l assess the influence and prognostic value of candidate baseline covariates to predict postoperative
improvement in the Oxford Hip and Knee Scores.
Methods
General approach
Two modelling approaches were used for analyses of both of the Oxford scores. First, third-degree
polynomial-based quantile regression models were used to estimate the change score (postoperative to
preoperative) using the preoperative Oxford score. Quantile regression seeks to extend the ideas, that the
population could be divided into several segments using quantiles or percentiles, to develop the models
in which the quantiles of the conditional distribution of the response variable are expressed as functions
of observed covariates.178 The 10th, 20th, 30th and 50th percentile models were produced and the
corresponding accuracy was assessed by visually comparing the estimated values, again with the observed
percentile values across the preoperative score range. From these relative threshold values, the preoperative
score for which the respective percentile matches the respective improvement criteria was estimated (see
Improvement criteria for further details). In addition, we compared the percentile model (from 1st to 99th)
of those achieving an important difference against the observed proportion of individuals who improved in
accordance with the improvement criteria. Given the very large size of the available data set, modelling
performance was internally validated by assessing sensitivity to key factors (time period, gender and age)
through carrying out subset analyses and not by selecting a random sample or bootstrapping approach.
The second approach used fractional polynomial logistic regressions. Using this approach, the benefit of
the baseline covariates on the capacity of benefit was investigated. Fractional polynomial regression was
introduced in terms of parsimonious modelling.179
The baseline covariates investigated in the logistic regression models were age (as a continuous variable),
gender, the presence or absence of 12 patient-reported comorbidities (heart disease, high blood pressure,
problems caused by stroke, leg pain when walking owing to poor circulation, lung disease, diabetes, kidney
disease, disease of the nervous system, liver disease, cancer, depression and arthritis) and symptom period
(up to 5 years or 6 to ≥ 10 years). For age, the optimal relationship was assessed individually between
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the variables using the fractional polynomial logistic regression when the default model included the
preoperative score. Comorbidities were assessed simultaneously with only those significant and with a
log-odds ratio (OR) of ≥ 0.8 remaining a candidate. For each of the candidate covariates, the discriminative
performance with only that covariate in addition to the preoperative score was calculated. Covariates were
selected for inclusion in the final model if the AUC with only the candidate covariate was ≥ 0.01 greater
than the AUC for the model with the preoperative score included. The performance of the final model was
assessed in terms of discrimination and calibration by calculating the AUC and producing calibration plots.
Sensitivity and specificity values for the estimated relative threshold were calculated with corresponding
95% CIs. Complete-case analyses were conducted throughout. Stata® version 14 was used for all of the
further statistical analyses looking at the threshold.
Data set
The NHS PROMs linked to HES (2009–15) was used. The inclusion criterion was that patients must have
undergone a primary procedure and those undergoing revision procedures were excluded. Using PROMs
and HES variables, primary only were selected. First, patients who have the same procedure [as identified
by ‘PROMS_PROC_CODE’ (a code identifying the type of procedure that the patient underwent)] carried
out on the same side of the body more than once (e.g. two primary hip replacements of the left hip) were
excluded based on the PROMs data. Using the variables ‘EPISODE_MATCH_RANK’ [a score is attributed to
each part of the linking process, in which the quality of the match is denoted by the rank with the lowest
rank (i.e. 1) being the highest-quality match; the scores for each possible match are compared and the
highest match is chosen] and ‘EPIKEY’, the PROMs and HES data were linked and duplicate entries were
identified and removed. The former variable ensured that the highest-quality match between HES and
PROMs is listed first, and the latter variable ensures that a unique sorting is produced. Based on this
sorting, we dropped the second observations from the duplicate pairs. In addition, patients who answered
that they have not had previous surgery of the type they were going to undergo were included, using the
‘Q1_PREVIOUS_SURGERY’ variable.
Approval
We successfully applied for access to the NHS PROMs/HES-linked data from NHS Digital (reference
NIC-392690-F7H2Q).
Improvement criteria
Patient benefit can be defined in various ways. We restricted the definition to improvement in OHS and
OKS patient-reported scores using standard approaches. Definitions of improvement were applied in this
chapter as follows:
B. medium ES (0.5) × SD of change score (MCID) – 5 (OHS and OKS)
E. anchor-based best cut-off point using the individual-level ROC approach from the literature – 8 (OHS)
or 7 (OKS).
A previously reported anchor-based best cut-off point was applied (using the NHS PROMs data set from
2009 to 2011).90 This was a ROC curve analysis with the probability of correctly identifying patients based
on an patient-reported anchor, ‘a little better’ versus ‘the same’ from the post-surgery evaluation in the
questionnaire. When it was used at an individual level (MIC from ROC analysis), any changes in the OHS
and OKS beyond 8 and 7 points, respectively, were considered as ‘clinically relevant’ changes.75 These
values lead (under improvement criterion E) to absolute threshold values for the OHS and OKS of 40 and
41 points, respectively. Corresponding values for definition B were as previously: 43 for both scores.
In addition, we also applied a 0.5 (medium, moderate practical importance) ES approach [as classified by
Cohen180] using the variability of the change scores as an approach consistent with work package 2.
It was calculated simply by using the SD of change scores of the candidate tools multiplied by the medium
ES (0.5): 0.5 × SD of change score (criterion B).181
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Results
Descriptive statistics
A total of 644,656 observations were available for PROMs data linked to HES (2009–15). After dropping
the identified duplicates from the data set linked to HES, there were 602,287 observations remaining
(289,808 for hip and 312,479 for knee). Excluding those patients who had not confirmed in the PROMs
questionnaire whether or not they had undergone previous surgery on the respective side reduced the
data set further (to 575,980; 277,786 for hip and 298,194 for knee). Of these, only a subset of patients
who had completed both the preoperative and the postoperative questionnaires were included, using the
‘Q1 and Q2 Complete’ variables (443,262; 214,038 for hip and 229,224 for knee). In addition, patients
who had submitted both the preoperative and the postoperative hip questionnaires with sufficient
procedure-specific data to derive scores were included, using the ‘Q1 and Q2 Complete’ variables
(209,761 for hip and 222,933 operations) (Figure 26).
Demographics
The patient characteristics for those included in the matched hip and knee data sets is provided in Table 52.
In total, 209,761 hip replacement surgeries were included; over half (125,058; 59.6%) were female, with
ages ranging from 13 to 100 years, with a mean age of 69 years. In total, 96,041 NHS PROMs linked to HES
(45.8%) were measured in 2009–11. In total, 222,933 knee replacement surgeries were included; over half
(126,885; 56.9%) were female, with ages ranging from 18 to 99 years, with a mean age of 69.6 years. In
total, 96,041 NHS PROMs linked to HES (45.8%) were measured for hip replacements and 102,448 (50.0%)
were measured for knee replacements in 2009–11. In total, 113,720 (54.2%) post-operation scores were
completed for hip and 120,485 (54.1%) for knee in 2012–15. Figure 27 shows histograms of the OHS and
OKS scores pre and post surgery.
(a)
Primary procedures in PROMS
linked to HES
(n = 289,808)
Primary procedure
(excluding patient-reported
previous procedures)
(n = 277,786)
Preoperative questionnaire complete
(n = 277,541)
Postoperative questionnaire complete
(n = 214,038)
Preoperative OHS complete
(n = 212,273)
Postoperative OHS complete
(n = 209,761)
(b)
Primary procedures in PROMS
linked to HES
(n = 312,479)
Primary procedure
(excluding patient-reported
previous procedures)
(n = 298,194)
Preoperative questionnaire complete
(n = 297,929)
Postoperative questionnaire complete
(n = 229,224)
Preoperative OKS complete
(n = 227,213)
Postoperative OKS complete
(n = 222,933)
FIGURE 26 Flow diagrams for hip and knee PROMs linked to HES data sets. (a) Hip; and (b) knee.
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TABLE 52 Patient characteristics in the NHS PROMs hip and knee replacement data sets
Characteristic Hip replacement (N= 209,760) Knee replacement (N= 222,933)
Age (years)
Mean 68.37 69.52
SD 10.46 8.92
Minimum 13 16
Maximum 100 102
Age category (years), n (%)
< 60 37,904 (18.07) 29,349 (13.16)
60–79 144,064 (68.68) 164,132 (73.62)
≥ 80 27,793 (13.25) 29,452 (13.21)
Gender, n (%)
Male 84,673 (40.37) 96,006 (43.06)
Female 125,058 (59.62) 126,885 (56.92)
Comorbidity, n (%)
Heart disease 19,679 (9.38) 23,340 (10.47)
High blood pressure 82,428 (39.30) 102,542 (46.00)
Stroke 2912 (1.39) 3733 (1.67)
Circulation 11,968 (5.71) 16,464 (7.39)
Lung disease 15,592 (7.43) 18,571 (8.33)
Diabetes 18,449 (8.80) 27,789 (12.47)
Kidney 3550 (1.69) 4022 (1.80)
Nervous system 1566 (0.75) 2155 (0.97)
Liver disease 1081 (0.52) 1199 (0.54)
Cancer 10,085 (4.81) 10,416 (4.67)
Depression 15,264 (7.28) 18,375 (8.24)
Arthritis 151,331 (72.14) 174,391 (78.23)
Comorbidity group, n (%)
0 29,933 (14.27) 22,121 (9.92)
1 79,168 (37.74) 73,599 (33.01)
2 63,076 (30.07) 74,649 (33.48)
≥ 3 37,584 (17.92) 52,564 (23.58)
Year of NHS PROMs, n (%)
2009–11 96,041 (45.79) 102,448 (45.95)
2012–15 113,720 (54.21) 120,485 (54.05)
Living arrangement, n (%)
I live with someone 151,669 (72.31) 164,451 (73.77)
I live alone 53,318 (25.42) 52,985 (23.77)
I live in a care home, etc. 259 (0.12) 219 (0.10)
Other 769 (0.37) 802 (0.36)
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TABLE 52 Patient characteristics in the NHS PROMs hip and knee replacement data sets (continued )
Characteristic Hip replacement (N= 209,760) Knee replacement (N= 222,933)
Symptom period (years), n (%)
< 1 29,053 (13.85) 11,041 (4.95)
1–5 142,960 (68.15) 116,195 (52.12)
6–10 23,108 (11.02) 48,340 (21.68)
> 10 13,588 (6.48) 46,273 (20.76)
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FIGURE 27 The NHS PROMs histograms. (a) OHS; and (b) OKS.
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Relative thresholds
Hip
Quantile regression was used to estimate the shape of the 10th, 20th, 30th and 50th percentile change in
OHS. For example, the prediction of the third-degree polynomial 50th quantile regression model was:
Change score (50th percentile) = 29:15 + 0:24 xi − 0:04 x2i + 0:0004 x
3
i + εi, (14)
where x is the preoperative score, εi.i.d.i ∼N(0, σ2) and i refers to the ith patient.
The observed postoperative change in the OHS against the preoperative score along with the observed
and estimated percentiles using the quantile regression model are shown in Figure 28. Estimated relative
thresholds using the E improvement criterion for the 10th, 20th, 30th and 50th percentiles are presented
in Table 53 for the whole data set (‘Total’) and also by key factors (age, gender and time period). There
was no clear sign of a different threshold value in accordance with the covariates, with some suggestion
that the group of patients aged ≥ 80 years had slightly lower estimates. Results based on the B
improvement criterion are available in Online Supplement 14.
Figure 28b shows the percentages improved using the A improvement criterion against preoperative score
observed and estimated using the predictions from the quantile regression models. Corresponding figures
presenting the findings in the six population subsets by age and gender are given in Online Supplement 14.
Knee
Quantile regression was used to estimate the shape of the 10th, 20th, 30th and 50th percentile change in
the OKS. For example, the prediction of the third-degree polynomial 50th quantile regression model was:
Change score (50th percentile) = 18:73 + 0:58 xi−0:04 x2i + 0:0004 x
3
i + εi, (15)
where x is the preoperative score, εi.i.d.i ∼N(0, σ2) and i refers to the ith observation.
The observed postoperative change in score against preoperative score along with the observed and
estimated percentiles using the quantile regression model are shown in Figure 29a. Estimated relative
thresholds using the E improvement criterion for 10th, 20th, 30th and 50th percentiles are presented in
the Table 54 for the whole data set (‘Total’) and also by key factors (age, gender and time period). There
was no clear sign of different threshold values in accordance with the covariates. Results based on the B
improvement criterion are available in Online Supplement 15.
Internal validation
Internal validation on the quantile regression estimates was carried out by applying quantile regression to
population subsets based on age, gender and year of operation (time period). The data set was split into
the 2009–11 and 2012–15 time period subsets to internally validate the estimates and check for sensitivity
within the data set to the time period. The two time period subpopulation analyses did not show distinct
shapes (Figures 30 and 31 provide the OHS and OKS results, respectively).
Figures are shown in Online Supplement 14 and the subsets showed some different patterns around the
relative threshold values for each percentile, particularly around low scores (see Figures 30 and 31).
The gender subpopulation analyses did not show distinct shapes (see Figures 30 and 31). Corresponding
figures presenting the findings in the six age-by-gender population subsets for both the OHS and the OKS
are given in Online Supplement 14.
Model performance
Sensitivity and specificity were calculated using the E improvement criterion as the ‘gold standard’
regarding the OHS and OKS relative thresholds for each of the quantile model. The OHS and OKS results
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FIGURE 28 The OHS: NHS PROMs. (a) Observed percentiles and 10th, 20th, 30th and 50th quantile regression curves
(coloured dots indicate each observational percentile and grey dots indicate the actual weighted observations);
and (b) proportion improved using improvement criterion E (observed and quantile regression model).
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TABLE 53 Hip: relative threshold using improvement criterion E (8-point OHS improvement)
Baseline covariate n
Percentiles
Predicted Observed
10th 20th 30th 50th 10th 20th 30th 50th
Total 209, 761 23 32 35 38 24 31 35 38
Age category (years)
< 60 37,904 26 33 36 38 27 32 38 38
60–79 144,064 24 32 35 38 24 32 35 38
≥80 27,793 19 27 32 36 19 26 31 36
Gender
Male 84,673 25 32 35 38 26 33 35 38
Female 125,058 22 31 34 38 23 31 35 38
Year of NHS PROMs
2009–11 96,041 22 31 34 38 20 31 35 38
2012–15 113,720 25 32 35 38 25 31 35 38
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FIGURE 29 The OKS: NHS PROMs. (a) Observed percentiles and 10th, 20th, 30th and 50th quantile regression curves
(coloured dots indicate each observational percentile and grey dots indicate the actual weighted observations;
and (b) proportion improved using improvement criterion E against preoperative score (observed and quantile
regression model).
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TABLE 54 Knee: relative threshold using improvement criterion E (7-point OKS improvement)
Baseline covariate n
Percentiles
Predicted Observed
10th 20th 30th 50th 10th 20th 30th 50th
Total 222,933 N/A 25 31 36 1 25 30 36
Age category (years)
< 60 29,349 N/A 18 29 35 1 21 30 35
60–79 164,132 N/A 26 31 36 1 26 31 36
≥ 80 29,452 13 24 30 35 15 26 30 36
Gender
Male 96,006 N/A 26 31 36 0 26 32 36
Female 126,885 N/A 25 30 35 1 25 30 36
Year of NHS PROMs
2009–11 102,448 N/A 24 30 35 1 23 30 36
2012–15 120,485 N/A 27 31 36 1 26 32 36
N/A, not applicable.
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FIGURE 30 The OHS: NHS PROMs. (a) Age; (b) gender; and (c) time period subset populations (observed change
and 50th quantile regression model). (continued )
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FIGURE 31 The OKS: NHS PROMs. (a) Age; (b) gender; and (c) time period subset populations (observed change and
50th quantile regression model). (continued )
0 5 10 15 20 25 30 35 40 45 48
C
h
an
g
e 
sc
o
re
 (
p
o
st
 –
 p
re
)
Preoperative OHS
– 10
0
8
18
28
48
38
(c)
2009 – 11
2012 – 15
Total with 95% CIs
Time period
FIGURE 30 The OHS: NHS PROMs. (a) Age; (b) gender; and (c) time period subset populations (observed change
and 50th quantile regression model).
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are shown in Tables 55 and 56, respectively. Relative threshold values from the 20th quantile regression
showed relatively good sensitivity and poor specificity outcomes compared with other thresholds from the
10th, 30th and 50th quantile regressions. Specificity outcomes for the 80% population coverage relative
threshold (i.e. 20th percentile) were 19 (95% CI 18 to 19) for the OHS and 35 (95% CI 34 to 35) for the
OKS. Specificity outcomes for the 50% population coverage relative threshold (i.e. 50th percentile) were 6
(95% CI 5 to 6) for the OHS and 5 (95% CI 5 to 6) for the OKS (see Table 4).
Figures 30 and 31 show close agreement with the estimated observed proportions across the range of
preoperative Oxford Hip and Knee Scores, both for the overall data set and by subpopulation.
0 5 10 15 20 25 30 35 40 45 48
C
h
an
g
e 
sc
o
re
 (
p
o
st
 –
 p
re
)
Preoperative OKS
– 10
0
7
17
27
47
37
(b)
Female
Male
Total with 95% CIs
Sex
0 5 10 15 20 25 30 35 40 45 48
C
h
an
g
e 
sc
o
re
 (
p
o
st
 –
 p
re
)
Preoperative OKS
– 10
0
7
17
27
47
37
(c)
2009 – 11
2012 – 15
Total with 95% CIs
Time period
FIGURE 31 The OKS: NHS PROMs. (a) Age; (b) gender; and (c) time period subset populations (observed change and
50th quantile regression model).
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TABLE 55 Hip: relative threshold using improvement criterion E (sensitivity and specificity)
Baseline
covariate
Percentiles
10th 20th 30th 50th
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Total 23 77 (77 to 77) 47 (47 to 48) 32 97 (97 to 97) 19 (18 to 19) 35 99 (99 to 99) 12 (12 to 12) 38 100 (100 to 100) 6 (6 to 7)
Age category (years)
< 60 26 87 (86 to 87) 37 (36 to 37) 33 98 (98 to 98) 16 (16 to 17) 36 100 (99 to 100) 10 (10 to 10) 38 100 (100 to 100) 6 (6 to 7)
60–80 24 81 (80 to 81) 44 (43 to 44) 32 97 (97 to 97) 19 (18 to 19) 35 99 (99 to 99) 12 (12 to 12) 38 100 (100 to 100) 6 (6 to 7)
≥ 80 19 61 (61 to 61) 61 (61 to 62) 27 89 (89 to 89) 34 (33 to 34) 32 97 (97 to 97) 19 (18 to 19) 36 100 (99 to 100) 10 (10 to 10)
Gender
Male 25 84 (84 to 84) 40 (40 to 41) 32 97 (97 to 97) 19 (18 to 19) 35 99 (99 to 99) 12 (12 to 12) 38 100 (100 to 100) 6 (6 to 7)
Female 22 74 (73 to 74) 51 (50 to 51) 31 96 (96 to 96) 22 (21 to 22) 34 99 (99 to 99) 14 (14 to 15) 38 100 (100 to 100) 6 (6 to 7)
Year of NHS PROMs
2009–11 22 74 (73 to 74) 51 (50 to 51) 31 96 (96 to 96) 22 (21 to 22) 34 99 (99 to 99) 14 (14 to 15) 38 100 (100 to 100) 6 (6 to 7)
2012–15 25 84 (84 to 84) 40 (40 to 41) 32 97 (97 to 97) 19 (18 to 19) 35 99 (99 to 99) 12 (12 to 12) 38 100 (100 to 100) 6 (6 to 7)
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TABLE 56 Knee: relative threshold using improvement criterion E (sensitivity and specificity)
Baseline
covariate
Percentile
10th 20th 30th 50th
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Threshold
score
Sensitivity
(95% CI)
Specificity
(95% CI)
Total – – – 25 83 (83 to 83) 35 (34 to 35) 31 96 (96 to 96) 15 (15 to 15) 36 100 (100 to 100) 5 (5 to 6)
Age category (years)
< 60 – – – 18 52 (52 to 53) 63 (63 to 64) 29 93 (93 to 93) 21 (20 to 21) 35 99 (99 to 99) 7 (6 to 7)
60–80 – – – 26 86 (86 to 87) 31 (30 to 31) 31 96 (96 to 96) 15 (15 to 15) 36 100 (100 to 100) 5 (5 to 6)
≥ 80 13 28 (28 to 28) 81 (80 to 81) 24 80 (79 to 80) 38 (38 to 39) 30 95 (95 to 95) 18 (18 to 18) 35 99 (99 to 99) 7 (6 to 7)
Gender
Male – – – 26 86 (86 to 87) 31 (30 to 31) 31 96 (96 to 96) 15 (15 to 15) 36 100 (100 to 100) 5 (5 to 6)
Female – – – 25 83 (83 to 83) 35 (34 to 35) 30 95 (95 to 95) 18 (18 to 18) 35 99 (99 to 99) 7 (6 to 7)
Year of NHS PROMs
2009–11 – – – 24 80 (79 to 80) 38 (38 to 39) 30 95 (95 to 95) 18 (18 to 18) 35 99 (99 to 99) 7 (6 to 7)
2012–15 – – – 27 89 (89 to 89) 27 (27 to 28) 31 96 (96 to 96) 15 (15 to 15) 36 100 (100 to 100) 5 (5 to 6)
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Influence of covariates
Fourth-degree fractional polynomial logistic regressions with dichotomised change scores (postoperative to
preoperative score) by the improvement criterion (A) were used to examine the benefit of the baseline
covariates on the capacity of benefit.
Hip
The selected fractional model that was selected had the following form:
ln
p^i
1− p^i
 
= 2:73 + 0:006 x3i −0:005 x
3
i ln xi + 0:002 x
3
i ln x
2
i −0:0002 x
3
i ln x
3
i , (16)
where x is preoperative score, p^i = N of improved/N of preoperative score and i refers to the ith patient.
Predicted probabilities with 95% CIs using the logistic regressions in comparison with the observational
proportion with 95% CIs are presented in Figure 32a. Generally, the fit was good, with the exception
of the lowest handful of preoperative scores. The AUC was 0.65 (95% CI 0.64 to 0.65). Model performance
was also examined using the calibration graphs in Figure 32, which showed a good level of calibration.
Knee
The selected fractional model had the following form:
ln
p^i
1− p^i
 
= 1:7 + 0:007 x3i −0:006 x
3
i ln xi + 0:002 x
3
i ln x
2
i −0:0002 x
3
i ln x
3
i , (17)
where x is the preoperative score, p^i = N of improved/N of preoperative score and i refers to the ith patient.
Predicted probabilities with 95% CIs using the logistic regressions in comparison with the observational
proportion with 95% CIs are presented in Figure 33a. Generally, the fit was good, with the exception of the
lowest handful of preoperative scores. The AUC was 0.61 (95% CI 0.61 to 0.62). Model performance was
also examined using the calibration graphs in Figure 33b, which showed a good level of calibration.
Selected models with baseline covariates
Hip
Following the model-building process, the selected model with covariates including circulation and depression
showed meaningful but marginal impacts on the OHS. The model had the following form:
ln
p^i
1− p^i
 
= 3:1 + 0:003x3i −0:003x
3
i ln xi + 0:001x
3
i ln x
2
i −0:0001x
3
i ln x
3
i −0:96 Circulationi
−0:71 Depressioni,
(18)
where x is preoperative score, p^ =
N of improved
N of preoperative score
and i refers to the ith observation.
The AUC was 0.68 (95% CI 0.67 to 0.68). The proportion improving and the calibration graphs were very
similar to the model without the additional covariates and, therefore, are not provided here.
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FIGURE 32 The OHS: NHS PROMs. (a) Proportion improved (improvement criterion E) and observed proportion
(logistic regression); and (b) calibration graph.
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Knee
Following the model-building process, the selected model including age, circulation, diabetes and
depression showed meaningful but marginal impacts on the OKS. It had the following form:
ln
p^i
1− p^i
 
= 1:4 + 0:005x3i −0:005x
3
i ln xi + 0:001x
3
i ln x
2
i −0:0001x
3
i ln x
3
i + 0:001 Age
2
i
−0:00001 Age3i −0:71 Circulationi−0:38 Diabetesi−0:45 Depressioni, (19)
where x is preoperative score, p^ =
N of improved
N of preoperative score
and i refers to the ith observation.
The area under the ROC curve, for the final model was 0.65 (95% CI 0.65 to 0.66). The proportion
improving and the calibration graphs were very similar to the model without the additional covariates and,
therefore, are not provided here.
Discussion
The postoperative score and the probability of improvement were modelled for both the OHS and the OKS.
In addition, we calculated threshold estimates using both of these estimates and assessed performance.
Strengths and limitations
Two different modelling approaches were used to get the robust and consistent estimated thresholds: logistic
and quantile regression. Unlike standard regression models, the quantile regression deals with the asymmetric
spread of outcomes and enables estimates of the corresponding proportion of individuals to be estimates.
Performance showed excellent agreement between the observed and estimated results for this approach,
with only the highest values showing some signs of an inadequate fit. This reflects both the regression
models used and also the very data sets that they were applied to. The results showed that the estimated
relative thresholds by percentiles and predicted probabilities were equal or similar to the thresholds from the
logistic regressions that the dichotomised outcomes (i.e. improved or not improved) used. In this study, the
relative thresholds were based on the quantile regressions and were reported for the 10th, 20th, 30th and
50th percentiles.
In addition, the baseline covariates were examined in terms of their impact on the patient’s capacity of
benefit, in addition to their impact on preoperative score. In terms of the potential threshold value, they
did not generally seem to have much influence, perhaps with the exception of the 80-years age group.
The PROMs data set linked to HES provided a very large and rich data source, which enabled robust and
reliable estimates. Internal validation was undertaken, dividing the data set into two time periods. Even the
data subsets were very large and there were no clear differences of threshold estimates between the two
internal data sets. The model diagnoses and validations that were performed suggested that the quantile
models were a good fit, except for the extremes of the Oxford Hip and Knee Scores.
This study defined improvement (and, by implication, the capacity of benefit) using a literature-reported
anchor-based best cut-off point.75 This score was calculated using the patient-reported anchor-based
question; however, there are various approaches to define the improvement. One of the approaches
applied in Chapters 4 and 6 was a MDC-based approach. We explored another definition (medium ES) in
this chapter and provided the results in Online Supplement 13. It is worth noting that even the anchor-
based approach is still somewhat crude and does not account for the preoperative state, which has been
shown in some settings to influence the magnitude of a difference (change) that would be considered
important by patients. Measurement errors are problematic in the repeatedly measured patient-reported
outcomes, and there will be several ways to control the measurement errors (e.g. using the adjusted
improvement score and applying advance statistical inference approaches such as Bayesian models with
computational methods). It is the applicability of the finding to an individual that is problematic; population
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estimates should be fair. The impact of measurement errors in prognostic modelling is an area of active
research. In terms of performance, the estimated proportion improvement should accurately reflect the
population. Based on Chapter 3, those within 6 points of a cut-off point (MDCs using an ICC of 0.9) could
plausibly have a value sufficient to meet the cut-off point. Further research may be required; care is needed
when applying to use the estimated relative thresholds in terms of this aspect. A related issue was that the
data set reflected patients who received arthroplasty and, therefore, it may not fully represent the population
of those who were considering arthroplasty. A further limitation of our analysis was the substantial amount
of missing data, which reflected the passive nature of data collection. Missing data analyses that utilised
available information on the missing data (which was very limited) are, in our view, very unlikely to
substantively alter the findings.
Conclusion
We estimated the postoperative scores and the probability of improvement based on both the OHS and
the OKS. From these, we calculated relative thresholds for the OHS and OKS. The model generally showed
good performance for predicting the probability of improvement for individuals at each preoperative score
level. The results clearly reflect both the substantial improvement in score from pre to post operation, but
also the uncertainty about where an individual patient will end up. The quantile regression nicely models
differing proportions of individuals and their expected outcomes.
A very large data set was used, which enabled a data-intensive approach (quantile regression) to be successfully
used, with only the extreme handful of values at each end of the scale showing uncertainty. The NHS PROMs
data set is arguably the best representation of the typical NHS patient available. Sensitivity to other factors was
also assessed; there was some suggestion that the ≥ 80-years age group were somewhat different. Overall,
the explanatory value of the available factors (collected routinely) were limited and a number showed no value.
There was a substantial amount of variability between the individuals’ postoperative outcomes, which is
unexplained.
As previously stated, it should be borne in mind that all of these analyses reflect the change in pain and
function estimated by the Oxford Hip and Knee Scores only. Other justifications for arthroplasty surgery
exist that would not be fully reflected in these data. Similarly, these analyses do not take into account the
potential risk of infection and other problems that may require further treatment (e.g. revision surgery).
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Chapter 7 Further health economic evaluation of
threshold values (work package 2)
Background
We extended and improved the analyses described in Chapter 5 to obtain more accurate estimates of
preoperative economic thresholds for the OKS and OHS using the NHS PROMs data linked to HES.
In particular, the PROMs/HES data set provides:
l Sufficient data to estimate the cost of admissions for primary surgery, revision or subsequent
re-admissions using the NHS Payment Grouper.
l The ability to link revisions and re-admissions with patients’ primary operations.
l Additional years of data with indicators of which operations were revisions that were not available in
the freely available PROMs data.
l Patients’ exact ages, rather than 10-year age bands.
l Data on age and sex for all patients. By contrast, the extract of PROMs data freely available online
omitted age and sex data for individuals (generally the very old and very young) to avoid the potential
for patients to be identified.
We did not evaluate the impact of additional covariates other than age and sex, because the variables
available in the PROMs/HES data extract had very little effect on prediction accuracy and have not been
included in the ACHE tool intended for general practice. The effect of BMI was not evaluated because this
variable is not included within PROMs/HES and it was not possible to obtain NJR data (in which BMI is
recorded) linked to PROMs/HES; subsequently, the only data sets providing BMI data were small and likely
to be underpowered.
Like the analyses described in Chapter 5, the economic evaluation comprised a cost–utility analysis evaluating
the cost-effectiveness of TKA or THA compared with no arthroplasty over a 10-year time horizon in a UK
setting from the perspective of the UK NHS (see Chapter 5, Background). However, it is worth noting that,
in the absence of linked NJR data, it is not possible to distinguish TKA and THA from other types of knee and
hip arthroplasty (e.g. hip resurfacing) or to reliably identify the indication for arthroplasty, and, therefore, all
analyses based on PROMs and/or HES data include all types of primary knee and hip arthroplasty conducted
for any indication.
Method
We conducted additional regression analyses on the new extract of PROMs/HES linked data and adapted
the Markov models described in Chapter 5 to accommodate the new regression models. The Markov model
structure and assumptions were generally identical to those described in Chapter 5, Model. In particular,
the analysis used a 10-year time horizon and used 2014 as the reference year for costs. We also took a NHS
perspective and focused on the costs of hospital admissions and consultations with health-care professionals
that were associated with the joint in question.
The model used the same assumptions described in Chapter 5, Other model assumptions and inputs,
with the following exceptions:
l The analyses described in this chapter allowed for mortality associated with all revision procedures. By
contrast, in Chapter 5, mortality associated with revisions was only included for all revisions > 12 months
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after primary arthroplasty and only if the mortality associated with revisions was expected to be > 10%
above all-cause mortality. In the analyses described in this chapter, the probability of dying in the year of
hip revision surgery was based on the mortality in the year of revision estimated by Pennington et al.121
However, we followed Pennington et al.119 in using the same model to predict mortality after revision
and primary knee arthroplasty.
l For both TKA and THA, we followed Pennington et al.119,121 by capping mortality in the year of revision
at a maximum of 10% above all-cause mortality to avoid extrapolating very high mortality rates to very
old patients, who were generally outside the sample used to estimate mortality rates. We also allowed
for the additional mortality associated with revisions taking place within 12 months of primary
arthroplasty (see Online Supplement 15).
l The cost of re-admissions and ambulatory consultations were taken into account for all health states and
in all years of the model.
l We followed the assumption used in Chapter 5 that QALYs in the year of revision were equal to the
average of the before-revision utility and the after-revision utility. Although PROMs specifically includes
data before revision and 6 months afterwards, calculating QALYs as the average of these utilities allows
for the fact that people are likely to have had a quality of life similar to the prerevision utility in the
months leading up to revision surgery and experience utility similar to that observed 6 months after
revision later in the year.
Revision rates, costs in the no arthroplasty arm and the rate of change in EQ-5D utility with age or over time
were the same as those used in Chapter 5, and mortality rates were also based on those by Pennington
et al.119,121 (see Online Supplement 12). In the hip model, the cost of ambulatory consultations was also
based on the same models used in Chapter 5.113 The following parameters were re-estimated (see Table 39):
l Mapping models predicting preoperative EQ-5D score based on preoperative Oxford Hip and Knee
Scores were re-estimated using the PROMs/HES extract, replacing the published algorithms that
were used previously.126,134 Re-estimating the mapping equations enabled us to consider non-linear
relationships between EQ-5D scores and Oxford Hip and Knee Scores and evaluate how EQ-5D utility
varies with patient’s age and sex.
l Models predicting EQ-5D utility 6 months after primary arthroplasty were re-estimated using PROMs/HES
data because this updated data set includes a larger sample and patients’ exact ages.
l The EQ-5D utilities before and after revision were re-estimated using PROMs/HES data because this data set
enables utility before and after revisions to be linked to the Oxford Hip and Knee Scores measured before
patients’ primary arthroplasty procedures and provides a far larger number of revisions than KAT or EPOS.66
l The costs of primary and revision arthroplasty were re-estimated using PROMs/HES data because this
data set is very large and up to date and provides sufficient information to use the NHS Payment
Grouper,152 thereby avoiding the additional assumptions that were necessary to estimate the cost of
re-admissions using KAT, COASt or published estimates.66,113,131
l The cost of re-admissions was re-estimated using PROMs/HES data because this large, up-to-date data
set enables the Oxford Hip and Knee Scores measured before patients’ primary arthroplasty procedures
to be linked to all subsequent re-admissions. This enabled the cost of re-admissions to be included in
the hip model; such costs were excluded from the analyses described in Chapter 5 as there were no
available data. Although re-admission costs following TKA could be estimated from KAT and COASt,
PROMs/HES provided a substantially larger and more up-to-date data set.
l The cost of community and outpatient visits were re-estimated for TKA in all years and for THA in year 1
to exclude the cost of re-admissions, which were now captured separately. The cost of community and
outpatient visits beyond year 1 in THA patients continued to be based on published estimates.113 The
methods and assumptions used to estimate the cost of community and outpatient visits were the same
as those described in Chapter 5, Costing analyses.
The next section describes how the PROMs/HES data were manipulated prior to conducting these regression
analyses. Additional details on the methods and results of each regression analysis are given in Online
Supplement 15.
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Methods for manipulating and analysing NHS Patient-Reported Outcome Measures/
Hospital Episode Statistics linked data
Outline of the approach
We obtained the complete NHS PROMs data set for all patients undergoing hip and knee arthroplasty
between April 2009 and October 2015, as well as admitted patient care (APC) data from HES. These two
data sets were linked and manipulated to create data sets on preoperative and 6-month utility, costs of
primary arthroplasty, costs of revision arthroplasty, utility before and after revisions, and the costs of
re-admissions related to arthroplasty. Hospital re-admissions were defined as related to arthroplasty if they
either took place within 30 days of primary arthroplasty or the patient had a primary diagnosis for hip or
knee arthritis, had a procedure code relating to the hip or knee joint or if the patient had a primary
diagnosis of infections commonly associated with hip or knee arthroplasty.
We used the NHS Local Payment Grouper for 2014/15152 and the corresponding tariffs from the National
Schedule 2014/15153 to derive the costs for primary and revision arthroplasty as well as for relevant
re-admissions. We assumed that all primary and revision arthroplasty procedures were elective. For
re-admissions, we distinguished between elective and non-elective admissions. Further details on data
cleaning, data manipulation and handling of missing data are provided in Online Supplement 15.
The resulting data sets were used to estimate inputs for the Markov models. They included 309,001
primary knee arthroplasty procedures, 286,812 primary hip arthroplasty procedures, 3403 knee revisions
and 2346 hip revisions. We also identified 171,459 relevant admissions, of which 75,803 took place within
the first 30 days, 41,583 were for patients who had a relevant primary diagnosis, 6613 had a relevant
procedure code and 83,774 were for patients who had a diagnosis of infection.
Regression analyses
Regression models were estimated in Stata® version 14 using the same methods as were described in
Chapter 5, Regression analyses. Details of specific methods used for each regression analyses are described
in Online Supplement 15. Variance–covariance matrices for the regression models are available from the
corresponding author on request.
Presentation of results and analysis of uncertainty
The same set of hypothetical individuals with different combinations of age, sex and clinical tool score were
run through the revised models using mean values for all parameters and using PSA. PSA and calculation
of 95% CrIs around the threshold were conducted in the same way as for Chapter 5, generating 2000
estimates of costs and QALYs with and without arthroplasty for each of the 260 hypothetical individuals in
both the knee and the hip models. Plots of the probability that arthroplasty is cost-effective against the
OHSs and OKSs were generated as described previously (see Chapter 5, Presentation of results and analysis
of uncertainty). The cost-effectiveness acceptability curves (CEACs) shown in Online Supplement 16 were
generated using the same methods but varying the ceiling ratio.
We conducted the following sensitivity analyses:
l taking a 5-, 20- or 60-year time horizon (cf. 10 years in the base-case analysis)
l assuming that EQ-5D utility without TJA worsens by 0.025 per year (see Chapter 5, Presentation of
results and analysis of uncertainty)168
l assuming that EQ-5D without TJA increases by 0.115 per year in the first year of the model and then
follows an age-related decline after that169
l assuming that patients accrued no costs in the absence of arthroplasty
l halving the cost in the absence of arthroplasty
l doubling the cost in the absence of arthroplasty
l discounting QALYs at 1.5% and costs at 3.5%
l no discounting.
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Results
Effect of Oxford Knee Score on cost-effectiveness of total knee arthroplasty
Regression analyses demonstrated that the preoperative OKS had a statistically significant effect on
preoperative EQ-5D utility, EQ-5D utility 6 months after surgery, EQ-5D utility before and after revision
surgery, the cost of primary arthroplasty, re-admission costs in year 1 and subsequent years, ambulatory
costs in year 1 and in subsequent years, and re-admission costs and ambulatory costs > 1 year after revision
surgery (p < 0.05) (see Online Supplement 15). However, the OKS had no significant impact on the cost of
revision surgery or the cost of re-admissions or ambulatory consultations in the year of revision surgery
(p > 0.05) (see Online Supplement 15 for results of all regression models).
The regression models predicting preoperative and 6-month EQ-5D utility were re-estimated using the
PROMs/HES extract (Figure 34 and see Online Supplement 15). The model of 6-month EQ-5D produced
extremely similar predictions as that used in Chapter 5 (see Figures 14 and 34). However, whereas Chapter 5
used a published linear model of the relationship between the OKS and EQ-5D that included baseline and
postoperative measurements,134 the analyses described in this chapter used the PROMs/HES extract to assess
how preoperative EQ-5D varies with age and gender as well as preoperative OKS and to explore non-linear
functions. The model selection process suggested that prediction accuracy was optimised by a Tobit model
including polynomials for OKS and age. This model predicted that EQ-5D utility would rise steeply as OKSs
rose from 40 to 48 (see Figure 34). The difference between preoperative and 6-month EQ-5D utility was
predicted to be negative for patients with a preoperative OKS of 45–46 or higher (depending on age). In
contrast, the regression functions used in Chapter 5 predicted the change in EQ-5D utility to be negative for
patients with an OKS of 41–44 or higher (see Figure 14). Although the observed data suggest that EQ-5D
utility rises more slowly as the OKS increases from 40 to 48 than is predicted by the Tobit model, the models
used in this chapter accurately predict that the change in EQ-5D after knee arthroplasty is negative for patients
with a preoperative OKS of 47, but positive for patients with a preoperative OKS of ≤ 44 (see Figure 34).
The Markov model predicted the costs and QALYs that each hypothetical individual would accrue over a
10-year period with and without arthroplasty, taking into account the change in EQ-5D utility predicted in
the models shown in Figure 34, operative mortality, the cost of primary and revision surgery, inpatient and
ambulatory care required by patients with and without arthroplasty and the changes in quality of life that
occur before/after revisions and as patients age.
The difference in QALYs between patients with and without arthroplasty was highest for patients with a
preoperative OKS of 6 or 7 and declined steadily with increasing OKSs; averaged across all ages, arthroplasty
gained 2.99 QALYs per patient with an OKS of 0, 4.05 QALYs per patient with an OKS of 6 and 0.19 QALYs
per patient with an OKS of 44. TKA was predicted to increase QALYs for all patients with an OKS of below
44–46, depending on age.
The difference in cost between patients with and without arthroplasty was lowest for patients with an
OKS of 16–19, but was markedly higher for patients with lower or higher than average OKSs. The model
predicted that TKA was less costly than no surgery for 50-year-old men with an OKS of between 15 and 18
and for 50-year-old women with an OKS of between 10 and 21. Averaged across all ages, the difference in
cost was £6457 per patient with an OKS of 0, £1898 per patient with an OKS of 16 and £6481 per patient
with an OKS of 48.
As was demonstrated in Chapter 5, the results demonstrate that TKA is highly cost-effective for the vast
majority of patients who currently undergo surgery (Table 57), although ICERs rose as the OKS increased
from 4 to 48. In particular, the decision grid shows only selected OKS values, focusing on values in the
region of the threshold; TKA costs < £20,000 per QALY gained for all age groups at the OKS values omitted
from the grid. As a result of re-estimating models using PROMs/HES data, TKA is more cost-effective
(i.e. has lower ICERs) in almost all groups compared with the analyses described in Chapter 5 (see Table 40).
In particular, TKA was dominated by no arthroplasty (i.e. produced fewer QALYs at a greater cost) only for
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FIGURE 34 Comparison of observed mean EQ-5D utility in PROMs/HES for patients with different preoperative OKSs against the predictions for the Tobit regression functions
used in the Markov model.
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patients with an OKS of 44–46 or greater (cf. an OKS of 42–45 in Chapter 5). The current analysis also
estimated that there was only a narrow band of one or two OKS values at which TKA improves patients’
health but is not cost-effective (the areas shown in dark and medium green in Table 57).
The economic threshold OKS (i.e. the highest OKS at which TKA costs < £20,000 per QALY gained, shown in
light blue in Table 57) was 44 (95% CrI 43 to 48) for 60-year-olds and 41 (95% CrI 40 to 42) for 90-year-olds
TABLE 57 Cost-effectiveness of TKA in patients with different ages and baseline OKSs (results averaged over men
and women)
Preoperative OKS
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
0 £1979 £1693 £1939 £2808 £5257 £2156
10 £41 £247 £577 £1195 £2656 £646
20 Dominant £278 £911 £2094 £4986 £1015
21 Dominant £355 £1035 £2325 £5523 £1150
24 £288 £711 £1543 £3190 £7473 £1693
28 £1158 £1412 £2393 £4401 £9907 £2582
29 £1404 £1596 £2589 £4625 £10,252 £2782
30 £1643 £1771 £2765 £4802 £10,460 £2962
31 £1870 £1936 £2922 £4934 £10,547 £3119
32 £2083 £2090 £3060 £5033 £10,547 £3256
33 £2285 £2236 £3187 £5111 £10,505 £3382
34 £2479 £2378 £3311 £5189 £10,467 £3504
35 £2675 £2523 £3446 £5288 £10,485 £3637
36 £2887 £2683 £3605 £5433 £10,618 £3796
37 £3132 £2871 £3811 £5658 £10,935 £4003
38 £3437 £3109 £4095 £6014 £11,547 £4291
39 £3846 £3428 £4509 £6582 £12,642 £4710
40 £4439 £3885 £5146 £7523 £14,615 £5357
41 £5377 £4590 £6205 £9199 £18,462 £6427
42 £7061 £5787 £8197 £12,653 £27,668 £8421
43 £10,813 £8158 £12,934 £22,592 £68,515 £13,060
44 £25,078 £14,537 £34,786 £172,396 Dominated £32,707
45 Dominated £67,573 Dominated Dominated Dominated Dominated
46 Dominated Dominated Dominated Dominated Dominated Dominated
47 Dominated Dominated Dominated Dominated Dominated Dominated
48 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold (95% CrI) 43 (43 to 48) 44 (43 to 48) 43 (43 to 44) 42 (42 to 43) 41 (40 to 42) 43 (43 to 44)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Dark green = dominant.
l Light green= ICER of < £20,000.
l Light blue= ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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(see Table 57). If a single threshold were to be set across all ages, a threshold of 43 (95% CrI 43 to 44) would
be the most cost-effective value to choose. This is somewhat higher than the threshold estimated in Chapter 5
(40, 95% CrI 39 to 42) (see Table 40). Overall, TKA costs < £20,000 per QALY gained compared with no
arthroplasty for 99.9% of patients who currently undergo surgery and costs < £5000 per QALY gained for
96.6% of patients who currently undergo surgery.
The effect of age on cost-effectiveness and thresholds was markedly less pronounced than in the analyses
described in Chapter 5. In addition, although ICERs were generally slightly lower for women than for men
(see Online Supplement 16), the economic threshold was identical for men and women.
However, there was a modest amount of uncertainty around the economic thresholds. The 95% CrI
demonstrated that we can be 95% confident that the economic threshold for all ages combined lies
between 43 and 44. The probability that TKA is cost-effective varied with age, OKS (Figure 35) and how
much the NHS is willing or able to pay per QALY gained (see Online Supplement 16). For 70-year-olds,
we can be > 99% confident that TKA is cost-effective at a £20,000-per-QALY ceiling ratio at an OKS of ≤ 42,
although this falls to 98% for patients with an OKS of 43, 18% for patients with an OKS of 44 and 2%
for patients with an OKS of 45. Substantially greater uncertainty is observed for patients aged 50 or 90.
CEACs for men and women at different ages are shown in Online Supplement 16.
Effect of Oxford Hip Score on the cost-effectiveness of total hip arthroplasty
Regression analyses demonstrated that the preoperative OHS had a statistically significant effect on
preoperative EQ-5D utility, EQ-5D utility 6 months after surgery, EQ-5D utility before and after revision
surgery, cost of primary arthroplasty and revision surgery, re-admission costs in year 1 and subsequent years,
ambulatory costs in year 1 and re-admission costs > 1 year after revision surgery (p < 0.05) (see Online
Supplement 15). However, the OHS had no significant impact on re-admission costs in the year of revision
(p > 0.05) (see Online Supplement 15 for the results of all regression models).
The Tobit models predicting EQ-5D before and 6 months after hip arthroplasty showed similar trends to
those for knee arthroplasty (Figure 36). In particular, the polynomial function predicting how preoperative
EQ-5D utility varies with the preoperative OHS predicted a sharp increase in EQ-5D as the OHS increases
from 40 to 48. The models predicted that arthroplasty would increase EQ-5D utility for patients with a
preoperative OHS of ≤ 45–46 or less (depending on age and gender) and would decrease EQ-5D utility for
patients with an OHS of ≥ 46–47. By contrast, within the observed data, the mean EQ-5D change was
positive for patients with an OHS of ≤ 47 and negative for patients with an OHS of 48, which suggests
that the estimated Tobit models may underestimate thresholds for THA (see Figure 36).
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Following the trends observed for change in EQ-5D utility (see Figure 36), the QALY gain from THA was
greatest for patients with an OHS of 5 or 6 and declined steadily with increasing OHSs; the average patient
with an OHS of 5 gained 5.28 QALYs, compared with 4.33 for patients with an OHS of 0 and 0.05 for
patients with an OHS of 46. The model predicted that, on average, THA would worsen health by up to
0.44 QALYs for patients with an OHS of 47 or 48, and for 80- or 90-year-olds with an OHS of 46.
The difference in costs between patients with and without THA was smallest for patients with an OHS of
1 (£1975 per patient, averaged across all ages). THA was predicted to be less costly than conducting no
arthroplasty surgery for 50-year-old women with an OHS of 1, but was more costly for all other groups.
The incremental cost of THA rose gradually as OHS increased from 1 to 48; the average incremental cost
across all ages was £5113 for patients with an OHS of 48.
The results demonstrate that THA is highly cost-effective for the vast majority of patients who currently
undergo surgery (Table 58). As was observed for TKA, ICERs for patients with high Oxford Hip and Knee
Scores were markedly lower than in the analyses described in Chapter 5 (see Table 45). For patients aged
TABLE 58 Cost-effectiveness of THA in patients with different ages and baseline OHSs (results averaged over men
and women)
Preoperative OHS
(selected values only)
Cost
Age (years)
50 60 70 80 90 Average
0 £92 £327 £501 £926 £1945 £533
10 £809 £792 £820 £1187 £2011 £923
18 £1413 £1330 £1368 £1776 £2899 £1491
20 £1640 £1537 £1580 £2058 £3369 £1724
21 £1760 £1651 £1696 £2214 £3632 £1852
24 £2148 £2009 £2065 £2710 £4479 £2257
28 £2584 £2409 £2472 £3253 £5410 £2705
29 £2656 £2474 £2537 £3334 £5548 £2776
30 £2711 £2524 £2586 £3391 £5646 £2828
35 £2833 £2634 £2683 £3474 £5752 £2932
40 £3412 £3169 £3228 £4188 £6991 £3529
41 £3786 £3515 £3590 £4695 £7911 £3929
42 £4397 £4079 £4186 £5557 £9533 £4590
43 £5474 £5066 £5247 £7173 £12,765 £5777
44 £7636 £7027 £7421 £10,842 £21,196 £8244
45 £13,344 £12,059 £13,428 £24,427 £76,368 £15,330
46 £50,387 £40,160 £64,676 Dominated Dominated £97,787
47 Dominated Dominated Dominated Dominated Dominated Dominated
48 Dominated Dominated Dominated Dominated Dominated Dominated
Threshold (95% CrI) 45 (44 to 46) 45 (44 to 46) 45 (44 to 46) 44 (44 to 45) 43 (43 to 44) 45 (44 to 45)
Notes
Values indicate the cost per QALY gained for TKA vs. no arthroplasty.
Shading key:
l Light green = ICER of < £20,000.
l Light blue = ICER of £20,000–30,000.
l Dark blue = ICER of > £30,000.
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≤ 70 years, THA cost < £20,000 per QALY gained when the OHS was ≤ 45. The economic threshold
reduced to 43 (95% CrI 43 to 44) for 90-year-olds. The economic threshold ignoring age and gender was
45 (95% CrI 44 to 45), markedly higher than the threshold of 42 estimated in Chapter 5 (see Table 45).
Age had little impact on ICERs and economic threshold compared with the estimates from Chapter 5.
Furthermore, gender had very little impact on ICERs and the economic threshold was the same for men
and women (see Online Supplement 16).
Total hip arthroplasty was found to cost < £20,000 per QALY gained compared with no arthroplasty for
99.96% of patients who currently undergo arthroplasty surgery and to cost < £5000 per QALY gained for
99.16% of patients.
The PSA demonstrated that we can be 95% confident that the economic threshold, ignoring age and sex,
is between 44 and 45. For 70-year-olds, the probability that THA is cost-effective was > 95% at an OHS of
≤ 44, 90% at an OHS of 45 and 5% at an OHS of 46 (Figure 37). There was markedly greater uncertainty
for patients aged 80 and 90 years.
Sensitivity analyses
Ten sensitivity analyses were conducted to evaluate the sensitivity of the results to changes in time horizon
and discount rates and to the assumptions made around EQ-5D utility and costs for patients who do not
undergo TJA (Table 59 and see Online Supplement 16). This demonstrated that the results are reasonably
robust to changes in all of the key assumptions. Halving the time horizon from 10 to 5 years reduced the
economic threshold by 1 point, whereas extending the time horizon had no impact. Reducing the discount
rates used to adjust for time preference or drastically changing the costs assumed to be accrued by
patients in the absence of arthroplasty had little or no impact.
Assuming that EQ-5D utility will decrease by 0.025 per year (a decrease 4–7 times larger than was assumed
in the base-case analysis) markedly increased the threshold Oxford Hip or Knee Score at which TJA ceases
to be cost-effective; indeed, in this analysis, THA was cost-effective for all patients < 80 years of age,
regardless of OHS. Conversely, making an extremely optimistic assumption about the efficacy of the first
year of non-operative management (assuming that EQ-5D utility would increase by 0.115 in the first year)169
reduced the economic threshold for TKA to 39 and reduced the economic for THA to 41. As discussed
previously, this figure is conservative because the non-surgical treatment used by Skou et al.169 was
relatively intensive.
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FIGURE 37 Effect of the Oxford Hip and Knee Scores on the probability that THA is cost-effective at a £20,000-per-
QALY ceiling ratio.
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Discussion
Summary of findings
Findings of the economic evaluation
The results presented in this chapter suggest that TJA is cost-effective for > 99.9% of patients who
currently undergo surgery if the NHS is willing to pay £20,000 per QALY gained. Averaging across men
and women of all ages, it is cost-effective to conduct TKA on patients with an OKS of ≤ 43 (95% CrI 43 to
44) and to conduct THA on patients with an OHS of ≤ 45 (95% CrI 44 to 45).
These thresholds are slightly higher than those estimated in Chapter 5, largely owing to re-estimation of
the models of preoperative EQ-5D utility to take account of age and gender and to allow for non-linear
relationships between Oxford Hip and Knee Scores and EQ-5D utility. The values presented in this chapter
make full use of the PROMs/HES linked data, which cover 608,170 knee and hip arthroplasty procedures,
including around 67.7% of the 897,619 operations conducted in England between April 2009 and
October 2015.162,182–184 Because the analyses described in Chapter 5 used small data sets for several key
parameters (including the cost of primary arthroplasty), the economic thresholds and cost-effectiveness
results presented in this chapter should be used in decision-making in preference to the results described
in Chapter 5 for the OKS and OHS.
The thresholds for TKA were also substantially higher than those estimated previously by Dakin et al.,2 who
used KAT data and estimated the economic threshold to be 39 for patients of ASA grades 1 and 2 and a
threshold of 34 for patients of ASA grade 3. As discussed in Chapter 5, Summary of the results, this
difference may arise from the substantially larger number of patients with high OKSs in PROMs data,
which enabled us to take account of non-linear relationships between OKS, costs and quality of life.
Nonetheless, the analyses described in this chapter confirm the earlier findings described in Chapter 5 and
by Dakin et al.2 that suggest that TKA is cost-effective for patients with an OKS of ≥ 30–39.
TABLE 59 Results of the sensitivity analysis
Sensitivity analysis
Economic threshold ignoring age and sex
Knee arthroplasty Hip arthroplasty
Base-case analysis 43 45
5-year time horizon 42 44
20-year time horizon 43 45
60-year (lifetime) time horizon 43 45
EQ-5D utility without TJA worsens by 0.025 per year 46 48
EQ-5D utility without TJA increases by 0.115 in the first year and
follows age-related decline thereafter
39 41
Assuming that patients accrued no costs in the absence of arthroplasty 43 44
Halving the cost in the absence of arthroplasty 43 45
Doubling the cost in the absence of arthroplasty 43 45
Discounting QALYs at 1.5% and costs at 3.5% 43 45
No discounting 43 45
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The economic thresholds are slightly higher than the absolute thresholds owing to differences in the
aims and principles of each analysis. The clinical thresholds are based on the probability that patients
will achieve a MIC in Oxford Hip or Knee Score following surgery, which was defined as 7 for the OHS
and 8 for the OKS. By contrast, the economic threshold is based on the difference in mean QALYs and
mean cost between patients who undergo arthroplasty and those who do not. Although the economic
analyses took account of patients’ life expectancy, surgical mortality and the cost of primary and revision
arthroplasty, the results are primarily driven by the mean change in EQ-5D utility following arthroplasty.
The PROMs/HES data demonstrate that, on average, arthroplasty increases patients’ EQ-5D utility at all
Oxford Hip and Knee Scores of ≤ 46. Although patients with Oxford Hip and Knee Scores between 42
and 46 cannot have a 7-point increase in score following surgery, 73.5% (845/1149) of these patients
nonetheless had an increase in Oxford Hip or Knee Score and 55.4% (453/817) of such patients had an
increase in EQ-5D utility; among patients with improvements in EQ-5D, the mean improvement was 0.215
following arthroplasty. Only 16.9% (138/817) had a decrease in EQ-5D utility; among these patients, the
mean change was –0.181. Because TKA costs around £5642,153 providing there are no complications and
the benefits of surgery last 10 years, EQ-5D utility needs to improve by only 0.032 after arthroplasty in
order for TKA to cost < £20,000 per QALY gained [0.032 = £5642/£20,000, all divided by 8.72 years
(10 years, discounted at 3.5% per annum)].
However, even though TJA is cost-effective for patients with high Oxford Hip and Knee Scores, many
patients may choose not to undergo surgery as they feel that the risks of surgery may outweigh the benefits.
In particular, most patients are likely to be risk averse and prefer to maintain their current level of quality of
life rather than undergo surgery that will, on average, improve their health but that carries a risk that their
joint will deteriorate or that they will die or have a serious cardiovascular complication as a result of surgery.
By contrast, the NHS as a whole spreads the risk across the population of patients (including the majority
who benefit and the minority who are worse off after surgery), and so may be able to ignore risk aversity in
their resource allocation decisions.
Nonetheless, the analyses described in this chapter demonstrate that there is no economic justification
for restricting access to TKA for patients with Oxford Hip and Knee Scores of ≤ 43, or restricting access
to THA for patients with Oxford Hip and Knee Scores of ≤ 45. The results also demonstrate that there is
no economic justification for using different thresholds for men and women and suggest that thresholds
based on cost-effectiveness vary little with age.
Strengths/limitations
Strengths and limitations of the economic modelling
The economic evaluation used the best available UK evidence, including PROMs/HES data on > 608,170
primary arthroplasty procedures and trial data sets following patients for up to 12 years after primary
arthroplasty. However, some model inputs, including ambulatory costs and the long-term changes in
EQ-5D utility, were based on smaller data sets such as KAT and COASt.
The biggest shortcoming of the analysis is the limited data on patients who have not undergone arthroplasty.
No UK longitudinal data following patients who have not undergone arthroplasty were available and the only
international data sets identified used the WOMAC.185,186 Within this analysis, we therefore assumed that the
costs accrued in the absence of arthroplasty would be the same as those accrued by COASt participants in
the year before surgery, and assumed that EQ-5D utility would decrease at the same rate as is observed in
the general population samples. In practice, many osteoarthritis patients are likely to experience a marked
worsening of symptoms in the absence of arthroplasty; taking account of this trend would raise the economic
threshold further. A sensitivity analysis allowing for EQ-5D utility worsening in patients who have not undergone
arthroplasty estimated economic thresholds to be 2–3 points higher than the base case. However, other
sensitivity analyses showed that thresholds would be substantially lower if non-surgical management markedly
improved patients’ quality of life and showed that even substantial changes to the assumptions about the costs
accrued by patients without arthroplasty had a negligible impact on the conclusions.
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For simplicity, the economic evaluation compared immediate TJA with a strategy of no arthroplasty for
10 years. The choice of a 10-year time horizon is arbitrary, although sensitivity analyses demonstrated
that this had little impact on the results. In practice, many patients whose symptoms are considered not
sufficiently severe to warrant surgery at the present time may have surgery in the future. However, given the
shortage of data on changes in Oxford Hip and Knee Scores in the absence of arthroplasty, the current
analysis provides a convenient assessment of the cost-effectiveness of arthroplasty that enables economic
thresholds to be estimated. We also excluded the cost of assessing patients to determine whether or not
they are appropriate candidates for surgery; the impact of including these costs is evaluated in Chapter 8,
which evaluates the cost-effectiveness of referral to surgical assessment compared with no referral.
The analyses took a NHS perspective and excluded the cost of medications, personal care, nursing homes,
convalescence, equipment, home modifications, lost productivity and informal care. It is likely that broadening
the perspective to include these wider costs and taking account of any deterioration in health in the absence
of arthroplasty would improve the cost-effectiveness of TJA and increase the economic threshold. Indeed, one
economic evaluation187 evaluating TKA in patients aged ≥ 90 years argued that TKA would be cost-saving
owing to reductions in the cost of nursing home placement.
The PSA suggested that there was very little parameter uncertainty around the economic threshold. The
95% CrIs take account of uncertainty around all model inputs and allow for correlations between regression
coefficients from the same regression model; these CrIs are narrow because most of the parameters are
estimated on PROMs/HES data on around 300,000 operations. However, the PSA does not take account of
uncertainty around the choice of regression function, uncertainty around model assumptions/structure or
methodological uncertainty.188
This analysis also cannot evaluate the impact of BMI on thresholds because it was not possible to obtain
NJR data linked to PROMs/HES within the time frame of this project, and the only available BMI data came
from comparatively small studies that may be underpowered to assess the impact of BMI over and above
the impact of the Oxford Hip and Knee Scores, age and sex. In the absence of NJR data, we also assumed
that the Oxford Hip and Knee Scores had no impact on revision rates.
Although the PROMs/HES extract includes data on > 608,018 primary arthroplasty procedures, only 0.5%
(2884/608,018) of the sample had Oxford Hip or Knee Scores of > 40. Furthermore, only 0.5% (3250/
608,018) of those in the sample were aged ≥ 90 years and 5.0% (30,437/608,018) were aged ≤ 50 years,
and the published estimates of mortality and revision rates excluded patients aged ≤ 55 or > 84 years.119,121
Results for 50- and 90-year-olds should therefore be interpreted with caution. Furthermore, the model
selection process described in Chapter 5, Regression analyses, is likely to select models that give best
prediction accuracy for patients with an OKS close to the mean, and place less importance on prediction
accuracy for patients with high Oxford Hip and Knee Scores. This may introduce additional uncertainty
around the economic threshold that is not captured within the PSA and the reported 95% CrIs. In particular,
the Tobit models predicting preoperative EQ-5D utility may overestimate EQ-5D utility for those patients
with Oxford Hip and Knee Scores of > 43 (see Figures 34 and 36), although the models appear to predict
change in EQ-5D utility accurately.
As described in Chapter 5, the current analyses are based on UK data and may not generalise to other
countries. Analyses conducted on KAT and COASt data sets and the published studies providing mortality
and revision rates excluded patients who did not undergo TJA.119,121 However, in the absence of NJR data,
it was not possible to reliably identify which primary arthroplasty procedures within the PROMs/HES data
set were TJA and which comprised unicompartmental knee replacement or hip resurfacing. Costs, QALYs
and cost-effectiveness may differ between different types of arthroplasty and between different indications
in ways that cannot be assessed using the current data.
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Further research needed for economic modelling
Further research is needed on the impact of BMI and to assess whether or not the Oxford Hip and Knee
Scores affect revision rates. Additional analyses using NJR data linked to PROMs and HES could also be
used to assess whether or not the Oxford Hip and Knee Scores affect the rate of revision surgery.
Further research is needed on the costs accrued in patients who do not undergo arthroplasty and on how
costs, Oxford Hip and Knee Scores and EQ-5D utility change over time in the absence of surgery.
Additional findings
We also developed additional models to map from the Oxford Hip and Knee Scores to EQ-5D utilities,
which could also be applied in other settings in which OKS or OHS data are available but EQ-5D utilities
are not. Coefficients for these models are given in Online Supplement 15. However, owing to the nature of
the economic evaluation, we considered only models based on OKS/OHS total score, rather than responses
to individual questions. As a result, these models have substantially worse prediction accuracy than those
developed by Dakin et al.134 and Pinedo-Villanueva et al.,126 which mapped from dummy variables for individual
questions. However, our OKS mapping model had better prediction accuracy than the simple OLS model
mapping from total OKS to EQ-5D utility developed by Dakin134 (MSE 0.047 vs. 0.052 in the preoperative
estimation sample). The models shown in Online Supplement 15 were estimated only on preoperative data
and may not perform as well in data sets that include postoperative scores. These analyses suggest that there
is a non-linear relationship between OKS/OHS total score and EQ-5D utility and that age and gender have a
significant effect on EQ-5D utility that is not explained by OKS/OHS. The models give good prediction accuracy,
although they may overestimate utility for patients with Oxford Hip or Knee Scores of > 43.
Conclusion
The economic evaluation demonstrates that TKA is cost-effective for patients with an OKS of ≤ 43, whereas
THA is cost-effective for patients with an OHS of ≤ 45. Therefore, it is not appropriate to restrict access to
arthroplasty for patients with Oxford Hip or Knee Scores below these limits on cost-effectiveness grounds.
The analysis also suggests that it is not cost-effective to set separate thresholds for men and women and
that age has little impact on economic thresholds.
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Chapter 8 Determining the outcome of using the
Arthroplasty Candidacy Help Engine tool in the NHS
(work package 3)
Background
Over the past decade, many clinical commissioning groups (CCGs) have used PROMs such as the Oxford
Hip and Knee Scores to set thresholds for arthroplasty. A 2014 review by the Royal College of Surgeons170
found that 31% (16/52) of CCGs that they reviewed imposed an OHS threshold. The thresholds used
have frequently been relatively low, such as 19 and 24 on the OKS and OHSs, respectively.170,171,176 The
work, described in Chapters 6 and 7 have shown that these thresholds are inappropriate, because patients
with an OKS or OHS of 19 or 24, respectively, have a ≥ 80% chance of a good outcome, and TKA and
THA would each cost < £10,000 per QALY gained for these patients.
Whereas a threshold of 24 would exclude 21% of current arthroplasty operations, avoiding referrals for
patients with a < 70% chance of a good outcome would exclude only 3% of patients who currently have
hip arthroplasty and 7% of those having knee arthroplasty. This demonstrates that the vast majority of
arthroplasty operations that are currently done in the UK are appropriate and are on patients who have a
high capacity to benefit. Furthermore, some of the patients with high Oxford Hip or Knee Scores may need
arthroplasty regardless of the referral thresholds (e.g. for indications other than osteoarthritis, or severe
deformity in the absence of other symptoms). However, there are likely to be many patients currently
managed in general practice or at musculoskeletal hubs who have high capacity to benefit who do not
currently undergo surgery; if the thresholds estimated in Chapters 6 and 7 were introduced, numbers of
referrals from this population might increase.
There is a shortage of published studies and national data on the patients who do not currently have
surgery, and there are no data on OKSs/OHSs for patients managed in primary care. We therefore
obtained data from the musculoskeletal hub that is run from the NOC in Oxford to get an initial estimate
of how the introduction of the ACHE tool and the choice of threshold may affect the number of referrals
and operations, costs and health benefits.
In the Thames Valley CCGs, osteoarthritis patients cannot be referred for consideration of joint surgery
unless their symptoms have a substantial impact on their quality of life and are refractory to non-surgical
treatment, including advice, activity and exercise.172,173 All patients with a BMI of ≥ 25 kg/m2 must also be
offered, and be strongly encouraged to participate in, a weight-loss programme. Until October 2016,
patients with an OKS of > 32 could only be listed for knee surgery if approved by two consultants.189
In practice, nearly all patients attending the NOC hub with knee or hip symptoms are asked to complete
the OKS or OHS and patients with a BMI of ≥ 40 kg/m2 cannot be listed for surgery until they have first
completed a monitored weight-loss programme.
This analysis aims to:
l Evaluate how the probability of referral and undergoing surgery varies with preoperative characteristics
in current clinical practice using an audit of a musculoskeletal hub.
l Estimate the number of patients who might be expected to be referred for surgical assessment or
undergo arthroplasty if the ACHE tool were introduced into NHS practice.
DOI: 10.3310/hta23320 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 32
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Price et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
145
l Assess how the economic thresholds estimated in Chapter 7 change when we take into account the
additional numbers of surgical assessments that would be required if the ACHE tool were introduced into
routine clinical practice and evaluate the cost-effectiveness of referring patients for surgical assessment
compared with no referral (rather than the cost-effectiveness of arthroplasty vs. no arthroplasty, as was
evaluated in Chapters 5 and 7).
l Assess the cost-effectiveness of using the ACHE tool with different thresholds or different probabilities
of benefiting from surgery to assess osteoarthritis patients attending the musculoskeletal hub compared
with current practice, from the perspective of the UK NHS.
The predictions of the impact the ACHE tool might have if it were introduced into clinical practice are,
by their nature, speculative. In particular, they rely on assumptions around how the ACHE tool would be
used in practice and what impact it would have on referrals. In addition, the analysis excludes patients who
are not currently referred by their GPs but might, in some circumstances, be candidates for arthroplasty,
because there are no data on this population. We also assumed that referral patterns across England are
the same as those in Oxfordshire, because this comprised the only data set available for analysis. The figures
presented in this chapter must therefore be interpreted with caution and represent initial estimates of the
direction and possible magnitude of changes that could be brought about by the ACHE tool.
Methods
General approach
We conducted an audit of medical records for patients who were referred to the NOC hub with knee or
hip pain. We used the results to estimate the probability that patients with different baseline characteristics
are referred from the hub to an orthopaedic surgeon and the probability that such patients then undergo
arthroplasty. These probabilities were then used to estimate the number of patients of different ages,
genders and with Oxford Hip and Knee Scores who may be referred nationally each year. The costs and
QALYs estimated for each patient group within the economic evaluation described in Chapter 7 were
multiplied by the number of patients anticipated to come forward based on the hub data to predict the
potential impact that the ACHE tool may have on cost and health benefits, and how such costs and
benefits may vary with the threshold.
In principle, the ACHE tool could be used at several points in the referral pathway. It could be used by
GPs to decide if or when to refer the patient to secondary care. Oxford Hip and Knee Scores or the ACHE
probability of benefit could be stated on the GP’s referral letter to help hub staff identify the next course
of action, or the tool could be used during a hub consultation to inform decisions about whether or not
the patient should be referred for surgical assessment. The ACHE tool could also be used at the surgical
assessment to guide discussions between the surgeon and the patient about whether or not arthroplasty
is appropriate. In this chapter, we assumed that the ACHE tool would be used only during face-to-face
consultations at the hub for three reasons. First, discussions with GPs and hub staff suggested that it is
likely to be most practical to use the ACHE tool at the hub rather than at the general practice. Second,
there are no reliable data on the total number of patients consulting their GPs about hip or knee pain who
are not currently referred, and no information on the distribution of Oxford Hip and Knee Scores for such
patients. By contrast, we were able to obtain a set of data for patients attending the NOC hub. Third,
although the ACHE tool may also be used to inform joint decision-making by the surgeon and patient
during the surgical assessment, we did not attempt to model the impact of using the ACHE tool during
the surgical assessment because the final decision to proceed or not with surgery is a more complex,
personalised, shared decision and cannot be easily modelled given current data.
Approval
We successfully sought permission to analyse anonymised data from the Oxford musculoskeletal hub
under direction of the lead and clinical director of Oxford University Hospitals NHS Foundation Trust
(Oxford University Hospitals research and development reference number 11603).
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Analysis of data from the Nuffield Orthopaedic Centre musculoskeletal hub
The primary analysis aimed to estimate how the probability that patients who attend face-to-face consultations
at the hub will be referred to secondary care varies with OKS/OHS, age and gender. Following a well-established
rule of thumb,190 we aimed to collect sufficient data to have at least 10 referrals from the hub to secondary care
for each of these three explanatory variables.
Two medically-qualified surgical research fellows extracted data on patients’ gender, age and OKS/OHS at
the time of each patient’s first face-to-face attendance at the hub into a pre-prepared data extraction table,
as well as details on the date of attendance and whether or not the patient was referred to secondary care
from the hub’s electronic medical records database. The date of any surgical assessment visit, whether or
not patients were listed for knee/hip arthroplasty and the date of surgery were also recorded. Free-text fields
were also used to record additional information on imaging, referrals to other clinics, other surgery and
other diagnoses. Additional data on OKSs were extracted from the clinical pathway database for patients
who had been referred directly for surgical assessment. Data on BMI were not extracted because BMI is not
part of the ACHE tool.
The following exclusion criteria were used to exclude from the analysis patients who are unlikely to use the
ACHE tool in clinical practice:
l Patients aged < 50 years because knee/hip pain in younger patients is unlikely to be caused by osteoarthritis.
l Patients for whom it was clear from the records that the symptoms were attributable to a condition
other than osteoarthritis. In particular, the analysis excluded patients with rheumatoid arthritis, fracture
(or arthritis secondary to fracture), gout, chondroid lesions, sports or other injuries, bone/joint
infections, bursitis or quadriceps rupture. Patients requiring limb reconstruction, those with hip pain
caused by previous spinal surgery and those recorded as having no mechanical symptoms were
also excluded.
l Patients who had previously had arthroplasty on the joint in question.
l Patients who had attended the hub or surgical assessment before July 2015, and patients for whom
medical records were inaccessible for research.
Patients referred for radiography, MRI or physiotherapy were in the analysis, regardless of whether or not
they attended a face-to-face hub assessment.
Modelling the treatment pathway
Decision tree model
We constructed a decision tree model of the treatment pathway based on a preliminary examination of
the data and consultation with hub staff (Figure 38). GPs’ letters referring patients to secondary care are
first reviewed by senior hub staff, who examine the patient’s radiographs, and take into account the GP’s
description of the patient’s symptoms, their BMI and what treatments have been previously tried.
As a result of this triage process, some patients are referred directly to surgical assessment, including those
who have severe symptoms and those who have previously been referred to secondary care but chose not
to have surgery at that time.
Triage also identifies some patients who can be managed in primary care and therefore do not need to
attend a face-to-face consultation at the hub or with an orthopaedic surgeon. These patients may have
mild symptoms, or may not have exhausted all of the non-surgical treatment options (e.g. advice and
information, activity and exercise, and, if appropriate weight loss).191–193 In other cases, it may be clear from
the referral letter that the patient is unfit for surgery or has a recent injury that needs more time to heal
before a secondary care assessment is necessary. Other patients are sent referral letters, but do not call to
book an appointment or miss booked appointments. A small minority of patients opt for non-NHS care.
In some cases, it is necessary to conduct radiography or other imaging before the patient can be assessed.
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The remaining patients attend the hub for a face-to-face assessment. This group tends to be those with
moderate symptoms, those for whom there is uncertainty around the clinical diagnosis and those patients
with BMIs of ≥ 40 kg/m2 who must be referred for a weight-loss programme before surgery. At the hub,
consultant physiotherapists or orthopaedic fellows assess the patient to confirm diagnosis. Although the
CCG no longer specifies a threshold Oxford Hip or Knee Score for referral,172,173 patients complete the
OKS or OHS to assess whether or not symptoms are sufficiently severe to warrant surgery and to guide
discussions about patients’ symptom profiles. Staff discuss with the patient what arthroplasty involves,
including the potential need for revision surgery, recovery times and the need for support at home after
hospital discharge, and how these might be affected by patients’ comorbidities and living arrangements.
Landmark injections, injections for trochanteric bursitis and diagnostic imaging may also be done during
the hub consultation. Obese patients are referred for monitored weight-loss programmes that must be
followed for 12 months before surgery. Based on the hub visit, patients may be referred to an assessment
consultation with a hip or knee surgeon if it is considered that they may be appropriate candidates for
arthroplasty, or for other interventions such as arthroscopy, interventional radiology or anterior cruciate
ligament repair. Other patients may be referred to other outpatient clinics, such as a sports injury clinic,
or rheumatology. Patients may also be referred for physiotherapy or other non-surgical management,
or may choose not to be referred because they have decided that they would prefer not to have surgery.
Patients attending a surgical assessment consultation will discuss the risks and benefits of surgery with an
orthopaedic surgeon and make an informed decision about whether or not to undergo arthroplasty or
another type of surgery, taking account of the severity of their symptoms and comorbidities.
Methods for estimating patient numbers
The decision tree model required estimation of five probabilities, shown in grey in Figure 38. We also evaluated
whether or not the probability of being referred by the hub to surgical assessment and the probability of
subsequently undergoing arthroplasty varied with Oxford Hip or Knee Score, age and sex. From these figures,
we estimated the probability that men and women aged 50, 60, 70, 80 and 90 years with different Oxford Hip
and Knee Scores will undergo arthroplasty after being referred by their GP with hip/knee symptoms.
Arthroplasty
P(arthroplasty|direct)
Directly referred to surgical assessment
P(direct referral)
No arthroplasty
#
Arthroplasty
P(arthroplasty|hub)
Attend surgical assessment
P(referred by hub)
No arthroplasty
Hub triage Attend MSK hub #
P(attend hub) Not referred to surgical 
assessment No arthroplasty
#
No face-to-face consultation with either 
surgeon or hub No arthroplasty
#
GP writes to the
hub to refer the
patient with knee/
hip symptoms
M
M
M
M
M
M
FIGURE 38 Schematic of the decision tree model. P(x) indicates the probability of x occurring; M indicates the
Markov model that is used to calculate payoffs for the relevant branch (green for the arthroplasty Markov model
and blue for the no-arthroplasty Markov model); and # indicates the residual probability (i.e. 1 minus the
probabilities of the other branches leading from the preceding chance node).
DETERMINING THE OUTCOME OF USING THE ARTHROPLASTY CANDIDACY HELP ENGINE TOOL (WORK PACKAGE 3)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
148
We then calculated how many patients in each of these groups would need to be referred with knee/hip
symptoms to account for the number of patients undergoing arthroplasty surgery across England each year.
The number of operations in each group was first calculated by multiplying the proportion of patients in
different age and sex groups (see Online Supplement 15) by the proportion of different Oxford Hip and Knee
Scores (see Online Supplement 12) and by the number of primary knee/hip replacements conducted solely
for osteoarthritis in England in 2014–15 (76,617 knee replacements and 69,313 hip replacements;154,165
see Chapter 5, Presentation of results and analysis of uncertainty). The number of patients in each group
who are likely to have been referred with knee/hip symptoms was then calculated by dividing the number
of operations in each group by the probability that each group of patients will undergo surgery.
We then estimated what impact using the ACHE tool at the hub might have on the number of referrals to
surgical assessment and on the number of operations. In practice, many patients who are not referred to
surgical assessment after their hub visit would not be considered candidates for arthroplasty regardless of
their Oxford Hip or Knee Scores. In particular, some patients may decide after their hub visit that they do
not want arthroplasty surgery, whereas others may be unsuitable owing to comorbid conditions. For the
purposes of estimating the potential impact of the ACHE tool, we therefore assumed that half of the
patients who are not currently referred from the hub to surgical assessment would not go on to surgical
assessment even if the ACHE tool were introduced, whereas the remaining patients will be referred only if
the ACHE tool predicts them to have capacity to benefit. We modelled the likely patient numbers if the
ACHE tool were used to restrict referral to patients with at least a 50%, 60%, 70%, 80% or 85%
probability of achieving a MID in Oxford Hip or Knee Score based on the data.
These patient numbers were used to assess the cost of the referral pathway by applying the costs described
in Cost inputs. The impact of changing the number of arthroplasty operations on total costs and QALYs
was then calculated by applying the costs and QALYs with and without arthroplasty that were estimated in
Chapter 7 to the number of patients in each group who were expected to undergo arthroplasty or not have
surgery within each scenario. The net health benefit of stratifying patients using the ACHE tool was also
evaluated using the methods described in Chapter 5, Presentation of results and analysis of uncertainty,
assuming a £20,000-per-QALY ceiling ratio.166,167
We also estimated the total costs and QALYs that would be accrued if all hub attendees were referred
for surgical assessment and those that would be accrued if no hub attendees were referred. From these
estimates, we calculated the cost-effectiveness of referring hub attendees of different ages, genders and
Oxford Scores to surgical assessment compared with no referral and produced alternative estimates of the
decision grids and economic thresholds that take account of the cost of surgical assessment. We also used
the ‘Goal Seek’ function in Microsoft Excel® 2010 to estimate the ICER at which the number of knee/hip
arthroplasty procedures that would be conducted using the economic threshold equal to a specific target.
The analysis made the following assumptions:
l Because there were no data on OKSs/OHSs patients who did not attend the hub, the probability of
attending a face-to-face visit at the hub and the probability that patients are referred directly to surgery
were assumed to be independent of Oxford Hip or Knee Score, age and sex. In practice, it is likely that
those patients referred directly to surgical assessment will have more-severe symptoms, whereas those
who attend neither the surgical assessment nor the hub may have less-severe symptoms. There may
also be differences in the probability of referral by age and sex. However, because we evaluated the
impact of the ACHE tool only in those patients attending the hub, allowing for variations in these
parameters by age and sex would have had little or no impact on the conclusions. These probabilities
were therefore estimated as the proportion of the osteoarthritis patients included in the analyses who
attended the hub or were referred directly to surgical assessment without attending the hub.
l For patients who were directly referred to surgical assessment, we assumed that the probability of
undergoing surgery was independent of Oxford Hip or Knee Score, age and sex under current practice.
As described above, this assumption is unlikely to have affected the estimates of the impact of the
ACHE tool on hub attendees.
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l The five probabilities estimated based on the NOC hub data were assumed to be representative of
clinical practice across the UK. Clinical practice at this hub is likely to differ from practices in other areas
in several respects (see Strengths, limitations and further research requirements). However, this
assumption was necessary as no other data were available.
l All patients were assumed to attend a surgical assessment visit before surgery, as was observed in
the audit.
l We assumed that the ACHE tool would not be used at the surgical assessment and that the probability
of undergoing surgery after attending surgical assessment (conditional on Oxford Hip or Knee Score,
age and sex) will be unaffected by the threshold used.
l Because there were insufficient data to evaluate non-linear functions, age and Oxford Hip and Knee
Score were assumed to have linear effects on the log-odds of being referred for surgical assessment
and on the log-odds of having surgery if referred.
l Patients who were on the waiting list for arthroplasty surgery or for whom surgery had been delayed
because of comorbidities (including high BMI scores) after being referred at the surgical assessment
were counted as having been referred for surgery.
Owing to time and resource constraints, we did not attempt to quantify the uncertainty around the results
presented in this chapter using PSA.
Regression methods
Logistic regression models were used to assess how patients’ Oxford Hip and Knee Scores, age and sex
affected the odds of being referred for surgical assessment and the odds of subsequently undergoing
surgery. Regression analyses and two-sample tests of proportions were conducted in Stata® version 14.
Comparisons of Oxford Hip or Knee Scores between patient groups were conducted using unpaired t-tests
conducted in Stata®; an F-test for equal variances was first conducted, which determined whether the t-test
assumed equal or unequal variance. Oxford Hip and Knee Scores in the hub sample were compared against
the population mean (nationally or in Oxfordshire) using a one-sample t-test in Stata®. Population means,
nationally and in Oxfordshire, were based on NHS PROMs reports,162,182–184,194,195 which provide average
preoperative OKSs and OHSs at the provider and commissioner level; the national average OKSs and OHSs
were based on 2014–15 data, although owing to be smaller numbers of operations, those for the NHS
Oxfordshire CCG comprise weighted average scores over all years from April 2009 to March 2015, and
these averages were weighted by the number of procedures conducted in each year.
Oxford Hip and Knee Scores, age and sex were initially considered as potential explanatory variables, but
were dropped from the regression analyses if they were found to be poor predictors. Given the sample of
around 100 patients attending the hub, it was not possible to follow the 10-fold cross-validation approach
used to select the regression specifications used in the Markov models. We therefore selected regression
models based on Akaike information criterion (AIC), testing variables in a prespecified sequence. We began
with a model including just the constant term and evaluated whether or not adding OHS or OKS to the
model reduced the AIC; if it did, we added in the Oxford Hip or Knee Score in the next step, and if not, we
kept the model as just constant. In the next step, we assessed whether or not adding age into the model
reduced the AIC, and in the final step, we assessed whether or not adding sex into the model reduced AIC.
The order in which variables were considered for the models (OHS or OKS, then age and then sex) was
specified in advance of data analysis; we hypothesised that disease severity (i.e. OHS and OKS) would be
most important, followed by age (because it is a proxy for comorbidities) and finally sex (because we had no
prior hypotheses about how this variable would affect referrals).
The data for patients attending the hub were also used to obtain two measures of the current threshold
OHS and OKS for referral. First, the absolute threshold was determined simply as the highest OHS and OKS
observed among the patients who were referred for surgical assessment. Second, the logistic threshold was
estimated from the regression output for the model selected using the process described in the previous
paragraph: the model coefficients were used to calculate the OHS or OKS at which the probability of being
referred for surgical assessment is 50%.
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Cost inputs
We assumed that each 40-minute hub attendance cost £58, whereas surgical assessment visits cost £132
(see Online Supplement 8). The costs of GP consultations and the hub triage process were excluded from
the analysis because they occurred before the hub attendance at which the ACHE tool is assumed to be
used. Similarly, the cost of radiography, imaging, physiotherapy, injections, weight-loss programmes,
missed appointments and referrals to other clinics was excluded because there is no reason to expect the
introduction of the ACHE tool to affect the proportion of patients requiring these resources.
Results
Results of the musculoskeletal hub audit
Results of the audit for knee replacement
Records were reviewed for 616 patients referred to the hub with knee symptoms, of whom 315 osteoarthritis
patients aged ≥ 50 years were included in the analysis (Figure 39). Of the 18 patients aged ≥ 50 years who
were excluded because of conditions other than osteoarthritis, five had rheumatoid arthritis, four had bone or
joint infections, two had injuries, one had gout, one had a chondroid lesion, one had no mechanical symptoms,
one had quadriceps rupture, one needed limb reconstruction and two had arthritis secondary to fracture.
Of the patients analysed, 44% (130/315) attended face-to-face consultations at the hub and 23% (71/315)
were referred directly to surgical assessment based on the hub triage.
Among the 68 patients who were referred directly to surgical assessment and had outcomes recorded,
56% (38/68) underwent or were awaiting surgery. Data on the OKS measured at the surgical assessment
visit were available for 27 of these patients registered in the Javlin study (URL: www.hra.nhs.uk/planning-
and-improving-research/application-summaries/research-summaries/local-javlin-registry-v10/; accessed
6 February 2019) who had a mean OKS of 15 (range 1–30). Among the 22 of these patients who went on
to have knee arthroplasty, the mean OKS was 14 (range 1–28), non-significantly higher than the average
for the five patients who did not have arthroplasty (mean score 21, range 10–30; p = 0.08).
Five of the 114 patients who did not attend face-to-face consultations at the hub or surgical assessment
were referred for physiotherapy, 60 had radiography, 16 had MRI and two had ultrasounds. Ten patients
had two of these contacts.
Among the 110 patients attending the hub who had complete data, the average OKS was 21 (range 1–48),
which was significantly higher than the average for patients undergoing arthroplasty nationally (mean score
18.43; p = 0.015) (Figure 40), but not significantly different from that in Oxfordshire (mean score 19.6;
p = 0.134).162,182–184,194,195 Of the 110 hub attendees, 49 (45%) were referred. OKS values were significantly
lower for those patients who were referred (mean score 18, range 3–41) than for those who were not
referred (mean score 23, range 1–48; p = 0.013). The highest OKS at which patients were referred to surgical
assessment was 41, although the second-highest score was 32. Logistic regression analyses suggested that
the odds of being referred for surgical assessment varied with OKS, although allowing for age and gender
worsened model fit. This analysis suggested that the odds of being referred to surgical assessment decreased
by 4.7% for each 1-point increase in OKS (p = 0.019), and suggested that the OKS at which patients have a
50% chance of being referred is just 16.
Among the 40 hub attendees who were referred to surgical assessment and had data on the outcome of
that consultation, 30% (12/40) underwent or were awaiting arthroplasty surgery: significantly fewer than
among those patients directly referred to surgical assessment [56% (38/68); p = 0.0092]. Among the sample
of hub attendees, OKS, age and gender did not predict which patients would undergo arthroplasty. This
may reflect the role of comorbidities and patient choice in the decisions made at the surgical assessment.
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Osteoarthritis patients
(n = 315)
Attended neither hub nor surgical
assessment
(n = 114)
Patients attending the hub
(n = 130)
Records for patients referred
to the hub with knee symptoms
(n = 616)
Patients used to estimate
the probability of referral
(n = 110)
• Referred, n = 49
71 patients referred 
directly to surgical 
assessment, of whom 
33 had arthroplasty, 
5 were awaiting surgery, 
one died before surgery 
and 3 in whom the 
outcome was unknown
Patients used to estimate the
probability of hub attendees
undergoing arthroplasty
(n = 40)
• Underwent surgery, n = 9
• Are awaiting surgery, n = 3
• Died before surgery, n = 1
• Duplicates, n = 40
• No access to patient records, n = 5
• Referred before July 2015, n = 21
• Aged < 50 years, n = 204
• Does not have osteoarthritis, n = 18
• Has previously had arthroplasty on the
   joint, n = 8
• Referred about another joint, n = 5
• Had no encounters related to the knee,
   n = 26
• Had past encounters but no recent ones,
   n = 2
• Had radiography, MRI, ultrasound,
   physiotherapy and/or injections only, n = 78
• Died before hub attendance, n = 0
• Awaiting a hub appointment, n = 0
• Missed booked hub appointment(s), n = 6
• Opted for non-NHS care, n = 1
• Patients had missing data on the outcome
   of surgical assessment, n = 8
• Is awaiting surgical assessment, n = 1
• Had missing Oxford score data, n = 8
• Had missing data on outcome of hub visit,
   n = 12
FIGURE 39 Patient flow diagram for patients referred with knee symptoms.
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For two patients (who both attended the hub), the medical notes indicated that it was necessary for the
patients to reduce weight before knee replacement could be conducted.
Results of the audit for hip replacement
We reviewed records for 1022 patients referred to the hub with hip symptoms, of whom 607 osteoarthritis
patients aged ≥ 50 years were included in the analysis (Figure 41). Among the 19 patients aged ≥ 50 years
who were excluded because they had conditions other than osteoarthritis, nine had rheumatoid arthritis,
three had fractures, two had bone or joint infections, two needed limb reconstruction, one had a sports
injury, one had no mechanical symptoms and one had hip symptoms caused by previous spinal surgery.
Face-to-face consultations at the hub were attended by 17% of patients (106/607), whereas 39% (236/607)
were referred directly to surgical assessment. Of the 235 patients who were directly referred to surgical
assessment and had known outcomes, 69% (161) had hip arthroplasty or were awaiting surgery. Because
Javlin recruited only knee patients in the period covered by our audit, no OHS data were available on this
patient group.
Of the 265 patients (44% of the total) who attended neither the hub nor the surgical assessment,
six had physiotherapy, four were referred to other clinics, 10 had hip injections, 186 had radiography,
eight had MRI and nine had ultrasound. Twenty-nine patients had two or more of these contacts.
Across the 101 hub attendees with complete data, the mean OHS was 23.7 (range 5–46), which was
significantly higher than the average for hip arthroplasty patients nationally (mean score 17.5; p < 0.001)
(Figure 42) and in Oxfordshire (mean score 18.7; p < 0.0001).162,182–184,194,195 Overall, 36% of hub attendees
(36/101) were referred for surgical assessment.
The mean OHS was non-significantly lower for patients who were referred (mean score 21, range: 5–44)
than for patients who were not referred (mean score 25, range 5–46; p = 0.057). One patient was referred
with a score of 44, although the second-highest score was 35. Logistic regression analysis suggested that
the odds of referral varied with OHS and gender but not age. Each 1-point increase in OHS reduced the
odds of referral by 3.9% (p = 0.062). The analysis also suggested that men attending the hub were twice as
likely to be referred than women, although the difference did not reach statistical significance (p = 0.147).
Women were more likely to attend the hub.
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FIGURE 40 Distribution of OKSs for patients attending the hub with knee pain compared with the distribution of
patients undergoing knee arthroplasty in England in PROMs/HES data (2009–15).
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Osteoarthritis patients
(n = 607)
Attended neither hub nor surgical
assessment
(n = 265)
Patients attending the hub
(n = 106)
Records for patients referred
to the hub with hip symptoms
(n = 1022)
Patients used to estimate
the probability of referral
(n = 101)
• Referred, n = 36
236 patients referred directly
to surgical assessment,
of whom 145 had arthroplasty,
16 are awaiting surgery,
1 died before surgery
and 1 in whom the
outcome is unknown
Patients used to estimate the
probability of hub attendees
undergoing arthroplasty
(n = 27)
• Underwent surgery, n = 10
• Are awaiting surgery, n = 0
• Died before surgery, n = 0
• Duplicates, n = 82
• No access to patient records, n = 7
• Referred before July 2015, n = 39
• Aged < 50 years, n = 234
• Does not have osteoarthritis, n = 19
• Has previously had arthroplasty on the
   joint, n = 16
• Referred about another joint, n = 18
• Had no encounters related to the hip, n = 29
• Had past encounters but no recent ones,
   n = 17
• Had radiography, MRI, ultrasound,
   physiotherapy and/or injections only, n = 208
• Died before hub attendance, n = 5
• Awaiting a hub appointment, n = 2
• Missed booked hub appointment(s), n = 3
• Opted for non-NHS care, n = 1
• Patients who had missing data on the
   outcome of surgical assessment, n = 9
• Had missing Oxford score data, n = 2
• Had missing data on outcome of hub visit,
   n = 3
FIGURE 41 Patient flow diagram for patients referred with hip symptoms.
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Among the hub attendees who were referred for surgical assessment, 37% (10/27) underwent hip
arthroplasty. Logistic regression analysis suggested that OHS, age and gender did not predict which
patients would undergo arthroplasty.
Medical records for one patient attending the hub and eight patients who were directly referred to surgical
assessment indicated that the patients needed to reduce weight. Of these, two patients had surgery delayed
because they needed to lose weight, after they had been directly referred to surgical assessment and then
referred for hip arthroplasty.
Anticipated patient numbers, budget impact and cost-effectiveness of the Arthroplasty
Candidacy Help Engine
Knee arthroplasty
We extrapolated the hub data to estimate the number of patients who may be referred to secondary care
with knee pain in England by dividing the number of knee arthroplasty procedures conducted on patients
with different OKSs, ages and genders by the probability of hub attendees undergoing surgery. This
suggested that GPs across England refer > 400,000 patients aged ≥ 50 years to secondary care with knee
osteoarthritis symptoms each year (Figure 43). Of these, > 170,000 patients might be expected to attend
the hub if all CCGs followed a treatment pathway similar to that in Oxfordshire. Among the hub attendees,
there may be around 80,000 referrals and 24,000 arthroplasty procedures, suggesting that around 53,000
of the 76,600 primary knee arthroplasty operations conducted for osteoarthritis each year are done on
patients who were directly referred to surgical assessment.
We also modelled the impact that the introduction of the ACHE tool might have on patient numbers, costs
and QALYs (Table 60). As discussed in Methods, we assumed that the ACHE tool would only be used in
face-to-face hub consultations and would not influence decisions about referrals or surgery in other settings.
We also assumed that 26% of all hub attendees (half of the 53% of hub attendees who are not currently
referred to surgical assessment) would not be referred regardless of the ACHE tool.
This analysis suggested that introducing the ACHE tool is likely to substantially increase the number of
referrals, the number of arthroplasty procedures, costs and health benefits. The ACHE tool was predicted to
be cost-effective compared with current practice if the value the NHS places on each QALY is £20,000; for
example, using the ACHE tool to identify patients with ≥ 70% of a good outcome (which is equivalent to
an OKS threshold of 32 for 60- to 79-year-old men and 30 for 60- to 79-year-old women) would lead to
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FIGURE 42 Distribution of OHSs for patients attending the hub with hip pain compared with the distribution of
patients undergoing hip arthroplasty in England in PROMs/HES data (2009–15).
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an additional 122,000 surgical assessments and 36,000 additional knee arthroplasty procedures. Taking
account of the patients who were directly referred to surgical assessment (and for whom it is assumed that
the ACHE tool would not be used), this equates to a 24% increase in the number of surgical assessments
and a 16% increase in the number of knee arthroplasty procedures. Conducting these additional operations
would cost an additional £33 million compared with current practice, but would gain > 29,000 healthy
years or QALYs over the 10-year time horizon. Compared with current practice, this strategy costs £1133
per QALY gained: well below the £20,000–30,000 that the NHS is typically willing to pay to gain 1 QALY.98
Taking into account the improved health for knee arthroplasty patients and the health forgone by spending
additional NHS money on knee arthroplasty rather than other services, using the ACHE tool with a 70%
cut-off point would gain the equivalent of 28,000 QALYs.
The number of referrals, procedures, costs and benefits increase as the capacity-to-benefit threshold is
decreased. Because the probability of a good outcome from TKA is < 85% for patients aged < 60 years
who have an OKS of ≥ 2 and for older patients with an OKS of 19–21 and above, referring only patients
with ≥ 85% chance of a good outcome would reduce the number of referrals and operations and save
money but would also reduce the health benefits.
Applying the health economic thresholds estimated in Chapter 7 would increase the number of referrals
and operations further, but would gain 33,000 QALYs compared with current practice and gain 3700 more
QALYs than referring patients who had a ≥ 70% chance of a good outcome. After taking into account the
health benefits that are forgone by spending money on knee arthroplasty rather than other NHS services,
using the health economic thresholds would gain around 31,000 QALYs compared with current practice.
Hip arthroplasty
Applying the same methods to hip data suggests that GPs in England refer around 235,000 patients with
hip osteoarthritis symptoms each year (Figure 44). Of these, around 41,000 would be expected to attend
the musculoskeletal hub if all CCGs followed the same referral pathway as that followed in Oxfordshire.
Around 18,000 hub attendees may be referred for surgical assessment, of whom around 7000 undergo hip
arthroplasty. However, the NOC hub data suggest that around 90% of hip arthroplasty procedures (around
63,000 operations nationally) are conducted on patients who were referred directly to surgical assessment
without attending the hub.
Knee arthroplasty
56%
Patients in England
(n = 52,553)
30%
Patients in England
(n = 24,063)
47%
Patients in England
(n = 80,211)
53%
22%
Patients in England
(n = 94,043)
37%
Patients in England
(n = 150,999)
41%
Patients in England
(n = 172,192)
Patients in England
(n = 417,233) 
Directly referred to surgical assessment
No knee arthroplasty
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Knee arthroplasty
Attend surgical assessment
No knee arthroplasty
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Not referred to surgical 
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FIGURE 43 Number of patients predicted to be referred with knee osteoarthritis symptoms in England.
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TABLE 60 Impact of the ACHE tool on patient numbers, costs and QALYs among the 172,192 knee patients attending the hub in England each year
Outcome
Current
practice
The ACHE tool referring patients with a specified probability of
achieving a good outcome Optimal health economic threshold
85% 80% 70% 60% 50%
Taking into account
assessment pathway
costs
Ignoring assessment
pathway costs
Range of threshold OKSs across age and
gender groups
N/A 1–20 2–27 27–32 32–35 34–37 40–44 41–44
Number of attendances at the surgical
outpatient visit
80,211 69,702 103,731 121,507 127,545 130,019 131,965 131,967
Number of arthroplasty procedures
conducted
24,063 20,911 31,119 36,452 38,263 39,006 39,589 39,590
Total cost of the assessment pathway (£) 20,397 19,005 23,511,404 25,865,310 26,664,801 26,992,441 27,250,072 27,250,414
10-year cost excluding the assessment
pathway (£)
1,077,817 1,067,131 1,091,969 1,105,648 1,112,839 1,116,290 1,119,389 1,119,394
Total cost (£) 1,098,213 1,086,137 1,115,481 1,131,513 1,139,503 1,143,282 1,146,639 1,146,645
Difference in cost vs. current practice (£) N/A –12,077 17,268 33,300 41,290 45,069 48,426 48,431
10-year QALYs 564,744 568,033 585,592 594,130 596,303 597,212 597,855 597,855
Difference in QALYs vs. current practice N/A 3289 20,848 29,385 31,559 32,468 33,111 33,111
Net health benefit (QALYs) 509,834 513,726 529,818 537,554 539,328 540,048 540,523 540,523.21
Difference in net health benefit vs. current
practice
N/A 3892 19,984 27,720 29,494 30,214 30,689 30,689
ICER vs. current practice N/A Dominant £828 £1133 £1308 £1388 £1463 £1463
ICER vs. next best non-dominated option N/A Dominant £1671 £1878 £3677 £4157 £5220 £20,470
N/A, not applicable.
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The model predicts that introducing the ACHE tool into clinical practice would increase the number of referrals,
the number of hip arthroplasty procedures, costs and health benefits (Table 61). Numbers of referrals and
operations, costs and health benefits increase as the threshold for referral is relaxed. However, all strategies are
cost-effective compared with current practice if the NHS is willing to pay ≥ £4000 per QALY gained.
Using the ACHE tool to identify patients with a ≥ 70% chance of a good outcome from hip arthroplasty
would result in around 13,000 additional referrals to surgical assessment and around 5000 additional
arthroplasty procedures in England each year. However, because we assumed that the ACHE tool would
have no impact on the 90% of hip arthroplasty procedures conducted on patients who did not attend the
hub, the total number of operations would increase by only 7%. This strategy would increase the total cost
of referrals and operations by around £25M, but would gain 16,000 QALYs. Even greater health benefits
and greater cost-effectiveness could be achieved using the economic thresholds described in Chapter 7.
Impact of assessment pathway costs on economic thresholds
We also re-estimated the economic thresholds presented in Chapter 7 to allow for the cost of the additional
surgical assessments that are conducted as a result of using different thresholds. This demonstrated that
taking account of the additional surgical assessments has a negligible impact on the economic thresholds.
The threshold for knee replacement reduced by 1 point for men aged 90 years but remained the same for
all other demographic groups (Table 62). The threshold for hip replacement was unaffected by taking into
account the cost of surgical assessments (Table 63). Applying these slightly revised thresholds rather than
those described in Chapter 7 would slightly reduce the number of referrals, operations and costs, slightly
increase net benefits and have a negligible impact on health (see Tables 60 and 61).
In practice, the number of arthroplasty procedures that CCGs or hospitals can commission or conduct is
likely to be limited by the available budget and the number of surgeons, operating theatres and beds. In this
resource-constrained environment, it is therefore extremely useful to be able to prioritise patients, such that
the finite number of operations is conducted on the patient groups that have the greatest capacity to benefit
and for whom treatment would be most cost-effective. Therefore, we further stratified the patient groups for
whom arthroplasty is cost-effective (i.e. costs < £20,000 per QALY gained) to indicate those patient groups
that would be the most cost-effective for arthroplasty if we wished to keep the total number of operations
the same as in 2014–15 (76,617 knee replacements and 69,313 hip replacements)154,165 or increase or
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FIGURE 44 Number of patients predicted to be referred with hip symptoms in England.
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TABLE 61 Impact of the ACHE tool on patient numbers, costs and QALYs among the 41,121 hip patients attending the hub in England each year
Outcome
Current
practice
The ACHE tool referring patients with a specified probability of
achieving a good outcome Optimal health economic threshold
85% 80% 70% 60% 50%
Taking into account
assessment pathway
costs
Ignoring
assessment
pathway costs
Range of threshold OHS values across age
and gender groups
N/A 22–31 26–33 31–36 34–38 36–39 43–45 43–45
Number of attendances at the surgical
outpatient visit
17,793 27,762 29,846 31,145 31,720 31,884 32,213 32,213
Number of arthroplasty procedures
conducted
6590 10,282 11,054 11,535 11,748 11,809 11,931 11,931
Total cost of the assessment pathway (£) 4,690,561 6,010,730 6,286,718 6,458,609 6,534,762 6,556,546 6,600,029 6,600,029
10-year cost excluding the assessment
pathway (£)
163,711,246 180,550,234 184,214,155 186,503,073 187,529,122 187,827,262 188,423,603 188,423,603
Total cost (£) 168,401,807 186,560,964 190,500,872 192,961,683 194,063,884 194,383,808 195,023,632 195,023,632
Difference in cost vs. current practice (£) N/A 18,159,157 22,099,066 24,559,876 25,662,078 25,982,001 26,621,825 26,621,825
10-year QALYs 123,674 137,629 138,976 139,718 140,038 140,129 140,288 140,288
Difference in QALYs vs. current practice N/A 13,955 15,302 16,043 16,364 16,455 16,614 16,614
Net health benefit (QALYs) 115,254 128,301 129,451 130,070 130,335 130,410 130,537 130,536.95
Difference in net health benefit vs. current
practice
N/A 13,047 14,197 14,815 15,080 15,156 15,283 15,283
ICER vs. current practice N/A £1301 £1444 £1531 £1568 £1579 £1602 £1602
ICER vs. next best non-dominated option N/A £1301 £2925 £3316 £3444 £3516 £4024 a
N/A, not applicable.
a The ICER cannot be calculated because the economic threshold (and therefore all costs and QALYs) is the same regardless of whether or not assessment pathway costs are taken
into account.
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TABLE 62 Cost-effectiveness of TKA in patients with different ages and baseline OKSs (averaged over men and women)
Preoperative OKS
(selected values only)
Cost/QALY
Age (years)
50 60 70 80 90
0 £2169 £1865 £2121 £3029 £5580
1 £1598 £1454 £1721 £2521 £4699
2 £1236 £1182 £1449 £2173 £4100
4 £788 £833 £1105 £1745 £3386
5 £636 £714 £992 £1612 £3177
6 £512 £619 £905 £1515 £3033
15 Dominant £306 £765 £1604 £3587
18 £19 £389 £958 £2012 £4549
19 £58 £446 £1060 £2207 £4995
23 £466 £873 £1700 £3321 £7488
24 £643 £1031 £1916 £3669 £8246
25 £848 £1207 £2146 £4026 £9009
27 £1323 £1591 £2618 £4703 £10,374
28 £1575 £1785 £2841 £4990 £10,890
29 £1825 £1973 £3044 £5225 £11,257
30 £2064 £2150 £3224 £5406 £11,472
31 £2288 £2313 £3379 £5537 £11,555
37 £3527 £3236 £4260 £6245 £11,907
38 £3843 £3483 £4560 £6623 £12,562
39 £4275 £3822 £5003 £7235 £13,742
40 £4908 £4313 £5692 £8254 £15,875
41 £5919 £5075 £6845 £10,077 £20,041
42 £7742 £6377 £9019 £13,841 £30,019
43 £11,817 £8963 £14,201 £24,683 £74,302
44 £27,326 £15,932 £38,125 £188,150 Dominated
45 Dominated £73,897 Dominated Dominated Dominated
46 Dominated Dominated Dominated Dominated Dominated
Threshold (see Chapter 8) 43 44 43 42 40
Threshold (see Chapter 7) 43 44 43 42 41
Notes
Values indicate the cost per QALY gained for referral to surgical assessment vs. no referral.
Shading key:
l Dark green = ICER of £20,000–30,000.
l Medium green= ICER of > £30,000
l Light green= ICER of between £3345 and £4262 (15%).
l Dark blue = ICER of between £2654 and £3345 (10%).
l Medium blue= ICER of between £2090 and £2654 (5%).
l Light blue= ICER of between £4262 and £20,000.
l Dark grey = ICER of < £1527 (–10%).
l Medium grey= ICER of between £1792 and £2090 (0%).
l Light grey= between £1527 and £1792 (–5%).
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TABLE 63 Cost-effectiveness of THA in patients with different ages and baseline OHSs (averaged over men
and women)
Preoperative OHS (selected values only)
Cost/QALY
Age (years)
50 60 70 80 90
0 £186 £420 £601 £1048 £2119
3 £681 £744 £843 £1169 £1958
12 £1013 £983 £1016 £1324 £2199
13 £1083 £1042 £1078 £1389 £2279
14 £1159 £1110 £1147 £1477 £2395
15 £1243 £1186 £1224 £1576 £2546
16 £1334 £1270 £1310 £1687 £2723
17 £1432 £1359 £1403 £1809 £2922
19 £1660 £1568 £1619 £2094 £3388
20 £1787 £1685 £1739 £2254 £3653
21 £1917 £1809 £1867 £2424 £3939
23 £2197 £2070 £2136 £2786 £4550
24 £2338 £2201 £2271 £2968 £4859
25 £2474 £2327 £2401 £3143 £5158
28 £2810 £2636 £2719 £3562 £5873
29 £2887 £2708 £2790 £3652 £6024
30 £2945 £2761 £2843 £3714 £6129
31 £2986 £2799 £2879 £3752 £6190
40 £3693 £3457 £3539 £4577 £7576
41 £4095 £3832 £3934 £5129 £8570
42 £4755 £4445 £4586 £6069 £10,327
43 £5917 £5519 £5746 £7832 £13,828
44 £8252 £7654 £8125 £11,837 £22,963
45 £14,420 £13,135 £14,704 £26,690 £82,853
46 £54,573 £43,824 £71,107 Dominated Dominated
47 Dominated Dominated Dominated Dominated Dominated
Threshold (see Chapter 8) 45 45 45 44 43
Threshold (see Chapter 7) 45 45 45 44 43
Notes
Values indicate the cost per QALY gained for referral to surgical assessment vs. no referral.
Shading key:
l Dark green = ICER of £20,000–30,000.
l Medium green = ICER of > £30,000.
l Light green = ICER of between £2771 and £5000.
l Dark blue = ICER of between £2186 and £2771 (5%).
l Medium blue = ICER of between £1703 and £2186 (2.5%).
l Light blue = ICER of between £5000 and £20,000.
l Dark grey = ICER of < £1138 (–5%).
l Medium grey = ICER of between £1356 and £1703 (0%).
l Light grey = between £1138 and £1356 (–2.5%).
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decrease this number by up to 15%. This analysis assumed that the number of operations conducted on
patients referred directly to surgical assessment remains the same.
This analysis suggested that if we were to limit the number of primary knee arthroplasty procedures
conducted for osteoarthritis to 88,109 (a value 15% greater than the number conducted in 2014–15), it
would be most cost-effective to refer those hub attendees for whom arthroplasty costs < £4262 per QALY
gained (Table 64). This would equate to a threshold OKS of 39 for 60-year-olds and 16 for 90-year-olds
(see Table 62). If we were to apply the ACHE tool at the hub in such a way as to restrict the number of
procedures to the same number conducted in 2014–15 (76,617), it would be most cost-effective to refer
those for whom arthroplasty costs < £2090 per QALY gained, which would result in restrictions for those
patients with very low OKSs as well as those with moderate to high OKSs. This result implies that the value
that the NHS currently places on QALYs gained through arthroplasty is £2090 per QALY gained.
A similar analysis was conducted for hip arthroplasty (see Table 64). However, because only 17% of hip
patients attend the hub (vs. 41% of knee patients), we examined only ±5% changes in the number of
operations. If we wished to limit the increase in the number of hip arthroplasty procedures conducted to
72,779 (a 5% increase on 2014–15), it would be cost-effective to operate on patients for whom
arthroplasty referrals cost < £2771 per QALY gained, which equates to a threshold OHS of 29 for
70-year-old women, or referring only those patients with a ≥ 85% chance of a good outcome.
Discussion
Summary of the findings and the implications for commissioners and hospitals
This analysis demonstrates that using the ACHE tool in a musculoskeletal hub to identify potential candidates
for arthroplasty is likely to be cost-effective and to substantially improve population health, but would
increase the number of referrals and arthroplasty procedures and increase costs to the NHS.
We also demonstrated that referrals, operations, costs, health improvements and net benefits increase as
referral criteria are relaxed to allow patients with a lower probability of achieving a good outcome to be
referred. Setting stringent referral criteria, such as requiring patients to have a ≥ 80% chance of a good
outcome, would limit the increases in costs and numbers of operations, but have a substantial opportunity
cost in terms of the health forgone compared with allowing patients with a lower chance of a good outcome
to undergo surgery. The most cost-effective strategy considered was to use the economic thresholds shown
in Tables 62 and 63. The economic thresholds shown in Tables 62 and 63 take account of the additional cost
of conducting additional surgical assessments and, therefore, provide a more comprehensive assessment of
cost-effectiveness than those shown in Tables 57 and 58. However, Tables 62 and 63 incorporate additional
assumptions around the proportion of patients attending surgical assessment who will go on to have
arthroplasty, which is not propagated through the analysis. Nonetheless, this analysis confirms the robustness
of the base-case economic evaluation, with thresholds changing only slightly when we take account of the
cost of the surgical assessment.
If it is necessary to limit the number of operations owing to the availability of NHS funds, surgeons,
operating theatres or beds, the decision grids shown in Tables 62 and 63 give an indication of which
patient groups represent best value for money. However, placing any limitation on the number of
operations conducted is likely to reduce the amount of health benefits that can be produced with the
available funds. For example, reducing the number of operations conducted by 5% compared with current
numbers means that we would only operate on patients for whom knee arthroplasty costs < £2654 per
QALY gained and those for whom hip arthroplasty costs < £1138 per QALY gained. By contrast, NICE
states that treatments costing < £20,000–30,000 per QALY gained should be considered cost-effective and
there is evidence that the threshold used in practice may be closer to £40,000 per QALY gained.98,196
Consequently, the money saved by restricting access to arthroplasty is likely to be spent on substantially
less cost-effective treatments, resulting in a net loss of health.
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TABLE 64 The ICERs and thresholds that achieve different numbers of arthroplasty procedures
Percentage change in the
total number of operations
compared with 2014–15
Total number of
primary arthroplasty
procedures conducted
in England each year
Number of such
operations conducted
on hub attendees
ICER for referral to surgical
assessment (vs. no referral)
that would produce this
number of referrals (£)
Maximum Oxford Hip
or Knee Score at which
a 70-year-old woman
would be treated
The minimum capacity
to benefit that is implied
by this threshold (%)
Knee arthroplasty
+15% 88,109 35,556 4262 35 58
+10% 84,278 31,725 3345 27 78
+5% 80,448 27,894 2654 24 81
0% 76,617 24,063 2090 21 84
–5% 72,786 20,232 1792 18 86
–10% 68,955 16,402 1527 16 87
Hip arthroplasty
+5% 72,779 10,055 2771 29 85
+2.5% 71,046 8323 2186 23 91
0% 69,313 6590 1703 19 92
–2.5% 67,580 4857 1356 16 93
–5% 65,848 3124 1138 14 94
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By contrast, there is no evidence to support the low thresholds used by many CCGs and these thresholds
do not represent good value for money.170 Referring only patients with Oxford Hip and Knee Scores of
≤ 24 would avoid 12,000 operations and save £51M compared with using the economic thresholds shown
in Chapter 7, but would lose the NHS 14,000 QALYs, even after taking account of the additional QALYs
that could be gained by spending the saved money on other services. Using a threshold of 18 would avoid
25,000 operations and save £92M compared with the economic thresholds, but would lose 38,000 QALYs.
The hub audit also demonstrates that Oxford Hip and Knee Scores are not the only factor taken into account
when hubs consider whether or not to refer patients for arthroplasty. First, the hubs play an important role in
confirming patients’ diagnoses and directing patients to other NHS services, such as rheumatology clinics or
physiotherapy. In Oxfordshire, the hubs also take account of BMI and refer overweight and obese patients
for weight-loss programmes. We were not able to assess the cost-effectiveness of these additional aspects of
the hub service because it was outside the scope of the study.
The audit also demonstrated that only 60% of the patients referred for surgical assessment underwent
arthroplasty [46% (50/108) for knees and 65% (171/262) for hips]. Many patients attended the surgical
assessment but decided not to have surgery on the basis of a detailed discussion with the surgeon about
the risks and benefits. However, some of the remaining patients had other surgery, such as arthroscopy,
meniscectomy and injections. Many patients will be referred to the surgical assessment with the intention
of having these other procedures, rather than arthroplasty.
Strengths, limitations and further research requirements
This chapter describes preliminary analyses that are intended to give a first estimate of the impact that
the ACHE tool might have in clinical practice and of how this impact may vary with the selected threshold.
Obtaining a more accurate estimate of the impact of the ACHE tool would require a tool to be piloted in a
representative sample of general practices or hubs. The analysis projects hypothetical scenarios based on a
number of assumptions that cannot be tested based on current data.
The analysis assumed that the trends observed at the NOC hub would apply nationally. In practice, there
are many reasons why referral patterns may differ geographically. First, in many CCGs, patients are referred
directly by GPs to surgical assessment and decision-making by GPs may differ markedly from that within a
hub. Second, guidelines for referring patients for arthroplasty and clinical practice in implementing these
guidelines differ substantially between CCGs. Some areas still use low threshold Oxford Hip and Knee
Scores (e.g. 24),170,171,176 whereas the Thames Valley CCGs used a threshold of 32 for knee arthroplasty
during the time period covered by this analysis and had abolished OHS thresholds for hip arthroplasty.172,189
The Thames Valley CCG also impose stricter guidelines on referring overweight or obese patients for
monitored weight-loss programmes before they can be referred for surgery. Oxfordshire CCG is in the
highest quintile for expenditure on musculoskeletal disease, but its rate of hip replacement is around or
just above the national average.197 Preoperative EQ-5D utility and the mean change in EQ-5D utility
and OHSs or OKSs following primary knee/hip arthroplasty are also similar to the national average.198 Data
from more hubs would be required to get a more accurate picture of how the ACHE tool would affect
referral patterns.
Further research is needed to assess the impact and cost-effectiveness of using the ACHE tool in general
practice, at the hub triage and in the surgical assessment. The analysis focused on those patients who
currently attend the hub, and evaluated the impact and cost-effectiveness of using the ACHE tool during
face-to-face hub consultations. There are currently no data on the Oxford Hip or Knee Scores of patients
visiting their GP with knee/hip osteoarthritis symptoms, and it is not known how the ACHE tool might
affect GPs’ referral decisions. As a result, it is not possible to assess the total impact of the ACHE tool;
if the ACHE tool were used widely by patients and/or GPs, it could prompt GPs to refer more patients to
hubs and surgical assessment, increasing the number of additional operations still further.
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The ACHE tool is also likely to be extremely useful for guiding discussions about the likely risks and benefits
of arthroplasty between patients and orthopaedic surgeons and may, therefore, affect the proportion of
surgical assessments that result in arthroplasty. However, it is impossible to reliably assess what impact this
tool would have had on patients’ and surgeons’ decisions using the current data.
It is unknown to what extent the ACHE tool would change referral patterns. In this analysis, we assumed
that 50% of people who do not currently get referred by the hub would not be referred regardless of the
ACHE tool, although this figure is arbitrary and a pilot study would be required to obtain evidence on this.
Furthermore, although we assumed that patients above the threshold would not be referred, there may be
some patients who are currently referred with high Oxford Hip and Knee Scores who would be referred
regardless (e.g. patients who have significant deformity but little or no pain).
The audit included only a small sample of patients, with only around 100 hub attendees having complete
data for each joint. In particular, the study included only seven patients aged ≥ 90 years and only eight hub
attendees with OHSs and OKSs of ≥ 40 across hips and knees combined. Therefore, models may be
extrapolating beyond the observed data.
The audit included patients who were referred to the hub during a 12-month period that ended only
1 month before data were extracted. Therefore, we may have underestimated the number of operations
conducted within this cohort because some patients may still be in the care pathway and may subsequently
go on to have surgery. In particular, patients are discharged from the hub when they are referred for
physiotherapy or weight-loss programmes and will be referred back to the hub if their symptoms persist
after completing the physiotherapy or weight-loss programme. This is likely to be the case for the 60 patients
who were excluded from the analysis as they had attended surgical assessments or hub consultations before
July 2015. Underestimating the number of operations within our cohort would mean that we may have
overestimated the number of patients being referred to hubs nationally and overestimated the likely impact
of the ACHE tool on numbers of operations, costs and QALYs.
It was difficult to reliably identify from medical records all of the patients who had previously had arthroplasty
on the joint in question or who had conditions other than osteoarthritis, particularly for those patients who
did not attend either the hub or the surgical assessment. Some of the patients included in the analysis may,
therefore, have had other conditions or been considering revision surgery. This may have caused us to
underestimate the probability that osteoarthritis patients will undergo primary arthroplasty, which would mean
that we could have underestimated the likely impact of the ACHE tool.
The audit collected no data on BMI, although obesity is one of the main reasons why patients are not
referred for surgery in Oxfordshire. Therefore, BMI is an omitted variable in all regression analyses. It is also
unclear to what extent the introduction of the ACHE tool would affect the referral of obese patients
compared with non-obese patients.
Equity implications
The results also suggest that the number of arthroplasty procedures conducted in the UK is well below the
figure that would be justifiable on cost-effectiveness grounds. Indeed, the number of operations currently
conducted would only be justifiable if the maximum the NHS was willing to pay for each QALY gained
through arthroplasty was just £1703–2100. Because there is evidence that the NHS routinely pays £20,000
or even £40,000 per QALY gained for patients with other conditions, this suggests that it would be better
value for money to reduce spending on other conditions in order to conduct additional arthroplasty
procedures.98,196 However, other factors can also play a role in the funding of health care, such as equity
considerations.
As described in Chapter 5, Equity implications, the introduction of the ACHE tool could help make access
to surgical assessments more equitable by removing postcode prescribing. We also found that at a
£20,000-per-QALY ceiling ratio, economic thresholds do not vary with gender and that there is therefore
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no economic benefit to setting different thresholds for men and women. However, there were some
differences between genders at lower ceiling ratios. Based on the social value judgements used by NICE,98
there is unlikely to be a justification for distinguishing between individuals on the basis of gender, as the
benefits and risks are very similar for men and women.
Age also had a relatively small impact on the economic threshold. Setting different economic OKS thresholds
for different age groups would result in five fewer knee arthroplasty procedures and increase the net health
benefit from the ACHE tool by 1 QALY across England each year. For hip arthroplasty, varying the economic
threshold with age would result in three fewer hip arthroplasty procedures, gaining 0.08 QALYs across
England each year. Because the benefits of setting different thresholds for different age groups are negligible,
it may therefore be simpler and more equitable to set a single threshold across all age groups. Furthermore,
as discussed in Chapter 5, Equity implications, there are few data for patients in the oldest age groups,
and it may be possible to identify patients who are likely to be at a high risk or have fewer benefits from
arthroplasty based on physical activity, general health and comorbidities, rather than age.
Conclusion
The analyses described in this chapter demonstrate that many patients with relatively low Oxford Hip and
Knee Scores are not currently referred for surgical assessment. In many cases, this is likely to be appropriate,
if the patient is medically unfit or has chosen not to have surgery. However, for other patients, surgery may
be appropriate, cost-effective and have a high chance of a good outcome.
The ACHE tool is likely to be cost-effective and improve health, but leads to increases in the number of
referrals and operations and a large increase in cost. Setting a high threshold Oxford Hip or Knee Score
or allowing patients with a modest probability of achieving a good outcome to be referred for surgical
assessment would be cost-effective and improve patient health, but produce a large increase in the number
of operations. Conversely, setting a low threshold Oxford Hip or Knee Score or referring only those patients
with a high probability (e.g. 80%) of a good outcome would deny cost-effective treatment to patients who
are likely to have a good outcome.
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Chapter 9 Evaluation of users’ opinions of
the Arthroplasty Candidacy Help Engine tool
(work package 3)
Overview
The aim of the study was to explore patient and GP opinion regarding the usability of the ACHE tool. To
do this, we developed digital materials to demonstrate the tool to patients, the public and GPs, together
with online surveys to gather opinions. Despite attempts to disseminate the survey widely, the response
rate and final number of completed surveys was very low. The limited information collected did suggest
some support for the ACHE tool and highlighted important issues to consider before implementation.
However, this work must be viewed as a pilot evaluation and more work is required to test the use of
the ACHE tool in practice.
Methods
General practitioner and patient/public survey development
Two surveys were developed: one specifically for GPs and the other for patients and the public. Each
survey contained questions relating to the use of the ACHE tool in the UK setting. The surveys were
developed, reviewed and revised in collaboration with (1) support from the user group, which included
patients and GPs; (2) GPs; (3) quantitative and qualitative researchers; and (4) the Nuffield Patient Liaison
Group (PLG), which included patient representatives and health-care professionals who consult, design
and conduct surveys for the well-being of patients. The Nuffield PLG has consulted on various research
projects, audits and service improvements projects in the trust. From the feedback received, it was
recommended that the survey and instructional video needed to give more detail on the ACHE tool.
Participants were approached by e-mail with a request to take part in the surveys. The e-mail contained
links to an instructional video regarding the ACHE tool, followed by an online ACHE tool to complete,
finally followed by an acceptability/usability survey. By clicking on the usability/acceptability survey link, the
patient is presented with a series of forms, using check boxes, drop-down selections and other standard
form elements including free text (Table 65).
TABLE 65 The websites for patient, public and GP ACHE information videos, together with links to the ACHE
online tool
Tool Website URL
GP video https://vimeo.com/angelsharp/review/181495797/8e90d797e7 (accessed 29 January 2019)
GP ACHE tool www.ndorms.ox.ac.uk/clinical-trials/current-trials-and-studies/ache-completed/
ache-tool/ache-tool-gps (accessed 29 January 2019)
GP usability survey https://cview.pro-mapp.com/9500-achegp#/ (accessed 29 January 2019)
Patient video https://vimeo.com/angelsharp/review/181484159/472f66f6c1 (accessed 29 January 2019)
Patient ACHE tool www.ndorms.ox.ac.uk/clinical-trials/current-trials-and-studies/ache-completed/
ache-tool/ache-tool-patients (accessed 29 January 2019)
Patient usability survey https://cview.pro-mapp.com/9500-achepatient#/ (accessed 29 January 2019)
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The Arthroplasty Candidacy Help Engine online tool
The online ACHE tool is based on the models developed in Chapter 6, in which a patient’s preoperative
Oxford Score is used to establish the probability of achieving at least a minimum level of meaningful
benefit. In addition, the tool uses sex and age as additional covariables.
Piloting the surveys
Once the questions were developed, face validity and content validity assessments of the survey were
judged by the ACHE user group (including patients and GPs), independent GPs and the PLG. These groups
determined content validity in terms of whether or not items were relevant and representative of a usability/
acceptability survey. The groups made recommendations regarding changes to the wording of questions,
as well as examining the overall survey’s ability in testing the use, usefulness and acceptability of the ACHE
tool for doctors and patients. Finally, the survey went to an information technology (IT) specialist for review,
who specifically looked at the user experience of having to click on the video, ACHE tool and usability/
acceptability survey. From this initial pilot testing, an invitation e-mail and link were sent to both patients
and GPs.
Participants
Several organisations were identified from both the user group and the steering group as potential links to
reach patients, the public and GPs. The General Medical Council, the Royal College of General Practitioners,
Arthritis Research UK (ARUK), the local Patient Advice and Liaison Service, INVOLVE (a national advisory
group that supports greater public involvement in NHS; www.invo.org.uk, accessed 6 February 2019) and,
for doctors, the NIHR Clinical Research Network (CRN). These groups were all approached to collaborate
in the study, allowing potential access to large numbers of doctor and patient representatives. The NIHR
CRN agreed to e-mail GPs on our behalf and INVOLVE agreed to e-mail patients on our behalf. Other
organisations agreed to advertise our survey and to provide a link to the survey website.
Data analysis
Numerical data were collected from closed questions and were analysed using descriptive statistics. The
surveys have also been designed so that participants have the freedom to express in their own words their
views in response to their answers.
Ethics approval
Ethics approval was granted for this study (research ethics committee reference 15/NE/0426).
Results
Unfortunately, we received very few completed surveys: 22 out of 271 from patient/public participants
(8%) and 10 out of 348 from GPs (3%).
The results of the collected surveys are presented in Tables 66 and 67 (see Appendices 1 and 3 for
additional data).
Patients and the public
We received 22 out of a possible 271 surveys from this group, giving a response rate of 8%. Sixteen were
from patients and six were from members of the public. All respondents indicated that the ACHE tool
would be useful to aid the referral process. There was some preference to complete the ACHE tool at
home before visiting the GP. Electronic use was supported; however, a minority of participants opted for a
paper-based approach. One of the most interesting findings was general support (86%) for the tool to be
used as a potential way of prioritising patients on a waiting list, although a cautious approach to this was
emphasised in general comments. Of those participating, 91% felt that they would use the tool to track
their disease state at home. The need for the tool to be used as part of a shared decision-making process
was a common theme in comments.
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General practitioners
We received very few completed surveys from GPs. Of 348 sent out, there were 10 responses, giving a
response rate of 3%. This is obviously a very limited sample of GP opinion.
A majority of GPs felt that the format in which the tool was presented made it feasible for use, although
there were a few comments questioning the potential for actual uptake by GPs in practice. In comparison
with patients and the public, just under half of those surveyed felt that the tool should be deployed during
the GP consultation compared with the tool being used at home. One comment suggested that the tool
could be sent to patients as a result of the consultation via e-mail, with the form then being filled out at
home. The majority of GPs surveyed were using a musculoskeletal hub for referral, but they felt that the
ACHE tool would be best deployed in the primary care setting rather than a hub.
TABLE 67 Results of the GP survey
Questions
Responses (%)
Yes No
1. In your practice, would you like to use a tool to objectively assess patients
need for referral for a surgical assessment?
90 10
2. Would it be feasible for you to use the tool in the format we have created? 90 10
3. Are your patients going through a musculoskeletal hub? 90 10
4. Do you think this tool should be preferably used in the musculoskeletal hub
instead of primary care?
20 80
5. In what format would you prefer to use the tool? 90 (electronically) 10 (on paper)
6. When do you think it would be best to ask patients to complete the
questionnaire (ACHE tool)?
60 (at home) 40 (during
consultation)
TABLE 66 Results of the patient and public survey
Questions
Responses (%)
Yes No
1. Do you think it would be helpful to have a standard questionnaire (ACHE tool)
to help GPs decide whether a patient should see a surgeon to discuss a hip or
knee replacement operation?
100 0
2. Would you be prepared to fill out a questionnaire (ACHE tool) about your hip
or knee condition to help you GP decide whether you should see a surgeon?
100 0
3. If the questionnaire (ACHE tool) could tell us who can benefit the most from
the operation, would you be happy with surgeons using the results to prioritise
the waiting list?
86 14
4. If you are not eligible for surgery, would you like to use the questionnaire
(ACHE tool) yourself to track your disease at home?
91 9
5. Where would you prefer to complete the questionnaire (ACHE tool)? 73 (at home) 27 (during
consultation)
6. How would you prefer to use the questionnaire (ACHE tool)? 90 (electronically) 10 (on paper)
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Conclusion
Owing to the very low response rates from patients, the public and GPs, it is difficult to draw strong
conclusions from our findings. It was encouraging to note from the limited responses we received that
patients, the public and GPs showed some support for use of the ACHE tool as a method of supporting the
referral process. Debate remained as to how to deliver the tool to patients in primary care: the principal
question centring around whether the tool should be completed by patients at the GP consultation or at
home (prior or after the consultation). It is clear that further work is required to test the ACHE tool in
practice, with more input from the potential stakeholders involved in its use.
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Chapter 10 The user group
I t is important to state that the establishment of a user group, and its role within the overall study, was akinto a patient and public involvement and stakeholder engagement process rather than a formal piece of
stand-alone qualitative research. For this reason, the methodology and process for the user group meetings
leant towards debate, common sense and consensus approach to the synthesis of ideas rather than the
utilisation of formal or sophisticated qualitative methodology (i.e. there was no intention to conduct a formal
Delphi exercise). The meetings were conducted as focus groups with a semistructured format. There was no
intention to report separately or publish the methodology or output of the user group.
Recruitment to the user group was undertaken with care to ensure full representation. A full list of the
names of the personnel attending the user group is given in Appendix 2. An emphasis was placed on
patient representation. Members included those from a dedicated patient organisation at the NOC: the
NOC Network and several patient representatives attended each meeting. The INVOLVE organisation was
also engaged in costing patient representatives’ involvement. On completion of the project and construction
of the ACHE tool, the research findings will be presented to the Patient & Research Engagement Forum at
the NOC. The purpose of this group is to further involve, inform and educate patients and the public in all
aspects of musculoskeletal research in Oxford to improve the relevance, quality and appropriateness of that
research from the patients’ perspective. The main target audience includes local residents, charities and
patient support groups, University of Oxford medical students, Oxford Brookes University health sciences
students, sixth form students with an interest in medicine from local schools, patients in local GP surgeries
and current/former patients of the NOC.
In addition to patient representatives from the Oxford (NOC) Patient Network and Bristol patient involvement
group [Patient Experience Partnership in Research group (PEP-R)], the user group also included GPs from
primary care, orthopaedic knee surgeons (also representing the British Association for Surgery of the Knee),
an orthopaedic hip surgeon (representing the British Hip Society), extended practitioner physiotherapists and
commissioners of hip and knee surgery from various CCGs.
There were four separate user group meetings, which were all timetabled at appropriate times in the study
schedule in accordance with the protocol. Although a complete chapter reporting the entire user involvement
throughout might be more cohesive and avoid short chapter reports, a decision was made for this report to
integrate each user group meeting in temporal sequence in accordance with the remainder of the project.
This is deemed more intuitive. Therefore, each of the meetings is reported in turn throughout the manuscript,
with some reports being necessarily concise.
User group meeting 1 (work package 1: introductory meeting)
The initial user group meeting (user group meeting 1) was held on 3 April 2014. The purpose of the
meeting was to introduce the project and its aims, provide an introduction of each member of the group
and provide an explanation of the role and expectations for the group. The meeting also sought to provide
an overview of PROMs and the current problem of thresholding for joint replacement within the NHS.
Those in attendance are listed in Table 68.
Prior to attending, each member received a concise information pack about the study and its requirements.
The agenda included a review of general progress of the project to date. Specifically, the group were given
instructions on how to familiarise themselves with some of the various scoring systems and how the voting
system would work at subsequent meetings. User group members were informed that before the next
meeting the research team intended to appraise the measurement properties of selected PROMs, calculate
missing measurement properties using data from existing databases and request the opinion of the user
group to shortlist the best-performing instruments. The group was informed that three to four instruments
were to be selected to go forward for threshold characteristics or health economic evaluation.
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User group meeting 2 (work package 1: instrument shortlisting)
The second user group meeting (user group meeting 2) was held on 14 January 2015. The purpose of the
meeting was to review the overall project aims, briefly remind members of the group’s role, briefly provide
an overview of the characteristics of PROMs scores and review any pertinent literature from a recent search.
The meeting sought, as a main aim, to share the measurement properties discovered for selected scoring
systems, identify gaps in the knowledge or information available for some scores and identify which scoring
systems should be ‘shortlisted’ for further consideration. A final aim of the investigators was to provide the
group with sufficient information for them to assess whether or not full threshold evaluation would be
possible for each instrument considering the availability of specific data sets for that specific instrument. The
meeting was considered an essential component of the overall study and one in which voting for potential
scores was required. The attendees are listed in Table 69.
The literature review and methods used to screen, categorise and establish measurement characteristics in
work package 1 were presented to the group by the chairperson using summary slides. The inclusion
criteria for screening each score was reported to the group. The inclusion criteria consisted of scores:
l that were defined as a standard scoring system
l that were readily available and presently used in clinical settings or research
l that were used for hip or knee replacement
l that were validated for the English-language population
l that had evidence of an obvious and appropriate validation study (i.e. on prospective data)
l in which the validation had been carried out on a sample size of > 50 subjects/patients.
The exclusion criteria used were also presented to the group. These were scores that:
l Were not fully patient reported or required clinician input.
l Required technical or clinical test information such as a MRI scan or radiographic report.
l Were not capable of demonstrating patients’ ‘capacity to benefit’ (i.e. cannot measure change).
This involved discussing responsiveness with the group.
TABLE 68 Attendees of user group meeting 1
Name Role
Karen Barker Clinical Director for Musculoskeletal Services at the NOC and Proposed Lead/Organiser of the
Therapy Project
Matthew Cheetham GP at Summertown Health Centre
Anne Clarkson Webb Extended-scope physiotherapist working with hip and knee team in Oxfordshire
Gill Dean GP working with sports injury and rheumatology
Kristina Harris Postdoctoral Associate/Lead Co-ordinator of ACHE Project
Jo Hewanicka PA to Andrew Price (minute-taking)
Laura Ingle (attended
via teleconference)
GP working with sports and exercise medicine; Musculoskeletal Service, Buckinghamshire
Kate Jackson (attended
via teleconference)
GP working in sports and exercise medicine for MOD and ARUK
Chip Johnson Retired GP from Manchester and patient
John Nolan (attended
via teleconference)
Consultant Orthopaedic Surgeon, Norwich; President Elect of the British Hip Society
Andrew Price Professor and Consultant Orthopaedic Surgeon; HTA ACHE Grant PI (standing in as Chairperson
for David Beard)
MOD, Ministry of Defence; PA, personal assistant; PI, principal investigator.
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The number of studies examined and screened were provided and presented to the group in a simple flow
diagram. The system and methodology used to identify records through various databases were presented.
The reasons for the exclusion of certain records were also presented to the group. It was reported that a
specific search was done for 67 identified instruments. Twenty-one new validation papers (in addition to
42 developmental papers) were identified. Twenty-one initially identified instruments were excluded
because of failure to meet appropriate criteria. A separate PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) diagram was used to convey exclusions to the user group. The group could not
use these data to make informed choices or contribute to selection. The purpose was to demonstrate the
methodology used and that that it was sufficiently rigorous, and demonstrate how the summary data had
been constructed.
The user group was introduced to the concepts required to assess suitability for each instrument and
how these criteria had been used to grade each instrument. This included test–retest reliability, internal
consistency, content validity, construct validity, responsiveness, interpretability, floor and ceiling effects,
acceptability and feasibility/burden. Owing to the variety in expertise and personnel type, this was revision
for some members and the introduction of new concepts for others. A simplified approach to explanation
was taken by the chairperson. Some understanding of these concepts was sought and confirmed by the
majority (by hand show) but members still had limited knowledge of some of the concepts.
TABLE 69 Attendees of user group meeting 2
Name Role
Karen Barker Clinical Director for Musculoskeletal Services at the NOC and Proposed Lead/Organiser of the
Therapy Project
David Beard Professor and Co-applicant of ACHE Project; Chairperson
Jennifer Bostock Patient Representative
Chad Lion Cachet Patient Representative
Anne Clarkson Webb Extended-scope Physiotherapist working with hip and knee team in Oxfordshire
Gill Dean GP working with sports injury and rheumatology
Kristina Harris Postdoctoral Associate/Lead Co-ordinator of ACHE Project
Jo Hewanicka PA to Andrew Price (minute-taking)
Kate Jackson GP working in sports and exercise medicine for MOD and ARUK
Anthony (Chip) Johnson Retired GP from Manchester and Patient Representative
Gillian Kempster Patient Representative
Jennie Kramer Patient Representative
Jiyang Li PA to David Beard
Fraser Old Patient Representative
Andrew Price Professor and Consultant Orthopaedic Surgeon; HTA ACHE Grant PI
Patricia Mary (Polly) Rubery Patient Representative
Mary Snow Patient Representative
Fiona Watt Rheumatologist
MOD, Ministry of Defence; PA, personal assistant; PI, principal investigator.
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The group were then informed of the availability of data sets for several of the scoring systems. Some
scores had no available data set and the group were informed of an intention by investigators to contact
the custodian of these data sets.
The group were also provided with the coding system used previously by the researchers to quantify
psychometric and operational criteria for each of the scores identified in the literature. This ranged from
‘not being reported’ to ‘no evidence to support the psychometric property’ to ‘good evidence’ in favour of
the stated criteria. This was a visual exercise to demonstrate summary findings from the literature. The
colour-coded system key is provided in Figure 45, which shows how measurement tools could be shown to
be lacking evidence of established validity. The range varied from no evidence to strong evidence. When
the evidence was considered equivocal, a mixed evidence label was attached. A matrix for all the selected
scores was used to present the findings to the user group.
Each score had been assessed and categorised for each listed property. The categorisation was added to
the assessment matrix and the allocations for each score were shown to the group. An example is provided
in Table 70. Here it can be seen (for the hip scores) that the OHS fulfils many of the required properties,
whereas other scores, such as the Hip Rating Questionnaire, fail to reach the required standard. All scores
were graded in this way.
0 Not reported
– No evidence in favour
+ Some limited evidence in favour
++ Some good evidence in favour
+++ Good evidence in favour
+/– Mixed evidence
FIGURE 45 The key showing the colour coding and classification presented to the user group for the validity
assessment matrix.
TABLE 70 Assessment of measurement tools matrix
Instrument HOOS HRQ PSI OHS
Number of studies 5 1 4 20
Reproducibility ++ + + ++
Internal consistency + 0 0 +++
Validity: content 0 0 ++ ++
Construct ++ + ++ +++
Responsiveness + + ++ +++
Interpretability 0 0 0 +++
Floor and ceiling/precision + 0 0 –/+
Acceptability 0 0 0 +++
Data accessible No No No Yes
HOOS, Hip Disability and Osteoarthritis Outcome Score; HRQ, Hip Rating Questionnaire; PSI, patient-specific index.
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Guidance about the quality of measurement characteristics for each of the instruments was provided by the
chairperson. The group members were requested to agree or disagree (by a simple hand-raising exercise to
vote) with the provisional decision made for the quality and number of measurement properties of each
score by the research team. Opportunities were given for members of the user group to raise any concerns
or ask any questions before voting. The nature of the data meant that nearly all propositions were accepted
unanimously by the user group. Some clarification was required for a few of the instruments, but once
clarified they were easily settled. Again, it should be noted that the exercise was not a formal qualitative
study process but a seeking of agreement from the user group.
The scores were designated in accordance with their domain or type of measurement (location). These
were hip scores, knee scores, lower limb scores, pain scores, utility scores, generic scores and other scores
(non-defined).
At the end of the voting exercise, three scores (from a possible 78) were agreed to have sufficiently
high-level evidence to support their validity and use for assessment of hip and knee replacement. These
were the WOMAC score, the OHS and the OKS. Four scores were considered to be potential candidates
and required further discussion: the Lower Extremity Functional Scale, the EQ-5D, SF-12 and the SF-36.
Five scores were considered to be unlikely candidates but some discussion and argument was required by
the group: WOMAC short form, Musculoskeletal Outcome Data Evaluation and Management System Hip
and Knee Core Scale (MODEMS HK), Aberdeen IAP, WHOQOL and MHAQ.
All others scores were considered to have insufficient evidence to demonstrate validity in the TKA/THA domain.
The chairperson summarised the findings for the group and consensus was achieved for five scores to be
taken forward for consideration into work package 2. These were the:
l Oxford Knee Score (knee score).
l Oxford Hip Score (hip score).
l Western Ontario and McMaster Universities Arthritis Index (lower limb score).
l Short Form questionnaire-12 items (generic score).
l Knee injury and Osteoarthritis Outcome Score – Physical Score (knee score).
It was revealed that the KOOS had no data set from which to further explore measurement properties. It
was agreed that the research team would contact the chief investigator (Dr Ewa Roos, Denmark) to see if
data could be supplied to permit this evaluation. The user group were asked if they were satisfied with the
process and accepted the outcome. No dissent or concern was registered.
User group meeting 3 (work package 2: threshold decisions)
Prior to the third user group meeting, a pre-user group meeting was held by the academic and analysis
personnel to review the progress made and discuss the calculations for clinical and health economic
thresholds. This meeting was held on 9 December 2015. The purpose was to ensure that any information
conveyed to the user group at the next meeting had been fully reviewed and agreed by the study group.
Those who attended are listed in Table 71.
A review of the work to determine clinical thresholds was presented to the user group. It was found and
reported that the Oxford Hip and Knee Scores had the most reliable data for estimating thresholds and
subsequently these scores (OHS/OKS) were the easiest for which to apply thresholds. The absolute
threshold was shown to be the determined theoretical upper limit. The method for calculating a relative
threshold was discussed.
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Following the review of clinical thresholds, a summary of the economic modelling was provided by
Helen Dakin. Using a cost-effectiveness framework, a summary of economic modelling was provided.
The economic modelling results for the OHS, OKS, WOMAC and SF-12 were reviewed by the study team.
There were several assumptions and limitations and these were discussed by the group. It was agreed that
the analysis could be presented to the user group.
The third user group meeting was held on 14 January 2016 (attendees are listed in Table 72). The purpose
of this meeting was to review the project and report any progress, present the calculated clinical thresholds,
present the newly established health-care economics and agree on the outcome scores to take forward to
work package 3 in the light of the new analysis.
Following an update on progress, the group was provided with a conceptual framework on which threshold
calculations had been based. The group was informed that the purpose of the meeting was to review the
methodology to date, review the choice of instrument/score taken forward, discuss the evidence from the
measurement characteristics and health economics and ultimately agree on an absolute threshold. The group
was also requested to identify what percentage of people (of the arthroplasty population) improving should
be considered adequate for definition of ‘benefit’ for future calculations. A variety of potential thresholds and
ranges existed and the pitfalls regarding the choice of these were also mooted.
The group was informed that, despite best efforts, it had proved impossible to obtain the KOOS data from
which to establish measurement properties. The KOOS had, therefore, been excluded from further work
or inclusion.
TABLE 71 Attendees of the pre-user-group meeting
Name Role
David Beard Professor and Co-applicant of ACHE Project; Chairperson
Andrew Price Professor and Consultant Orthopaedic Surgeon; HTA ACHE Grant PI
Elena Benedetto ACHE Project Co-ordinator (Oxford)
Kristina Harris Research Fellow (Oxford)
Alastair Gray Health Economics (Oxford)
Helen Dakin Health Economics (Oxford)
Peter Eibich Health Economics (Oxford)
Ashley Blom Professor of Orthopaedic Surgery (Bristol)
Adrian Sayers Statistician (Bristol)
Laura Miller Statistician (Bristol)
Jonathan Cook Statistician (Oxford)
Andrew Judge Statistician (Oxford)
Ray Fitzpatrick Public Health (Oxford)
Elizabeth Gibbons Public Health (Oxford)
Jill Dawson Public Health (Oxford)
Jo Hewanicka PA to Andrew Price
Jiyang Li PA to David Beard
PA, personal assistant; PI, principal investigator.
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The group was informed about how thresholds for clinical benefit were calculated. The ‘absolute threshold’
was defined as the value beyond which we can be very confident that an individual could not improve despite
intervention. The ‘relative threshold’ was defined as the range of values for which individuals could still improve
but ‘relative’ to their pre-intervention status. Four methods can be used to define the ‘improvement’ after
surgery. Each were explained in turn. It was suggested to the user group that that definition D (based on SD 0.5
– ‘medium’ ES) was most suitable for the purpose. The members approved the decision with a show of hands.
Using the adopted ‘improvement descriptor’, the results for each of the four chosen instruments were
shown to the group. It was seen that the OHS/OKS had the most reliable data for estimating thresholds
and are the easiest scores to apply thresholds to, but with less detail than the other two. The WOMAC
and SF-12 were also shown but the calculations are based on small data sets and with a select population
(clinical trial data sets). This was considered a shortcoming.
The health-care economics analysis was described to the group following the descriptions of clinical benefit
thresholds (HD). In accordance with the pre-user group meeting, a summary of economic modelling was
provided for the user group. Preliminary results for the OKS, OHS, WOMAC and SF-12 were shown.
Assumptions and limitations were highlighted. A conclusion was that it remained impossible to identify
non-cost-effective practices using the WOMAC score because of the lack of available data.
TABLE 72 Attendees of user group meeting 3
Name Role
David Beard Professor and Co-applicant of ACHE Project; Chairperson
Andrew Price Professor and Consultant Orthopaedic Surgeon; HTA ACHE Grant PI
Alastair Gray Director of the Health Economic Research Centre and Professor of Health
Economics
Helen Dakin Senior Researcher in Health Economics
Peter Eibich Senior Researcher in Health Economics
Jonathan Cook Associate Professor of Statistics
Sujin Kang Senior Statistician
Elena Benedetto ACHE Project Co-ordinator
Karen Barker Clinical Director for Musculoskeletal Services at the NOC
Sharon Barrington OCCG Lead for elective care
Kate Jackson GP working in sports and exercise medicine for MOD and ARUK
Gill Dean GP working with sports injury and rheumatology
Laura Ingle GP in Botley
Matthew Cheetham GP in Summertown
Fraser Old Patient Representative
Anthony (Chip) Johnson Retired GP from Manchester and Patient Representative
Anne Clarkson Webb Extended-scope Physiotherapist working with hip and knee team in Oxfordshire
Fiona Watt Consultant Rheumatologist
Patricia Mary (Polly) Rubery Patient Representative
MOD, Ministry of Defence; OCCG, Oxfordshire Clinical Commissioning Group; PI, principal investigator.
DOI: 10.3310/hta23320 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 32
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Price et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
177
Issues that were raised by the user group included:
l Why radiography and other tests were not included in the evaluation tool. Explanations were given
that the tool had to stand alone and be easily used in primary care.
l Whether or not the data sets identified were generally adequate for purpose. Reassurance was provided.
l Whether or not the preoperative and postoperative data had been screened with sufficient granularity
to determine the change for each range of preoperative scores. It was explained that this level of
analysis could not be carried out for all the candidate scores owing to limitation in some data sets.
l It was asked if more variables would be included in the model. The group was informed that age and
gender would be included. Other factors were to be explored for inclusion if data and time allowed.
Some inclusion of other factors was incorporated in the final version.
The user group agreed on the following statements:
l That the methodology for the analysis on the clinical and health economics thresholds on the four
selected scores is appropriate.
l That the OHS/OKS are selected as the scores to be incorporated into the ACHE tool, based on the
evidence presented and an understanding that large data sets (national PROM collection) are only
available for these instruments.
l That the absolute thresholds for OHS/OKS are evidence based and acceptable.
l That the ‘relative’ threshold, which describes the percentage of probability to improve after
surgery, should not be a specific set value.
l The probability to improve should be used to help patients to make a decision on having or not
having surgery.
Agreement was requested by a show of hands. The OKS and OHS were the scores chosen to be used for
the final ACHE tool, and this was passed unanimously.
User group meeting 4 (work package 3: extended user group –
completion)
The final user group meeting was held on 13 October 2016. The aim of this meeting was to demonstrate
the constructed tool; identify any specific issues with the current iteration of the ACHE tool, especially from
individual representative groups; and achieve project sign-off. Some exploration of how to trial the new
tool (in musculoskeletal hubs or general practice) was intended. Those who attended are listed in Table 73.
Following the progress update, the group were shown the development pathway and mock-ups of a
potential IT interface that could be used to host the new ACHE scoring system The ACHE system was
shown to the user group using a prototype computer-based system to demonstrate potential and facilitate
discussion on its utility.
The mock-up tool consisted of a plot of preoperative Oxford Hip and Knee Scores with a distribution of
90,000 patients (with osteoarthritis before they had a knee replacement), showing different regions (colour
coded) for areas of different capacity to benefit in accordance with preoperative score (Figure 46). An example
of an individual patient’s score was marked on the plot (see Figure 46). The likely capacity to benefit for that
patient was shown and, therefore, implied a recommendation for management (refer on to secondary care or
not). It was shown that patients with scores of < 38 can almost certainly benefit (85% chance) (green zone)
and patients with scores of > 45 cannot benefit (red zone) (absolute threshold). The amber zone (38–45)
is an area of more uncertain capacity to benefit.
For the mock tool, the amber area was extracted and enhanced to show how the capacity to benefit varies
within the equivocal range of 38–45 for a particular OKS or OHS (Figure 47).
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Preoperative OKS
0 38 45 48
85% chance of benefit
No chance of benefit
FIGURE 46 Distribution of the preoperative OKSs of 90,000 patients with knee osteoarthritis.
TABLE 73 Attendees of user group meeting 4
Name Role
Sharon Barrington CCG
David Beard Professor of Musculoskeletal Sciences; Co-Director of SITU Oxford; Chairperson
Chad Lion Cachet Patient Representative
Anne Clarkson-Webb Extended-scope Practitioner
Jonathan Cook Senior Statistician
Helen Dakin Health Economist
Gill Dean GP
Vida Field Patient Representative
Anthony Johnson Patient Representative
Jiyang Li Observer
Fraser Old Patient Representative
Andrew Price Professor of Orthopaedic Surgery; Consultant Surgeon; Chief Investigator
James Smith Study Co-ordinator
Fiona Watt Consultant Rheumatologist
Tim Wilton President of British Orthopaedic Association
SITU, Surgical Intervention Trials Unit.
38
85%
50%
OKS
45
4160%
FIGURE 47 Demonstration of capacity to benefit when the OKS is in the equivocal range and when the example
OKS is 41.
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Candidacy was then expressed using three categories:
1. Yes – your score indicates that you are very likely to benefit from knee replacement.
2. No – your score indicates it is highly unlikely that you will benefit from knee replacement.
3. Maybe – your score indicates it is possible that you might benefit from knee replacement. Your clinician
will discuss the chance of benefit.
The discussion about the implications of the ACHE tool in practice from a health economics perspective (HD)
provoked varied responses. Historically, commissioners have used cut-off thresholds for surgery of 18 or 24
(an arbitrary threshold) and this was found to be inappropriate given the new ACHE data. It would deny
cost-effective treatment. A threshold of 24 would exclude 21% of current arthroplasty operations. The work
showed that for hip replacement, if a threshold of 35 was set, this might suggest that ≥ 70% of patients
have the capacity to benefit from THA. Only 2% of patients currently having surgery would be excluded.
A further exercise with the group explored models for the frequency of referral to secondary care if the
ACHE tool were introduced or not. It was shown that, overall, (1) the ACHE tool is likely to be cost-effective
and improve health, but may lead to additional operations, (2) setting a high threshold or a low probability
of benefit will be cost-effective and improve patient health, (3) the ACHE tool may increase numbers of
referrals, numbers of operations and costs, (4) setting a low threshold or high probability of benefit will
deny cost-effective surgery to patients who are likely to have a good outcome. These concepts were
delivered to the group and discussed.
The user group expressed a variety of opinions and queries following demonstration. These could be defined
in accordance with participant type: patients, clinicians (surgeons and physiotherapists) and commissioners.
Each groups’ comments are described in brief in the following sections.
Patients
l Patients were happy with the video example of the ACHE tool. They considered the tool a useful
adjunct to decision-making.
l Patients were concerned about when they would complete the assessment: before seeing the GP or
while with the GP. Both are an option and field testing will provide more information. Ideally, the
patients complete the tool at home to leave time for discussion with the clinician in the appointment.
l There were some concerns that the tool could be used to restrict access to care and treatment.
l Some patients suggested that it would be useful if the tool could be operated in a paper-based system
rather than being entirely electronic.
l There was a concern that not all GPs would use the tool, leaving an inequality of access to care.
l Patients themselves suggested that it was possible to manipulate or ‘game’ the output to obtain surgical
treatment. No solution for gaming could be offered at that time.
l Most patients were highly satisfied with being in the decision-making process for both the design of
the tool and the individual decision-making for themselves.
l Some patients were worried that they did not fully understand the complexity of the science behind
achieving a threshold score.
Clinicians
Clinicians involved in the delivery of the ACHE tool would be surgical staff in secondary care, physiotherapists
(perhaps in a musculoskeletal hub) and GPs. Views expressed included the following:
l The GPs felt that the system was useful and suited their needs providing that it was time efficient.
l Some GPs felt that it undermined their autonomy.
l There was some concern that IT integration may be difficult.
l The GPs asked when and where they could get the ACHE tool, where it would be completed and if
they would have sufficient time to engage with it.
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l There were strong opinions expressed in support of the evidence-based format of the tool.
l Clinicians in secondary care asked if there could be higher levels of integration into more complex
decision-making.
l There was concern among several participants about the use of the ACHE tool for rationing purposes.
l Several members requested that it should not replace appropriate shared decision-making instruments.
l It was thought to be of great help for extended-scope physiotherapists working in hub environments.
Commissioners
l Commissioners were largely supportive. It was thought to be of great help for musculoskeletal hubs.
l They felt that the evidence-based nature of obtaining threshold values was much more suitable than
current practice. This was echoed by CCG representatives.
The next stage of testing and rollout was discussed. It was proposed that a survey evaluation of potential
users’ opinions of the ACHE tool (GPs and patients) would be valuable. Furthermore, the determination
of GP and patient opinion regarding the content and acceptability of the completed ACHE tool would also
be valuable.
On completion of the feedback session, a final summary of the ACHE project was provided to the user
group (DB). The initial premise for the study was reviewed, outlining the arbitrary nature of current thresholds
for arthroplasty. From the outset, the ACHE tool had the potential to show that (1) thresholding was not
possible or appropriate using PROMs scores, (2) the current thresholds were adequate and correctly guiding
access to secondary care and arthroplasty and (3) the current thresholds were incorrect and that the
population has greater capacity to benefit from arthroplasty. The group agreed that finding 3 is likely to be
the output message and this may have resource implications, which are discussed in Chapter 11.
A final round of questions was put to the group by the chairperson and generated the following
consensus responses:
Would the ACHE tool (version 1) be a useful addition to the clinical pathway? [All user group members
responded ‘Yes, very useful’.]
Do you think there is a role for ACHE to be deployed nationally (in hubs or primary care) to standardise
management nationally? [A unanimous ‘Yes’ to this question was received.]
Do you believe that one day a tool like ACHE will be mandated nationally in the patient pathway?
[Members also voted ‘yes’ to this question but there was widespread opinion from the members that
more research was needed on this subject.]
The user group members reflected on the entire project and were given the opportunity to provide any
final comments. They were satisfied that a useful instrument to guide hip and knee patients’ referrals to
secondary care had been developed. All gave their support for rollout into clinical practice, but emphasised
the requirement for further research to guide deployment and selection of relative thresholds.
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Chapter 11 Discussion
The study was carried out in a sequenced way using mixed methodologies and each part of study will beconsidered in turn in this chapter.
Systematic review
The systematic review that was undertaken was extremely comprehensive, identifying 36 PROMs that have
been previously used to assess outcomes for patients undergoing hip or knee replacement. What was
notable was the very low levels of supporting literature to define the measurement properties of most of
the scores in this population. Three condition- and site-specific scores were identified as the best-performing
scores: WOMAC, OKS and OHS. In addition, the SF-12 score was identified as the best-performing general
quality-of-life measure. The results did not show strong evidence to support the use of the EQ-5D as an
outcome measure for hip and knee replacement patients. This was surprising given the widespread use of
the score in the NHS to measure the outcome of hip and knee replacements (national PROMs collection).
Further evidence is clearly required to define the validity of using the EQ-5D in this population and, in fact,
it was recognised that all of these scores required further study to define missing measurement properties.
Calculation of measurement properties
The data sets available allowed the calculation of most of the missing measurement properties for a number
of the scores identified as possible candidate scores from the systematic review. This process was dependent
on the nature of the data sets available to the research team. We were able to determine further measurement
characteristics on the WOMAC, OHS, OKS, SF-12 and EQ-5D. The work allowed a comprehensive assessment
of the scores to be produced for the user group to assess.
Selecting a set of candidate scores
The user group process was used to select a series of candidate scores. The process generated a shortlist
of candidate scores to take forward to work package 2: the OKS, OHS, WOMAC and SF-12. The KOOS-PS
was also identified as an option but concern about available data was expressed. The OHS and OKS were
identified as the condition- and site-specific scores with the most comprehensive evidence for adequate
measurement properties. This is perhaps not surprising as they were designed to measure outcome in
the specific population under consideration. However, the WOMAC score also had very encouraging
properties and was an equally valid score to take forward into the candidate score group. The advantage of
this score is its nature as a generic non-site-specific score and it could potentially be used as a single score in
the ACHE tool. One generic non-condition-specific score was selected, the SF-12, owing to its profile of
measurement properties, greatly enhanced by the calculation of measurement properties in the second part
of work package 2. The EQ-5D is widely used in assessing health status change in the NHS and is routinely
collected in patients undergoing hip and knee replacement, with a significant number of previous
publications. However, from the published literature and our own calculations, its measurement properties,
specifically within the hip and knee arthroplasty population, were deemed inadequate and it was not taken
forward as a candidate score.
Calculation of threshold values
The aim of this section was to identify, for each shortlisted instrument, a set of thresholds for candidacy for
arthroplasty surgery. We developed a model based on calculating thresholds based on an individual’s capacity
to benefit from arthroplasty, depending on their preoperative score. This would enable determination of an
upper ‘absolute threshold’ in which no meaningful benefit could be achieved by undergoing arthroplasty.
In addition, ‘relative thresholds’ could be determined, in which the probability of obtaining benefit could
be determined as preoperative scores varied. Prior to determining threshold values, we defined a level of
improvement that would indicate that the patient had benefited from surgery. We standardised our approach
so that we could accommodate all the candidate scores given the data sets and prior information available to
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us. We were able to determine absolute and relative thresholds for all the scores as outlined in Chapter 5 in a
fair and scientific manner. Both the value of the preoperative score and the variability of change for individuals
with the same score were apparent across the multitude of analyses conducted for the different scores.
However, the OHS/OKS had the best data available and hence had the most robust findings.
Calculation of economic thresholds
The health economic analysis used the same data sets to assess how the cost-effectiveness of arthroplasty
varied with each individual score and estimate economic thresholds. The economic evaluation described in
Chapter 5 demonstrated that economic thresholds could be estimated for the OKS and OHS. However, no
thresholds could be estimated for the WOMAC because TKA and THA were cost-effective at all WOMAC
scores for patients aged 60 or 70 years. Thresholds for other age groups were higher than the scores
observed in the available data. Thresholds for the SF-12 physical score varied with mental score and TJA
was cost-effective for all patients aged < 90 years with mental scores of 70.
Selection of final score
In the third user group meeting, we were able to display the results of the threshold and health economic
analysis together in a comparative manner, with the aim of selecting scores to take forward to work package 3.
After considering the data and analysis undertaken, the group was in agreement that the OHS and OKS were
the most appropriate scores to select. These scores had demonstrated excellent measurement properties and
the data available had allowed a comprehensive assessment of both clinical and health economic thresholds.
In addition, the scores are already widely used in the NHS in the assessment of hip and knee replacement,
whereas the WOMAC and SF-12 scores are not.
Further analysis of the Oxford Hip and Knee Scores to produce the
Arthroplasty Candidacy Help Engine tool
Having identified the OHS and OKS as the chosen scoring systems to use in the ACHE tool, it was then
possible to undertake a more detailed analysis of the national NHS PROM–HES linked data set to enable the
construction of the ACHE tool. Using a large NHS PROMs database enabled us to model the probability of
a good outcome for patients after hip or knee replacement over the full range of preoperative scores. We
were also able to determine this for patients of differing ages and genders, to some extent personalising the
ACHE probability graph to the individual (Figure 48). However, the majority of factors that we were able
to consider in the model did not affect the outcome to a significant degree and any improvements in
prognostic value were limited.
Our model calculates the probability of improvement at each preoperative score. The overall pattern of
probability was similar for both hip and knee patients, although hip patients are slightly more likely to
do well for any given preoperative score. The peak probability for improvement occurs for both hip and
knee replacement when the preoperative score is < 20, with approximately 90% of hip and 85% of knee
patients gaining significant benefit. These percentages change as the preoperative score increases, with
75% of patients obtaining benefit at scores of 35 for hip and 30 for knee. For a 50% chance of gaining
benefit, the scores are 36 for knee patients and 38 for hip. The absolute thresholds (i.e. when no benefit
can be achieved) were estimated to be 40 for hip replacement and 41 for knee replacement. Using this
methodology, the absolute thresholds are very slightly less than those calculated earlier in the project
(43 for hip and knee) using, in our view, the less useful MCID (B) criterion owing to the limitations in the
information available for the other candidate scores.
The final economic evaluation for the OKS and OHS (averaging across demographic groups) demonstrated
that TJA is cost-effective for > 99.9% of patients who currently undergo surgery. The analysis demonstrated
that it is cost-effective to conduct TKA on patients with an OKS of ≤ 43 (95% CrI 43 to 44) and to conduct
THA on patients with an OHS of ≤ 45 (95% CrI 44 to 45) (see Chapter 7). The economic thresholds varied
slightly with age, but not with gender. The PSA suggested that there was relatively little parameter
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uncertainty around the results, whereas sensitivity analyses suggested that the results were robust to
changes in key assumptions.
The economic thresholds are slightly higher than the relative thresholds, because the economic thresholds
are based on the difference in mean QALYs and mean cost between patients who undergo arthroplasty
and those who do not, whereas the absolute clinical thresholds are based on the probability that a patient
will achieve a MIC in Oxford Hip or Knee Score following surgery (see Chapter 7, Findings of the economic
evaluation). The clinical analyses estimate that patients with an OKS of ≥ 41 have a 0% chance of achieving
a good outcome (defined as a 7-point increase in OKS) because the OKS cannot exceed 48. In contrast,
because PROMs/HES data demonstrate that the mean change in EQ-5D utility is 0.057 among patients with
an OKS of 43, the economic evaluation estimates that these patients will, on average, gain 0.46 QALYs over
the 10 years following arthroplasty and that TKA costs £13,617 per QALY gained for this patient group.
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FIGURE 48 Specimen ACHE graphs showing the probability of a good outcome after (a) knee replacement and
(b) hip replacement, depending on preoperative Oxford Hip and Knee Scores.
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The apparent discrepancy arises for three main reasons. First, most of the patients who do not achieve a ‘good
outcome’ (meet the improvement criterion) nonetheless have some increase in the absolute clinical scores.
Second, the clinical analyses do not taken into account any cost implications. Third, the cost-effectiveness
analyses are based on the change in EQ-5D utility, whereas the clinical analyses are based on change in
Oxford Hip or Knee Score. Piloting and qualitative work may be needed to identify the best way to make the
issues clear to patients and clinicians using the ACHE tool in clinical practice.
One additional area of controversy comprises whether or not the ACHE tool should reflect differences in the
probability of a good outcome between patients of different ages and genders given the characteristics’
limited apparent prognostic value. This choice has potential implications for equity and fairness, particularly
if the ACHE tool were used as part of mandatory referral criteria. When setting national guidelines, NICE is
permitted to differentiate between individuals based on age or gender in their guidelines only if these are
indicators of the risks or benefits of interventions.98 Our analyses found that age had produced a limited
effect on the probability of a MIC in both Oxford Hip and Knee Scores, perhaps driven by difference in
those aged ≥ 80 years. Age had a significant effect on preoperative and postoperative EQ-5D scores, and
the cost of primary arthroplasty also influenced the cost-effectiveness. Gender did not seem to influence the
probability of a MIC in Oxford Hip and Knee Scores, but had a statistically significant effect on the cost
of primary arthroplasty. However, these analyses were based on a very large data set (PROMs/HES data)
in which even small differences may be statistically significant. Age and gender had an additional effect
on cost-effectiveness by influencing surgical mortality, revision rates and all-cause mortality. However,
economic thresholds varied little with age and were the same for men and women. Furthermore, the
economic evaluation found that the benefits of setting different thresholds for patients of different ages
was negligible, and there was no benefit from setting different thresholds for men and women.
Addressing our stated research questions
Can clinical tools for assessment of a patient’s suitability for knee or hip replacement be
used to set thresholds for operation?
This study has demonstrated that the OHS and OKS (both clinical tools previously used for assessment of a
patient’s suitability for knee or hip replacement) can be used to set preoperative thresholds for intervention,
based on assessing an individual’s capacity to benefit (in terms of PROM score) from surgery. It is important
to note that there was substantial individual variation in the change in score by pre score and also that there
may be other benefits and risks that are not reflected in the Oxford Hip and Knee Scores.
How does the choice of threshold affect the cost-effectiveness of the procedure and
subsequent improvements in patient quality of life?
We have demonstrated that hip and knee replacement is cost-effective for all levels of threshold, up to and
including the absolute threshold (a preoperative score above which no meaningful benefit can be gained
by a patient), based on the widely used ceiling ratio of £20,000 per QALY gained. Our work does show
that, in general, the procedures are more cost-effective at lower preoperative scores, but even as the
absolute threshold is approached, arthroplasty remains cost-effective. This reflects the very large health
gains made by the many patients who undergo this surgery, which outweigh the cost of surgery and the
small decrease in quality of life experienced by a small minority of patients. Age and gender have no
meaningful effect on these outcomes.
Using the Arthroplasty Candidacy Help Engine tool in the NHS
To develop the ACHE tool, we determined a way of linking preoperative OHSs and OKSs to the probability
of an individual patient having a good outcome after hip or knee replacement. The next stage of the work
was to construct a method of delivering the ACHE tool to patients and clinicians involved in the pathway.
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The ACHE tool has been designed to support the referral decision that a GP or a musculoskeletal referral
hub makes with a patient. The tool is not designed for use in secondary care, in which a more complex
package of personalised decision support is required. In addition to being a tool used by GPs and referral
hubs, the ACHE tool could also be accessible to patients directly. In this way, the tool and the process of
referral can be understood and is transparent. This was discussed in the third user group meeting and we
gained support for our approach of developing an electronic web-based delivery vehicle for the ACHE tool.
The user group did raise the question of whether or not this may limit access for those patients who do
not have access to, or do not use, the internet. The choice of a web-based vehicle was also based on the
observed success of other online GP referral aids such as Keele University’s STarT Back Tool (www.keele.ac.
uk/sbst/startbacktool/sbtoolonline/), which was developed in, and is widely used, in the NHS.
We believe that the issue of restriction of access to non-internet users could be addressed by the tool
being used during the GP consultation, accessed by the GP and filled in together or after the patient had
completed a paper version of the OHS and OKS. The development of a web-based ACHE tool also allowed
us to show the tool to patients and GPs in work package 3.
Assessing the impact of the Arthroplasty Candidacy Help Engine tool on the
NHS pathway
The first part of work package 3 was aimed at modelling the effect of using the ACHE tool in the NHS
setting. We investigated the potential impact of using the tool in one NHS referral hub, in which patients
who are referred from general practice are assessed for potential referral to secondary care, and then
extrapolated this to the NHS through modelling methods. National PROMs data demonstrate that virtually
all patients who currently undergo hip and knee replacement lie within the threshold values that we have
calculated, so its introduction is unlikely to reduce the current referral rate. Within the example of care we
investigated, which we believe is generally reflective of the NHS, we found that a proportion of patients
were not referred for surgical assessment despite having scores below the threshold level. We explored the
effect of using the ACHE tool set at different threshold levels (1–44 for knee replacement and 22–45 for hip
replacement). We accounted for the fact that not all of these patients would consider surgery (and hence
would not be referred), but estimated that a proportion of such patients would consider surgery
and, therefore, would wish to be referred. This modelling exercise demonstrated that the ACHE tool could
potentially increase the number of patients being referred for surgery if a threshold of > 21 for knee and
> 19 for hip replacement was used. However, because TJA is highly cost-effective, even a policy of referring
patients with a 50% chance of a good outcome is likely to be cost-effective and improve population health,
taking account of the health benefits forgone by spending money on arthroplasty rather than other
health services.
This study has shown that thresholds for referral based around a preoperative Oxford Hip or Knee Score
can be implemented, based on considering an individual’s capacity to benefit. Having established that,
the aim of the study was not to set the threshold at any specific level, but rather to explore the effect of
different threshold levels being used at an individual and population level.
If the tool were used and threshold values were set at levels previously suggested and used in the NHS
(19–24), the effect would be to potentially prevent many patients undergoing appropriate care and not
being given access to highly cost-effective treatment.
The economic evaluation demonstrated that setting a threshold close to the absolute threshold (41/42)
would be cost-effective on a population level. However, on an individual-level, setting a high threshold
would mean that significant numbers of patients would be referred who have only a low probability of
having a good outcome. This would seem unrealistic, as treatment would be offered to some patients
(with scores approaching 40) for whom there was very low probability of improvement.
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Setting the threshold scores at a level at which patients had approximately a 75% chance of a good
outcome (around 30 for knee and 35 for hip) would mean that referrals (and in turn total numbers of
operations) may increase, but would ensure patients’ access to appropriate, cost-effective care.
In practice, the number of operations may be limited by the availability of NHS funds, surgeons, operating
theatres or beds. If such operational constraints prevent the referral of all patient groups for whom TJA is likely
to be beneficial and cost-effective, a threshold probability of a good outcome or the decision grids shown in
Chapter 8 could be used to identify and prioritise those patient groups for whom TJA is most beneficial or
represents the best value for money. However, placing any limitation on the number of operations conducted
is likely to reduce the amount of health benefits that can be produced with the available funds.
Patient, public and general practitioners’ views
The low response rate to our patient/public and GP survey means that the results in reality represent a pilot
study of patient, public and GP views. Both surveys identified support for the use of the ACHE tool in supporting
the referral process around hip and knee replacement. All groups felt that an online electronic vehicle for the
tool was best, although 10% of patients stated a preference for a paper-based tool. Patients would mainly
like to use the tool at home, before or after a consultation, whereas opinion was split among GPs regarding
whether the tool was best filled in outside the consultation or embedded within the discussion in the clinic.
Of note was the view from patients regarding the ACHE tool being used to prioritise patients for surgery. The
pilot data suggests that more information should be gathered as to the usability of the tool with these groups.
Views from the extended user group meeting
The final extended user group meeting was designed to facilitate a discussion as to the eventual use of the
ACHE tool in the NHS. There was overall support for its design and the evidence that supported it. In turn,
there was encouraging support to test its use within the NHS in a controlled manner, with some caution
expressed about making any decision as to the level of relative threshold that should be used.
Further research
Our work has demonstrated that the OHS and OKS can be used within the ACHE tool to assist patients
and clinicians in deciding who should be referred for hip and knee surgery. Within the different threshold
levels explored in the study, there is overwhelming evidence as to the cost-effectiveness of hip and knee
replacement. However, our work has highlighted the need for more research:
l What would the level of uptake be by patients, GPs and other health-care workers involved in the
referral process for hip and knee replacement if the ACHE tool were introduced to the NHS?
l What is the impact of the ACHE tool on the numbers of patients referred for hip and knee
replacement?
l What is the best method of delivery for the ACHE tool (i.e. electronic or paper format)?
l In general practice, how should the ACHE tool be best integrated into the patient consultation?
l Would the ACHE tool be susceptible to ‘gaming’ if used within the NHS?
l What probability of success, following hip and knee replacement, is acceptable to patients, and how
does this vary between groups (e.g. gender, age and co-morbidity)?
l Can the ACHE tool be directly linked to secondary care following referral (e.g. forming the basis of a
more complex personalised decision support tool in secondary care)?
l What is the impact of other patient characteristics (e.g. BMI and smoking) on the post-surgery outcome
and cost-effectiveness of hip and knee replacement, and do thresholds for arthroplasty vary with
other factors?
l Additional primary data are needed on how clinical tool scores, costs and utility change over time in
the absence of arthroplasty and on how patients who do not have arthroplasty are managed in routine
clinical practice. These data are essential to fully understand what impact arthroplasty has on disease
and provide data to inform future economic evaluations.
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l Can a WOMAC version of the tool be developed? This may require additional primary data collection
on the WOMAC.
l There is a need to assess whether or not revision rates vary with presurgery OKSs and OHSs. We have
demonstrated that the preoperative OKS and OHS predict postoperative scores, costs and EQ-5D utility.
However, future research should assess whether or not the rate of revisions also varies with Oxford Hip
and Knee Scores and whether or not taking account of any variation in revision rates improves shared
decision-making or affects the economic threshold.
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Chapter 12 Conclusions
We have shown that scoring systems routinely used to assess hip and knee replacement outcomescan be used to provide an individual an estimate of their chances of improving after hip or knee
replacement.
We have determined, based on the data available to us at the time of this study, that the Oxford Hip and
Knee Scores are the best-suited measures for this purpose within the NHS.
We have identified that the WOMAC is highly likely to be able to fulfil this role as well, but that more data
are required to assess it.
We have determined absolute thresholds for the Oxford Hip and Knee Scores (41/48 and 42/48,
respectively) at which there is likely to be no benefit from surgery.
We have created a scientific method for calculating a patient’s probability of having a good outcome after
hip or knee surgery based on their preoperative level of symptoms (as measured by the Oxford Hip and
Knee Scores), age and gender, allowing us the ability to determine the outcome for patients when
different ‘relative’ thresholds for referral are set.
We have shown that hip and knee replacements are both highly cost-effective up to the absolute
threshold scores.
We have produced a web-based vehicle to deliver the above model to patients and GPs for use in the NHS –
the ACHE tool.
We have modelled the effect of the ACHE tool on the NHS, demonstrating that its introduction is likely to
be cost-effective. We have determined that at whichever level of relative threshold introduced it may
increase referral rates and the numbers of patients undergoing surgery.
We have collected pilot data that suggest that patients and GPs may welcome the use of the ACHE tool
into clinical practice; however, more work is required to fully demonstrate this.
We conclude that the ACHE tool should be tested within the NHS to determine its usability, uptake and
effect of referral patterns within the NHS.
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Appendix 1 Additional data relating to Chapter 9
(unedited general practitioner comments)
As part of the survey carried out with GPs a number of free-text comments were recorded. The free-textcomments are listed below in an unedited format:
l Looks promising! Will need a lot of publicity, however, to sell to colleagues.
l Useful where patient pressure for surgery but not really appropriate.
l Too long many GP’s won’t use it in this format. May be better to give patient to take home to
answer and bring back at next appointment for inputting into computerised tool. Many GP’s won’t
use it in this format. Great idea though.
l Hip and knee referrals go to physio for assessment. They then refer onwards to orthopaedics if
needed – unless evidence of server OA [osteoarthritis] radiologically (which can be referred directly
to orthopaedics.
l Excellent tool but there might be exceptions and need to allow for this.
l If used by GP would potentially avoid unnecessary referrals. Also acts as a tool to aid discussion
with GP about management options.
l The MSK [musculoskeletal] hub is not the right environment. In an ideal world the tool would have
a threshold that would allow the patient to bypass the MSK hub altogether and be referred directly
in to an orthopaedic clinic.
l I think it is good to get patients thinking about surgery BEFORE the hub. This might also
reduce referrals!
l By e-mail preferable – can e-mail them a link during the consult, have them complete it at home
and return to me.
l Paper at home electronically in practice.
l Ideally at home, but in surgery not a disaster, as pretty quick to complete.
l The tool seems to require a degree of understanding stats/interpreting risk by both GP and patient.
l Too long.
l Problem if the patient comes with 2 or 3 other problems! But we can focus on hip/knee and ask
them to return to discuss other problems.
l Can aid discussion with patients about management options.
l But it has to be user-friendly and quick, as the hip/knee problem is likely to be one of 2 or 3
problems the patient brings to the consultation!
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Appendix 2 Complete list of user group members
Name Role
Alastair Gray Professor of Health Economics
Andrew Price Professor and Consultant Orthopaedic Surgeon (Chief Investigator)
Anne Clarkson Webb Extended Scope Physiotherapist NOC
Anthony Johnson Retired GP and Patient Representative
Chad Lion Cachet Patient Representative
David Beard Professor of Musculoskeletal Sciences, Co-Director of SITU Oxford, Chairperson
Elena Benedetto ACHE Project Co-ordinator
Fiona Watt Consultant Rheumatologist
Fraser Old Patient Representative
Gill Dean GP working with Sports Injury and Rheumatology
Gillian Kempster Patient Representative
Helen Dakin Senior Researcher in Health Economics
James Smith Study Co-ordinator
Jannie Kramer Patient Representative
Jennifer Bostock Patient Representative
Jiyang Li PA to David Beard
Jo Hewanicka PA to Andrew Price
John Nolan Consultant Orthopaedic Surgeon and President Elect of British Hip Society
Jonathon Cook Associate Professor of Statistics
Karen Barker Clinical Director for Musculoskeletal Services at the NOC
Kate Jackson GP working in Sports and Exercise Medicine for MOD and ARUK
Kristina Harris Post Doctoral Associate/Lead Co-ordinator of ACHE Project
Laura Ingle GP
Mary Snow Patient Representative
Matthew Cheerham GP
Patricia Mary Rubery Patient Representative
Peter Eibich Senior Research in Health Economics
Sharon Barrington OCCG Lead for Elective Care
Sujin Kang Senior Statistician
Tim Wilton President of British Orthopaedic Association
Vida Field Patient Representative
PA, personal assistant.
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Appendix 3 Additional data relating to Chapter 9
(unedited patient and public comments)
As part of the survey carried out with patients and the public a number of free-text comments wererecorded. The free-text comments are listed below in an unedited format:
l Allow patient to complete these BEFORE attending the doctor to speed up the consultation time.
l As long as it does not become an inflexible tick-box process.
l However it is important to stress that a decision for treatment whatever that treatment is, should
be made jointly i.e. the GP and the patient. It is not the GP who decides on their own whether
a patient should see a consultant/surgeon. The patient may choose to wait; they may wish to
continue taking medication.
l Useful additional tool for both GPs and patients but clearly both should factor in other relevant
information e.g. recovery time, availability of physiotherapy, etc.
l If this had existed, I would have welcomed some form of self-assessment.
l Complete with GP or at home? Happy with either really although if completing at home it would
be good to have a GP discussion after this.
l I can always keep a note of my responses, and score to discuss with my GP at an appointment
should this be necessary. Is there any way a copy of the questionnaire can be saved on a
home computer?
l Paper or electronically? Either.
l I don’t care either way.
l I think a follow-up face-to-face in-depth discussion between patient and surgeon would be
essential before making that decision. Ticks in a box cannot express the amount of pain and
suffering that a face and voice does.
l But only if it was going to make a difference to eligibility.
l It is extremely difficult to record the level of pain. Consider more use be made of radiography and
scans to determine degree of bone loss.
l A good tool for both the GP and the patient.
l I think this is a good starting tool but possibly needs a few, more detailed questions, i.e. could do
with drilling deeper, otherwise I think it is too open for inaccurate reporting and decision-making.
For example, if pain is intolerable, is that sporadically in short bursts of 5–10 minutes or waves of
half an hour, does it last all day, or does it get worse as the day goes on or is it relieved by certain
movement or action. If it affects work or day-to-day tasks, in what way and what action is taken to
relieve it or to be able to carry on. There aren’t any questions about increased or decreased pain or
pain management, which I think would be useful and should influence the decision-making.
l Shouldn’t occupation and levels and types of activity and medication be taken into consideration?
And as mentioned previously, there should be questions to ascertain a benchmark for an
individual’s pain threshold and resilience to pain.
l I would also like to know how age influences the decision-making and prioritising. My perception
is that a joint operation is left until as late as possible, especially hip operations which are
synonymous with older patients and giving them a decent quality of later life, but in my humble
opinion, a 35-year-old’s quality of life for the next 20 years, while they can be and are still active
and having to work, is surely worth prioritising as much as a 75-year-old’s next 20 years?
l I realise that if a GP is completing this with the patient, there is the potential risk of rushing it or
not giving as accurate information as would be useful because 10 minutes is not a long time;
perhaps there could be an advisory note to the effect that a double appointment is required to
complete the questionnaire?
l Show on a scale the weighting factors based on the input criteria, i.e. if I changed an entry from
‘moderate pain’ to ‘severe pain’ what effect that has on the results – as this can be subjective.
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l Also – explain how to grade your pain levels as they differ so much from person to person.
Also – going up and down stairs – do you hear your knees making a noise? And at other times.
l The questionnaire does not really reflect the reality of the condition, or at least mine. It is not a
matter of ‘last four weeks’, but of sometimes one, sometimes another. The degree of pain or
difficulty in doing something can vary radically over as little as half an hour from bad to better to
bad again, so that e.g. little pain and moderate pain are not constants. A ‘sometimes’ choice
would make a much more accurate choice.
l What are you doing for those patients who do not have access to a computer, and will need time
to become familiar with a new process? This primarily I would imagine would be elderly people.
l Technology is being heavily invested in as a support tool for clinical decision-making (vs. GPs
decision-making!) in a number of areas. Would it be sensible to consider GPs surgeries having a
computer in the waiting room set up with all the tools, and a support staff there to help
familiarise patients.
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